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Abstract 
Antibodies are indispensable binding molecules in research, diagnostics 
and therapy. Nevertheless, antibodies are afflicted with problems, such as poor 
expression and limited stability, especially in the intracellular milieu. Thus, superior 
alternatives would be of great value. This thesis describes the first successful 
selections of binding molecules and inhibitors from designed ankyrin repeat (AR) 
protein libraries. 
 
In the first part of this thesis, designed AR proteins and ribosome display are 
introduced. Binding molecules based on AR proteins were devised to create an 
alternative to antibodies, overcoming some antibody-related problems. 
Designed AR proteins combine high affinity and specificity in target binding with 
high expression levels and high stabilities in all conditions. The selections of AR 
proteins binding to the given target proteins were achieved by ribosome 
display, an in vitro selection technology, ideally suited to identify or evolve 
binding molecules from combinatorial protein libraries. As no transformation step 
limits the size of the applicable library, this technology is ideal to handle very 
large libraries. Advances in the selection protocol were established, including an 
optimized approach for the generation of the library construction and the 
selection in the presence of detergents, allowing panning for membrane protein 
binders. 
 
The second part of this thesis describes the initial work in selecting binding 
molecules and inhibitors from designed AR protein libraries. As general proof-of-
concept, several different target proteins were chosen, including maltose 
binding protein (MBP) of Escherichia coli (E. coli), aminoglycoside 
phosphotransferase (APH), the eukaryotic protein kinases p38, JNK1, JNK2 and 
AMPK, further, Sec YEG, a membrane protein of E. coli responsible for protein 
export and finally a non-structural protein of Semliki Forest Virus. Against these 
target proteins, specific binding molecules were obtained, demonstrating the 
power of designed AR protein libraries. The crystal structure of a selected AR 
protein in complex with its target protein (MBP) visualized the binding interaction 
at atomic resolution and revealed an interface indistinguishable from natural 
protein-protein interactions. 
To demonstrate intracellular functionality of designed AR proteins, inhibitors 
against APH were selected. APH is a bacterial kinase and mediates kanamycin 
resistance in different pathogenic bacteria. A combined selection-screening 
approach yielded AR proteins that inhibited APH intracellularly, conferring 
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kanamycin sensitivity. The most potent of the selected inhibitors mediated a 
phenotype comparable to the APH gene knock out. The selected AR proteins 
also inhibited the enzyme in vitro, and the binding constants were in the low to 
sub-nanomolar range. Detailed biochemical characterization of the most 
potent inhibitor, including structure determination of the enzyme/inhibitor 
complex rationalized the inhibition mechanism. The AR protein bound and 
stabilized the kinase in an unproductive conformation, thus causing inhibition.  
To monitor the ribosome-display selection process, to further enrich the 
binders, and to again demonstrate intracellular efficacy of the AR proteins, 
protein complementation assay (PCA) was applied after each ribosome-display 
selection round for JNK2 binding molecules. The obtained results indicated that 
only two rounds of ribosome display are sufficient to select nanomolar binders, 
and that an enrichment factor of 106 per round was achieved. All selected 
binders were fully functional in the cellular cytoplasm. The specificity of the 
selected AR proteins was very high, as they only interacted with the target 
protein JNK2, but did not bind to JNK1, which shows 81% identity on the protein 
sequence level. 
 
In conclusion, this thesis demonstrates that designed AR proteins are a true 
alternative to antibodies, surpassing them in several biophysical properties. The 
selected AR proteins bound their targets with high specificity and affinity, were 
very stable, fully functional inside the cell and successful in crystallization trials.  
These results open new possibilities in the fields of target validation, 
functional and structural genomics and might even be of use for diagnostic and 
therapeutic applications.  
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Zusammenfassung 
Antikörper sind unersetzliche Bindemoleküle in der Forschung, der Diagnose 
und der Therapie. Trotzdem sind Antikörper mit verschiedenen Problemen 
behaftet, so wie teure Produktion und limitierte Stabilität, vor allem in der Zelle.  
Deshalb wären bessere Moleküle von grossem Wert. Diese Arbeit beschreibt die 
erste erfolgreiche Selektion von Bindemolekülen und Inhibitoren aus „Designed 
Ankyrin Repeat (AR) Protein“ Bibliotheken.  
 
Im ersten Teil dieser Arbeit werden „Designed AR Proteine“ und „Ribosome 
Display“ vorgestellt.  AR Protein-basierte Binder waren konzipiert worden, um 
eine Alternative zu Antikörpern zu schaffen, welche die antikörperspezifischen 
Probleme beheben würde. „Designed AR Proteine“ sollten hochaffines und 
hochspezifisches Binden, mit guter Expression und hoher Stabilität, auch unter 
reduzierenden Bedingungen, verbinden. Die Selektionen von Bindern aus AR 
Protein Bibliotheken wurden mittels „Ribosome Display“ bewerkstelligt. Diese in 
vitro Selektionstechnologie ist ideal um aus Proteinbibliotheken Binder zu 
selektionieren. Da kein Transformationschritt die Biblothekgrösse begrenzt, ist 
„Ribosome Display“ ideal um sehr grosse Bibliotheken in Selektionen zu 
verwenden. Aktuelle Verbesserungen im Selektionsprotokoll werden hier 
beschrieben, welche eine optimierte Strategie zur Bibliothekskonstruktion 
beinhalten, sowie die Möglichkeit zur Selektion in Gegenwart von Detergenzien, 
was die Selektion von Membranproteinbindern erlaubt.  
 
Der zweite Teil dieser Arbeit beschreibt die ersten Erfolge bei der Selektion 
von Bindern und Inhibitoren aus den „Designed AR Protein“ Bibliotheken. Eine 
Vielzahl von Zielmolekülen wurde gewählt, unter anderem Maltose-binde-
Protein (MBP) von Escherichia coli (E. coli), aminoglycoside phosphotransferase 
(APH), die eukaryotischen protein kinasen p38, JNK1, JNK2 und AMPK, weiter Sec 
YEG, ein Membranprotein aus E. coli, verantwortlich für den Proteinexport und 
schliesslich nicht-struktur-assoziierte Protein des Semliki Forest Virus. Gegen 
sämtliche dieser Zielmoleküle wurden spezifische Binder generiert, was die 
Qualität der AR Proteinbibliothek unterstreicht. Eine Kristallstruktur von einem AR 
Protein in Komplex mit seinem Zielmolekül visualisierte die Bindung mit atomarer 
Auflösung und beschtätigte eine natürliche Protein-Protein Interaktion. 
Der nächste Schritt war die Demonstration der intrazellulären Funktionalität 
der AR Proteine. Zu diesem Zweck wurde APH als Zielmolekül ausgewählt. APH ist 
eine bakterielle Kinase, die pathogenen Bakterien Kanamycin Resistenz 
vermittelt. Ein kombiniertes Selektions-Screening Verfahren brachte 
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verschiedene AR Proteine hervor, die APH inhibierten und dabei die Kanamycin 
Sensitivität wiederherstellten. Die potentesten Inhibitoren erwirkten beim 
Bakterium einen Phänotyp, wie er bei Abwesenheit des APH Gens auftritt. Die 
selektionierten Inhibitoren inhibierten das Enzym auch in vitro und die Affinität 
war im tief- bis sub-nanomolaren Bereich. Der Inhibitionsmechanismus des 
besten Inhibitors wurde mittels einer detaillierten biochemischen und 
strukturellen Analyse aufgeklärt. Das AR Protein interagierte und stabilisierte eine 
nicht aktive Konformation des Enzyms 
Um den Selektionsprozess zu erfassen, um die Binder weiter anzureichern 
und um nochmals die intrazelluläre Funktionalität der AR Proteine zu zeigen 
wurde ein Protein-Komplemetationstest nach jeder Ribosome-Display 
Selektionsrunde gegen JNK2 verwendet.  Die Resultate zeigten, dass nur zwei 
Selektionsrunden nötig waren, um Binder mit nanomolarer Affinität zu 
selektionieren. Dies entspricht einem Anreicherungsfaktor von etwa 106 pro 
Selektionsrunde. Alle identifizierten JNK2 Binder waren funktional in der Zelle und 
waren sehr zielmolekülespezifisch; sie erlauben zwischen JNK2 und JNK1 zu 
unterscheiden, die zu 81% identisch sind.  
 
Diese Resultate zeigen klar auf, dass es uns gelungen ist eine 
vielversprechende Alternative zu Antikörpern zu generieren, welche diese in 
wichtigen Punkten sogar übertrifft. Die selektionierten AR Proteine interagierten 
mit den entsprechenden Zielmolekülen mit hoher Affinität und Spezifität, waren 
sehr stabil, funktional in der Zelle und äusserst erfolgreich in 
Kristallisationsansätzen. 
Zusammenfassend lässt sich sagen, dass die AR Protein Technologie neue 
Möglichkeiten in den Bereichen Target Validation, Genomprojekten und 
möglicherweise sogar in der Diagnose und der Therapie öffnet. 
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2  Introduction 
General Remarks 
Proteins are fundamental to life. They play crucial roles in nearly all 
biological processes: enzymes catalyse chemical reactions, structural proteins 
are responsible for cellular architecture, receptors are involved in signal 
transduction and antibodies fight intruders. Understanding life at a molecular 
level will involve the understanding of proteins. This thesis addresses proteins at 
different levels. 
 
First, technologies are discussed, which allow the engineering of proteins. 
The goal is to understand proteins and to improve them, such that they might be 
applied to biological problems. Two approaches dominate the field of protein 
engineering: “rational design” and “directed evolution”. Both approaches have 
been applied successfully and might be combined, as they are truly 
complementary.  
Second, the discussed methods of protein engineering are applied to 
generate binding molecules. Up to date, the binding molecule of choice was 
the antibody. As antibodies were almost the only binding molecules, which 
could specifically bind any given target with high affinity and specificity, they 
were used in a wide range of applications, including research, diagnostics and 
therapy. Nevertheless antibodies suffer from limitations originating from their 
biophysical properties. A valid alternative is presented: designed Ankyrin repeat 
(AR) proteins. These proteins bind their targets as antibodies do, but overcome 
the limitations of antibodies.  
The generation of AR protein as antibody alternative was achieved by a 
combination of rational design and directed evolution, giving evidence for the 
power of the synergy of these approaches. 
1. Protein Engineering 
The distinct amino acid sequence of a protein defines its three dimensional 
structure and with that its function. Therefore, mutations in the sequence can 
alter structure and function. The goal of protein engineering is to change the 
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sequence of a given protein to improve its biophysical characteristics. Different 
approaches can be chosen to achieve this goal: “rational design”, “directed 
evolution” or a combination thereof.  
1.1 Rational design  
In the rational design approaches, information about a protein (or a class 
thereof) is collected and rationalized to predict beneficial mutations. The more 
information about the target protein (and proteins in general) is available, the 
higher the probability of success.  These in silico methods can be applied to the 
generation of novel binding specificities (Looger et al., 2003), enzyme 
engineering (Dwyer et al., 2004), addressing protein structure and folding 
problems (Kuhlman et al., 2003, Ventura & Serrano, 2004) and engineering of 
protein stability (Steipe et al., 1994, Kuhlman & Baker, 2004).  
Recently, different groups published remarkable results. Hellinga and co-
workers used rational design to generate specific high-affinity receptors, based 
on periplasmic binding protein (PBP). This protein superfamily is known to bind a 
wide variety of different ligands and many high resolution structures with ligands 
bound have been determined (Dwyer et al., 2004). The redesign to alter the 
ligand specificity of the PBP comprised the following steps: First, all side chains 
interacting with the natural ligand were identified and replaced by alanine, 
defining the so called “primary coordination sphere” (PCS). An ensemble of 
possible conformations of a putative ligand was then placed in the potential 
binding pocket and its most promising conformations were fixed. Using a side 
chain rotamer library and a dead-end elimination algorithm, a PCS for each 
ligand conformation was calculated.  Optimal sequences were identified 
determining the global energy minimum and ranked according to dead-end 
elimination energy, protein-ligand van der Waals contact energy, number of 
unsatisfied hydrogen bonds and ligand exposed surface area. Finally, a small 
number of top-ranked designs were tested experimentally. By this approach 
specific high affinity receptors to different ligands were successfully generated, 
which were fully functional in vivo (Looger et al., 2003). The same group even 
went one step further and designed enzymatic activity into a PBP (Dwyer et al., 
2004). A three step design approach was applied to generate a novel enzyme. 
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First, key interactions for catalysis, which were geometrically fixed, were defined. 
Second, positions for the catalytic side chain were identified by a combinatorial 
approach. Third, the remaining complementary surface was generated around 
the defined substrate. This approach yielded PCB variants that showed triose 
phosphate isomerase activity with a 105-106 fold rate enhancement compared 
to the uncatalyzed reaction. The most active PCB variant was able to 
complement the wild-type enzyme in E. coli, supporting growth under 
glugoneogenic conditions. 
Another impressive example of the power of rational design was the 
prediction of an artificial protein, which had all the hallmarks of a natural one. 
Baker and co-workers applied an approach that iterates between sequence 
optimisation and structure prediction. A model of a novel protein topology, 
which was not found in the Protein Data Bank (PDB), was defined. Three 
dimensional starting models were generated by assembling three- and nine-
residue fragments from the PDB with secondary structures consistent with 
defined novel protein topology. Then, the sequence and the structure were 
simultaneously optimized by cycling between sequence design and structure 
optimization. The crystal structure of the designed protein matched the 
predicted one almost perfectly (Kuhlman et al., 2003).  
While the energy minimizing approaches are based on an understanding of 
the three-dimensional structure, another approach, termed consensus design, 
makes use of sequence information. Here, the alignment of homologous 
sequences is used to define a consensus sequence with improved 
characteristics (Steipe et al., 1994, Forrer et al., 2004). The underlying idea is that 
the functionally important amino acids are more conserved than others. 
Comparing all available sequences will define the most conserved choice for 
each position, resulting in the optimal sequence. This approach is very 
dependent on the sequences included in the alignment process, with chances 
for success rising with the number of available sequences. As more and more 
sequence data are available from genome sequencing projects, this approach 
gains strength.   
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1.2 Directed Evolution 
Natural evolution describes a simple process of optimization. Every organism 
carries its master plan as genes encoded on DNA (genotype). These genes 
encode proteins, which are the actual working tools (phenotype). Mutations 
occur spontaneously and at random positions at the DNA level and can 
manifest themselves as altered proteins. If, by chance, a mutation is beneficial 
for the organism, this individual is selected by the criterion of fitness and will pass 
its improved master plan on to the next generation.  
This natural evolutionary principle of succeeding rounds of diversification 
followed by selection of the fittest can be mimicked in the test tube to evolve 
proteins with improved characteristics in an approach called “directed 
evolution” (Plückthun et al., 2000; Farinas et al., 2001). In an experimental set-up, 
the genotype must be linked to the phenotype, as seen in nature, and a 
selection pressure must be applied to a starting population, to identify potential 
candidates. Short generation times combined with large and diverse starting 
populations allow more individuals to enter the game and therefore raise the 
chances of success.  
 
2. Binding Molecules 
As more and more genome sequencing projects are completed, the 
number of identified genes is rising drastically (Venter et al., 2004). The main task 
now lies in the assignment of function to the proteins encoded in these genes. 
Specific binders to these proteins would facilitate their investigation, allowing 
determination of localization in vivo, detection on Western blots, 
immunoprecipitation experiments and possibly help structure determination of 
the target protein. In some cases the binding molecule might even find use in 
diagnostic applications or serve as a lead compound in the drug discovery 
process. Specific binding molecules are often proteins, in most cases antibodies. 
 
6  Introduction 
2.1 Antibodies 
The most common binding proteins are antibodies. These proteins are 
naturally produced by B-lymphocytes as key elements of the humoral immune 
response of all vertebrates to fight intruders. Thereby antibodies have to be able 
to discriminate between self and non-self. Nature achieves this by creating 
antibody libraries, which are depleted of “self”-recognizing antibodies. During B-
lymphocyte maturation antibody gene rearrangement creates stretches coding 
for variable surface loops on the antibody framework, which are termed 
complementary determining regions (CDRs) (Tonegawa, 1983). The CDRs of an 
antibody can interact with the target and are therefore responsible for specific 
binding. Every single B-lymphocyte expresses a distinct antibody. During B-cell 
maturation “self” recognizing individuals are negatively selected, all others have 
the potential to recognize an intruder. The human body produces around 109 
distinct B-lymphocytes (Winter, 1998). This large diversity of naturally produced 
antibodies can be used to select target-specific antibodies by immunization. 
The target protein is injected into a laboratory animal, which induces an 
immune response and leads to production of specific antibodies. Nevertheless 
antibodies suffer from limitations: They are built from several domains and suffer 
from high production costs. Furthermore, they contain stabilizing disulfide bonds, 
which can not form in the reducing environment of the cellular cytoplasm, 
making intracellular applications very difficult (Biocca & Cattaneo, 1995). 
 
2.2 Alternative scaffolds - designed ankyrin repeat proteins 
The natural principle of generating a pool or a library of proteins with a 
randomized surface area can be transferred from antibodies to other proteins 
(reviewed in Skerra, 2000). An ideal alternative to antibodies would be built of 
one small domain, would be well expressed and contain no cysteines, while still 
retaining the beneficial properties of antibodies such as tight and specific 
binding. The approach described here is based on the ankyrin repeat (AR) 
protein as scaffold. AR proteins are, next to antibodies, the most abundant class 
of binding molecules found in nature (Sedgwick & Smerdon, 1999). Unlike 
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antibodies they do not contain any disulfide bonds and are found in all cellular 
compartments. AR proteins occur in all phyla and mediate protein-protein 
interactions with affinities in the nanomolar to picomolar range (Binz et al., 2003). 
They often act as natural intracellular modulators of many biological processes 
(Brotherton et al., 1998; Russo et al., 1998). AR proteins are built of consecutive 
homologous repeats, which assemble to form elongated proteins with a 
continuous hydrophobic core.  
Our “rational design” approach combined structure and consensus 
analyses to engineer an AR module of 33 amino acids with fixed framework 
residues and randomized potential interaction residues. This module was used as 
a building block to create combinatorial libraries of designed AR proteins of 
different sizes, with diversities greater than 1010 (Binz et al., 2003). The same 
approach was also applied to Leucine rich repeat proteins (Stumpp et al., 
2003). The unique modular architecture of repeat proteins allows module 
shuffling, insertion and deletion. Furthermore, the binding surface is not restricted 
in its dimension, as it may be adapted to the target by addition or removal of 
repeat modules (Forrer et al., 2003). 
In all approaches based on antibodies or alternative frameworks, a pool of 
proteins, termed a protein library, is used for binder generation. Usually, the 
diversified amino acids of a protein library are not distributed randomly over the 
whole protein, but are located in surface loops or other well-defined locations 
(Figure 1). The constant part of the protein is called the framework, which 
ensures the correct protein fold, while the randomized positions are potentially 
involved in binding. In this way, all individuals of the library have the same 
overall topology, showing the protein class specific fold, but have a randomized 
surface for potential target interaction (Figure 1). 
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Figure 1. Comparison of a single chain antibody fragment (scFv) and a 
designed ankyrin repeat (AR) protein. The scFv is depicted in ribbon 
representation, while the AR protein is depicted in space-fill representation. For 
both the conserved framework residues are colored in grey, while the 
randomised potential interaction residues are in red.  
3. Selecting Binding Molecules 
Thirty years ago, immunization of test animals was the only way to generate 
target specific antibodies (Köhler & Milstein, 1975). This procedure was not 
optimal. Some targets were not immunogenic, others were not stable in the 
laboratory animal or simply too toxic, failing to give rise to specific binders. In 
any case, the selection process, taking place in the animal, was a black box, 
virtually uncontrollable, with an uncertain outcome. To overcome these 
limitations and to put the selection process in the hands of the researcher, novel 
selection methods were developed. These methods also opened the door for 
selection of proteins other than antibodies. 
The starting point of every selection is a protein library. These libraries are 
used for selections to pick out those proteins which show specific binding. In 
analogy to the natural evolution principle, the library is the starting population. 
The larger and more diverse the starting population is, the higher the probability 
will be to find an individual with the desired properties.  
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3.1 In vivo selection technologies  
In vivo selection technologies link the desired binding event to cellular 
survival. A cellular protein, with a selectable phenotype, is genetically divided in 
two parts and the potential interaction partners are genetically fused to each 
part. If they indeed interact and form a complex, the divided protein is reunited, 
is active and gives rise to a selectable phenotype. This principle is applied in the 
protein complementation assay (PCA), yeast two hybrid, bacterial two-hybrid 
and many other systems (Fields & Song, 1989; Michnick et al., 2000). In any case 
the interaction occurs in vivo and the precise selection conditions are difficult to 
control.  
 
3.2 In vitro selection technologies - Phage Display 
To gain control over the selection conditions, the selection step must 
happen in vitro. For this purpose in vitro selection technologies were established. 
The most prominent one is phage display (Smith, 1985). The protein of interest is 
genetically fused to a phage coat protein. Every phage displays a distinct 
protein, carrying the corresponding gene inside, thereby achieving the 
necessary coupling of genotype and phenotype. The whole population of 
phages, each displaying a different protein variant, can be incubated with 
immobilized target protein and the phages displaying a protein interacting with 
the target can be captured. While the selection process now is carried out in 
vitro, phage production still happens in vivo. This brings limitations in respect to 
the size of the starting population due to transformation limitations.  
 
3.3 Complete in vitro selection technologies - Ribosome Display 
Complete in vitro display technologies overcome these limitations. These 
systems are based on in vitro translation to achieve the necessary coupling of 
genotype and phenotype by different experimental tricks. In this thesis the focus 
lies on ribosome display (Hanes & Plückthun, 1997; He & Taussig, 1997; 
Mattheakis et al., 1994). Ribosome display relies on non-covalent ternary 
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complexes, which are formed during in vitro translation. They contain mRNA 
(genotype), ribosome and nascent polypeptide (phenotype). The coding 
sequence of the investigated protein is genetically fused to a C-terminal tether, 
such that the domain of interest can fold while the tether is still in the ribosomal 
tunnel. This fusion construct lacks a stop codon at the mRNA level, thus 
preventing release of the mRNA and the polypeptide from the ribosome. High 
concentrations of magnesium and low temperatures further stabilize the 
ribosomal complex. These complexes can be used directly to select for 
properties of the displayed protein. This complete in vitro technology allows the 
handling of very large starting populations and shortens the selection time to a 
minimum.  
 
4. Combining Approaches 
As mentioned above the approaches used for of protein engineering can 
be divided into two categories: “rational design” and “directed evolution”. The 
debate about which approach is superior is ongoing. In principle this discussion 
is out of place, as “rational design” and “directed evolution” are absolutely 
complementary to each other (van Regenmortel, 2000). One central drawback 
of rational design is that the outcome sequences, defined in silico, will still have 
to be tested in a wet lab, limiting throughput. Here, “directed evolution” 
methods can be applied to test more sequences, raising the chances for 
success. The outcome of “directed evolution” experiments, on the other hand, is 
directly linked to the sequences in the starting population. If there are no good 
individuals present in the first place, they cannot be selected. Here “rational 
design” can improve the quality of the starting population, increasing the 
chances of finding the desired clones.  
The work presented here is one example of the synergistic combination of 
both approaches for the successful generation of novel binding proteins. 
Rational design was applied to generate combinatorial AR protein libraries, 
ensuring a high quality population of potential binders (Binz et al., 2003). These 
libraries were the starting point for selection experiments by ribosome display, 
allowing the rapid selection of binders from very large libraries.  
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Proof-of-concept selection experiments yielded AR protein binders to a 
whole range of different target proteins. The binding mode was analyzed with 
respect to specificity and affinity, showing specific binding in the nanomolar 
range. The crystal structure of a complex, visualizing the binding interface at 
atomic resolution, revealed a protein-protein interaction, indistinguishable from 
natural ones.  
The potential of intracellular applications was demonstrated by selection of 
AR proteins inhibiting a bacterial kinase responsible for kanamycin resistance. 
The selected inhibitors created an in vivo “knock down” showing kanamycin 
sensitivity. The most potent enzyme inhibitors were almost as efficient as the total 
gene knock out. Again, a crystal structure helped to rationalize the binding and 
inhibition mechanism. 
Finally, the ribosome-display selection process for JNK2 binding molecules 
was monitored by a protein complementation assay. The obtained results 
indicated that only two rounds of ribosome display are sufficient to select 
nanomolar binders, and that an enrichment factor of 106 per round was 
achieved. All selected binders were fully functional in the cellular cytoplasm and 
the specificity of the selected AR proteins was very high as they only interacted 
with the target JNK2, but did not bind to JNK1, which shares 81% sequence 
identity on the protein sequence level.  
 
Our results suggest that AR proteins are a valid alternative to antibodies, 
with equal or superior characteristics. The described approach demonstrates 
the power of the combination of “rational design” and “directed evolution”. 
Having completed the proof-of-concept experiments, the focus is now on 
generating high quality binding molecules for research, diagnostics and 
therapeutics.  
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Designing Repeat Proteins: Well-expressed, Soluble
and Stable Proteins from Combinatorial Libraries of
Consensus Ankyrin Repeat Proteins
H. Kaspar Binz, Michael T. Stumpp, Patrik Forrer, Patrick Amstutz and
Andreas Plu¨ckthun*
Biochemisches Institut
Universita¨t Zu¨rich
Winterthurerstrasse 190
CH-8057 Zu¨rich, Switzerland
We describe an efﬁcient way to generate combinatorial libraries of stable,
soluble and well-expressed ankyrin repeat (AR) proteins. Using a combi-
nation of sequence and structure consensus analyses, we designed a 33
amino acid residue AR module with seven randomized positions having
a theoretical diversity of 7.2 £ 107. Different numbers of this module were
cloned between N and C-terminal capping repeats, i.e. ARs designed to
shield the hydrophobic core of stacked AR modules. In this manner, com-
binatorial libraries of designed AR proteins consisting of four to six
repeats were generated, thereby potentiating the theoretical diversity. All
randomly chosen library members were expressed in soluble form in the
cytoplasm of Escherichia coli in amounts up to 200 mg per 1 l of shake-
ﬂask culture. Virtually pure proteins were obtained in a single puriﬁcation
step. The designed AR proteins are monomeric and display CD spectra
identical with those of natural AR proteins. At the same time, our AR pro-
teins are highly thermostable, with Tm values ranging from 66 8C to well
above 85 8C. Thus, our combinatorial library members possess the proper-
ties required for biotechnological applications. Moreover, the favorable
biophysical properties and the modularity of the AR fold may account,
partly, for the abundance of natural AR proteins.
q 2003 Elsevier Ltd. All rights reserved.
Keywords: ankyrin repeat; combinatorial library; consensus sequence;
protein design; scaffold*Corresponding author
Introduction
Repeat proteins mediate numerous key protein–
protein interactions in nature.1,2 Their repetitive
architecture permits the adaptation of their size
and thus their variable and modular binding
surface to a target protein, leading to high-afﬁnity
interactions. We developed a strategy that exploits
this modular architecture for the generation of
combinatorial libraries of repeat proteins with
novel binding speciﬁcities (Figure 1).3 Our strategy
consists of designing a self-compatible repeat
module for a given repeat type. In such a repeat
module, residues important for maintaining the
repeat structure (i.e. framework residues) are
deﬁned, while potential target interaction residues
are randomized. Such self-compatible repeat
modules can then be joined repetitively to yield a
stack of repeats. To form repeat domains, the con-
tinuous hydrophobic core of this stack is sealed by
N and C-terminal capping repeats (Figure 1). We
hypothesized that, by using this strategy, libraries
of repeat proteins of different lengths with very
large and highly diversiﬁed interaction surfaces
could be generated. Our strategy is thus in clear
contrast to the traditional scaffold approach,
which would consist of randomizing the surface
or loops of a well characterized natural protein
whose dimensions are ﬁxed.4,5
Ankyrin repeat (AR) proteins constitute a very
attractive class of repeat proteins to test our
strategy. AR proteins mediate many important
protein–protein interactions in virtually all
species,6 and are found intracellularly, extracellularly
0022-2836/$ - see front matter q 2003 Elsevier Ltd. All rights reserved.
E-mail address of the corresponding author:
plueckthun@bioc.unizh.ch
Abbreviations used: AR, ankyrin repeat; IMAC,
immobilized metal-ion afﬁnity chromatography; PDB,
Protein Data Bank.
doi:10.1016/S0022-2836(03)00896-9 J. Mol. Biol. (2003) 332, 489–503
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and in membrane-bound form, indicating that
these proteins can adapt to many different environ-
ments. The fact that there are more than 2000
known AR proteins (.14,000 ARs)7 underscores
their importance in nature. AR domains are com-
posed of stacked ARs, consisting typically of 33
amino acid residues, each forming a b-turn
followed by two antiparallel helices and a loop
reaching the b-turn of the next repeat (Figure 2).8,9
Usually, four to six repeats6 assemble into domains,
but the crystal structure of ankyrin R, consisting of
12 ARs in a single domain, was reported recently,10
indicating that there is virtually no limit to the
number of repeats that can fold in one AR domain.
Even though different parts of the surface of AR
domains could, in principle, be involved in pro-
tein–protein interactions,10 most AR domains
interact with their cognate partners via the pro-
truding b-turns and the following a-helices.
Typically, several adjacent repeats establish con-
tact. This patch-wise interaction mode leads to
high-afﬁnity interactions, exempliﬁed by the
mouse GA-binding protein (GABP) b1 binding
GABPa with a KD of 0.78 nM or by IkBa inhibiting
the DNA binding of NF-kB with a Ki of 3.1 nM.
11,12
We implemented our novel strategy on AR
proteins and generated combinatorial libraries of
designed AR proteins of distinct repeat numbers.
Here, we describe the design, construction and
analysis of these libraries. The accompanying
paper by Stumpp et al.13 describes the implemen-
tation of our strategy on leucine-rich repeat
proteins, another abundant repeat protein class.
Results
A key step in our strategy (Figure 1) is the design
of self-compatible repeat modules.3 This should
ensure the proper stacking of the repeat modules
into repeat domains. ARs feature a high degree of
sequence and structure conservation and, thus,
one way to generate self-compatible repeats is
through consensus design. In consensus design,
the conserved intra- and interrepeat interactions
characteristic for the AR domain fold are imple-
mented into the repeat module. In addition, con-
sensus design may lead to improved repeat
stability.3 We describe here the design of a consen-
sus AR, in which conserved framework residues
are ﬁxed and in which potential target interaction
residues are randomized. The design is based on
sequence and structure consensus analyses.
AR consensus sequence deﬁnition using
sequence databases
The ﬁrst important task for our consensus design
was to choose an appropriate sequence data set.
The SMART database7 provided a large number of
functionally unbiased AR sequences and was
therefore chosen as the starting point. Numbering
of the positions of the AR consensus was adapted
from that used by Sedgwick & Smerdon.9 The
Clustal W14 alignment of ARs was downloaded
from SMART. The data set was further reduced to
those sequences matching the length of the 33
amino acid residue consensus described
earlier.6,9,15,16 Only repeats without extra insertions
or deletions were considered for the consensus
deﬁnition. The resulting alignment of 229 ARs
yielded consensus A containing residues 3–32
(Figure 3). To further reﬁne consensus A and to
deﬁne the lacking residues (1, 2 and 33), consensus
A was circularly permutated and the lacking resi-
dues and those without clear preference (frequency
Figure 1. The strategy to generate designed AR protein libraries. From structure and sequence alignments of natural
ARs, a self-compatible AR module is designed. This repeat module consists of ﬁxed framework residues and random-
ized potential interaction residues (shown in red stick mode). Various numbers of this AR module (here three) are then
cloned between N and C-terminal capping repeats. By using this strategy, combinatorial libraries of designed AR
proteins of varying repeat numbers can be generated. The randomized positions on several adjacent repeats create a
large potential interaction surface presented on a rigid AR scaffold. This Figure was created using PDB entries
1AWC21 and 1MJ029 with the help of MOLMOL.54
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#30%) were chosen from the alignment of repeats
of AR proteins with known structure. The resulting
consensus B (Figure 3) was subjected to a BLAST17
search against GenBank.18 The resulting top 200
BLAST hits were manually aligned and analyzed,
yielding consensus C (Figure 3). An alignment of
2220 AR sequences stored in the PFAM database19
conﬁrmed the choice of the most frequent amino
acids of consensus C (threshold 30%).
AR consensus reﬁnement using structural data
To extend our sequence database analyses, we
decided to include structural data for the ﬁnal
reﬁnement leading to consensus D (Figure 3). The
structural analysis included the ten AR protein 3D
structures 1YCS,8 1AP7,20 1AWC,21 1A5E,22 1IKN,23
1NFI,24 1MYO,25 1IHB,26 1DCQ27 and 1SW6.28 In a
ﬁrst step, the PDB ﬁles were used to deﬁne poten-
tial target interaction residues and framework
residues.
Potential target interaction positions
From 3D structures of complexes of AR domains
with target proteins (1AWC, 1YCS, 1IKN, 1NFI),
target interaction residues were identiﬁed using
NACCESS† by analyzing the change in solvent-
accessible surface area of AR domain residues
upon complex formation. Interactions mostly
involve the b-turns and the ﬁrst a-helices of the
AR proteins, i.e. positions 2, 3, 5, 13, 14 and 33 of
the repeats. In consensus D (Figure 3), these pos-
itions were permitted to contain any amino acid
except glycine, proline (both structurally unfavor-
able) or cysteine (may form unwanted disulﬁde
bonds). All other positions in the consensus were
deﬁned as framework residues, and we thus tried
to assign deﬁned amino acids to these positions.
Framework positions
Positions 1 and 4 were deﬁned as Asp and Gly,
respectively, as these residues are frequent (Asp1
37%, Gly4 75% in BLAST search) and form a
network of H-bonds extending over consecutive
b-turns.29 Furthermore, position 4 asks for a
positive f angle, and is thus best accommodated
by Gly. The motif TPLHL for positions 6 to 10 is
highly conserved in natural ARs. Thr6 forms
several H-bonds to His9 (Figure 2), Pro7 breaks
into a-helix 1 and is in the hydrophobic core. Leu8
lies in the hydrophobic core, pointing towards
helix 2 and towards the next repeat. In addition to
making H-bonds to Thr6, His9 establishes H-bond
contact to Ala32 and to the next repeat (random-
ized position 5; Figure 2). Leu10 points towards
helix 1 of the previous repeat, and probably
stabilizes the interface between two repeat
modules. Since Leu10 is the least conserved
Figure 2. Crystal structure of the unselected N3C
library member E3_5 (PDB entry: 1MJ0)29 illustrated
with MOLMOL.54 (a) Potential interaction residues of
the middle AR module (residues 77–109) are displayed
in red on the AR framework in ribbon representation.
The potential interaction residues are located in the
b-turn and the concave surface of the L-shaped repeat.
The partly randomized framework position 26 is dis-
played in magenta. The structural elements of the AR
are labeled. (b) Hydrophobic framework residues and
alanine residues pointing into the core of the middle AR
module are colored in green on the AR in ribbon
representation. (c) A rotated view of this middle AR
module, which shows more clearly the TPLHLAA motif
(residues 6–12) of the ﬁrst a-helix with its characteristic
H-bond pattern. Hydrophobic residues and alanine
residues are colored in green, Thr6 and His9 are colored
in blue and H-bonds are colored in red. The loop has
been cut in this representation. (d) Crystal structure of
E3_5 displaying a large potential interaction surface
built by the randomized positions (shown in red stick
mode). The N and C-terminal capping repeats and the
internal repeat modules are colored in green, light blue
and dark blue, respectively.
†http://wolf.bms.umist.ac.uk/naccess/
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residue in the TPLHL motif (30% frequency in the
BLAST search), and since it is, in part, surface
exposed, it could, in principle, have been con-
sidered as potential target interaction residue. The
TPLHL motif represents the N-terminal helix-cap
of the ﬁrst a-helix. The small hydrophobic helix-
formers Ala11 and Ala12 are important for the
overall shape of ARs (Figure 2). Their small size
allows the repeat to be conical in form, narrow at
the bottom and wide at the top.10 Gly15 breaks out
of helix 2 and has a positive f angle. His16 is
semi-buried and forms side-chain H-bonds to
helix 1 of the previous repeat as well as backbone
H-bonds to Ala11, Ile19 and Val20. Position 17
was not clear from database statistics (Leu being
most prevalent with 26% in the BLAST search).
From structural considerations, however, it is likely
that a leucine residue would stabilize the repeat
interface and could be the initiator of helix 2. For
these reasons, and because of its high a-helical
propensity,30 we chose Leu at this position. Helix 2
is amphipathic and contributes to the overall
shape of the AR. Larger amino acid residues in
the hydrophobic core are situated closer to the
loop, leading to increasing helix-helix distances.
Several positions in helix 2 were not well deﬁned
in the consensus from database analyses and were
thus assigned using other decision parameters.
Glu18 was chosen because it occurs repeatedly in
the cdk4 inhibitor p18 (chain B of PDB entry
1IHB)26 and can thus apparently be tolerated
multiple times. Similarly, Glu21 occurs repeatedly
in GABPb1 (chain B of PDB entry 1AWC, here
called 1AWC_B).21 Since positions 18 and 21 are
well separated in space, both negative charges
should be tolerated. Ile19 was chosen because it
ﬁts similarly as Val, but has a higher a-helical
propensity.30 Ile19 is part of the hydrophobic core
(Figure 2), and so is Val20, which was deﬁned
from sequence analysis. Leu22, Leu23 and Leu24
constitute a rather conserved patch in the upper
part of the hydrophobic core (Figure 2). However,
position 22 was chosen to be Val, as this occurs
repeatedly in GABPb1. Lys25 was chosen, because
it has the opposite charge of Glu21 and, as the
latter, occurs repeatedly in GABPb1. Arg could
have also been chosen in this position. Position 26
was ambiguous, although Asn was most abundant.
Ala was prominent in the alignment; however, to
control the distance of the repeats, the amino acid
at this position should ﬁll enough space and
should probably be polar. His was an alternative
but there was the danger of creating a charge belt
Lys25/His26 across the repeat domain. Tyr was
another alternative suggested by GABPb1. Finally,
a combination of His, Tyr and Asn was chosen,
since these amino acids can be encoded by the
HAC codon. Gly27 breaks out of helix 2 having a
positive f angle and initiates the loop. Ala28
points into the hydrophobic core to anchor the
loop (Figure 2), as do Val30 and Ala32. Asp29 and
Asn31 are important for H-bond networking and
keeping contact between the consecutive repeats.29
The ﬁnal consensus D is displayed in Figure 3.
Figure 3. Stepwise deﬁnition of the AR consensus used in the present study. The amino acid frequency color code is
indicated in the panel. For orientation, the secondary structure elements are indicated above the sequences. Consensus
A was derived from an alignment of 229 ARs of the SMART database. It contained only residues 3–32 of the AR con-
sensus. The sequence of consensus B was derived from consensus A, where lacking or non-conserved (cut-off #30%)
residues were substituted by residues resulting from an alignment of repeats of AR proteins with known structure. A
circularly permutated form of consensus B (starting from residue V20) was submitted for a BLAST search against
GenBank. Through the circular permutation, residues 1, 2 and 33 could be analyzed and the consensus could be
reﬁned. Consensus C was derived from the BLAST search with consensus B. Structure-based considerations (see
Results) led from consensus C to consensus D, the ﬁnal sequence of the designed AR module. In consensus D, the
potential target interaction residues are highlighted in red.
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When checking pairs, triplets and quadruplets of
amino acids of consensus D, all combinations
occurred at least once in natural ARs, except the two
quadruplets in theHLEIV sequencemotif. Taken as a
whole, consensus D was designed to encode self-
compatible repeat modules that are built from
conserved framework residues and randomized
potential target interaction residues.
Design of capping repeats
Like other repeat proteins (see the accompanying
paper13), natural AR domains have specialized
terminal repeats (capping repeats) that function to
seal the hydrophobic core of a stack of ARs
(Figure 4). While the internal ARs have two hydro-
phobic repeat–repeat interfaces, the capping
repeats have only one such interface and the
exposed surface is hydrophilic (Figure 4). We thus
reasoned that these capping repeats are needed in
order to form a stable, well-folded AR domain,
and we included capping repeats in our strategy.3
We decided to adapt naturally occurring capping
ARs to our designed modules. The choice of appro-
priate capping repeats was based on two criteria:
(i) the structure had to be known; and (ii) they
had to be as compatible and thus as homologous
as possible to our designed repeat module. When
joining four, ﬁve or six designed repeat modules
in silico and subjecting these sequences to BLAST
searches against the PDB, mouse GABPb1 was
always the best hit. We thus decided to adapt the
capping repeats of GABPb1 for our design. While
residues 1–26 of the N-terminal capping repeat,
which form the two anti-parallel a-helices, were
taken directly from 1AWC_B, the loop sequence
GAPFT was changed to GADVNA. There were
two reasons for this change: (i) modeling suggested
that the bulky GAPFT loop did not sterically match
the consensus GADVNA loop of the neighboring
repeat. Phe in the GAPFT loop serves as a spacer
between the N-terminal repeat and the second
repeat of GABPb1 and appears in combination
with Ala in position 26 of the second repeat,
where our design had adopted bigger residues. (ii)
For cloning purposes, the end of the loop had to
contain the sequence Asp-Val. The ﬁnally chosen
sequence for the N-terminal capping repeat was
therefore: DLGKKLLE AARAGQDDEV RILMAN
GADV.
Figure 4. Charge distribution and hydrophobicity of AR surfaces. The charge distribution and hydrophobicity of the
middle AR module of E3_5 (PDB entry: 1MJ0),29 an unselected N3C library member, is compared to the N and
C-terminal capping repeats of the same molecule. (a) The N-terminal capping repeat, seen in a lateral view from the
N terminus, i.e. from the “outside” of the protein. (b) The middle repeat, seen from the same direction as in (a), i.e.
exposing an otherwise buried surface. (c) The middle repeat, seen in a lateral view from the C terminus, i.e. an other-
wise buried surface is shown. (d) The C-terminal capping AR seen in the same view as (c), i.e. from the “outside” of
the protein. For orientation, the ARs are represented in ribbons on top. In the middle, charge representations are
given with negative charges in red and positive charges in blue. The hydrophobicity is illustrated in the bottom row
with hydrophobic side-chains in green. The solvent-exposed capping repeats have surfaces that are more charged
than the repeat–repeat interfaces of the middle repeat. Likewise, larger hydrophobic areas characterize the repeat–
repeat interfaces of the middle repeat in (b) and (c) compared to smaller hydrophobic patches of the solvent-exposed
capping repeats in (a) and (d). The Figure and the charge calculations were made using MOLMOL.54
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The C-terminal capping repeat (Figure 4)
consisted of amino acid residues 129 to the end of
1AWC_B. However, the b-turn had to be adapted
to our design, and was changed from the sequence
SKFC to DKFG. Ser was replaced by Asp to ﬁt the
consensus, and Cys was changed to Gly as in the
consensus to prevent problems in oxidizing
environments. The chosen sequence was: VNAQ
DKFGKT AFDISIDNGN EDLAEILQ.
PHD secondary structure prediction31 of a con-
struct consisting of the N-terminal capping AR,
three AR modules and the C-terminal capping AR
was in accordance with our design. For this
analysis, the randomized positions and position 26
of the AR modules were not deﬁned (i.e. residues
submitted as x). In a prediction of degradation by
scanning for PEST32 sequences and by an analysis
with PEPTIDESORT of the GCG package,33 a
construct consisting of the N-terminal capping
AR, three AR modules and the C-terminal capping
AR showed results equivalent to GABPb1 (in this
case, the randomized positions and position 26 of
the AR modules were deﬁned using the corre-
sponding residues of GABPb1).
Assembly of DNA libraries encoding designed
AR domains
The peptide sequences of consensus D (Figure 3)
and the N and C-terminal capping repeats were
backtranslated into DNA using codons optimal for
Escherichia coli expression.33 Multiple copies of a
single base were prevented if possible. The codons
of the randomized positions (2, 3, 5, 13, 14 and 33)
of the designed AR module were encoded by tri-
nucleotides, since they efﬁciently restrict vari-
ability by encoding library positions with a
deﬁned mixture of speciﬁc base triplets.34 Using
this strategy, we allowed A, D, E, H, K, N, Q, R, S,
T with 7% probability each, and F, I, L, M, V, W, Y
with 4.3% probability each. The randomized
framework position 26 was deﬁned by the
degenerate codon HAC, which codes for His, Tyr
or Asn.
The modular structure of repeat domains
suggests assembling them in a stepwise fashion.
Hence, the capping repeats and the designed AR
module were assembled separately. The constant
N and C-terminal capping repeats were PCR-
assembled and subcloned individually into
pPANK (see Materials and Methods). The
designed AR modules were PCR-assembled and
subcloned for sequence analysis; ﬁve of eight
modules showed no error. To construct DNA
cassettes encoding whole AR domains, PCR-
assembled designed repeat modules were ligated
stepwise to the previously PCR-assembled
N-terminal capping repeat by using type IIs
restriction enzymes (Figure 5). By this strategy,
DNA pools encoding the N-terminal capping
repeat and two (N2), three (N3) or four (N4)
designed AR modules were obtained. These
ligation products were then cloned into a vector
containing the cloned C-terminal capping repeat
to obtain DNA encoding full-length proteins
(Figure 5). The full-length proteins were termed
N2C, N3C and N4C, reﬂecting their content of
two, three or four repeat modules, respectively,
between the N and the C-terminal capping repeats
(resulting in four, ﬁve or six repeats in total).
With the seven randomized positions per
designed AR module, the theoretical diversity
amounts to 3 £ 176 ¼ 7.2 £ 107 per repeat. The
N2C and N3C libraries will thus have theoretical
diversities of (3 £ 176)2 ¼ 5.2 £ 1015 and
(3 £ 176)3 ¼ 3.8 £ 1023, respectively.
Sequence analysis of unselected
library members
Having cloned libraries of AR proteins of
distinct repeat numbers, we wanted to assess their
quality at the DNA level. Analysis of single library
members should reveal possible sequence bias.
DNA sequencing showed that eight of 14 N2C con-
structs, six of 19 N3C and four of 19 N4C were
correct at the DNA level (i.e. no frameshift, no
stop codon, correct framework residue codons and
correct trinucleotide codons). The percentage of
correct clones decreased with increasing repeat
number, as expected. Sequencing of 28 erroneous
constructs revealed that 11 errors were located in
the N-terminal capping AR, which was generated
by assembly PCR using standard oligonucleotides.
This high error rate is probably due to the lower
quality of these standard oligonucleotides com-
pared to the oligonucleotides containing trinucleo-
tide mixtures. The remaining mutations were
located in the designed repeat modules. Four of
the 28 errors resulted in frameshifts.
Each designed repeat module of 33 amino acid
residues contained six randomized positions,
which were encoded by trinucleotides.34 In total,
777 randomized positions containing trinucleotides
were sequenced, showing an approximately
random distribution of the codons. As in the
leucine-rich repeat protein libraries used by
Stumpp et al.,13 Asn was overrepresented (12.1%
versus 7% expected). Glu, Gln, Arg and Trp were
underrepresented (3.1%, 2.3%, 4.4% and 2.3%
found versus 7%, 7%, 7% and 4.3% expected,
respectively). The other codons were found at a
frequency less than 2% different from the expected
value (see Materials and Methods). Twelve
mutations were observed that were not encoded
by trinucleotides (one amber, two Gly, nine other
amino acids), but were most probably accumulated
during the extensive PCR. Apart from these, no
undesired codon (Cys, Gly, Pro, stop) was found
in the trinucleotide positions. In rare cases (0.4%),
entire trinucleotides were missing. The seventh
randomized position, consensus framework posi-
tion 26, was occupied by 30% His, 30% Asn and
40% Tyr (128 positions sequenced). Hence, no clear
sequence bias was detectable at any randomized
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position. Importantly, 75% of the designed AR
modules were correct.
Biophysical characterization of randomly
chosen library members
We wanted to validate both our strategy and our
AR library design by the biophysical analysis of
unselected library members, i.e. randomly chosen
constructs with correct DNA sequences. The
analysis consisted of expression and solubility
tests, CD spectroscopy and thermal denaturation.
Furthermore, equilibrium unfolding and crystallo-
graphy were performed.29
A ﬁrst expression screening revealed that all of
the above library members that were correct at the
DNA level could indeed be expressed in soluble
form in large amounts in E. coli. The corresponding
proteins ran at the expected molecular mass
position during SDS-15% PAGE. Six of the correct
clones, named E2_5 and E2_17 (N2C library mem-
bers), E3_5 and E3_19 (N3C library members) and
E4_2 and E4_8 (N4C library members) were chosen
randomly to be analyzed further. Expression at
37 8C (Figure 6) yielded up to 200 mg/l of soluble
protein. Immobilized metal-ion afﬁnity chromato-
graphy (IMAC) puriﬁcation yielded pure protein
in a single step, as judged from SDS-15% PAGE
(Figure 6). The molecular mass values of the
proteins were conﬁrmed by mass spectroscopy. At
10 mg/ml in TBS150 (pH 8.0; see Materials and
Methods), the proteins remained soluble and did
not aggregate over several weeks at 4 8C. An
IMAC puriﬁcation of E3_5 gave sufﬁciently pure
material to successfully determine its structure by
X-ray crystallography (Figure 2).29
Following SDS-15% PAGE, additional bands
were occasionally observed with slightly higher or
lower apparent molecular mass than expected.
Gel-ﬁltration, mass spectroscopy (data not shown)
Figure 5. Assembly of designed AR domains at the DNA level and DNA sequence of a designed AR module. (a) The
N-terminal capping AR and the designed AR modules are generated by assembly PCR. The N-terminal capping AR is
ligated to the ﬁrst AR module using the type IIs restriction enzymes Bpi I and Bsa I. To the resulting N1 molecule, more
AR modules can be ligated step by step, yielding N2, N3, N4 and longer molecules. Once the desired number of AR
modules is connected to the N-terminal capping AR, the construct can be cloned into a vector containing the
C-terminal capping AR. By this strategy, AR domains of N1C, N2C, N3C, N4C and longer can be generated. The use
of type IIs restriction enzymes ensures the seamless junction of the repeats in a directional manner. Type II restriction
sites are represented by black boxes, type IIs restriction sites by light grey boxes. The AR module is represented as a
grey box, the N and C-terminal ankyrin capping modules as white boxes. (b) The assembly PCR product of a single
AR module is shown. The restriction enzyme recognition sites are shown as grey boxes and the cutting sites are
indicated with continuous lines. Note that the DNA recognition sites of the type IIs restriction enzymes are distant
from their cleavage site, and thus these sites are lost upon cleavage.
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and dynamic light-scattering29 could not conﬁrm
the presence of any protein species other than the
expected one. Extensive boiling in SDS and SDS/
urea buffer did, however, change the pattern and
the relative band intensity in SDS-PAGE analyses,
suggesting that the multiple bands correspond to
different conformers, which are stable during
SDS-PAGE.
Size-exclusion chromatography showed that ﬁve
of the six designed AR proteins were monomeric,
and only a single protein species was observed
(Figure 7; Table 1). The sixth protein, E4_2, could
be puriﬁed as a monomer. However, it turned into
a mixture of monomer and (presumably) dimer
over time at 4 8C (Figure 7). The molecular mass
values obtained from the gel-ﬁltration studies are
given in Table 1. The observed molecular mass is
always slightly higher (by a factor of 1.25 to 1.42)
than the calculated value, which can be interpreted
to reﬂect the elongated shape of AR domains in
combination with a ﬂexible N-terminal tail (MRGS-
HHHHHHGS), which leads to increased hydro-
dynamic radii of the molecules. In addition, the
monomeric state of E3_5 was conﬁrmed by its
Figure 6. Expression and puriﬁcation of unselected AR
protein library members. (a) Crude extracts of E. coli
XL1-Blue expressing six consensus AR proteins (see
Materials and Methods). Proteins were expressed for
four hours and the cell lysates were analyzed by SDS-
15% PAGE (lane 1, E2_5; 2, E2_17; 3, E3_5; 4, E3_19; 5,
E4_2; 6, E4_8). (b) Single-step IMAC puriﬁcation of
E3_5, an unselected N3C library member (lane 1, column
ﬂow-through of the overloaded column; 2, last 1 ml of
column wash; 3–8, elution fractions). The size marker is
indicated in kDa.
Figure 7. Size-exclusion chromatography of designed
AR proteins. The chromatograms of N2C (E2_5 and
E2_17), N3C (E3_5 and E3_19) and N4C (E4_2 and
E4_8) molecules are shown. All molecules are mono-
meric, except E4_2, which is a mixture of monomer and
(presumably) dimer. The void volume ðV0 ¼ 0:95 mlÞ;
the total volume ðVt ¼ 2:4 mlÞ and the molecular mass
standards (phage protein D with an apparent mass of
17.6 kDa; phage protein SHP, a trimer with an apparent
mass of 50.2 kDa)55 are indicated by broken gray lines in
the graph.
Table 1. Table 1 Biophysical data of designed AR
proteins of varying length
Protein
CD222
(MRE)a
MWcalc
(kDa)b
MWobs
(kDa)c
Tm
(8C)d
DG
(kcal/mol)e
E2_5 211,600 14.4 19 79 11.4 ^ 0.7
E2_17 210,300 14.4 18 70 9.5 ^ 0.6
E3_5 211,300 17.7 23 .85 14.8 ^ 2.0
E3_19 212,000 17.8 24 66 9.6 ^ 0.5
E4_2f 29400 21.2 30 85 –
E4_8 211,900 21.3 29 79 21.1 ^ 1.3
a Mean residue ellipticity (deg cm2 dmol21) at 222 nm.
b As calculated from the sequence.
c As determined by gel-ﬁltration.
d As determined by thermal unfolding observing the CD
signal at 222 nm.
e Data from Ref. 29.
f E4_2 is a mixture between a monomer and (presumably) a
dimer. The monomer value is listed in MWobs.
Figure 8. Circular dichroism spectra of designed AR
proteins. The spectra of two unselected members from
the N2C (E2_5 and E2_17), N3C (E3_5 and E3_19) and
N4C (E4_2 and E4_8) library are shown. All proteins
exhibit spectra and a-helical content identical with
those of natural AR proteins.
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crystal structure.29 We therefore conclude that the
majority of the proteins are stable monomers.
The CD spectra of the IMAC-puriﬁed protein
samples were determined (Figure 8; Table 1). The
recorded spectra can be superimposed on the
spectra of natural AR proteins such as myo-
trophin,35 notch,36 p19,37 and an engineered form
of p16, p16(D1-8)-His.38 The secondary structure
composition of our designed AR proteins thus
corresponds to natural AR proteins. In the case of
E4_2, oligomerization may inﬂuence the spectrum.
Combining the CD data with the ﬁndings from
the protein expression and gel-ﬁltration experi-
ments, we conclude that the designed AR proteins
form soluble, monomeric domains having an AR
domain fold as designed. For E3_5, the AR domain
fold was conﬁrmed by X-ray crystallography
(Figure 2).29
Thermal stability
To assess the thermal stability of the randomly
chosen AR protein library members, heat
denaturation was measured by observing the CD
signal at 222 nm. All proteins showed cooperative
unfolding while exhibiting considerable heat
resistance (Figure 9; Table 1). The midpoints of the
cooperative transitions in physiological buffer
were between 66 8C and more than 85 8C (Table 1).
For E4_2, a discontinuity in the CD signal in the
pre-transition baseline was observed, probably
due to a shift of the monomer/dimer mixture
towards a single molecular species. The midpoint
of denaturation of E3_5 could not be determined,
since the post-transition baseline was not reached
after heating the sample to 95 8C. The heat
denaturation was only partly reversible for all
proteins. The observed high degree of thermal
stability reﬂects the high degree of thermodynamic
stability of the designed AR proteins.29 In GdmCl
equilibrium unfolding experiments, the proteins
showed cooperative unfolding with midpoints
from 2.9 M to 5.1 M GdmCl. Assuming two-state
unfolding, DG values of unfolding from 9.5 kcal/
mol to 21.1 kcal/mol were calculated (Table 1).29
Module-wise elongation of AR domains
The N3C library member E3_5 was used to
demonstrate the feasibility of a module-wise
elongation of AR domains by single repeats.
Using PCR cloning, we elongated the N3 part of
E3_5 to N5C and N6C domains. Again, the corre-
sponding proteins were expressed in large
amounts and could be puriﬁed in a single IMAC
puriﬁcation step. Moreover, the proteins exhibited
CD spectra identical with those of the other
designed AR proteins. In size-exclusion chromato-
graphy, two N5C proteins were monomeric with
an apparent molecular mass of 39.2 kDa (expected
24.7 kDa) and 37.7 kDa (expected 24.7 kDa),
respectively. One N6C protein was monomeric
with an apparent molecular mass of 42.7 kDa
(expected 28.2 kDa). One N5C protein was a
mixture between oligomers and a monomer with
an apparent molecular mass of 38.1 kDa (expected
24.7 kDa). One N6C protein had a monomer peak
at 44.2 kDa (expected 28.2 kDa) but showed some
aggregation.
Discussion
The designed AR proteins possess very
favorable biophysical properties
We have developed a novel strategy for con-
structing combinatorial repeat protein libraries.3
Here, we have applied this strategy to AR proteins.
The accompanying paper by Stumpp et al.13 shows
Figure 9. Thermal denaturation of designed AR pro-
teins. Six unselected members of designed AR protein
libraries were measured, two each from the N2C (E2_5
and E2_17), N3C (E3_5 and E3_19) and N4C (E4_2 and
E4_8) libraries. The denaturation was monitored by
observing the CD signal at 222 nm (see Materials and
Methods). The CD signal is represented as a percentage
of the initial CD signal at 10 8C. Note that this represen-
tation makes no assumption about the pre-transition or
post-transition baseline.
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the application of this strategy to leucine-rich
repeat proteins. Using the strategy described here,
we were able to generate combinatorial libraries of
AR proteins of varying length. The analysis of
unselected library members revealed that our
design leads to AR proteins with very favorable
biophysical properties. We focused our analysis on
N2C, N3C and N4C library members, since most
natural AR proteins possess repeat numbers in
this range. Like natural AR proteins, our designed
AR proteins can be expressed in large amounts
(Figure 6) but, while the expression of natural AR
proteins often results in the formation of inclusion
bodies, our designed proteins are expressed in
soluble form in the cytoplasm of E. coli and remain
soluble and folded over weeks at 4 8C. The
designed AR proteins are monomeric (Figure 7;
Table 1) and, as indicated by CD spectroscopy,
they exhibit secondary structure compositions
indistinguishable from those of natural AR
proteins (Figure 8; Table 1). The crystal structure
of the N3C library member E3_5 was determined
and it was shown that the designed protein has an
AR domain fold.29
In thermal denaturation, unselected library
members showed cooperative unfolding with mid-
points of the cooperative transition ranging from
66 8C to above 85 8C (Figure 9; Table 1). Natural
AR proteins that have been tested denature around
or below 50 8C, as indicated by CD measurements
of notch variants (N4C and N5C) and myotrophin
(N2C).35,39 Thermal denaturation midpoints
depend very much on experimental conditions
such as protein concentration, buffer composition
and the temperature ramp, i.e. the kinetics of
unfolding and aggregation. However, the differ-
ences in stability between natural and designed
AR proteins are large enough to indicate that our
designed AR proteins are considerably more
stable. The thermal denaturation data reﬂect the
high-level thermodynamic stabilities measured by
denaturant-induced equilibrium unfolding of the
unselected AR proteins presented here (Table 1).29
We were able to design a self-compatible AR
module, which could be cloned in various
numbers between designed capping ARs, leading
to well-expressed, soluble, folded and stable AR
domains.
Consensus design of AR proteins
Besides its importance for the self-compatibility
of AR modules, our consensus design resulted in
very stable AR proteins (Figure 9 and Table 1).29
These results are consistent with effects of
previous consensus design approaches. Consensus
strategies have been used to generate enzymes
with improved thermostability40 and to improve
antibody stability.41–43 Stability is not a main
selection criterion in the evolution of proteins,
once a threshold stability is reached that allows
the protein to fulﬁl a function.44 The most stable
variants may not necessarily be implemented by
naturally occurring sequences, but they may be
encoded by consensus or “canonical” sequences.43
We used extensive structural criteria to ﬁnally
decide on the consensus sequence. We observed a
remarkable gain in stability, suggesting that the
juxtaposition of AR modules had a synergistic
effect.
When examining the crystal structure of E3_5
(Figure 2), we were able to pinpoint several
features of the designed AR proteins that could
explain this increased stability, such as the absence
of irregularities or the presence of extended
H-bond networks.29 These stability ﬁndings are
similar to data published recently by Mosavi
et al.,45 who analyzed full consensus AR proteins.
These full consensus AR proteins are based on a
slightly different consensus sequence compared to
ours. Differences in the two consensus sequences
are mainly at positions where they considered
sequence data for consensus deﬁnition, while we
used structural decision parameters (framework
residue positions Val19, Lys21, Leu22, Glu25,
Ala26 vs. Ile19, Glu21, Val22, Lys25, and a mixture
of His, Asn and Tyr at position 26 in our molecules;
see Results). The structures of their full consensus
proteins are nearly identical with the structure of
our designed ARs in E3_5 (RMSDCa 0.51 A˚ com-
pared to PDB entry 1N0Q). Another important
difference is the presence of capping repeats
(Figure 4) sealing the stack of designed ARs in our
molecules compared to the full consensus AR pro-
teins described by Mosavi et al.45 Experimentally,
the proteins described by Mosavi et al.45 are more
soluble at acidic pH (pH 4–5) than at neutral pH,
while our proteins are soluble and stable under
physiological conditions (20–50 mM Tris–HCl
(pH 6.5–8.5), 50–500 mM NaCl). Both the differ-
ences in consensus sequence and the presence of
capping ARs in our constructs might lead to this
altered behavior. Nevertheless, both studies show
that the AR framework is intrinsically very stable.
This stability could, in part, account for the
abundance of AR proteins in nature. Main and
co-workers46 recently reported the consensus
design of tetratricopeptide repeat proteins of
different repeat numbers. They also observed high
thermal stability of the consensus designed
proteins.
Module-wise assembly of AR proteins
The modular nature of AR proteins suggests
assembling repeat domains module-wise. We used
type IIs restriction enzymes for this purpose,
which allow the cloning of repeats in a directional
manner, independent of the repeat sequence
(Figure 5). The advantage of type IIs restriction
enzymes is the freedom of choice of the ligation
site. It could, in principle, be placed in any part of
the repeat module except for the randomized posi-
tions. We did not want to affect the capping repeat
structure and sequence; therefore, the ligation site
could not be placed in any of the a-helices or in
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the short loop connecting the helices. The only
remaining possibility was the loop connecting the
second a-helix with the b-turn of the next repeat.
Similar to the approach described in the accom-
panying paper,13 the chosen cloning strategy using
type IIs restriction enzymes (Figure 5) allows a
number of evolution strategies that are amenable
only to repeat proteins. For example, repeats
might be shufﬂed, added or subtracted. In nature,
the IkBa/Bcl-3 pair gives an example of such a
repeat extension, where the repeat number reﬂects
the different binding properties of these
molecules.47 We have shown the feasibility of this
extension approach for the designed AR proteins
by elongating E3_5 (N3C) to N5C or N6C.
In addition to repeat shufﬂing and module-wise
addition or subtraction of single repeats, other
evolution strategies are amenable to our molecules.
Alterations from the 33 amino acid residue consen-
sus, similar to what is observed in single repeats of
IkBa,23,24 Swi628 or the INK4 family members, could
be used for the improvement of selected binding
molecules via in vitro evolution or rational design.
Another evolution strategy could involve increas-
ing or decreasing the AR domain curvature, which
can be achieved by varying speciﬁc framework
residues.10
Designed AR proteins in biotechnology
Our ﬁndings show that we have libraries of well-
behaved AR proteins for use in selection
procedures. The proteins are expressed in large
amounts, they are soluble, monomeric and stable
under physiological conditions, they are cysteine-
free and allow a great variety of amino acids in
the randomized positions. Therefore, these
molecules exactly match the requirements for
novel scaffolds to be used for the generation of
novel binding proteins. The stability of the consen-
sus designed AR proteins is sufﬁciently high that
some losses in stability can be tolerated during the
course of directed evolution of the designed AR
proteins.
In our AR domains, the potential target inter-
action residues are located in the b-turn and the
ﬁrst a-helix of each repeat module, creating a
large and modular interaction surface (Figure 2).3,29
This interaction mode extends and combines
previous concepts in the ﬁeld of combinatorial
libraries. Usually, either ﬂexible loops (e.g.
Knappik et al.41) or rigid, ﬂat surfaces (e.g. Nord
et al.48) were randomized, but not a combination of
turns and helices, which constitute a continuous
surface that can be extended by adding more
repeats.
We have recently used designed N2C and N3C
AR protein libraries in ribosome display49,50 selec-
tions against various globular proteins. Speciﬁc
nanomolar binders were obtained, which prove
the success of designed AR proteins as novel scaf-
folds for molecular recognition. A detailed analysis
of these experiments will be published elsewhere.
Because of their favorable biophysical properties,
designed AR proteins could ideally serve as recog-
nition molecules on protein chips. Similarly, the
absence of intracellular aggregation or misfolding
and the absence of cysteine residues would allow
these proteins to be used as intracellular protein
binders or enzyme inhibitors. In this regard,
designed AR proteins could be an attractive and
more stable alternative to intrabodies.51
Conclusions
We have successfully implemented our novel
strategy harnessing the modular nature of repeat
proteins for the generation of designed AR protein
libraries. Through sequence and structure consen-
sus analyses, we designed an AR module com-
posed of ﬁxed framework positions and
randomized potential interaction positions. AR
domains were generated by cloning two, three or
four designed modules between N and C-terminal
capping repeats. All tested proteins exhibit very
favorable biophysical properties. They can be
expressed in soluble form in large amounts and
they can be puriﬁed easily. They are monomeric
and show CD spectra indistinguishable from those
of natural AR proteins. Furthermore, they are
exceptionally resistant to heat denaturation. These
ﬁndings suggest that the abundance of natural AR
proteins is, at least in part, based on the excep-
tional properties of the AR framework, a stable
and modular protein–protein interaction motif.
Our ﬁndings show that we can build modular and
stable proteins with randomized surfaces that may
be used to create novel binding molecules. The
modular structure of repeat proteins will allow
completely new evolution strategies that are not
feasible with classical scaffolds.
Material and Methods
In silico analysis
We used the SMART†,7 the GenBank‡,18 and the
PDB§ 52 databases for our analyses. Clustal Wk 14 and
BLAST{ 17 were used for alignments. Structural model-
ing was done with InsightII (Accelrys, USA). NACCESS
helped to identify target interaction residues from
structures of complexes. PHD predictiona 31 was used
for secondary structure prediction. PESTb 32 and
PEPTIDESORT of GCG (Accelrys, USA)33 were used to
†http://smart.embl-heidelberg.de
‡http://www.ncbi.nlm.nih.gov/Genbank/
§http://www.pdb.org
khttp://www.ch.embnet.org/software/ClustalW.
html
{http://www.ncbi.nlm.nih.gov/blast/
ahttp://cubic.bioc.columbia.edu/predictprotein/
bhttp://www.at.embnet.org/embnet/tools/bio/
PESTﬁnd/
Designing Ankyrin Repeat Protein Libraries 499
28 Ankyrin Repeat Libraries
compare designed and natural AR proteins. GCG was
used for designing the DNA sequence.
General molecular biology
Unless stated otherwise, all experiments were per-
formed as described.53 Enzymes and buffers were from
New England Biolabs (USA) or Fermentas (Lithuania).
The cloning and production strain was E. coli XL1-Blue
(Stratagene, USA). The cloning and protein expression
vector was pPANK, a pQE30 (QIAgen, Germany) deriva-
tive lacking the Bbs I and Bsa I sites. pPANK was gener-
ated via PCR-cloning using the oligonucleotides Bbs I
(50-TGATTTCTCGAGGTGTAGTCGAAAGGGCCTCGTG-
30), Bsa I (50-GCAATGATACCGCGAGAACCACGCTCA
CCGGC-30) and Avr2 (50-CCGCCGCTCTAGAGGGAAA
CCTAGGGCTGCCTCGCGCG-30) and pQE30 as tem-
plate. The oligonucleotides Bbs I and Bsa I were used to
generate a PCR product, which was used as primer in a
second PCR reaction together with oligonucleotide
Avr2. The resulting PCR product was Xho I/Xba I-
digested and ligated to the Xho I/Xba I promoter frag-
ment of pQE30.
Synthesis of DNA encoding AR proteins
Oligonucleotides incorporating mixed trinucleotides
as building blocks34 were from MorphoSys AG
(Germany). INT1:
50-CTGACGTTAACGCTNNNGACNNNNNNGGTN
NNACTCCGCTGCACCTGGC-30 and INT2:
50-ACTCCGCTGCACCTGGCTGCTNNNNNNGGTC
ACCTGGAAATCG-30.
NNN represents a mixture of trinucleotides encoding
the amino acids A, D, E, H, K, N, Q, R, S, T (7% each)
and F, I, L, M, V, W, Y (4.3% each). Standard oligonucleo-
tides were from Microsynth (Switzerland).
INT3: 50-AACGTCAGCACCGTDCTTCAGCAGAAC
TTCA ACGATTTCCAGGTGACC-30; D represents any
of the nucleotides A, G or T).
INT4: 50-AGCAGCCAGGTGCAGCGGAGT-30.
INT5: 50-TTCCGCGGATCCTAGGAAGACCTGACGT
TAAC GCT-3.
INT6: 5 0-TTTGGGAAGCTTCTAGAAGACAACGT
CAGCAC CGT-30.
INT6a: 50-TTTGGGAAGCTTCTAAGGTCTCACGT
CAGCAC CGT-30.
INT6b: 50-TTTGGGAAGCTTCTAAGGTCTC-30.
EWT1: 5 0-TTCCGCGGATCCGACCTGGGTAA
GAAACTGCT GGAAGCTGCTCGTGCTGGTCAGGAC
GACGAAG-30.
EWT2: 50-AACGTCAGCACCGTTAGCCATCAGGA
TACGAA CTTCGTCGTCCTGACC-30.
EWT3: 50-TTCCGCGGATCCGACCTGGG-30.
TEN3: 50-TTCCGCGGATCCG-30.
WTC1: 50-CTGACGTTAACGCTCAGGACAAATTCG
GTAAG ACCGCTTTCGACATCTCCATCGACAACGG
TAACGA GG-30.
WTC2: 50-TTGCAGGATTTCAGCCAGGTCCTCGT
TACCGTT GTC-30.
WTC3: 50-TTTGGGAAGCTTCTATTGCAGGATTTCA
GC-30.
The AR modules were generated by assembly PCR
using oligonucleotides INT1, INT2, INT3, INT4, INT5
and INT6a, and Ventw Polymerase (one minute annealing
at 50 8C; standard buffer with a ﬁnal concentration of
5.5 mM MgSO4). A subset of the resulting PCR product
was cloned via BamHI/HindIII into pPANK and
sequenced using standard techniques. The AR module
sequence is shown in Figure 5.
The N-terminal capping AR was prepared by
assembly PCR using oligonucleotides EWT1, EWT2,
TEN3 and INT6. The resulting DNA was cloned via
BamHI/HindIII into pPANK. The DNA sequence was
veriﬁed using standard techniques. The C-terminal
capping AR was prepared similarly, but by using oligo-
nucleotides WTC1, WTC2, WTC3 and INT5.
The ligation of the DNA encoding an AR protein from
single AR modules and AR capping repeats is
represented schematically in Figure 5. To clone DNA
encoding AR proteins, the PCR-assembled N-terminal
capping AR (using oligonucleotides EWT1, EWT2,
TEN3 and INT6a) was cut with Bsa I and ligated to a
Bpi I-cut AR module. The ligation product, termed N1
(where N denotes the N-terminal capping repeat and
the digit is the number of randomized repeat modules),
was PCR-ampliﬁed using oligonucleotides EWT3 and
INT6b. The ampliﬁed product was cleaved again with
Bsa I. The subsequent ligation to Bpi I-cut AR modules
started a new cycle of elongation, which was repeated
until the desired number of AR modules was added to
the N-terminal capping AR (termed N2, N3, N4 etc.).
DNA corresponding to PCR-ampliﬁed N2, N3 and N4
were then cut with BamHI/Bsa I and ligated to a
BamHI/Bpi I-cut pPANK containing the C-terminal cap-
ping AR (Figure 5). This yielded cloned DNA molecules
encoding N2C, N3C and N4C AR protein libraries
(where N denotes the N-terminal capping repeat, the
digit is the number of randomized repeat modules and
C is the C-terminal capping repeat).
An unselected N3C library member (named E3_5,
see below) was used as template for repeat protein
elongation. Using the oligonucleotides EWT3 and
INT6a, fragments corresponding to N, N1, N2 and N3
were generated by PCR. The N3 fragment was isolated
and then reampliﬁed using oligonucleotides EWT3 and
INT6b. Elongation of the N3 to N5 and N6 fragments
and cloning to N5C and N6C molecules was carried out
as described above.
Screening for protein expression and
DNA sequencing
An SDS-15% PAGE screening of single unselected
clones was performed using 10 ml cultures. A stationary
overnight culture (5 ml of LB, 1% (w/v) glucose,
100 mg/l of ampicillin; 37 8C) was used to inoculate the
cultures (1 ml of inoculum in 9 ml of the above medium).
After one hour, protein expression was induced using
200 mM IPTG and cultures were incubated for ﬁve
hours. In parallel, all screened clones were subjected to
DNA sequence analysis. Two unselected clones of the
libraries N2C (clone names: E2_5 and E2_17), N3C
(E3_5 and E3_19) and N4C (E4_2 and E4_8) were chosen
for subsequent protein analyses.
Protein expression and puriﬁcation
The N2C, N3C, N4C, N5C and N6C clones were
expressed as follows: 25 ml of stationary overnight
cultures (LB, 1% glucose, 100 mg/l of ampicillin; 37 8C)
were used to inoculate 1 l cultures (same medium). At
A600 ¼ 0:7; the cultures were induced with 300 mM IPTG
and incubated for four hours. Samples were analyzed
by SDS-15% PAGE (Figure 6). The cultures were
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centrifuged and the resulting pellets were resuspended
in 40 ml of TBS500 (50 mM Tris–HCl (pH 8.0), 500 mM
NaCl) and sonicated. The lysate was recentrifuged and
glycerol (10% ﬁnal concentration) and imidazole
(20 mM ﬁnal concentration) were added to the resulting
supernatant. Proteins were puriﬁed over a Ni-nitrilo-
triacetic acid column (2.5 ml column volume) according
to the manufacturer’s instructions (QIAgen, Germany;
Figure 6).
Size-exclusion chromatography
IMAC-puriﬁed proteins were analyzed on a Superdex
75 gel-ﬁltration column (Amersham Pharmacia Biotech,
USA) using a Pharmacia SMART system at a ﬂow-rate
of 60 ml/minute and with TBS150 (50 mM Tris–HCl (pH
7.4), 150 mM NaCl) as running buffer (Figure 7).
CD spectroscopy
Circular dichroism spectra were recorded in 10 mM
sodium phosphate buffer (pH 6.5), 100 mM NaCl, using
10 mM puriﬁed protein on a Jasco J-715 instrument
(Jasco, Japan). The CD signal was converted to mean
residue ellipticity using the concentration of the sample
determined spectrophotometrically at 280 nm under
denaturing conditions (Figure 8).
Heat denaturation was performed in 20 mM sodium
phosphate (pH 7.4), 200 mM NaCl with 10 mM protein
and a temperature shift from 10 8C to 95 8C within 120
minutes. CD data were collected at 222 nm every 20
seconds with a bandwidth of 2 nm and 16 seconds
response time (Figure 9).
Data Bank accession numbers
The DNA and amino acid sequences of proteins E2_5,
E2_17, E3_5, E3_19, E4_2 and E4_8 have been deposited
in GenBank18 with accession numbers AY195851,
AY195852, AY195853, AY195854, AY195855 and
AY195856, respectively. The DNA sequence of pPANK
has been deposited in GenBank18 (accession number
AY327140).
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In vitro display techniques are powerful tools to select
polypeptide binders against various target molecules. Novel
applications include maturation of protein affinity and stability,
selection for enzymatic activity, and the display of cDNA and
random polypeptide libraries. Taken together, these display
techniques have great potential for biotechnological, medical
and proteomic applications.
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Abbreviations
PCR polymerase chain reaction
scFv single-chain Fv 
Introduction
The growing interest of the research community and phar-
maceutical companies in protein–protein interactions has
led to an increasing demand for sophisticated methods for
the rapid identification, characterization, and potential
improvement of interaction partners. The most popular of
these methods, namely the yeast two-hybrid system [1] and
phage display [2] (see the article by Sidhu and Pelletier in
this issue pp 340–347), are limited by the involvement of
living cells in the process of library generation or screening.
This is not the case for in vitro selection technologies. In
these techniques the number of molecules that can be han-
dled is not limited by cellular transformation efficiencies;
thus, very large libraries of up to 1014 members can be built.
This feature also facilitates directed evolution experiments,
in which rounds of randomization and selection alternate, 
as transformation can be avoided between rounds.
Furthermore, special reagents such as the reducing agent
dithiothreitol or detergents can be added to select binders
under conditions chosen by the experimentor.
Two main groups of in vitro selection technologies can be
distinguished. The first group imitates the compartmen-
talization of living cells by performing translation and
selection within a water-in-oil emulsion [3–5]; this method
was recently summarized in an excellent review [6]. This
compartmentalization ensures the coupling of genotype
and phenotype — a prerequisite for any selection method.
The second group, the in vitro display technologies, makes
use of a physical link between messenger RNA (mRNA)
and nascent polypeptide during translation to couple geno-
type and phenotype. The most popular in vitro display
technologies are ribosome display and mRNA display
(reviewed in [7–12]). This review focuses on the recent
advances in the field of in vitro display methods and 
discusses the potential of these technologies for future
applications in basic and applied research.
In vitro display technologies
Ribosome display (Figure 1a) was first developed by
Mattheakis et al. [13] for the selection of peptides and fur-
ther improved for the selection of folded proteins by Hanes
and Plückthun [14] and He and Taussig [15]. This method
relies on non-covalent ternary complexes of mRNA, ribo-
some and nascent polypeptide, ensuring the coupling of
genotype and phenotype. A fusion protein is constructed in
which the the domain of interest is fused to a C-terminal
tether, such that this domain can fold while the tether is
still in the ribosomal tunnel. This fusion construct lacks a
stop codon at the mRNA level, thus preventing release of
the mRNA and the polypeptide from the ribosome. High
concentrations of magnesium and low temperature further
stabilize the ternary complex. These complexes, which are
formed during in vitro translation, can directly be used to
select for the properties of the displayed protein.
The related technology of mRNA display (Figure 1b),
which has also been termed ‘mRNA–protein fusions’ [16]
or ‘in vitro virus’ [17], was predominantly developed by
Roberts and Szostak. This method relies on the covalent
coupling of mRNA to the nascent polypeptide. The
mRNA is first covalently linked to a short DNA linker
carrying a puromycin moiety. The library is then translat-
ed in vitro, as in ribosome display. When the ribosome
reaches the RNA–DNA junction the ribosome stalls and
the puromycin moiety enters the peptidyltransferase site
of the ribosome and forms a covalent linkage to the
nascent polypeptide. The protein and the mRNA are
thus coupled and are subsequently isolated from the 
ribosome and purified. In the current protocol, a cDNA
strand is then synthesized to form a less sticky
RNA–DNA hybrid and these complexes are finally used
for selection. 
The protocol of mRNA display has been significantly
improved since it was first reported by extending the
method from the display of short peptides to proteins [9].
The authors were also able to increase the yield of func-
tional mRNA–protein fusions about 40-fold compared
with the original protocol. Furthermore, the laborious link-
age of mRNA to the puromycin-containing DNA linker,
thus far an enzymatic ligation reaction, was also signifi-
cantly improved [18,19]. In the new method, a DNA linker
carrying a psoralen moiety is hybridized to the end of the
mRNA and directly photo-crosslinked to the mRNA.
These improvements have opened the door for mRNA
display to handle complex protein libraries, as has been
possible with ribosome display [11,15,20,21•,22••,23,24]. 
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The stability of mRNA was repeatedly discussed as a weak
point of both ribosome and mRNA display, as RNA is 
susceptible to hydrolysis and nuclease degradation.
Nevertheless, for ribosome display it has been shown that
the ternary complexes are stable for up to at least 15 days
(C Zahnd et al., unpublished data). To improve the stabili-
ty of mRNA display, Kurz et al. [25•] reported a method to
replace the mRNA molecule within the mRNA–protein
complex with its double-stranded cDNA. This methodol-
ogy may be especially attractive for selections under harsh
conditions (e.g. high temperatures).
Improved library quality by preselection
The success of selection experiments depends to a large
extent on the quality of the library. Although the theoreti-
cal size of a library is virtually unlimited, the transformation
Figure 1
In vitro display technologies. (a) Schematic
representation of a ribosome display selection
round. A DNA library encoding the proteins of
interest is genetically fused to a tether, which
allows the protein to fold while the tether is
still in the ribosomal tunnel. The resulting
construct, which lacks a stop codon, is
transcribed in vitro into mRNA and further
translated in vitro. The translation is stopped
such that stable ternary complexes of mRNA,
ribosomes and nascent polypeptides are
formed. These complexes are directly used for
binding selection on the immobilized target.
The mRNA of the bound complexes is
rescued by dissociating the ribosome with
EDTA. A reverse transcription reaction
followed by PCR yields the genetic
information of the selected clones. These
clones can then be analyzed or used as input
for the next selection round. (b) Schematic
representation of a mRNA display selection
round. A DNA library encoding the proteins of
interest is transcribed in vitro. The resulting
mRNA is covalently fused to a short DNA
linker which carries a puromycin moiety at its
3 -end. This linking can be achieved by
hybridization and subsequent photo-
crosslinking of a psoralen-labeled DNA linker
to the mRNA (as shown here) or by an
enzymatic ligation reaction (not shown). The
resulting construct is translated in vitro.
During translation the ribosome reaches the
RNA–DNA junction and stalls. This allows the
puromycin moiety to bind to the ribosomal A
site. Thereby, the nascent polypeptide is
transferred to the puromycin moiety leading to
a covalent mRNA–polypeptide fusion. The
mRNA–fusion complex is subsequently
purified and the first cDNA strand is
synthesized. A selection for binding on
immobilized ligand is then carried out and the
bound complexes are eluted. The following
PCR yields the genetic information of the
selected clones. These clones can then be
analyzed or used as input for the next
selection round. In both (a) and (b), black lines
correspond to DNA and dotted lines
correspond to mRNA. In (b) the star
represents the puromycin moiety. For
simplicity, the crosslinked mRNA—DNA hybrid
is not shown after the in vitro translation step.
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efficiency for yeast (107–108 cells/ g DNA) and for
Escherichia coli (109–1010 cells/ g DNA) limits the achiev-
able library size. By contrast, in vitro display technologies
can handle libraries with up to 1014 members, depending
only on the scale of the in vitro translation used. A common
way to generate libraries involves the use of degenerate
oligonucleotides; however, such oligonucleotides often
contain deletions that result in frame-shifts and the appear-
ance of stop codons, thus decreasing the effective library
size. One way to avoid this is to use trinucleotides [26] as
building blocks, because even if deletions do occur the 
correct reading frame is still maintained. 
A generally useful approach to enlarge the percentage of
correct (i.e. in-frame and full-length) clones in a library is
to eliminate problematic sequences through preselection.
Because of the large library size accessible in the in vitro
display technologies, a useful library diversity is main-
tained even after preselection. The library is cloned
between an N- and C-terminal tag and displayed such that
selection for the occurrence of these tags will yield 
in-frame and full-length polypeptides. Premature stop
codons cause the ribosome to dissociate, and frame-shifts
will alter the C-terminal tag. Nonetheless, suppressor
tRNA present in the extract or mistakes in the synthesis
machinery appear to still let a fraction of undesired mole-
cules slip through this ‘filter’. Cho et al. [27•] performed
such a preselection using mRNA display. In this way they
were able to remove a large fraction of the non-functional
proteins from a large-scale in vitro translation (10 ml), thus
improving the proportion of correct proteins in three 
different libraries by up to two orders of magnitude. They
still maintained a final complexity of about 1013
full-length molecules.
Selection experiments with two of these libraries have
been published. From one such library, Keefe and Szostak
[28••] were able to select polypeptides, presumably with a
folded structure, that were able to bind ATP. This library
consisted of a completely random stretch of 80 amino
acids, which had been preselected as described above. All
selected sequences were full-length, indicating that 
preselection was successful. From their results, the authors
estimated the number of ATP binders in a random
sequence to be 1 in 1011, which underlines the necessity of
having a high-quality full-length library, and a selection
method capable of handling libraries of this size. 
Using the second of these preselected libraries [27•], 
consisting of amphipathic -helical or -strand segments,
Wilson et al. [29] selected for streptavidin binders. The
highest affinity of the selected peptides for streptavidin
was about 5 nM, in contrast to micromolar affinities of 
peptides selected in previous phage-display experiments
[30]. However, all of the selected peptides were derived
from frame-shifted sequences, even though preselection
had been performed. Because the library was designed
with restricted codon frequencies, such frame-shifted
sequences had a 700-fold increased probability of contain-
ing the known streptavidin-binding consensus sequence
His-Pro-Gln. These results also demonstrate how impor-
tant the design of the initial library is, as the selected
molecules had no similarity to the designed -helical or
-stranded elements. Even though preselection was 
performed, the rare frame-shifted sequences prevailed
over the much more abundant in-frame sequences.
Nevertheless, the preselection approach using in vitro
display technologies may be a powerful tool for improving
library quality in terms of enlarging the proportion of 
correct library members. 
Directed evolution of proteins
Natural evolution has efficiently adapted proteins to their
tasks under given environmental conditions. Nevertheless,
the technological or medical application of proteins often
places different demands on them; thus, their performance
needs to be optimized. Using the Darwinian principle,
evolution of polypeptides can now be conducted in the
test tube: a pool of molecules (library) is subjected to alter-
nating rounds of selection and randomization. If the
randomization is carried out on the whole library, not only
the original library is screened for the best molecules but
the library composition is also adapted from round to round
so that sequences not present in the original library
become accessible to selection. With this approach, Hanes
et al. [21•] selected, by ribosome display, a set of different
antibody single-chain Fv (scFv) fragments from a synthetic
naïve library, with up to 40-fold improved affinities when
compared with the progenitor sequences present in the
original library. All of the selected antibodies had accumu-
lated mutations as a result of amplification with a
low-fidelity DNA polymerase. This work demonstrated
that protein evolution can be an intrinsic part of each 
ribosome display cycle. By including an additional diversi-
fication step in each round of ribosome display to increase
the error rate even further, for example, by error-prone
polymerase chain reaction (PCR) [31,32] (described in the
article by Kurtzman et al. in this issue pp 361–370) or DNA
shuffling [33], Jermutus et al. [22••] further confirmed the
potential of ribosome display for directed in vitro protein
evolution. They demonstrated that distinct and pre-
dictable biophysical characteristics of scFvs, affinity and
stability, can be rapidly and efficiently evolved by combin-
ing these techniques (see below). Similarly, mRNA display
in combination with error-prone PCR proved to be a 
powerful approach for in vitro evolution of proteins as
shown by Keefe and Szostak [28••] (see above). Thus, the
work of these groups demonstrated that the PCR amplifi-
cation step inherent to ribosome and mRNA display can be
directly exploited for in vitro protein evolution by relaxing
the accuracy of pool replication during selection cycles.
The large library size accessible by these in vitro display
techniques further supports successful evolution experi-
ments. Taken together, ribosome and mRNA display have
great potential for directed protein evolution.
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Maturation of protein affinity
Protein affinity maturation with molecular evolution tech-
nologies is an important step in producing selective and
high-affinity binding proteins for applications in biotech-
nology and medicine [23]. Both ribosome display and
mRNA display have allowed selection for binding proteins
to a wide variety of targets, such as small compounds
[22••,28••], peptides [20], whole proteins [21•,23,24,34••]
or even a specific DNA structure [35••].
Recent work now also demonstrates that in vitro display
technologies have great potential for the maturation of
high-affinity protein binders. Hanes et al. [21•] isolated
picomolar affinity scFvs from a synthetic naïve library by
combining the intrinsic selection and evolution power of
ribosome display. An ‘off-rate’ selection procedure may
further favor protein affinity maturation [36]. In off-rate
selection, a pool of polypeptides is bound to an immobi-
lized ligand. By adding an excess of free ligand, every
dissociating library member will be immediately trapped.
After incubation, only those binders with the lowest 
off-rate will remain bound to the immobilized antigen.
Thus, increasing the incubation time with the competitive
ligand increases the selection pressure applied. As the on-
rate normally only changes within a relatively small
window, lowering the off-rate will result in increased bind-
ing affinity. Using such off-rate selections over a period of
up to ten days, Jermutus et al. [22••] were able to improve
an antifluorescein scFv that already had a high initial affin-
ity of 1.1 nM a further 30-fold. Using the same strategy,
peptide-binding scFvs were evolved to affinities in the low
picomolar range (C Zahnd et al., unpublished data). These
results demonstrate that off-rate selection is a valuable tool
to select high-affinity binders from libraries. Interestingly,
the mRNA — normally thought to be a very labile entity
— was stable under these experimental conditions for
more than 15 days.
Taken together, these results demonstrate that in vitro display
technologies are not only valuable tools for the selection of
binding molecules, but also for protein affinity maturation —
either of a given molecule or in conjunction with the selection
process from the initial library. This may have important
implications in biotechnological and medical applications.
Maturation of protein stability
A common requirement for most biotechnological and
medical applications of proteins is that they possess an
intrinsic high stability against denaturation. Stability 
engineering is still a difficult task [37–40]. Evolutionary
methods to perform stability engineering have shown
promise, especially methods that employ phage display
(reviewed in [41]). In a model system using antibody scFv
fragments, Jermutus et al. [22••] have shown that ribosome
display may be a valuable tool for in vitro evolution of pro-
tein stability. Antibody scFv fragments were evolved that
are stable in the absence of disulfide bonds, which are nor-
mally required for their stability [37]. When the disulfide
bond was allowed to reform, these scFv mutants were
more stable than the corresponding wild-type protein, as
indicated by urea denaturation experiments. They gave
higher yields of functional protein upon periplasmic
expression in E. coli, where disulfide bonds do form. Most
importantly, the selected scFv mutants could also be func-
tionally expressed in the reducing environment of the
cytoplasm; an uncommon feature of an antibody scFv frag-
ment. This study illustrates the versatility of the ribosome
display approach — expression and selection can take
place in a cytoplasmic-like environment, when dithiothre-
itol is added. Such stable and well-behaved antibodies
might find application in tumor targeting [42] and as effec-
tive intrabodies [43,44] for the intracellular inactivation of
proteins. Stability engineering of proteins by using heat or
proteases as selection pressure (reviewed in [41]) may also
be achievable with in vitro display technologies, especially
for mRNA display.
Selection for enzymatic activity
It has been stated several times [6,41,45,46] that a combina-
tion of directed evolution and the use of display technologies
provides a powerful strategy to evolve improved biocatalysts.
Although it is known that enzymes can be functionally dis-
played on the ribosome [47], ribosome display had so far not
been used to select for enzymatic activity. In this technique
the genetic information (i.e. the mRNA) is not covalently
attached to the protein. Thus, the mRNA can be simply 
eluted, even in applications based on suicide inhibitors,
where the selected protein is covalently bound to the target. 
P Amstutz et al. (unpublished data) have performed a selec-
tion for enzymatic activity using ribosome display. Using a
-lactamase suicide inhibitor, an active RTEM- -lactamase
was successfully enriched over an inactive mutant. In these
experiments the efficiency of activity selection was compara-
ble to selection for affinity using a -lactamase ligand.
Overall, in vitro display methods may open new roads for the
selection of catalytically active proteins.
Display of cDNA products
Phage display and two-hybrid systems are well-established
methods to screen or select cDNA libraries for binders
[1,2,48,49]. Recently, two groups investigated the potential of
in vitro display techniques for the display of cDNA products.
Bieberich et al. [50] reported the specific isolation of the
cDNA of sialyltransferase II by functional binding of the
encoded enzyme to its substrate, ganglioside GD3, in a sin-
gle-tube coupled ribosome display system. It remains unclear,
however, if their ribosome display construct is free of a stop
codon and if it contains an appropriate C-terminal tether. The
demonstration that ribosome display can be performed in a
single well of a microtiter plate may have implications for pro-
teomic applications where automation and high-throughput
screening are essential. By using cDNA product libraries 
displayed on mRNA, Hammond et al. [34••] isolated both
previously known and several novel binders of the antiapop-
totic protein Bcl-XL. The binding affinities of these isolated
proteins ranged from approximately 2 nM to 10 M. 
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In contrast to phage display or two-hybrid systems, in vitro
display techniques are not biased by cytotoxic or secretion-
incompatible cDNA products. In addition, in vitro display
libraries can be preselected (see above) to improve their
quality. Taken together, in vitro display of cDNA product
libraries may be an interesting approach for proteomic
applications, where the ultimate objectives are to func-
tionally display all proteins and to minimize any selection
or expression bias. 
Conclusions
In vitro display technologies, namely ribosome and mRNA
display, prove to be valuable tools for many applications
other than merely selecting polypeptide binders. They
have great potential for directed evolution of protein 
stability and affinity, the generation of high-quality
libraries by in vitro preselection, the selection of enzymatic
activities, and the display of cDNA and random-peptide
libraries. In addition, these technologies have several fea-
tures that should make them amenable to standardization
and automation: they comprise fast selection cycles, allow
the processing of huge libraries, are not limited by cellular
transformations, and are not biased by in vivo environ-
ments. We envision that in vitro display technologies will
have a great impact on applications in biotechnology, 
medicine and proteomics.
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Ribosome Display: In vitro Selection of Protein-Protein Interactions 
Patrick Amstutz, Hans Kaspar Binz, Christian Zahnd and Andreas Plückthun*
I. Introduction 
Ribosome display is an in vitro technology to identify and evolve proteins or peptides binding to a 
given target (Fig. 1) (Hanes et al., 2000a). While most selection technologies need living cells to
achieve the essential coupling of genotype and phenotype, ribosome display uses the ribosomal
complexes formed during in vitro translation to generate the physical coupling between polypeptide
(phenotype) and mRNA (genotype)(Amstutz et al., 2001). Hence, no transformation step limiting the 
size of the usable library is necessary, allowing the selection from very large combinatorial libraries. In
addition, the rapid selection cycles require an integral PCR step, which can be used for randomization,
making this method ideal for directed evolution experiments. The fact that the ribosomal complex used
for selection is not covalent allows an uncomplicated separation of the mRNA from the selected
ribosomal complexes, even if the selected molecules bind the target with very high affinity or are even
trapped covalently (Amstutz et al., 2002; Jermutus et al., 2001). All these benefits make ribosome
display a good alternative to other selection techniques such as phage display (Smith, 1985).
Ribosome display has been successfully applied for the selection of peptides (Matsuura and
Plückthun, 2003; Mattheakis et al., 1994), as well as folded proteins such as antibody fragments
(Hanes and Plückthun, 1997; He and Taussig, 1997; Irving et al., 2001). Ribosome display can also
be considered for the screening of cDNA libraries for interaction partners. Ribosome display ultimately
selects always for a specific binding event. However, by carefully designing the selection pressure,
molecules can be selected for many other parameters, such as enzymatic turnover (by selection with
a suicide inhibitor, or active site ligand) (Amstutz et al., 2002; Takahashi et al., 2002), protein stability 
(by selecting for binding under conditions where most library members will not fold) (Jermutus et al., 
2001), or protein biophysical properties (resistance to proteases and non-binding to hydrophobic
surfaces) (Matsuura and Plückthun, 2003). It is the combination of this array of selection pressures
with the convenient PCR-based randomisation techniques that makes ribosome display a powerful
and versatile technology.
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Figure 1. Ribosome display selection cycle. The DNA of the library of interest, fused in frame to a 
spacer carrying no stop codon, is transcribed in vitro. The resulting mRNA is used for in vitro
translation. After a short time of translation (a few minutes) the ribosomes have probably run to the
end of the mRNA and synthesized the encoded protein, but because of the absence of the stop 
codon, the protein remains connected to the tRNA. Stopping the translation reaction in ice-cold buffer 
with a high Mg2+ concentration stabilizes this ternary complex, consisting of mRNA, ribosome and
nascent protein. The spacer, occupying the ribosomal tunnel, enables the domain of interest to fold on
the ribosome. These ribosomal complexes are used for affinity selection. After washing, the mRNA of
the selected complexes is released by complex dissociation. The genetic information of binders is
rescued by RT-PCR, yielding a PCR product ready to go for the next selection cycle.
II. Materials and Instrumentation 
A. Reagents
The following chemicals and enzymes are necessary to prepare the extract and to perform ribosome
display selections: Luria broth base (GibcoBRL, 12795-084); agarose (Invitrogen 30391-023); glucose
(Fluka 49150); potassium dihydrogen phosphate (KH2PO4, Fluka 60230); di-potassium hydrogen
phosphate (K2HPO4·3H2O, Merck 1.05099.1000); yeast extract (GibcoBRL 30393-037); thiamine
(Sigma T-4625); Tris-acetate (Serva 37190); magnesium acetate (MgAc, Sigma M-0631); potassium
acetate (KAc, Fluka 60034); L-glutamic acid monopotassium salt monohydrate (KGlu, Fluka 49601) 20
natural amino acids (Sigma LAA-21 kit); adenosinetriphosphate (ATP, Roche Diagnostics 519 987);
phosphoenolpyruvate trisodium salt (PEP, Fluka 79435); pyruvate kinase (Fluka 83328); GTP (Sigma, 
G-8877); cAMP (Sigma A-6885); acetylphosphate (Sigma A-0262); E. coli tRNA (Sigma R-4251);
folinic acid (Fluka 47612); PEG 8000 (Fluka 81268); 1,4-dithio-treitol (DTT, Promega, V3155); sodium
chloride (NaCl, Fluka, 71376); Tween-20 (Sigma, P-7949); neutravidin (Pierce 31000); bovine serum 
albumin (BSA, Fluka 05476), Sacchoromyces cerevisiae RNA (Fluka 83847); ribonuclease inhibitor
RNasin (Promega N211B); reverse transcriptase Stratascript (50 U/ µl, Stratagene 600085-51); 10x 
Stratascript buffer (Stratagene 600085-52); dNTPs (5 mM of each dNTP, Eurogentec NU-0010-50);
DNA-polymerase for PCR (e.g., Vent® polymerase, NEB M0254L); PCR buffer (e.g., thermopol buffer, 
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delivered with Vent® polymerase), dimethylsulfoxide (DMSO, Fluka 41640); NTPs (50 mM, Sigma);
nitrocefin (Calbiochem 484400); Hepes (Sigma H-3375); spermidine (Sigma S-2501); T7 RNA 
polymerase (NEB M0251L); lithium chloride (LiCl, Fluka 62476); 100% ethanol (EtOH); sodium
acetate (NaAc, Fluka 71180); heparin (Fluka 51550); disodium ethylenediaminetetraacetate (EDTA, 
Fluka 03680); T4 DNA-ligase (MBI Fermentas EL0011); 4-morpholinopropanesulfonic acid (MOPS,
Fluka 69949); boric acid (Fluka 15660); guanidine thiocyanate (Fluka 50990); N,N-dimethyl formamide
(Sigma Aldrich 27.054-7); 37% formaldehyde (Fluka 47629); UHP water; if proteins are displayed that 
depend on the correct formation of disulfide bonds protein disulfide isomerase should be used (PDI;
Sigma P3818); 35S-methionine (PerkinElmer NEG009H); triethylamine (Sigma-Aldrich 90335);
OptiPhase2 scintillation liquid (PerkinElmer 1200-436) 
B. Buffers 
The following buffers are used in standard ribosome display selection rounds and we advise to 
prepare stocks: Tris-buffered saline (TBS: 50 mM TrisHCl pH 7.4 at 4 °C; 150 mM NaCl), TBS with 
Tween (TBST: TBS with 0.05 % (500 µl/l) Tween-20), washing buffer with Tween (WBT: 50 mM Tris-
acetate pH 7.5 at 4°C; 150 mM NaCl; 50 mM MgAc; 0.05% Tween-20) and elution buffer (EB: 50 mM
Tris-acetate pH 7.5 at 4°C; 150 mM NaCl; 50 mM EDTA); 10 x MOPS (0.2 M MOPS pH 7, 50 mM
sodium acetate, 10 mM EDTA); 10 x TBE buffer: (89 mM Tris-buffered saline, 89 mM boric
acid, 10 mM EDTA)
Note: the washing buffer used for ribosome display can be adjusted to any particular requirements
given by the target molecule. Different buffer salts and detergents are compatible, only the Mg2+
concentration should be held at around 50 mM. If a new buffer composition is applied, a test ribosome
display selection round with a known binder is recommended to determine compatibility.
C. Oligonucleotides 
αssrA DNA (200 µM, 5’- TTAAGCTGCTAAAGCGTAGTTTTCGTCGTTTGCGACTA-3’, standard 
quality)
T7B : Forward RD primer. Introduces T7 promotor and part of the 5'-loop (100 µM, 5’-
ATACGAAATTAATACGACTCACTATAGGGAGACCACAACGG-3’)
SDplus: Forward RD primer. Introduces the Shine-Dalgarno sequence and connects the T7 promoter
with the FLAG-tag: 5’-AGACCACAACGGTTTCCCAATAATTTTGTTTAACTTTAAGAAGGAGATAT-
ATCCATGGCGGACTACAAAGATGACG-3’
tolAk: Reverse primer for RD used with tolA as spacer introducing a stabilizing 3’-loop (100 µM 5’- 
CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGCCGCTTTCTTTCT-3’)
RDlinktolA: 5’-GGGGAAAGCTTTATATGGCCTCGGGGGCCGAATTCGAATCTGGTGGCCAGAAG-
CAAGCTGAAGAGGCG-3’
Primers (reverse and forward) specific for the library of interest, which must introduce appropriate
restriction sites for ligation into the ribosome display vector. 
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D. Bacterial Strain and Plasmid 
We use E. coli strain MRE600 for the preparation of the extract. This strain is RNase I deficient
(Kushner, 2002) and does not contain any antibiotic resistance (Wade and Robinson, 1966).
Ribosome display vector (pRDV), containing β-lactamase as insert (gene bank accession: AY327136).
E. Laboratory Equipment and Hardware
The following material will be used in ribosome display: ART filter pipet tips (10 µl, 20 µl, 200 µl, 1000 
µl, nucleic acid and nuclease free tips, Molecular Bioproducts); QIAquick PCR purification and gel
extraction kit (QIAgen 28104 and 28704); Maxisorp plate (Nunc-Immuno™ plate, Nunc 430341); Step
pipet (Eppendorf Multipipette Plus 4981 000.019) with 5 ml and 10 ml tips (Eppendorf 0030 069.250 
and 0030 069.269); Plastic seal (Carning Inc., Costar® 6524); RNase free 1.5 ml reaction vials 
(MolecularBioProducts 3445); Roche high pure RNA isolation kit (Roche 1 828 655); 0.2 mm syringe
filter (Millipore SLGPR25KS); Dialysis tubing with a molecular weight cut-off of 6000-8000 Da. (for
example: Spectrum Laboratories SpectraPor 132 650)
Furthermore, standard laboratory equipment is needed such as: Sorvall RC-5C Plus centrifuge with
rotors SS-34 and GS-3 or equivalent; refrigerated table centrifuge; Shaker incubator; 5 l and 100 ml
baffled shake flasks for E. coli culture; Emulsiflex (Avestin, Canada) or French Press (American
Instrument Company, AMINCO); 4°C room; Liquid nitrogen (N2); ELISA-plate shaker; UV/VIS
spectrophotometer; Agarose gel electrophoresis system; Latex gloves, Speed-Vac (Savant Speed Vac
Concentrator SVC100H); -20°C and –80°C freezer; Scintillation counter
III. Procedures 
A. Preparation of S30-Extract 
The preparation of the S30-Extract is performed according to Lesley, Zubay and Pratt, with minor 
modifications (Chen and Zubay, 1983; Lesley, 1995; Pratt, 1984; Zubay, 1973). 
General consideration: 1 liter E. coli culture yields approximately 8 ml extract. If you plan to do
ribosome display at a large scale, grow several cultures in parallel. It is important that the cells used
for extract preparation are harvested in an early logarithmic phase. If the libraries used for selection
contain disulfide bonds, one should omit DTT from the extract. If no disulfides need to be formed 1
mM DTT can be added to the S30 buffer as it increases the translation efficiency slightly. 
Material, solutions and strain: 
Solutions, Strain and Hardware:
E. coli strain MRE600 (Wade and Robinson, 1966); Luria broth base; Incomplete rich medium: 5.6 g/l 
KH2PO4, 37.8 g/l K2HPO4·3H2O, 10 g/l yeast extract, 15 mg/l thiamine - after autoclaving add 50 ml
40% (w/v) glucose sterile filtered; 0.1 M MgAc; 10x S30 buffer: 100 mM Tris-acetate pH 7.5 at 4 °C,
140 mM MgAc, 600 mM KAc - store at 4 °C or chill buffer in ice bath before use; 10 ml preincubation
mix - must be prepared immediately before use: 3.75 ml 2 M Tris-acetate pH 7.5 at 4 °C, 71 µl 3 M
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MgAc, 75 µl amino acid mix (10 mM of each of the 20 natural amino acids), 0.3 ml 0.2 M ATP, 0.2 g
PEP, 50 U pyruvate kinase.
Material: 5 l baffled flasks; shaker at 37°C for E. coli culture; refrigerated centrifuges (GS-3, SS-34); 
dialysis tubing MW cut-off 6000 - 8000 Da.; Emulsiflex or French press.
Steps
Day 1: 
1. Prepare an LB/glucose plate and streak out MRE600 on the plate. Grow it overnight at 37°C 
2. Prepare all chemicals, media and buffers for E. coli extract preparation: Autoclave 1 l incomplete
rich medium, 500 ml of LB/glucose medium and one 100 ml and one 5 l shake flask. Prepare 50
ml 40% glucose, 10 ml 0.1 M MgAc and 1 l 10x S30 buffer (use it as 1x S30 buffer afterwards). All 
buffers should be stored at 4°C. 
Day 2: 
3. Prepare an overnight preculture by inoculating 50 ml LB/glucose medium with a colony of MRE
600, which is shaken overnight at 37°C. 
Day 3: 
4. Add 1 l incomplete rich medium into the 5 l shake flask and add 50 ml 40% glucose and 10 ml 
0.1M MgAc both by sterile filtration (0.2 µm syringe filter). 
5. Inoculate the culture with 10 ml overnight culture (approximately 1%) and let it shake at 37°C to 
OD600 = 1.0 – 1.2. Then transfer the culture in an ice-water bath and quickly add 100 g ice (small
shovel) to the culture. Shake the culture in the ice-water bath by hand for 5 minutes. Collect the
cell pellet by centrifugation at 4°C (15 min, GS-3, 5000 rpm). Wash the pellet at least 3 times with
50-100 ml of S30 buffer. 
6. Determine the weight of the pellets (typically 1-1.5 g/l). The cell pellet can now be shock-frozen in 
liquid nitrogen and stored at -80 °C until further processing. Do not store the pellets longer than 2
days.
Day 4: 
Do wear gloves during all following steps!
7. Thaw the pellets on ice and resuspend the cells in S30 buffer (50 ml). Centrifuge at 4°C, full speed
in an appropriate centrifuge to collect the cell pellet. Resuspend the cells in 4 ml/g (wet cell 
weight) S30 buffer.
8. Lyse the cells with one passage through an EmulsiFlex (approximately 17000 psi) or a French
press (at 1000 psi). Repeating passages will decrease translation activity. Centrifuge the lysate at 
4°C for 30 min (SS-34, 20000 g). Take the supernatant and repeat this centrifugation step.
9. Transfer the supernatant to a 50 ml Falcon tube. Add preincubation mix (1 ml/6.5 ml supernatant)
and incubate at RT for 60 min by slowly shaking the tube. In this step most endogenous RNA and
DNA will be degraded by nucleases and translation will run out. 
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10. Transfer the extract into a dialysis device (MW cut-off 6000-8000 Da) and dialyze the extract 3 
times for at least 4 h each at 4°C against S30 buffer (500 ml). Dialyse overnight in a fourth step.
Day 5: 
11. Transfer the extract into a single 50 ml tube. Aliquot the extract into RNase-free tubes immediately
(for example 110 µl and 55 µl aliquots, use filter tips to avoid RNase contamination) and directly
freeze the aliquots in liquid nitrogen. Store the aliquoted extract at -80 °C (it will be fully active for 
months to years).
B. Premix Preparation and Extract Optimization
The premix provides the S30-extract with all amino acids (except for methionine, see below), tRNAs,
the energy regeneration system and salts, which are needed for translation. For optimal translation
efficiency every premix should be adjusted to fit the corresponding extract, especially with respect to
the concentration of magnesium, potassium, PEG8000 and amount of extract. The PremixA recipe
given below contains only minimal concentrations of KGlu, MgAc and PEG-8000. By performing
translations (compare section F) using a test mRNA and by gradually adding increasing amounts of 
these components, the translation efficiency of the extract will be optimized to its maximal activity. The
optimization of the premix to the S30-extract is optimally done by translating the mRNA encoding an
enzyme, whose activity is easily determined, such as e.g. β-lactamase. We routinely use a cysteine-
free version of the enzyme (Laminet and Plückthun, 1989) in a ribosome display suitable format
(described in section C) for optimization.
Solutions
You will need approximately equivalent amounts of premix and extract. PremixA: 250 mM Tris-acetate
pH 7.5 at 4°C, 1.75 mM of each amino acid except methionine, 10 mM ATP, 2.5 mM GTP, 5 mM
cAMP, 150 mM acetylphosphate, 2.5 mg/ml E. coli tRNA, 0.1 mg/ml folinic acid, 4 µM α−ssrA DNA. 
KGlu (180 - 220 mM), MgAc (10 - 15 mM) and PEG-8000 (5 - 15 % w/v) have to be adjusted to the
corresponding extract. 
β-lactamase assay buffer: Dissolve 5.3 mg nitrocefin in 250 µl DMSO and add this to 50 ml 50 mM 
potassium phosphate buffer (pH 7) (Laminet and Plückthun, 1989).
Steps
To avoid RNase contamination use filter tips and wear gloves for all of the following steps.
1. Mix all components to yield PremixA. 
2. Incubate the premix in a waterbath at 37 °C to solubilize all components.
3. Perform different in vitro translations in parallel of β-lactamase mRNA as described below (Section
F). Add increasing concentrations of MgAc (10 - 15 mM), KGlu (180 - 220 mM), PEG-8000 (5 -
15% w/v of premix) and amount of extract (30 - 50 µl for a 110 µl translation reaction).
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4. First optimize the MgAc concentration, then the KGlu concentration and last the PEG-8000
concentration. The translation time relevant for optimization should be around 10 min. Stop
translation by diluting the reaction 5 times in WBT. 
5. To detect β-lactamase activity, use a nitrocefin assay. Use 10 - 20 µl of the stopped translation per 
ml β-lactamase assay buffer and follow the reaction with a photospectrometer at 486 nm.
6. After determining the conditions giving the highest activity, add the chemicals at the optimal
concentration to the PremixA stock yielding PremixZ, optimized for this very batch of extract. 
7. Aliquot the PremixZ in RNase-free tubes and shock freeze the samples in liquid nitrogen (for
example 500 µl aliquots). 
Figure 2. Generation of the ribosome display construct. For ribosome display the library of interest
has to be flanked by an upstream promoter region and a C-terminal spacer carrying no stop codon
(Fig. 3). A) The library is PCR amplified with primers carrying restriction sites suitable for ligation into
the ribosome display vector (pRDV), which carries the necessary library flanking regions. The PCR 
product of the library is digested and ligated into pRDV. A second PCR on this ligation reaction with
the primers T7B and tolAk yields a PCR product ready for in vitro transcription. B) Alternatively, the 
ribosome display construct can be generated by assembly PCR. The library and the spacer are PCR
amplified separately with primers, so that the C-terminal part of the library and the N-terminal part of 
the spacer share overlapping sequences. An assembly PCR with the library and the spacer DNA,
using appropriate primers, finally yields the ribosome display construct. In vitro transcription of the
PCR product of either A) or B) yields mRNA carrying 5’- and 3’-stemloops (which make the mRNA
more stable toward exonuclease digestion), a ribosome binding site (RBS), the library of interest and a
spacer carrying no stop codon. By stopping the in vitro translation in ice-cold buffer with high Mg2+
concentration, stable complexes of mRNA, ribosome and nascent protein are formed, ready for 
panning.
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C. Preparation of the Ribosome Display Construct 
To perform ribosome display one needs a high quality library in the appropriate format. In this section
we will not explain how to generate this library, as this entirely depends on the experimental goal, but
how to convert an existing one into a format suitable for ribosome display.
A ribosome display construct is composed of a T7 promoter, followed by a ribosomal binding site and
an open reading frame, which in turn consists of the library fused in frame to a C-terminal spacer
polypeptide which has no stop codon (Fig. 2; Fig. 3). The lack of the stop codon prevents the binding
of the termination factors TF-1, TF-2 and TF-3. A high magnesium concentration “sinters” the
ribosome, which consists largely of folded RNA with a protein coat. The low temperature presumably
prevents the hydrolysis of the peptidyl-tRNA and minimizes mRNA degradation. All these measures
together ensure that the ternary complex of mRNA (genotype), ribosome and displayed protein
(phenotype) remains stable. The C-terminal spacer (usually derived from tonB, tolA, M13 gpIII or pD), 
which will partially remain in the ribosomal tunnel, ensures that the library protein can fold and is
displayed on the ribosome. The T7-promoter allows efficient in vitro transcription of the construct. A 5’-
and a 3’-stemloop protect the mRNA against exonucleases.
Figure 3. DNA sequence of the expression cassette of the ribosome display vector (pRDV). The
mRNA is produced from a T7 promoter starting with a 5’-stemloop, with no additional overhang. The
ribosome binding site (RBS), also called Shine-Dalgarno sequence, is located upstream of the start 
codon. The open reading frame consists of a FLAG-tag, the β-lactamase gene (serving as a dummy
insert) in frame with a protein spacer, here tolA. Different restriction sites allow the cloning of the 
library into pRDV to replace the β-lactamase gene.
Solutions, Plasmids and Strains: 
QIAquick PCR purification and gel extraction kit; pRDV; appropriate restriction enzymes; T4-DNA-
ligase
a) Generation of the Ribosome Display Construct via pRDV
To accelerate the procedure of bringing a library into the ribosome display format, we generated a
vector containing the necessary flanking regions (ribosome display vector, pRDV; Fig. 2). The library
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is PCR amplified, cut with the appropriate restriction enzymes and ligated into the vector such that it is
in frame with the spacer (Fig. 3). A second PCR on this ligation product directly amplifies the library
with all features necessary for ribosome display: the T7-promoter, the RBS and the spacer without
stop codon (Fig. 2). This PCR product is directly used for in vitro transcription, to yield the library-
mRNA ready to go. The main advantages of the ribosome display vector are that one can generate
large amounts of it (mini to maxi prep), it is easy to handle and always provides error-free library
flanking regions. The use of the vector is not only interesting for the initial generation of the ribosome
display construct, but also for the first selection rounds. If one only amplifies the library gene of the
selected clones after the panning procedure without all the flanking regions, one is able to even
recover library members partly degraded by RNases in the flanking regions. The recovered genes are
then re-ligated into pRDV and one is again ready to go for another round of selection.
Steps:
1. Amplify the library with primers carrying the appropriate restriction sites for cloning into pRDV (Fig 
3).
2. Digest the PCR product and purify it using QIAquick columns (≥150 ng; amount depending on the
library size). pRDV is digested, optionally dephosphorylated and the backbone is agarose-gel
purified. The vector insert has to be removed, as it would also ligate to the library DNA,
decreasing the final complexity.
3. Ligate the PCR product of the library into pRDV (molar ratio insert:vector = 7:1). 
4. Perform a PCR reaction on the ligation mix with the forward primer T7B (annealing on the T7
promoter with a stabilizing 5’-loop) and the reverse primer tolAk (annealing on the C-terminal
spacer carrying a stabilizing 3’-loop).
5. Analyze the DNA on an agarose gel, checking size, purity and amount. If the band is sharp and
indicates a concentration higher than 40 ng/µl, the PCR product is directly (i.e. without purification)
used for in vitro transcription.
b) Generation of the Ribosome Display Construct via Assembly PCR
In some cases, it may be preferable not to ligate the library into pRDV, but to use PCR assembly to 
generate the ribosome display construct (Fig. 2). In this case, both the library and the spacer (e.g.
tolA) are PCR amplified, so that the 3’-end of the library and the 5’-end of the spacer share
overlapping sequences (Fig. 2). The PCR products of the library and the spacer are assembled and
amplified with the primers SDplus (introducing the ribosome binding site and the connection to the T7-
promoter) and tolAk. A final PCR reaction with the primers T7B (introducing the T7-promoter) and
tolAk completes the construct, ready for transcription (Fig. 2). 
Steps:
1. Amplify the library of interest with appropriate primers, introducing the FLAG-tag at the 5’-end of
the library, on which the primer SDplus can anneal in step 3. The reverse primer should anneal
on the library and add an overlap corresponding to RDlinktolA. There is no need to introduce
restriction sites, however, we strongly recommend the use of the same primers as for the cloning
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into the RDV, to have the possibility of using pRDV and to reduce the number of different
fragments.
2. Amplify the ribosome display spacer using the primers RDlinktolA (forward) and tolAk (reverse).
Thereby, the forward primer generates an overlap between the library and the spacer. 
3. In an assembly-PCR reaction, the spacer is fused to the library. Mix DNA of the library with an
excess of spacer DNA and perform 7 cycles of PCR without the addition of primers. For this step, 
we use a lower annealing temperature as for the normal amplification. After 7 cycles, add primers
tolAk and SDplus to the reaction and perform another 25 cycles of amplification.
4. Isolate the full-length band from an agarose gel and amplify the band using the primers T7B and 
tolAk.
5. Analyze the DNA on an agarose gel, checking size, purity and amount. If the band is sharp and
indicates a concentration higher than 40 ng/µl, the PCR product is directly (i.e. without
purification) used for in vitro transcription. 
D. Transcription of PCR Products 
Solutions and Hardware:
5xT7 polymerase buffer: 200 mM Hepes pH 7.6, 30 mM MgAc, 2 mM spermidine, 40 mM DTT; NTPs 
(50 mM each); T7 RNA polymerase; RNasin; 6M LiCl; 70% EtOH; 100% EtOH; 3M NaAc; agarose; 
guanidine thiocyanate; formamide; 37% formaldehyde; MOPS;
Speed Vac; heating blocks; UV/VIS spectrophotometer
Steps
To avoid RNase contamination use filter tips and wear gloves for all of the following steps.
1. Mix the components for the following reaction using the PCR product from section C. The PCR
product should not be purified. Add 20.0 µl 5x T7 polymerase buffer, 14.0 µl NTPs (50 mM each),
4.00 µl T7 RNA polymerase, 2.00 µl RNasin, 22.5 µl PCR product, 37.5 µl UHP. Let the 
transcription reaction run for 2-3 hours at 37 - 38°C.
2. Add 100 µl UHP and 200 µl 6 M LiCl, both ice-cold, and place on ice for 30 min, before
centrifugation at 20000 g (4°C, 30 min). Discard supernatant and wash the pellet with 500 µl ice-
cold 70% EtOH. Shortly dry the pellet on your bench (5 min, open lid) and take it up in 200 µl ice-
cold UHP. Make sure it dissolved completely, before centrifuging at 20000 g (4°C, 5 min). 
3. Transfer 180 µl supernatant to a new tube and add 20 µl 3 M sodium acetate and 500 µl ice-cold
100% EtOH. Keep the solution on ice or at -20°C for 30 min, before centrifuging it at 20000 g (4°C,
30 min). Discard the supernatant wash the pellet with 500 µl ice-cold 70% EtOH. Discard the
supernatant and finally dry the pellet in a Speed-Vac apparatus.
4. Take up the mRNA pellet in 30 µl ice-cold UHP and make sure it dissolved completely. Take 2 µl
of this solution and dilute to 500 µl with ice-cold UHP for OD260 quantification and immediately N2-
freeze the rest of the RNA for further use.
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5. Immediately (the RNA will be degraded and the signal will increase) measure the OD260. For RNA,
an OD260 of 1 corresponds to a concentration of 40 µg/ml.
6. Add UHP to the RNA stock in order to reach a standard concentration of 2.5 µg/µl.
7. The RNA quality can optionally be checked by agarose gel electrophoresis. Cast an agarose gel
(1.5 %, depending on your RNA size) adding 2% w/v of 1 M guanidine thiocyanate . Denature 5 µg
(i.e. 2 µl) RNA for 10 min at 70°C in 15.5 µl loading buffer (10 µl formamide, 3.5 µl 37% 
formaldehyde, 2 µl MOPS), place it on ice and load the gel.
E. Target Molecule Immobilization
To perform a selection, the target molecule must be immobilized in a conformation relevant for further
applications. A very promising way to do so is to biotinylate the target molecule and immobilize it via 
neutravidin or streptavidin. Biotinylation can be done chemically with commercially available reagents,
either attaching the biotin to cysteine or lysine residues. The problem of this unspecific approach is
that biotinylation might destroy epitopes. Alternatively, the target protein can be expressed in
recombinant form with a biotinylation tag, i.e. a peptide sequence, which is recognized and
biotinylated by the E. coli biotinylation enzyme BirA (Schatz, 1993). If for any reason biotinylation is no
option, one can either immobilize the target molecule directly on the hydrophobic surface of a
microtiter plate well, or use a specific antibody, which itself can easily be immobilized via protein A or 
G. Note that the buffers used here may have to be adapted to the needs of the target molecules.
Solutions and Hardware
TBS, TBST, WBT at 4°C 
Maxisorp plate; plastic seal; step pipet; plate shaker; 20 µM stock neutravidin; BSA; target molecule of 
choice
Steps
To avoid RNase contamination use filter tips and wear gloves for all of the following steps. We also
recommend carrying out the selection, RT and PCR in duplicate, to check the reproducibility of the
selection. Therefore, one target molecule is routinely immobilized in two wells.
Day 1: 
1. Wash a Maxisorp plate 3 times with TBS and beat dry. Pipet (with a step pipet) 100 µl of a 66 nM
neutravidin solution in TBS into the wells. Seal with plastic and store overnight at 4°C. If the target
molecule is not biotinylated it can also be directly immobilized as the neutravidin is, but it might
denature at least partly during this procedure.
Day 2 (Day of the Ribosome Display Round):
2. Wash the plate incubated overnight with cold TBS three times. Add 300 µl 0.5% BSA in TBS to the 
wells (with a step pipet) to block all hydrophobic surfaces with BSA. Seal the plate with plastic and 
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incubate on a shaker for 1 h at RT. If you directly immobilized the target molecule, incubate the 
BSA solution 2 h at 4°C and proceed directly to step 5.
3. Wash the plate three times with TBS, beat dry and add 200 µl 0.5% BSA in TBS to each well (step
pipet).
4. Add 5 µl of the target molecule (~10 µM) to the respective well. Use biotinylated target molecule
void of free biotin. Seal with plastic and incubate on shaker for 1 h at 4°C. To avoid binders to BSA 
or neutravidin, it is recommended to immobilize the target molecule only in every second well, and
use the alternate wells for pre-panning.
5. Wash the plate 4 times with TBS, to get rid of the unbound target molecule. Wash at least once
with WBT (step pipet) to equilibrate the well with the ribosome display buffer. Incubate wells that 
will not directly be used for panning with WBT (amount of liquid as will be used for panning). Keep
the plate at 4°C. 
F. In vitro Translation 
Solutions
UHP; WBT; WBT with 0.5% BSA; heparin (200 mg/ml); methionine (200 mM); S30 extract; PremixZ;
the mRNA of the library; optionally PDI (4 mg/ml, reconstituted from lyophilized protein); all buffers 
should be kept on ice, the RNA in liquid nitrogen unless stated otherwise.
Steps
We recommend carrying out the panning in duplicate, to check the reproducibility of the selection. To 
avoid RNase contamination use filter tips and wear gloves for all of the following steps.
1. Mix the following components (amounts given are for one reaction): 13.0 µl UHP water, 2.0 µl Met 
(200 mM), 41.0 µl PremixZ (thaw on ice, vortex before pipetting) and 50.0 µl extract. Volumes
might vary, depending on the batch of S30 extract. This mix can be kept on ice for a short period
(few minutes). If disulfide bridges are to be formed: add 0.625 µl PDI (4 mg/ml).
2. Add 4 µl mRNA (2.5 µg/µl) into a fresh RNase-free tube and freeze it in liquid nitrogen. 
3. Add the translation mix to the frozen mRNA, dissolve the pellet by flicking the tube and translate
for 6-12 min at 37°C. 
4. In the meantime, prepare 440 µl stopping buffer (WBT with 0.5% BSA and 12.5 µl/ml heparin (200
mg/ml)) in RNase-free tubes and put them on ice. 
5. After the 6-12 min translation, pipet 100 µl translation into the ice-cold stopping buffer to stop
translation (always keep the ribosomal complexes on ice or at 4°C).
6. Centrifuge at 20000 g, 4°C for 5 minutes and use the supernatant containing the ribosomal
complexes for panning.
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G. Panning
Solutions and Hardware
WBT; EB; yeast RNA (25 µg/µl); cold room; microtiter plate shaker; Roche High Pure RNA isolation
kit.
Steps
All the following steps should be performed in a cold room (at 4°C or slightly below). The low
temperature guarantees complex and mRNA stability. Under such conditions ribosomal complexes
have survived off-rate selection procedures of 10 days and longer. During all binding and elution steps
shake the microtiter plate gently. To avoid RNase contamination use filter tips and wear gloves.
1. Add 100 - 200 µl stopped translation mix to the well, where no target molecule is immobilized and
incubate for 1 h. In this prepanning step all BSA-binding, neutravidin-binding or simply sticky 
complexes are removed. If unspecific complexes are causing problems, more than one pre-
panning step should be done.
2. Transfer the solution to the well with the immobilized target molecule and incubate for 1 h. 
3. Wash the well to remove non-binding complexes. The time span of the washing step and the
number of washing steps equals the selection pressure. One usually starts with short washing
times in the first rounds (only rinsing six times) and increases the washing periods for later rounds
(up to 3-4 h). As washing is always a dilution, it is important to fill the wells to the top and
exchange the buffer many times (at least six times, in all rounds!). If harsher selection pressure
than simple washing is required, for example to select for affinities below nM, one should consider
immobilisation of low target molecule concentrations, competitive elution (with free target molecule
in the solution) or off-rate selection procedures (see section J). 
4. Before the mRNA of the selected complexes is eluted, prepare 3 RNase-free tubes for each well 
to be eluted. One tube with 400 µl lysis buffer of the Roche RNA-purification kit to purify the RNA, 
one tube to collect the purified mRNA and one tube for reverse transcription. Also prepare one
Roche-RNA purification column for each well to be eluted. Label all tubes and columns
appropriately.
5. Calculate and prepare the amount of elution buffer you need (200 µl/well) and add 50 µg/ml S.
cerevisiae RNA (2 µl of a 25 µg/µl stock per ml) to it. Keep the buffer on ice. 
6. Elution is done in the cold room. Wash your well one last time with WBT, then remove the
supernatant completely and beat the plate dry. Add 100 µl ribosome display elution buffer, shake
for 10 minutes, then transfer this eluate to the tube containing the lysis buffer and mix well. Repeat
this procedure with another 100 µl of elution buffer. In the lysis buffer, the RNA is stable and can
be brought to room temperature.
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H. RT-PCR 
Solutions and Hardware
Roche High Pure RNA isolation kit; 100 mM DTT; RNasin; Stratascript (50 U/ µl; Stratagene); dNTPs;
DNA-polymerase; oligonucleotides; 10x Stratascript buffer; polymerase buffer; DMSO; agarose. 
Steps
The RNA purification is done according to the Roche protocol, with slight modifications. All the
centrifugation steps are carried out a 4°C.
mRNA Purification
1. Just before the RNA-purification, thaw the reagents for the reverse transcription (DTT, 10x
Superscript buffer, dNTPs, oligonucleotide for reverse transcription).
2. Set two heating blocks to 70°C and 50°C respectively.
3. Apply the lysis buffer/eluate mixture on the column and spin for 1 minute at 8000 g. Discard the
flow-through and wash with 500 µl buffer 1 (black capped bottle in the Roche kit; the DNAse
incubation step, described in the Roche protocol is not necessary). Discard the flow-through and
wash with 500 µl buffer 2 (blue capped bottle in the Roche kit). Discard the flow-through. Add 100
µl buffer 2 (blue cap) and spin for 2 minutes at 13000 g. Transfer the column to a tube to collect
the RNA. 
4. Elute with 30 µl Roche elution buffer (at 8000 g for 1 min) and directly put the RNA containing
collection tube to 70°C for 10 minutes to denaturate the RNA. During this incubation time, pipet
the reverse transcription (i.e. directly proceed with step 5). 
Reverse Transcription
5. In a mastermix tube, add the following components (amounts given are for one reaction): 0.25 µl
reverse primer (100 µM), 0.50 µl dNTP (5 mM each), 0.50 µl RNasin, 0.50 µl Stratascript, 2.00 µl
10x Strascript buffer, 2.00 µl DTT (100 mM), 2.00 µl UHP. Distribute the RT-mix (7.75 µl) to the 
previously labelled tubes and keep them on ice. 
6. Spin the denatured eluted RNA-samples shortly and set them on ice. Add 12.25 µl of the eluted
RNA to the RT-mix (N2-freeze the rest of the RNA directly after adding it to the reaction).
7. Place the RT-reaction on the 50°C heat block for 45 minutes.
PCR
8. Mix the following components (amounts given are for one reaction): 5.00 µl Thermopol buffer, 2.00
µl dNTPs, 2.50 µl DMSO, 1.00 µl forward primer (100 µM), 1.00 µl reverse primer (100 µM), 5.00 
µl RT-template, 0.50 µl polymerase, 33.0 µl UHP. PCR results can be improved if a hot start is 
performed (adding the polymerase in the 5 min preincubation step at 95°C). 
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9. Run the following PCR program (to be adapted according to primers and template): 5 min at 95°C,
X times (30 sec at 95°C, 30 sec at 50°C, 1 min at 72°C), 5 min at 72°C, 4°C infinitely. Adjust the
number of cycles (X = 25 - 45) to the corresponding selection round.
10. Verify the PCR product quality by an appropriate agarose gel electrophoresis.
11. Usually the quality of the PCR product is not good enough to be used directly for in vitro
transcription to generate mRNA for the next round. The desired band is gel purified and a second
PCR is performed on the purified first PCR to yield high quality DNA. 
12. If you wish to check the pool of selected clones for binders, ligate the selected library members
after PCR amplification into a vector suitable for expression, transform E. coli to obtain individual
clones and test binding specificity, for example by crude extract ELISA. To asses the specificity of 
the binders, one can either compare binding of the selected molecules to the specific target
molecule to the binding to an unrelated molecule, or test the ability that the specific binding can be 
inhibited by adding the purified unbiotinylated target molecule. The level of inhibition gives a first
crude estimate of the affinity.
Troubleshooting:
RT-PCR
If the RT-PCR with the forward (e.g. T7B) and reverse (e.g. tolAk) primers does not yield a high quality
product, one can amplify only the coding region of the selected library members. This usually
improves the yield and the quality of the PCR product. This is most likely due to the fact that RNAses
degrade the mRNA from the ends. Amplifying only the central (library) stretch can rescue partly
degraded clones. The PCR product of the library stretch is subsequently religated into pRDV as
described in section C. As this procedure rescues more clones than the PCR of the whole construct,
we would recommend it for the first rounds, to guarantee that no binders are lost.
Panning Controls 
Ribosome display has many error-sensitive steps. It is therefore recommended to do the panning, RT
and PCR in duplicate, to check the reproducibility of the selection. Specific binders should be enriched
from round to round. This should correlate with the number of PCR cycles needed to amplify the DNA
after RT, which should decrease from round to round. Usually one can reduce the cycle number by 
around five per round. If the selection pressure is increased, the yield will drop. When enrichment is
observed (for ankyrin repeat protein libraries, e.g. after round two, while for antibody libraries after
round 3 to 4), one can test the specificity of the selected pool by comparing panning results against
the correct and an unrelated target molecule. If the pool is specific, only the correct target molecule
will give a PCR product after RT. If the pool gives also a signal with the unspecific target molecule, the
majority of the clones are still unspecific. However, there might also be a population of specific binders
in the pool. An additional panning round with increased pre-panning can reduce the background.
Alternatively, single clone analysis might directly yield specific binders.
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I. Radioimmunoassay (RIA) 
The radioimmunoassay (RIA) is another fast and convenient method to check whether specific target
binding molecules have been enriched in a pool (Hanes et al., 1998). It can be used for the evaluation
of both selected pools and individual binders. The RNA of a pool or single binder is translated in the
presence of radioactively labelled 35S-methionine. Therefore, the radioactive protein which binds to the
surface-immobilized target molecule can easily be quantified. The binding should be performed in the
presence and absence of soluble competitor target molecules, and a control for unspecific binding
should be included. In the competition assay, the minimal concentration of competitor still leading to
half inhibition of the maximal binding signal is a crude measure for the affinity. Therefore, RIA
facilitates the ranking of the affinities of different clones isolated after affinity maturation.
Solutions and Hardware
The general handling is the same as for the in vitro translation. However, the radioactive material must
be handled with the appropriate precautions. Do the radioactive work in a designated area of your
laboratory. We recommend to use filter tips and to wear gloves during the experiment. We recommend
doing the RIA in duplicate.
UHP; WBT; WBT with 0.5% BSA; milk powder; heparin (200 mg/ml); 35S-methionine (10 mCi/ml,
1175 Ci/mmol); S30 extract; PremixZ; mRNA of a selected pool or single binders; pRDV; optionally
PDI (4 mg/ml); 0.1 M triethylamine; liquid scintillation cocktail “OptiPhase2”.
Scintillation counter, ELISA-plate shaker
Steps
RNA Preparation
1a. The analysis of whole pools of potential binders can be performed similar to a normal ribosome
display round. A PCR reaction is performed on the selected pool but with primers introducing a 3’-
stop codon and the standard ribosome display 5’-end (including T7-promotor and ribosome
binding site). From this PCR product, RNA is produced as described in section D.
1b. Alternatively, if you wish to analyze single binders, the PCR product from step 1a is digested with
the appropriate restriction enzymes and ligated into the ribosome display vector (RDV). After
transformation, plasmids are isolated from single colonies. The transcription can be performed
directly from the plasmid, which should be present at a concentration of at least 100 ng/µl.
RIA
2. Prepare a Maxisorp plate with immobilized target molecules as described in section E. 
3. Perform in vitro translations as described in section F with the following modifications: instead of
cold methionine use 2 µl of 35S-methionine (0.3 µM, 50 µCi/ml final concentration) per 110 µl
reaction and perform the translation for 30-45 min at 37°C.
4. Stop the translation with 440 µl WBT and centrifuge the samples for 5 min at 14000 rpm, 4°C. 
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5. Aliquot the supernatant and dilute the samples with 4% milk in WBT to a final concentration of 1% 
milk. For inhibition studies, different concentrations of competitor should be added to the different
aliquots and the mixture should be equilibrated for 1 h at room temperature prior to step 6. 
6. Split the samples to at least duplicates and apply them to the blocked plate. Let the protein bind to
the target molecule by slowly shaking for maximally 30 min. 
7. Wash the plate rigorously 5-10 times with WBT. 
8. Elute bound protein with 100 µl of a 0.1 M solution of triethylamine (10 min at room temperature).
9. Transfer the eluates into scintillation tubes containing 5 ml scintillation solution “OptiPhase2”. 
10.Quantify the radioactivity in a scintillation counter.
IV. Comments
In this section we would like to state some observations we made during the years of performing
ribosome display and give a summary how ribosome display can be used for directed evolution
experiments.
Selection from Naïve Libraries 
Naïve libraries, in our hands synthetic antibody libraries or designed repeat protein libraries, are a 
difficult challenge for selection experiments. The task is to select the specific binders, which are few in
numbers, out of a very large number of non-binders. The outcome of such experiments is not only
dependent on the presence of high affinity binders in the library, but also on the behavior, or 
“stickiness”, of the rest of the library population. In other words, selection must be directed towards
specific binding, in contrast to non-specific binding. This can be achieved with experimental tricks,
such as introducing a pre-panning step, or by trying to reduce the stickiness of the library population.
For the selection with naïve scFv libraries it has turned out that six selection rounds were necessary to
obtain specific binders (Hanes et al., 2000b). The designed ankyrin repeat protein libraries routinely
yield binders after only three to four rounds. We suspect this might be due to the fact that these repeat
proteins, which are extremely well expressed in E. coli, fold well and are very stable, are also
displayed better in vitro than scFv fragments, which are intrinsically somewhat more aggregation
prone.
Affinity Maturation of Binders 
In vitro evolution, the alternation of diversification and selection, is a powerful strategy to improve
proteins. Ribosome display is an ideal platform to perform such experiments. It allows very fast 
selection cycles and the PCR step is ideal to generate diversity in between the selection rounds. This
diversification of the selected pools by random mutations increases the sampled sequence space.
Error prone PCR, e.g. using high Mn2+ concentrations (Leung et al., 1989), imbalanced dNTP
concentrations (Cadwell and Joyce, 1994) or nucleotide analogues (Zaccolo and Gherardi, 1999;
Zaccolo et al., 1996), is one strategy often applied to achieve diversification. Another powerful strategy 
to create diversity is DNA shuffling on the selected pools in between the rounds (Stemmer, 1994).
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When compared to a selection experiment from a naïve library the challenge in affinity maturation is
different. The applied library will usually be created from a single clone or a pool of clones, which are
already good binders. Since we do not select for binding as such but for better binding, we need an
adjustable selection pressure (Jermutus et al., 2001). In principle, there are two strategies to select
tight binders out of a pool of binders. 
The first affinity maturation strategy is to supply very little of the immobilized antigen. The concept is
that the binders all compete with each other and at equilibrium, the tight binders keep the binding
spaces occupied. In practice, however, there are several complications to this concept. At extremely 
low target molecule concentrations, the relative proportion of unspecific binding sites gets very high
(BSA, neutravidin), so that great care has to be taken to avoid unspecific binders. Also, if medium
affinity binders outnumber the tight binders, the enrichment will be very slow. Finally, if binding is very 
tight, the equilibrium is reached exceedingly slow.
The second very successful strategy for affinity maturation is off-rate selection. The assumption
fundamental to off-rate selection is that the on-rate of most protein-protein interactions is in the range
of 105-106 M-1sec-1 (Wodak and Janin, 2002) and protein ligand interactions in the range of 106-107 M-
1sec-1, such that the affinity is largely governed by the off-rate. By first incubating the ribosome-
displayed polypeptide with biotinylated target molecule (typically for one hour) followed by the addition
of a large excess of non-biotinylated target (1000-fold excess), the selection pressure is governed by
the dissociation of the binders from the biotinylated target. While tight binders will remain bound to the
biotinylated target, others will dissociate and then rebind to the excess of unbiotinylated target. The
incubation time equals the selection pressure and should be adjusted to the expected off-rate. If the
recovery is poor, it is often useful to include a non-selective round to enrich the binders.
Evolution of Properties other than High Affinity Binding 
The selection strategies for molecular properties other than high affinity binding have been
summarised in the Introduction. A library can be evolved for these properties, just as it can be for 
affinity. It exceeds the scope of this chapter to discuss each strategy in detail, and there are many
more possibilities, which have not been experimentally explored.
Acknowledgment
The authors would like to thank all former and present members of the Plückthun laboratory involved
in ribosome display who helped in developing the present protocol. 
18
Ribosome Display 59
Amstutz et al. Ribosome Display: In vitro Selection of Protein-Protein Interactions
V. References 
Amstutz, P., Forrer, P., Zahnd, C. and Plückthun, A. (2001). In vitro display technologies: novel
developments and applications. Curr. Opin. Biotechnol. 12, 400-405.
Amstutz, P., Pelletier, J. N., Guggisberg, A., Jermutus, L., Cesaro-Tadic, S., Zahnd, C. and Plückthun,
A. (2002). In vitro selection for catalytic activity with ribosome display. J. Am. Chem. Soc. 124,
9396-9403.
Cadwell, R. C. and Joyce, G. F. (1994). Mutagenic PCR. PCR Methods Appl. 3, 136-140. 
Chen, H. Z. and Zubay, G. (1983). Prokaryotic coupled transcription-translation. Methods Enzymol.
101, 674-690.
Hanes, J., Jermutus, L. and Plückthun, A. (2000a). Selecting and evolving functional proteins in vitro
by ribosome display. Methods Enzymol. 328, 404-430.
Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H. R. and Pluckthun, A. (1998). Ribosome
display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries.
Proc. Natl Acad. Sci. USA 95, 14130-14135.
Hanes, J. and Plückthun, A. (1997). In vitro selection and evolution of functional proteins by using
ribosome display. Proc. Natl Acad. Sci. USA 94, 4937-4942.
Hanes, J., Schaffitzel, C., Knappik, A. and Plückthun, A. (2000b). Picomolar affinity antibodies from a
fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18,
1287-1292.
He, M. and Taussig, M. J. (1997). Antibody-ribosome-mRNA (ARM) complexes as efficient selection
particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 25,
5132-5134.
Irving, R. A., Coia, G., Roberts, A., Nuttall, S. D. and Hudson, P. J. (2001). Ribosome display and 
affinity maturation: from antibodies to single V- domains and steps towards cancer
therapeutics. J. Immunol. Methods 248, 31-45. 
Jermutus, L., Honegger, A., Schwesinger, F., Hanes, J. and Plückthun, A. (2001). Tailoring in vitro
evolution for protein affinity or stability. Proc. Natl Acad. Sci. USA 98, 75-80.
Kushner, S. R. (2002). mRNA decay in Escherichia coli comes of age. J. Bacteriol. 184, 4658-4665.
Laminet, A. A. and Plückthun, A. (1989). The precursor of beta-lactamase: purification, properties and
folding kinetics. Embo J. 8, 1469-1477.
Lesley, S. A. (1995). Preparation and use of E. coli S-30 extracts. Methods Mol. Biol. 37, 265-278. 
Leung, D. W., Chen, E. and Goeddel, D. V. (1989). A method for random mutagenesis of a defined
DNA segment using a modified polymerase chain reaction. Technique 1, 11-15.
Matsuura, T. and Plückthun, A. (2003). Selection based on the folding properties of proteins with
ribosome display. FEBS Lett. 539, 24-28.
Mattheakis, L. C., Bhatt, R. R. and Dower, W. J. (1994). An in vitro polysome display system for
identifying ligands from very large peptide libraries. Proc. Natl Acad. Sci. USA 91, 9022-9026.
Pratt, J. M. (1984). Coupled transcription-translation in prokaryotic cell-free systems. In Current
protocols (Hemes, B. D. and Higgins, S. J., eds.), pp. 179-209. IRL Press, Oxford.
19
60 Ribosome Display
Ribosome Display: In vitro Selection of Protein-Protein Interactions  Amstutz et al.
Schatz, P. J. (1993). Use of peptide libraries to map the substrate specificity of a peptide- modifying
enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli.
Biotechnology (New York) 11, 1138-1143.
Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens
on the virion surface. Science 228, 1315-1317.
Stemmer, W. P. (1994). Rapid evolution of a protein in vitro by DNA shuffling. Nature 370, 389-391.
Takahashi, F., Ebihara, T., Mie, M., Yanagida, Y., Endo, Y., Kobatake, E. and Aizawa, M. (2002).
Ribosome display for selection of active dihydrofolate reductase mutants using immobilized
methotrexate on agarose beads. FEBS Lett. 514, 106-110.
Wade, H. E. and Robinson, H. K. (1966). Magnesium ion-independent ribonucleic acid depolymerases
in bacteria. Biochem. J. 101, 467-479.
Wodak, S. J. and Janin, J. (2002). Structural basis of macromolecular recognition. Adv. Prot. Chem.
61, 9-73. 
Zaccolo, M. and Gherardi, E. (1999). The effect of high-frequency random mutagenesis on in vitro
protein evolution: a study on TEM-1 beta-lactamase. J. Mol. Biol. 285, 775-783.
Zaccolo, M., Williams, D. M., Brown, D. M. and Gherardi, E. (1996). An approach to random
mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. J.
Mol. Biol. 255, 589-603.
Zubay, G. (1973). In vitro synthesis of protein in microbial systems. Annu. Rev. Genet. 7, 267-287.
Ribosome Display 61
Amstutz et al. Ribosome Display: In vitro Selection of Protein-Protein Interactions
Addresses of Suppliers:
Avestin Europe GmbH
Weinheimer Str. 64b
D68309 Mannheim
Germany
Corning B.V. 
Life Sciences
Koolhovenlaan 12 
NL-1119 NE Schiphol-Rijk
The Netherlands
EMD Biosciences, Inc.
CALBIOCHEM®
10394 Pacific Center Court
San Diego, California 92121
USA
Eppendorf AG 
Barkhausenweg 1 
D-22339 Hamburg
Germany
FERMENTAS UAB 
V.Graiciuno 8,
Vilnius 2028 
Lithuania
Fluka
Industriestrasse 25 
CH-9471 Buchs
Switzerland
Hoffmann-La Roche Ltd, Diagnostics Division
Grenzacherstrasse 124
CH-4070 Basel
Switzerland
Invitrogen AG
Elisabethenstrasse 3 
Postfach 533 
CH-4019 Basel
Switzerland
Merck KGaA
Frankfurter Str. 250 
D-64293 Darmstadt
Germany
Millipore
290 Concord Rd. 
Billerica, MA 01821
USA
Molecular BioProducts, Inc.
9880 Mesa Rim Road 
San Diego, CA 92121-2979
USA
New England Biolabs, Inc.
32 Tozer Road
Beverly, MA 01915-5599
USA
NUNC
Kamstrupvej 90 
Postbox 280
DK-4000 Roskilde
Denmark
PerkinElmer
45 William Street
Wellesley, MA 02481-4078
USA
Pierce Biotechnology
P.O. Box 117
Rockford, IL 61105
USA
QIAGEN AG 
Auf dem Wolf 39 
CH-4052 Basel
Switzerland
Spectrum Laboratories, Inc. 
America and Asia Pacific
18617 Broadwick Street 
Rancho Dominguez, CA 90220
USA
Stratagene Corporate Office
11011 N. Torrey Pines Road
La Jolla, CA 92037
USA
21
 
 Chapter 4 
High-affinity Binders Selected from 
Designed Ankyrin Repeat Protein 
Libraries 
 
 
Contents 
High-affinity Binders Selected from Designed Ankyrin Repeat Protein Libraries  
Contents 63 
High-affinity Binders Selected from Designed Ankyrin Repeat Protein Libraries 65 
1. Introduction 65 
2. Results 65 
2.1 Designed AR protein libraries 65 
2.2 Ribosome-display selection against MBP 66 
2.3 Selected AR proteins show high affinity and specificity 67 
2.4 Selection of specific high-affinity MAPK binders 67 
2.5 Structure determination of off7 in complex with MBP 68 
64  Selection for Binders 
2.6 Analysis of the interaction of off7 and MBP 68 
2.7 A comparison to natural protein-protein interactions 69 
3. Discussion 69 
4. Methods 70 
5. Acknowledgements 72 
6. References 72 
7. Supplementary information 73 
Selection for Binders 65
A RT I C L E S
Repeat proteins are ubiquitous binding molecules fundamental to
many biological processes1–3. Their modular architecture is presum-
ably the key to their evolutionary success4. Repeat proteins are charac-
terized by consecutive homologous structural units (repeats), which
stack to form an elongated protein domain with a continuous
hydrophobic core3. In principle, this architecture allows their binding
specificities to evolve not only by point mutations but also by inser-
tion, deletion or shuffling of repeats5. This evolutionary strategy might
enable repeat proteins to acquire new functions by adjusting their sur-
face without jeopardizing their overall topology. AR proteins are one
prominent repeat protein family illustrating the binding versatility of
repeat proteins. They occur throughout all phyla and mediate protein-
protein interactions in the nucleus or cytoplasm, or while anchored to
the membrane or when secreted into the extracellular space6. AR pro-
teins are built from stacked, 33 amino acid repeats, each forming a 
β-turn that is followed by two antiparallel α-helices and a loop reach-
ing the β-turn of the next repeat7. In most known complexes, the 
β-turn and the first α-helix mediate the interactions with the target,
and different numbers of adjacent repeats are involved in binding7.
The reported target binding affinities of natural AR proteins are in the
low nanomolar range8,9.
In biotechnology and biomedical research, antibodies and fragments
thereof are the most widely used specific, high-affinity binding mole-
cules. Antibodies can be generated against essentially any target either
by immunization or by using natural or rationally designed antibody
libraries in vitro10,11. Yet, many antibodies have relatively low expression
yields, a tendency to aggregate and a dependence on disulfide bonds
for stability. An ideal alternative protein scaffold would have none of
these drawbacks while still exhibiting the same affinity and specificity
as antibodies. Previous attempts to generate alternative binding mole-
cules relied on either loop or surface randomization of protein scaf-
folds, which are typically small and always fixed in dimension12–14.
We present here the results of a different strategy15 to design and
select alternative protein scaffolds, relying on the modularity of AR
proteins (Fig. 1). We generated combinatorial libraries of consensus-
designed AR proteins of varying sizes (that is, varying repeat numbers)
with randomized potential interaction surfaces. Unselected library
members are very well expressed, soluble, thermodynamically stable
and show the typical AR domain fold16,17. Here, we show the success-
ful selection of binding molecules from these libraries, proving that
our design strategy works. We selected specific binders with high
affinities for the Escherichia coli maltose binding protein (MBP) and
two eukaryotic mitogen-activated protein kinases (MAPKs). The crys-
tal structure of one of the selected binders in complex with MBP was
determined, revealing atomic level insights into the mode of target
interaction of this class of designed binding molecules.
RESULTS
Designed AR protein libraries
We designed a consensus AR module consisting of six diversified
potential interaction residues (which can be any amino acid except
cysteine, glycine and proline) and 27 framework residues (26 are fixed
and one is allowed to be asparagine, histidine or tyrosine). This mod-
ule was designed from sequence alignments and structural analyses
(Fig. 1)16. The randomized potential interaction residues are located in
the β-turn and the first α-helix of the AR module. We cloned varying
numbers of this repeat module between capping repeats, which are
special terminal repeats of AR domains shielding the hydrophobic
1Biochemisches Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. 2These authors contributed equally to this work. Correspondence
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repeat protein libraries
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We report here the evolution of ankyrin repeat (AR) proteins in vitro for specific, high-affinity target binding. Using a consensus
design strategy, we generated combinatorial libraries of AR proteins of varying repeat numbers with diversified binding surfaces.
Libraries of two and three repeats, flanked by ‘capping repeats,’ were used in ribosome-display selections against maltose
binding protein (MBP) and two eukaryotic kinases. We rapidly enriched target-specific binders with affinities in the low
nanomolar range and determined the crystal structure of one of the selected AR proteins in complex with MBP at 2.3 Å
resolution. The interaction relies on the randomized positions of the designed AR protein and is comparable to natural,
heterodimeric protein-protein interactions. Thus, our AR protein libraries are valuable sources for binding molecules and,
because of the very favorable biophysical properties of the designed AR proteins, an attractive alternative to antibody libraries.
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core (Fig. 1). We thereby increased the size of the potential interaction
surface and potentiated its diversity. This strategy provided combina-
torial libraries of designed AR proteins with distinct repeat numbers.
The libraries were named N2C and N3C, indicating proteins had an
N-terminal capping repeat, two and three, respectively, designed (and
randomized) AR modules and a C-terminal capping repeat (Fig. 1).
We used the N2C and N3C libraries for the selections, because AR 
proteins of this length are very abundant in nature6. Unselected mem-
bers of these libraries were expressed in soluble form at about 200 mg/l
in E. coli shake flask cultures. These proteins were monomeric, showed
circular dichroism (CD) spectra indistinguishable from natural AR
proteins16 and the AR fold was confirmed by a crystal structure of an
unselected library member17. Similar to designed proteins in other
consensus repeat protein studies18,19, our designed AR proteins
showed high thermodynamic stability during unfolding induced 
by heat16 and denaturants17. Hence, the consensus-designed AR pro-
teins are stable scaffolds with large and modular potential interaction
surfaces. The theoretical diversities of these libraries are 5.2·1015 (N2C)
and 3.8·1023 (N3C)16. The DNA libraries used in the selections con-
tained at least 1010 individual members each as estimated from the
amount of ligated library DNA. The library diversities were further
increased in subsequent PCR cycles.
Ribosome-display selection against MBP
We chose E. coli MBP as the first target protein for evaluating our
libraries, because it can be obtained in large amounts in pure form and
because its structure is known (Protein Data Bank (PDB) entry
1LLS)20. We did the ribosome-display selections21 with biotinylated
MBP bound to neutravidin in microtiter plates. An enrichment of
binders was observed after the second selection round both for the
N2C and the N3C libraries. We performed a total of four to five selec-
tion rounds before analyzing single, selected library members.
We screened individual selected AR proteins for MBP binding by an
enzyme-linked immunosorbent assay (ELISA) using crude E. coli
extracts. Of 60 N3C AR proteins screened, 18 gave a specific signal
(signal/background ≥ 10), compared to 4 of 56 N2C molecules.
Sequencing of the 18 MBP binding N3C AR proteins revealed that
they could be divided into at least three sequence groups (see
Supplementary Fig. 1 online). However, identical clones were never
found and considerable diversity was left, indicating that an even more
stringent selection pressure could be applied. For the N2C clones the
sequence analysis was less conclusive because of the limited data set.
Nevertheless, some repeats of N2C molecules showed striking
sequence similarities to repeats of the selected N3C proteins. In both
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Figure 1 Construction of designed AR protein libraries. (a) Sequences of 
the N-terminal capping AR, the designed AR module and the C-terminal
capping AR. The secondary structure elements are indicated above the
sequences. The designed AR module consists of 26 defined framework
residues, six randomized potential interaction residues (red x, any of the 
20 natural amino acids except cysteine, glycine or proline) and one
randomized framework residue (z, any of the amino acids asparagine,
histidine or tyrosine). The designed AR module was derived via sequence
and structure consensus analyses16. (b) Schematic representation of the
library generation of designed AR proteins. Note that this assembly is
represented on the protein level, whereas the real library assembly is on 
the DNA level. By assembling an N-terminal capping AR (green), varying
numbers of the designed AR module (blue) and a C-terminal capping AR
(cyan), combinatorial libraries of designed AR proteins of different repeat
numbers were generated (side chains of the randomized potential interaction
residues are shown in stick-mode in red). (c) Ribbon representation of the
selected MBP binding AR protein off7 (colors as in b). This binder is derived
from a library consisting of a N-terminal capping AR, three designed AR
modules and a C-terminal capping AR. This figure was made with MolMol49.
a
b
Figure 2 Expression, purification and SPR analysis of selected AR proteins.
(a) Expression and purification of the selected MBP binders mbp3_16 (1),
off7 (2) and mbp3_5 (3). At OD600 = 0.6, the noninduced (– Ind.) cultures
were induced with 0.5 mM IPTG and grown for 4 h at 37 °C (+ Ind.). After
cell lysis, the AR proteins are in the soluble fraction (Sol.). Insol., insoluble
fraction. The proteins were then purified in a single IMAC purification step
(Purif.). (b) BIAcore analysis of off7. Different concentrations of off7 (0, 2,
5, 10, 20, 50 and 100 nM) were applied to a flow cell with immobilized
MBP for 2 min, followed by washing with buffer flow. The global fit is
indicated in the figure by red dashed lines (see Table 1 for the extracted
kinetic data).
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N2C and N3C molecules, aromatic residues appeared frequently and
thus seem to be important in the selected sequences (see
Supplementary Fig. 1 online).
Framework mutations were randomly scattered and occurred at low
frequencies but were present in all molecules (on average, 3.8 amino
acid mutations per N3C and 2.4 mutations per N2C molecule; see
Supplementary Fig. 1 online). Each library member went through at
least 450 PCR cycles (library generation and selection), which might
explain this finding. The mutations are mostly of a conservative
nature, and thus the fold of the AR domains is most probably not
affected by the alteration of the framework (see description of the
crystal structure below).
Selected AR proteins show high affinity and specificity
The selected AR proteins were expressed at high levels in soluble form
in the cytoplasm of E. coli (up to 200 mg/l) and purified to homogene-
ity by a single immobilized metal ion affinity chromatography (IMAC)
purification step (Fig. 2a). We screened 21 clones (4 N2C, 17 N3C) by
surface plasmon resonance (SPR). Using the purified AR proteins at
1 µM, we first compared the on- and off-rates of MBP binding. Three
AR proteins with slow off-rates were analyzed at multiple concentra-
tions and evaluated with a global kinetic fit (N2C: mbp3_16; N3C: off7
and mbp3_5) (Fig. 2b and Table 1). off7, a selected N3C molecule, had
the highest affinity for MBP (KD= 4.4 nM). The N2C molecule
mbp3_16 had a dissociation constant of KD= 17 nM. Hence, both N2C
and N3C molecules can be selected to bind MBP with high affinity.
Clones that went through five selection rounds had higher affinities
for MBP than clones that were selected through four rounds. In SPR
experiments, the N3C library member off7 was specific and did not
cross-react with phage lambda protein D22, streptavidin or the amino-
glycoside-3′-phosphotransferase APH(3′)-IIIa, a bacterial kanamycin
resistance protein23.
To further investigate specificity, ELISA experiments were done with
purified MBP-binding AR proteins (Fig. 3). mbp3_16, off7 and
mbp3_5 are specific for MBP and do not interact with phage lambda
protein D22, APH23 or neutravidin (Fig. 3a). In a competition ELISA
experiment, the binding of off7 to immobilized MBP could be inhib-
ited by preincubation with free MBP (Fig. 3b). The affinity estimated
from these experiments was consistent with the SPR measurements
(50% inhibition at 10 nM). The unselected N3C AR library member
E3_516,17 did not interact with MBP, indicating that the designed AR
domain scaffolds per se do not bind MBP (Fig. 3b).
At a concentration of 15 µM, off7 is monomeric (as indicated by
size exclusion chromatography) and shows a CD spectrum identical to
that of E3_5 (ref. 16), which has an AR domain fold17 (data not
shown).
Selection of specific high-affinity MAPK binders
To further evaluate the potential of our AR protein libraries, we 
chose the eukaryotic protein kinases JNK2 and p38 as our next target
proteins (see ref. 24 and references therein). We did a total of four 
ribosome-display selection rounds with the N2C library before com-
paring single, selected library members. Screening 15 clones each, we
obtained ten ELISA-positive JNK2 binders and ten ELISA-positive 
p38 binders. The sequence of one representative member for each of
these target-specific groups is given in Supplementary Figure 1 online.
These MAPK binders share many features of the selected MBP
binders. They have affinities in the low nM range (Table 1); they can be
expressed at high levels in soluble form in the cytoplasm of E. coli and
purified to homogeneity by a single IMAC purification step (data not
shown); their randomized positions are enriched in aromatic amino
acids (see Supplementary Fig. 1 online). To investigate their target
specificity, we did ELISA experiments with purified, selected AR 
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Table 1  Kinetic binding data of selected clones determined by
surface plasmon resonance
Target Clone name (length) kon [M–1s–1] koff [s–1] KD [M]
MBP off7 (N3C) 4.2·105 1.9·10–3 4.4·10–9
mbp3_5 (N3C) 2.0·105 4.4·10–3 22·10–9
mbp3_16 (N2C) 6.0·105 1.0·10–2 17·10–9
JNK2 JNK2_2_3 (N2C) 9.7·105 2.0·10–3 2.1·10–9
p38 p38_2_3 (N2C) 9.5·105 3.5·10–3 3.7·10–9
a
b
c
Figure 3 ELISAs with selected AR proteins. (a) Specificity of MBP binders.
The interaction of the proteins mbp3_16, off7 and mbp3_5 (each 50 nM;
control with no AR protein) with immobilized MBP, pD, APH and neutra-
vidin is shown. (b) Competition ELISA illustrating the interaction between
the selected AR protein off7 and MBP. off7 (5 nM) was incubated with
varying concentrations of free MBP before binding on immobilized MBP. 
The binding to MBP of off7 can be specifically inhibited by increasing
concentrations of free MBP in solution. An unselected AR protein of the N3C
library (*) showed no interaction with MBP (100 nM of E3_5)16,17, giving a
signal identical to that of the control (no AR protein on immobilized MBP).
(c) Specificity comparison of an MBP, a JNK2 and a p38 binder. The
interaction of 100 nM each of the proteins off7 (binds MBP), JNK2_2_3
(binds JNK2), p38_2_3 (binds p38) and E3_5 (unselected N3C library
member) with MBP, JNK2, p38, APH, pD and BSA is shown. Note that in 
all representations the background binding of the detection antibodies has
not been subtracted.
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proteins (Fig. 3c). All binders were highly specific for the target pro-
teins that were used to select them. Most importantly, the AR proteins
allow perfect discrimination between the homologous MAPKs (51%
identity and 59% similarity between JNK2 and p38 on the amino acid
level in our format).
Structure determination of off7 in complex with MBP
To validate our AR randomization scheme and to analyze the selected
interaction at the atomic level, we determined the crystal structure of
one binder (off7) in complex with MBP (see Methods). The phasing
problem was solved by molecular replacement using E3_5, a designed
N3C AR protein17 as a search model without using the phases of the
larger MBP. Hence, when used in cocrystallization studies, AR proteins
may serve as valuable tools to obtain first phases and finally the struc-
ture of its binding partner. The results of the data collection and ref-
inement are shown in Supplementary Table 1 online. As can be seen in
the crystal structure (Figs. 4 and 5), the AR protein binds the open
form of MBP20 creating an elongated complex. For the AR protein,
clear electron density starts at Ser12, but no or only very weak electron
density was observed for the N-terminal His6 tag. The electron density
is clear until the second-to-last amino acid
(Leu168). In the complex, the AR protein has
the typical AR domain fold and is highly sim-
ilar to the known structure of the designed
AR protein E3_5 (root-mean-square devia-
tion of the Cα atoms (r.m.s.d.Cα) < 1 Å)17.
The main differences between the two struc-
tures are found in the β-turn region of repeat
module 1 (second repeat), where the Cα chain
shows a maximal r.m.s.d.Cα of 2.1 Å. The 
H-bond network, which most probably stabi-
lizes the β-turn region17, is conserved and
undisturbed. off7 has three framework muta-
tions (K16R, N74D and H125Y) not present
in the library design, but they are conservative
and in accordance with the AR domain fold,
and only Y125 is involved in MBP binding
(see below).
MBP was found in the open conformation
with no ligand bound20. A superposition on
PDB entry 1LLS20 shows very few differences
(r.m.s.d.Cα < 0.9 Å). The N-terminal His6
tag and the C terminus of MBP are not
defined in the electron density. Clear density
extends from Gly19 to Gly387.
Analysis of the interaction of off7 with
MBP
The interaction of the AR protein off7 with
MBP was analyzed as described in the
Methods section. The only direct interaction
between off7 and MBP in the crystal lattice is
the selected heterodimer interface (Fig. 4).
Crystal packing contacts are mainly between
adjacent off7 molecules and between adjacent
MBP molecules. The heterodimer interface is
formed by the concave randomized surface of
the AR protein off7 (611 Å2 buried surface)
and a slightly larger convex surface on the
MBP (656 Å2 buried surface), resulting in a
total buried surface area of 1,267 Å2 (Fig. 5).
The off7/MBP complex is further characterized by six H-bonds and a
planarity index of 2.125. The details of the interaction are listed in
Table 2 and in Supplementary Table 2 online.
The interaction of off7 involves residues from all three randomized
repeat modules, although the randomized repeat modules 2 and 3
(constituting repeats 3 and 4 in the protein because of the capping
repeats) contribute more to the binding than the randomized repeat
module 1 does. In total, 9 out of 18 randomized potential interaction
residues are involved in the binding to MBP. The interface is character-
ized by a large number of aromatic residues, which account for 73% of
the buried surface area on off7 (Fig. 4 and Supplementary Table 2
online). Among these residues, the tyrosines cover 28% of the buried
surface area and are involved in four H-bonds (Tyr56, Tyr81, Tyr89
and Tyr125). In the interface (Fig. 4), tyrosines have a dual role being
both H-bond formers and hydrophobic contact mediators. Besides the
four tyrosines, Trp90 and Asp110 also form H-bonds. Three frame-
work residues (Leu86, Asp110 and Tyr125) form part of the interac-
tion surface. Two (Asp110 and Tyr125) form H-bonds to MBP (Fig. 4)
and the third (Leu86) is engaged in hydrophobic interactions.
Interestingly, Tyr125 is a framework mutation (H125Y). With the
578 VOLUME 22 NUMBER 5 MAY 2004  NATURE BIOTECHNOLOGY
a d
b
c
Figure 4 Crystal structure of the designed AR protein off7 in complex with MBP. (a,b) Two perpendicu-
lar views of the complex are shown. MBP is on the left (blue), off7 on the right (ochre). The interaction
residues are highlighted in stick-mode in red (off7) and blue (MBP), respectively. (c) A close stereo
view on the H-bond pattern in similar view as in b. Note that in this representation only residues
involved in H-bonds (green dashed lines) are shown. For orientation, some residues involved in 
H-bonding are labeled. Figure 4a–c were made with MolMol49. (d) Ligplot48 representation of the
interaction between MBP (chain B, blue) and off7 (chain A, red). H-bonds (in green) including the 
H-bond distances as well as residues and atoms involved in hydrophobic contacts (indicated by red 
or blue rays) are shown.
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exception of the high percentage of aromatic amino acids, the residue
composition of the off7 interface is comparable to other AR protein
complexes. However, the small and functionally biased set of only
seven structurally analyzed natural AR protein complexes limits the
comparison to their average amino acid composition in the binding
interface.
The interaction surface of MBP is located on helices H7, H9 and
H17 (Fig. 4 and Supplementary Table 2 online). Four lysines (Lys151,
Lys154, Lys214 and Lys216) are involved in four H-bonds and together
form approximately 60% of the buried surface area on the MBP sur-
face (Fig. 4). Every lysine of MBP is in contact with a tyrosine of off7
resulting in three H-bonds and five hydrophobic contacts (see
Supplementary Table 2 online). In general, the surface of the MBP is
rather negatively charged except for the spot where off7 binds, where
there is a positively charged surface patch formed by the four lysines.
A comparison to natural protein-protein interactions
We compared the off7/MBP complex to all available complex crystal
structures of AR proteins, to natural heterodimer complexes, to anti-
body-antigen complexes and to an affibody complex (see Methods
section and Table 2). The off7/MBP interaction is comparable to 
natural protein-protein interactions25. The 611 Å2 buried surface area,
one H-bond per 100 Å2 buried surface area and the planarity value of
2.1 of off7, are all within the normal parameters of heterodimer 
complexes (Table 2)25. The buried surface area is at the lower limit of
antibody-antigen complexes26, whereas the affinity is comparable to
high affinity monovalent antibody-antigen binding. Otherwise, all
values seem to fit the standard parameters for antibody-antigen com-
plexes quite well, but are also similar to those of heterodimer com-
plexes. Natural AR protein interactions can be very diverse in size,
composition and in the structural elements involved (Fig. 5 and
Table 2). Our randomization scheme of the β-turn and the first 
α-helix of the designed AR modules was based on crystal structures of
natural AR complexes, where it was clear that the AR scaffold is
directly used for binding16. Because 50% of the randomized target
interaction residues that were selected do indeed interact with MBP,
the interaction mode is very similar to that of natural AR proteins,
such as the GABPβ1 (Fig. 5), which partly inspired our library
design16. In comparison to the natural AR proteins, off7 has a slightly
smaller buried surface area but a higher H-bond density (Table 2).
Recently the structure of an affibody, another designed binding
molecule, based on the staphylococcal three-helix bundle protein A, in
complex with its target protein was published27. The complex shows a
slightly larger buried surface area than the off7/MBP complex but with
a comparable number of H-bonds (Table 2). The affibody has a 
thousand-fold lower affinity for its target28 than the AR protein off7 
does for MBP (KD = 6 µM vs. KD = 4.4 nM, respectively). This is pro-
bably because this affibody is in a molten globule state and assumes a
defined structure only upon binding29, leading to a loss of entropy that
reduces the overall free energy of binding and thus the observed affinity.
DISCUSSION
We designed AR protein libraries of varying repeat numbers using a
consensus design strategy15–17. Here we show the successful selection
of binding molecules from these libraries. The properties of the
designed AR proteins perfectly match the criteria for alternative scaf-
folds. They are expressed at a high level in soluble form, are
monomeric and do not contain any cysteines16. Unlike previously pre-
sented scaffolds (for reviews see refs. 12,13), which typically use either
randomized loops or a randomized surface on a given protein scaffold
for binding, AR proteins use both β-turns and a randomized surface.
Most importantly, they are not restricted in dimension because of
their modular architecture (Fig. 1). Thus, the interaction surface can
be adapted by adding more repeat modules. The favorable properties
of the molecules in the starting libraries seem to positively influence
both the speed of selection and its outcome. In only four to five 
ribosome-display selection rounds, we were able to enrich the pool in
specific, high-affinity protein binders from the N2C and N3C libraries,
which appears to be faster than ribosome-display selections from anti-
body single-chain Fv libraries30.
The selected AR proteins retain the advantageous properties of the
designed AR proteins, being expressed in high amounts in soluble
form and free of cysteines (Fig. 2). The selected clones specifically rec-
ognize the target protein against which they were selected and do not
cross-react with other proteins as shown by ELISA (Fig. 3). The affini-
ties of the selected clones are in the low nanomolar range (Table 1 and
Fig. 2), the association rates are in the typical range for protein-protein
interactions (that is, 105–106 M–1s–1)31 and the dissociation rates are in
the range of 10–2 to 2·10–3 s–1 (Table 1). We anticipate that these off-
rates can probably be improved further by a diversification step fol-
lowed by an off-rate ribosome-display selection round32. Such a
diversification step could involve not only classical error-prone PCR,
but also, more interestingly, strategies purely amenable to repeat pro-
teins such as repeat shuffling or repeat elongation.
The selected AR protein sequences contain a high number of aro-
matic residues (see Supplementary Fig. 1 online) and in the case of
off7, seven aromatic amino acids are involved in MBP binding (Fig. 4),
including four prominent tyrosines (Supplementary Table 2 online).
Interestingly, high tyrosine content has also been noted in antibody
binding sites26. The dual interaction role of tyrosine as H-bond former
and hydrophobic contact mediator (see Results)33 is probably the 
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Figure 5 Open sandwich illustrations of the interaction surfaces of AR
proteins and their targets. (a–c) GRASP50 shape complementarity represent-
ations of the interactions between off7 and MBP (shape complementarity,
0.739) (a), GABPβ1 and GABPα (PDB entry 1AWC; shape complementarity,
0.665) (b), and p18INK4c and CDK6 (PDB entry 1G3N; shape complement-
arity, 0.688) (c), respectively. The complex is shown on the left with the AR
proteins in a backbone worm representation (α-helices in blue, β-turns in
green) and the target protein in a surface representation. The open sandwich
surface representations are shown in the middle (AR proteins) and on the
right (targets). The contact areas are stained according to the shape
complementarities from orange (low) to red (high).
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reason for this accumulation. In addition, aromatic residues are gener-
ally enriched in protein-protein interaction interfaces25.
Apart from the high content of aromatic residues, the crystal struc-
ture of the off7/MBP complex reveals an interaction interface that is
comparable to that found in natural heterodimer and antibody-
antigen complexes (Table 2)25. It also shows that the AR protein binds
its target with the randomized amino acids (Fig. 4 and Supplementary
Table 2 online), hence validating our randomization scheme. In the
crystal structure of the complex, off7 shows the typical AR domain
fold with a high similarity to the unselected N3C library member E3_5
(ref. 17). In solution, the uncomplexed, monomeric off7 shows a CD
spectrum virtually identical to that of E3_5 (ref. 16). Thus, the back-
bone of off7 does not seem to be rearranged in a substantial way upon
binding to MBP but rather seems to interact in a key-to-lock mecha-
nism. Such a rigid-body interaction may be advantageous both for
affinity (low entropic costs upon binding) and specificity (conforma-
tional restriction). p18, a natural AR protein interacting with CDK4/6
(Fig. 5), also has a low r.m.s.d.Cα of < 0.9 Å between the complexed
(PDB entry 1G3N) and the uncomplexed (PDB entry 1IHB) AR pro-
tein. However, the interaction with CDK4/6 leads to structural alter-
ations in the target34. In contrast to those of the rigid AR domain
scaffolds, the binding site of antibodies seem to be able to adopt differ-
ent conformations. The loops of the complementarity-determining
region of typical protein binding antibodies can undergo substantial
changes upon binding35 and the loop flexibility might even be used to
accomplish multispecificity36.
Here, we have successfully validated our AR proteins as designed
binding molecules using MBP and two MAPKs as model targets, and
thus have introduced a binding molecule with very favorable proper-
ties. The combination of the high expression level of designed AR 
proteins (200 mg/l soluble protein in shake flasks), their high thermo-
dynamic stability (9.5 to 21 kcal/mol17), the absence of cysteines, the
fast enrichment of binders (four selection rounds), their low nanomo-
lar affinities along with high specificities and their modular architec-
ture compares favorably with reports on antibodies and other
alternative scaffolds (such as protein A28, lipocalins14, fibronectin37 or
green fluorescent protein38). Our results open the door for a number
of applications. Apart from being useful in capturing molecules on
protein chips or in affinity purification—typical applications for
designed binding molecules—designed AR proteins are especially
suited for intracellular applications. Their high stability, the absence of
disulfide bonds and the selectable high affinities are optimal prerequi-
sites for intracellular inhibitors39, where antibodies are less than ideal.
Generally, AR proteins are also conceivable in therapeutic applications,
which are currently a domain of recombinant antibodies. As we have
shown here, it is possible to both cocrystallize a target protein with a
designed binding AR protein and determine its crystal structure with
the help of the AR protein. Hence, designed binding AR proteins could
be used in cocrystallization and structure determination of proteins dif-
ficult to crystallize, similar to what has been shown with antibodies40.
METHODS
Molecular biology. Unless stated otherwise, all experiments were done accord-
ing to protocols found in reference 41. Enzymes and buffers were from New
England Biolabs (NEB) or Fermentas. All PCR reactions were done using the
proofreading Vent-polymerase (NEB).
Vectors used in antigen production. The different vectors that were prepared
for the present study are described in detail in the Supplementary Methods
online. pQEMBP (GenBank accession no. AY327141) was used for the expres-
sion of His-tagged, nonbiotinylated MBP. pAT224 (AY327139) was used for the
expression of His-tagged, biotinylated MBP. pAT222 (AY327137) was used for
the production of His-tagged, biotinylated pD. pAT222_JNK2 and
pAT222_p38 were used for the production of His-tagged, biotinylated JNK2
and p38, respectively. All pAT222 and pAT224 constructs carry an Avi tag for
biotinylation at the N terminus and a His6 tag at the C terminus. pBirAcm
(Avidity) was used for in vivo biotinylation.
Antigen production and purification. The biotinylated proteins pD, MBP,
JNK2 and p38 (plasmids pAT222, pAT224, pAT222_JNK2 and pAT222_p38)
were produced using in vivo biotinylation with plasmid pBirAcm in E. coli XL-1
Blue (Stratagene) according to the protocols of Avidity and QIAgen. Efficient
biotinylation was confirmed by ELISA and blotting with a streptavidin-alkaline
phosphatase conjugate (Roche) and mass spectrometry. Nonbiotinylated MBP
for the ELISA analysis and crystallization was produced in the same way as the
AR proteins16 using pQEMBP in E. coli XL-1 Blue. The protein purification was
carried out as described16.
Ribosome-display vector (pRDV; AY327136). The cloning of pRDV is
described in detail in the Supplementary Methods online. pRDV contains all
flanking DNA regions necessary for ribosome display: the T7-promoter, the
ribosomal binding site and an in-frame tolA gene spacer. Hence, by simple liga-
tion of the DNA encoding the combinatorial library into pRDV and by a PCR
using this ligation mix as template, all features necessary for ribosome display
are added to the library. The use of pRDV has the advantage that it always pro-
vides error-free library flanking regions and that it saves a number of working
steps compared to the standard PCR approach for library generation21.
Generation of combinatorial libraries. The AR protein library generation has
been described16. We changed that protocol in this study in that all ARs, that is,
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Table 2  Comparison between AR protein complexes and other protein-protein interactions
PDB entry Resolution ∆ASAa in Å2 No. H-bonds No. H-bonds/100 Å2 ∆ASAa No. of salt bridges Planarity No. of bridging H2O
1awc 2.2 853.62 5 0.58 0 2.30 3
1bi7 3.4 1205.5 7 0.29 4 2.50 0
1blx 1.9 845.4 11 1.30 1 2.50 12
1g3n 2.9 843.3 12 1.42 1 2.20 0
1ikn 2.3 763.96 2 0.26 n.d. 2.73 0
1oy3 2.1 1593.9 7 0.44 n.d. 4.01 10
1ycsb 2.2 713.7 7 1.00 1 2.60 1
1svx (off7/MBP) 2.3 611.2 6 1.00 0 2.10 0
1lp1 (Affibody) 2.3 848.9 6 0.71 0 2.00 2
Antibody-antigen complexesc – 777 ± 135 – 1.1 ± 0.5 – 2.2 ± 0.4 –
Heterodimeric protein-protein – 983 ± 582 – 1.1 ± 0.5 – 2.8 ± 0.9 –
complexes c
aSurface area per molecule occluded upon complex formation. b1ycs uses a different binding surface than the other AR proteins in this table. cAccording to ref. 25.
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the N-terminal capping AR, the designed repeat module and the C-terminal
capping AR were used as PCR products for the assembly of the libraries. In the
present study, both the N- and the C-terminal capping repeat were amplified by
PCR from cloned and verified sequences to reduce sequence errors. In this way,
AR protein libraries consisting of an N-terminal capping AR, two or three
designed AR modules and a C-terminal capping AR (N2C and N3C libraries)
were assembled. To convert the libraries to the ribosome-display format, they
were amplified by PCR using oligonucleotides EWT4 (5′-TTCCTCATGAGAG
GATCGCATCACCATCACCATCACGGATCCGACCTGGG-3′) and WTC4 (5′-
TTTGGGAAGCTTTTGCAGGATTTCAGC-3′) and ligated into pRDV using
the restriction enzymes BspHI (or NcoI for pRDV) and HindIII. The ligation
product was purified using QIAquick (QIAgen) columns. The purified ligation
served as template for a PCR using oligonucleotides RDVf1 (5′-CCTTTTGCT
CACATGACCCG-3′) and tolAk (5′-CCGCACACCAGTAAGGTGTGCGGTT
TCAGTTGCCGCTTTCTTTCT-3′). Thereby, combinatorial N2C and N3C
DNA libraries were generated in the ribosome-display format.
Ribosome display. The PCR-amplified libraries were transcribed and selections
were done as described21. For the selection, the biotinylated antigen was immo-
bilized as follows: neutravidin (66 nM, 100 µl/well; Pierce) in TBS150 (50 mM
Tris HCl, pH 7.4, 150 mM NaCl) was immobilized on a Maxisorp plate (Nunc)
by overnight incubation at 4 °C. The wells were then blocked with 300 µl 0.5%
BSA (Fluka) in TBS150 for 1 h at 23 °C. Biotinylated antigen (100 µl, 1 µM) in
TBS150 with 0.5% BSA was allowed to bind for 1 h at 4 °C. Before the ribo-
some-display round, the wells were extensively washed with washing buffer
WBT (50 mM Tris acetic acid, pH 7.5, 150 mM NaCl, 50 mM Mg(CH3COO
–)2,
0.05% Tween 20). A ribosome-display round consisted of two 30-min pre-
panning steps on neutravidin and a 1 h binding step on the target protein. After
washing, RNA purification and reverse transcription (with oligonucleotide
tolAk), a first PCR was done using oligonucleotides T7B (5′-ATACGAAAT
TAATACGACTCACTATAGGGAGACCACAACGG-3′) and tolAk. This RT-
PCR product was purified on an agarose gel and reamplified in a second PCR
using the same oligonucleotides. The second PCR product served as template
for the next round of ribosome display. The number of RT-PCR cycles was
reduced from 40 to 30 to 25 in the first three rounds to monitor the enrichment
of binders. Binders were analyzed after four or five rounds.
Analysis of selected binders. From the selected DNA pools, the AR open read-
ing frame was amplified by PCR and cloned into pQE30 (QIAgen) via
BamHI/HindIII (oligonucleotides: EWT3: 5′-TTCCGCGGATCCGAC-
CTGGG-3′ and WTC4). The DNA sequences were determined using standard
techniques. The sequences of the MBP binding proteins off7 (AY326424),
MBP3_5 (AY326425) and MBP3_16 (AY326426) have been deposited in
GenBank. The amino acid sequences of all sequenced clones are listed in
Supplementary Figure 1 online. For the ELISA screening, the crude extract of
0.6 ml protein expression cultures was used (expression according to QIAgen).
The cell pellets were lysed with 50 µl B-Per (Pierce) and the lysates were mixed
with 250 µl TBS500 (50 mM Tris HCl, pH 8.0, 500 mM NaCl) each. For quanti-
tative ELISA, BIAcore, CD, analytical gel-filtration and crystallization, single,
selected library members were produced on a liter scale and purified as
described16. CD spectroscopy and analytical gel-filtration were done as
described16 using 15 µM protein in TBS150 (pH 7.4).
ELISA. Biotinylated antigens were immobilized on neutravidin-coated plates as
described above. For the screening of the pools, 100 µl of the above crude
extracts were applied to wells with or without immobilized antigen for 1 h at 
4 °C. After extensive washing with TBS150, binding was detected with an anti-
RGS-His antibody (QIAgen; detects only the RGS-His6-tag of the AR protein,
not the His6-tag of the antigen), an anti-mouse-IgG-alkaline phosphatase con-
jugate (Pierce) and p-nitrophenylphosphate (Fluka). Quantitative ELISAs were
done in the same manner, except purified protein was used (see Fig. 3). For
competition ELISA, the purified AR protein off7 was incubated with varying
amounts of free MBP before (4 °C, 100 min) and during the binding reaction
(see Fig. 3).
Surface plasmon resonance (SPR). SPR was measured using a BIAcore 3000
instrument (BIAcore). The running buffer was 20 mM HEPES, pH 7.4,
150 mM NaCl and 0.005% Tween 20. A streptavidin SA chip (BIAcore) was
used with 480 RU biotinylated MBP immobilized (440 RU JNK2 and 450 RU
p38, respectively). The interactions were measured at a flow of 60 µl/min with 
5 min buffer flow, 2 min injection of MBP-binding AR protein in varying con-
centrations (10 pM to 200 nM) and an off-rate measurement of 40 min with
buffer flow. The signal of an uncoated reference cell was subtracted from the
measurements. Inhibition BIAcore measurements gave results similar to that of
the kinetic analyses (data not shown). The p38 and JNK2 binders were meas-
ured similarly, but with an injection time of 3 min. The kinetic data of the inter-
action were evaluated with a global fit using BIAevaluation 3.0 (BIAcore),
Scrubber (BioLogic software) and Clamp42.
Complex purification and crystallization. MBP and the selected MBP-binding
AR proteins off7, mbp3_5 and mbp3_16 were produced as described above.
The cell pellets of 1-liter bacterial culture of each MBP and off7 (or mbp3_5 or
mbp3_16) were pooled and then lysed using an Emulsiflex C5 (Avestin) fol-
lowed by additional sonication. The proteins were purified using an IMAC col-
umn as described16, followed by a preparative Superdex-75 (Amersham
Pharmacia) size exclusion chromatography step in 10 mM Tris HCl, pH 7.6 and
100 mM NaCl. For every protein mixture, the peak fraction with the smallest
molecular weight containing both MBP and the AR protein in equimolar
amounts, as determined by SDS-PAGE, was collected and used for crystalliza-
tion. Light scattering of these fractions was measured as described17. It showed
a monodisperse particle distribution for all three complexes. For the off7/MBP
complex (61.4 kDa calculated mass for the 1:1 complex) an average radius of
3.6 nm, equivalent to a hydrated particle of 95 kDa, was estimated, which corre-
sponds to a nonhydrated particle of 65 kDa. The off7/MBP complex crystal-
lized readily and was further analyzed. The protein complex was concentrated
to 26 mg/ml for crystallization. Initial crystallization screening was done in 
96-well, sitting drop, square well crystallization plates (Greiner Bio-One). The
reservoirs were filled with 100 µl reservoir solution using an 8-channel pipette
from a 2 ml 96-well, deep-well block into the crystallization plate. Using an 
8-channel pipette, 2 µl of reservoir solution were pipetted in the crystallization
well and mixed with 2 µl of protein solution. The initial crystals were refined
using standard techniques. The crystals used for data collection grew in about
2–3 weeks in 30% PEG 6000, 0.1 M Tris HCl pH 8–9, 100 mM NaCl in a hang-
ing drop experiment with 500 µl reservoir, 2 µl protein solution mixed with 2 µl
water and 2 µl reservoir solution. For data collection the crystals were soaked in
the mother liquid with 10% ethylene glycol for about 30 s to 1 min and flash
frozen in a cryostream at 100 K.
Data collection, reduction, structure solution and refinement. Data were col-
lected at the European Synchrotron Radiation Facility beamline ID14-1. The
data were processed using MOSFLM, SCALA and TRUNCATE43. The crystal
belonged to space group P21, with a Matthews coefficient of VM = 2.1 Å
3/Da,
corresponding to an estimated water content of 39%.
The crystal structure was determined by molecular replacement using the
program AmoRe44, with the structure of the unselected N3C library member
E3_5 (PDB entry 1MJ017) as a search model. A conventional AmoRe protocol
(rotation, translation, rigid body refinement) was applied yielding a solution.
This information was used to obtain a first electron density. At this point only
the AR protein was clearly visible in the electron density. A solvent flipping pro-
tocol was then applied to modify the map45. MBP in its open form (PDB entry
1LLS)20 was positioned in the resulting electron density using program O46.
Because about a third of MBP was visible, manual building would have been
feasible as well. The rest of the model building was carried out using the pro-
gram O46, the structure refinement was done in CNS45 resulting in a final
model with an R-factor of 19.5 % and an Rfree-factor of 24.9 % (Supplementary
Table 1 online).
Analysis of the complexes. The structural analysis of the complexes was done as
suggested25. H-bonds and hydrophobic interactions were calculated with
HBPLUS47, LIGPLOT48 and DIMPLOT48 using the default settings. Other
parameters were calculated using the protein-protein interaction server
http://www.biochem.ucl.ac.uk/bsm/PP/server/index.html25 or CNS45.
The atomic coordinates of the described complex were deposited in the PDB
(PDB-ID: 1SVX).
Note: Supplementary information is available on the Nature Biotechnology website.
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Supplementary information on methods: 
Antigen cloning and production: The vector for the expression 
of His-tagged, non-biotinylated MBP, pQE_MBP, was 
constructed by inserting the PCR amplified MBP gene into 
pAT115, a pAT37 derivative1, in which the NheI/XbaI fragment 
was replaced by the corresponding fragment of pQE60 
(QIAgen, Germany) to remove the additional NcoI site. The 
MBP gene was amplified from pMAL-c2X (New England 
Biolabs) with oligonucleotides MTS23 (5’-
GGGAATTCTCATGAAAACTGAAGAAGGTAAACTGG-3’) and 
MTS24 (5’-CGGGATCCAGTCTGCGCGTCTTTCAGG-3’), and 
the product was cloned into pAT115 with the restriction 
enzymes BspHI (or NcoI for pAT115) and BamHI.
The vectors for the expression of biotinylated, His-tagged pD 
(pAT222) or MBP (pAT224) were generated in several steps. 
The basis of the constructs is pAT194, which was itself 
generated in two steps. First, the NheI/XbaI fragment of 
pAT115 (contains the terminator as well as a silent 
chloramphenicol gene) was replaced by the sole terminator 
sequence of pQE30 (QIAgen), which was amplified by PCR 
using oligonucleotides MTS19 (5’-
GGGAATTCGCTAGCAGTACTGCGATGAGTGGCAG-3’) and 
MTS20 (5’-GCTCTAGAGCGGCGGATTTGTCC-3’), yielding 
pQc-pD. Second, the lacIq gene of pZS4-Int12 was PCR 
amplified using oligonucleotides MTS21 (5’-
GGGAATTCGCTAGCCTAGGGAAGGCGAAGCGGCATGC-
3’) and MTS22 (5’-GCTCTAGAGATTTCCCTCGACAATTCGC-
3’), cut with NheI/XbaI and inserted into XbaI-cut pQc-pD, 
yielding pAT194. This ligation allows the insertion of the lacIq
fragment in both orientations. We chose the orientation 
opposite to the T5 expression cassette. A functional test using 
E. coli strain BL21(DE3) showed that the plasmid pAT194 
provided functional lac repressor protein. 
pAT194 was used to construct the biotinylation vectors. For 
the insertion of the N-terminal biotinylation tag3,
oligonucleotides MTS33 (5’-
AATTCATTAAAGAGGAGAAATTAACTATGGCTGGTCTGAA
C-3’) and MTS34 (5’-
TATCGTTCAGACCAGCCATAGTTAATTTCTCCTCTTTAATG-
3’) as well as MTS35 (5’-
GATATCTTCGAAGCTCAGAAAATCGAATGGCACGAAGGTT
C-3’) and MTS36 (5’-
CATGGAACCTTCGTGCCATTCGATTTTCTGAGCTTCGAAG
A-3’) were annealed separately, phosphorylated using T4 
polynucleotide kinase and ligated into pAT194, previously cut 
with EcoRI/NcoI, yielding pAT215. A PCR was made with 
pAT215 as the template with oligonucleotides oli266 (5’-
CGTAGCTCAGCTCATTAGTGATGGTGATGGTGATGAGAAG
CTTGGGCTGCAGGTCGACCC-3’) and oli267 (5’-
ATCGGATCCATGGGCACCGCAACCGCGCCC-3’) and the 
resulting PCR product was cloned into pAT215 via 
NcoI/Bpu1102I, yielding pAT222. pAT222 has an ORF under 
the control of a T5 promotor, consisting of the biotinylation 
tag:phage lambda protein D:multiple cloning site:His6 tag. The 
phage lambda protein D in pAT222 has a truncated N-
terminus. This was done to reduce the size of the flexible N-
terminus in order to retain high level expression. pAT224, the 
vector for the production of biotinylated MBP, was generated 
on the basis of pAT222, replacing the protein D gene 
NcoI/BamHI by a PCR amplified MBP gene of pQE-MBP 
(oligonucleotides MBPavitagf (5’-
GAAGGTTCCATGGGGAAAACTGAAGAAGGTAAACTG-3’) 
and MTS24). 
The vectors for the expression of biotinylated, His-tagged 
JNK2 (pAT222_JNK2) and p38 (pAT222_p38) were generated 
by PCR cloning. The kinase templates4 were amplified using 
oligonucleotides jnk2f (5’-
TTCCGCGGATCCGGTACCTCCGACTCTAAATGTGACAGTC 
AG-3’) and jnk2r (5’-
AAACCCAAGCTTGTCGACAGCCTTCAAGG-3’) or p38f (5’-
TTCCGCGGATCCGGTACCTCTCAGGAGCGTCCGACCTTC
TACCGTCAGGAGCTGAACAAG-3’) and p38r2 (5’-
AAACCCCTGCAGGGGACTCCATCTCTTCTTGGTC-3’) and 
the PCR products were cloned into pAT222 via BamHI/HindIII 
(JNK2) or BamHI/PstI (p38). 
Protein production and purification: The biotinylated proteins 
pD, MBP, JNK2 and p38 (plasmids pAT222, pAT224, 
pAT222_JNK2 and pAT222_p38) were produced by in vivo
biotinylation with plasmid pBirAcm of Avidity Inc. (Denver, Co, 
USA) in E. coli XL-1 Blue (Stratagene, USA) according to the 
protocols of Avidity and QIAgen. Non-biotinylated MBP for 
analysis and crystallization was produced in the same way as 
the AR proteins5 using pQE-MBP in E. coli XL-1 Blue. The 
protein purification has been described5. Biotinylation was 
confirmed using ELISA and blotting with a streptavidin-alkaline 
phosphatase conjugate (Roche, Basel, Switzerland) and mass 
spectrometry. 
Ribosome-display vector (pRDV; AY327136): To create a 
vector suitable for ribosome display, E-lactamase (as a control 
insert6) was  
PCR amplified with oligonucleotides blaf (5’-
TATCCATGGCGGACTACAAAGATGACGATGACAAAGGATC
CCACCCAGAAACGCTG-3’) and rBLA (5’-
TTGCTTCTGAAGCTTTCCCCAATGCTTAATC-3’), cut with 
HindIII and ligated to the HindIII cut tolA gene6, which was 
amplified with the oligonucleotides tolAfor (5’-
TATACCCAAGCTTTATATGGCCTCGGGGGCCGAATTCGGA
TCTGGTGGCCAGAAGCAAGCTGAA-3’) and tolArev (5’-
GGAAGATCTCTACTACGGTTTGAAGTCCAATGG-3’). The 
resulting E-lactamase:tolA fusion construct was cut NcoI/BglII
and cloned into NcoI/BamHI cut pTFT747. The sequence of the 
resulting plasmid pRDV was verified using standard 
techniques.
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Supplementary Table 1. Statistics for data collection and refinement of the off7/MBP complex. 
Data collection: 
Space group       P21
Cell dimensions, Å     a= 74.68, b= 45.15, c= 79.57 D= J= 90.0, E= 107.24 
Resolution limits, Å       25.0 - 2.3 
Observed reflections     total: 385166 unique: 22902 
Completeness,%       98.7 (99.0)* 
Redundancy       2.9 
Rsym (% on I)       7.8 (34.8)* 
Refinement:
Resolution range, Å      2.3 
R-factor/Rfree, %       19.5/24.9 
Ordered water molecules      214 
rms deviation from ideal geometry:  
Bond lengths, Å        0.006 
Bond angles, °        1.14 
Average B factor, Å2       34.6 
* Numbers in parentheses refer to the highest-resolution shell. 
Supplementary Table 2. List of the major hydrophobic interactions and H-bonds in the off7/MBP complex. 
off7 interaction residue 
(repeat module #)a H-bond
b MBP interaction residue 
(helix #)a
THR  48 *c (1)         LYS 216 (H9) 
TYR  56 * (1)         LYS 216 (H9) 
TYR  56 * (1) OH<-NZ  (3.11 Å)        LYS 154 (H7) 
VAL  78 * (2)        SER 366 (H17) 
VAL  78 * (2)        GLY 367 (H17) 
PHE  79 * (2)        LYS 214 (H9) 
PHE  79 * (2)         VAL 210 (H9) 
PHE  79 * (2)         ALA 365 (H17) 
TYR  81 * (2)        LYS 214 (H9) 
TYR  81 * (2) OH<-ND2 (2.80 Å)        ASN 215 (H9) 
LEU  86   (2)         LYS 216 (H9) 
TYR  89 * (2)        ASN 215 (H9) 
TYR  89 * (2)         HIS 217 (H9) 
TYR  89 * (2) O<-NZ   (2.85 Å)        LYS 151 (H7) 
TRP  90 * (2) NE1->O  (3.08 Å)        ASN 215 (H9) 
TRP  90 * (2)         HIS 217 (H9) 
TRP  90 * (2)         ASP 150 (H7) 
ASP 110   (3) OD2<-NZ (2.68 Å)        LYS 214 (H9) 
ASP 112 * (3)         LYS 214 (H9) 
TRP 123 * (3)        LYS 151 (H7) 
TRP 123 * (3)         ALA 148 (H7) 
TYR 125   (3) OH<-NZ  (2.48 Å)        LYS 151 (H7) 
a
 A cut-off of 3.9 Å was applied for hydrophobic interactions. Bold entries denote residues contributing with more than 5% to the
total buried surface area. 
b
 A cut-off of 3.9 Å for donor-acceptor and 2.5 Å for hydrogen-acceptor was applied. 
c
 A star indicates that this amino acid is located in a randomized library position of off7. 
 
 Chapter 5 
Kinase Inhibitors from Designed Ankyrin 
Repeat Protein Libraries: Selection and 
Analysis 
 
Contents 
Chapter 5                                                                                                                      77 
Kinase Inhibitors from Designed Ankyrin Repeat Protein Libraries: Selection and  
Analysis                                                                                                                         77 
Contents                                                                                                                       77 
Intracellular Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin 
Repeat Proteins                                                                                                            79 
1. Introduction 79 
2. Materials and Methods 80 
3. Results 81 
3.1 Selection for APH binders with ribosome display 81 
3.2 Screening for APH inhibitors by replica plating 81 
3.3 In vivo performance (MIC) 82 
3.4 Expression profile of the selected AR proteins 83 
3.5 Size exclusion chromatography of AR proteins and complexes 83 
3.6 Binding constants and specificities of the inhibitors 84 
78  Kinase Inhibition 
3.7 In vitro inhibition of APH 84 
4. Discussion 84 
4.1 Intracellular protein inhibitors 85 
4.2 In vivo inhibition of APH 86 
4.3 Targeting eukaryotic protein kinases 86 
5. Acknowledgements 87 
6. References 87 
7. Supplemental Data 87 
 
Allosteric Inhibtion of Aminoglycoside Phosphotransferase by a Designed 
Ankyrin Repeat Protein                                                                                               90 
8. Introduction 91 
9. Results and Discussion 92 
9.1 The different Structure Determination and Overall Structure of mAPH/AR_3a 
Inhibitor Complex 92 
9.2 mAPH/AR_3a Conformations in the Asymmetric Unit 92 
9.3 mAPH/AR_3a Complex Structure 92 
9.4 Structural Differences of Free and Inhibited APH 93 
9.5 BIAcore analysis 96 
9.6 Inhibition 96 
9.7 Inhibition mechanism 97 
9.8 Comparison to other AR protein kinase inhibitors and Gleevec: implications for 
drug design and cell biology 98 
10. Experimental Procedures 100 
11. Acknowledgements 101 
12. References 101 
13. Supplemental Data 102 
Preview: Allostery Trumps Antibiotic Resistance                                                     104 
Kinase Inhibition 79
Intracellular Kinase Inhibitors Selected from Combinatorial
Libraries of Designed Ankyrin Repeat Proteins*□S
Received for publication, February 15, 2005, and in revised form, April 25, 2005
Published, JBC Papers in Press, April 25, 2005, DOI 10.1074/jbc.M501746200
Patrick Amstutz‡, H. Kaspar Binz‡§, Petra Parizek, Michael T. Stumpp, Andreas Kohl,
Markus G. Gru¨tter, Patrik Forrer¶, and Andreas Plu¨ckthun
From the Department of Biochemistry, University of Zu¨rich, Winterthurerstrasse 190, Zu¨rich CH-8057, Switzerland
The specific intracellular inhibition of protein activ-
ity at the protein level allows the determination of pro-
tein function in the cellular context. We demonstrate
here the use of designed ankyrin repeat proteins as
tailor-made intracellular kinase inhibitors. The target
was aminoglycoside phosphotransferase (3)-IIIa (APH),
which mediates resistance to aminoglycoside antibiot-
ics in pathogenic bacteria and shares structural homol-
ogy with eukaryotic protein kinases. Combining a selec-
tion and screening approach, we isolated 198 potential
APH inhibitors from highly diverse combinatorial li-
braries of designed ankyrin repeat proteins. A detailed
analysis of several inhibitors revealed that they bind
APH with high specificity and with affinities down to
the subnanomolar range. In vitro, the most potent inhib-
itors showed complete enzyme inhibition, and in vivo, a
phenotype comparable with the gene knockout was ob-
served, fully restoring antibiotic sensitivity in resistant
bacteria. These results underline the great potential of
designed ankyrin repeat proteins for modulation of in-
tracellular protein function.
In the postgenomic era, the functional analysis of the pro-
teins encoded in the genomes is the rate-limiting step in un-
derstanding cellular processes. Most approaches in use today
do not target the protein of interest directly but prevent its
synthesis, either by total gene knockout (e.g. by homologous
recombination), by antisense technologies, or by RNA interfer-
ence (RNAi)1 (1, 2). Although these technologies have gener-
ated remarkable insights into some intracellular protein func-
tions, they suffer from a number of limitations. Total gene
knockouts are often difficult to achieve and might even be
lethal to the studied organism. Furthermore, the effects can be
compromised by compensating changes in the regulation of
other genes. The effect of antisense technologies is often not
very strong. In a number of cases, even an 80% reduction of
mRNA has no effect on the phenotype caused by the protein (3).
Furthermore, the interpretation of results obtained from RNAi
can be complicated by the up-regulation of other genes, limita-
tion in specificity, and induction of the interferon response
(4, 5). Finally, all methods that prevent the synthesis of the
entire protein only allow the description of a loss-of-function
phenotype.
The use of molecules acting at the protein level is a comple-
mentary approach. This approach has the additional advan-
tage that single functions, domains or posttranslational modi-
fications of a protein may be targeted, without removing the
whole protein. Inhibitors of proteins can also be used in subse-
quent studies of the target protein in vitro and might then even
be used as first lead compounds in the drug discovery process or
at least simulate the effect of a future small molecule drug.
Both constrained peptides (6–9) and single-chain antibody
fragments (scFv (10)) have been applied for in vivo protein
inhibition. In most cases, it is rather difficult to obtain high-
affinity peptides to a target protein due to their high flexibility
and the resulting loss of peptide chain entropy upon binding,
limiting the free energy of binding, and thus the generation of
high-affinity antibody fragments to a given target has been
pursued more often (11). However, the drawback of antibodies
is that their functionality is compromised in the reducing en-
vironment inside the cell, since the stabilizing intramolecular
disulfide bonds are not formed (12). Whereas a number of
antibody frameworks have been reported that are stable in the
reducing environment (10, 13–15), the stability in the reducing
state still does not reach that of other proteins. The solution to
this problem is to use alternative binding proteins without
disulfide bonds. Such alternative scaffolds have been developed
(16–18), but only one intracellular selection for binding mole-
cules with the yeast two-hybrid system has been published
(19); no intracellular inhibitors have been reported to date.
We previously reported the generation of designed ankyrin
repeat (AR) proteins as high-affinity binders with a great po-
tential for intracellular applications (20, 21). Next to antibod-
ies, repeat proteins are the most abundant class of binding
molecules found in nature (22–24). They often act as intracel-
lular enzyme modulators (e.g. as inhibitors of kinases) (25).
Unlike antibodies, AR proteins do not contain disulfide bonds
and are found in all cellular compartments, mediating protein-
protein interactions with affinities in the nanomolar to picomo-
lar range. AR proteins are built of consecutive homologous
repeats, which assemble to form elongated domains with a
continuous hydrophobic core. The number of repeats found in
natural AR proteins varies from 2 to over 30 (26, 27). We used
* This work was supported by the Swiss National Centre of Compe-
tence in Research in Structural Biology and the Swiss Krebsliga. The
costs of publication of this article were defrayed in part by the payment
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this fact.
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THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 26, Issue of July 1, pp. 24715–24722, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 24715
80 Kinase Inhibition
this modular architecture to generate designed AR protein
libraries. By structure and sequence consensus analyses, we
engineered an AR module of 33 amino acids with fixed frame-
work residues and randomized potential interaction residues
(28). This module was used as building block to create combi-
natorial libraries of designed AR proteins of different repeat
numbers (Fig. 1). Members of these libraries are very well
expressed, monomeric in solution, highly soluble, and stable
(28). By x-ray crystallography, the expected AR domain fold
could be verified (29). Specific binders to maltose-binding pro-
tein (MBP) of Escherichia coli and two human mitogen-acti-
vated protein kinases (JNK2 and p38) have been selected with
dissociation constants in the low nanomolar range (20).
Here, we report the first tailor-made enzyme inhibitors based
on designed AR proteins. Using a combination of in vitro selection
and in vivo screening, we isolated designed AR proteins that
specifically bind and inhibit aminoglycoside phosphotransferase
type (3)-IIIa (APH). APH is a bacterial kinase conferring resist-
ance to aminoglycoside antibiotics (30) and can serve as a model
system, since it shows structural homology to eukaryotic protein
kinases (EPKs). We show that the selected AR proteins inhibit
APH both in vitro and in vivo. Based on these results, the use of
designed AR proteins as specific kinase inhibitors and as general
intracellularly active tools is discussed. We describe elsewhere
(31) the crystal structure of one selected APH-inhibiting AR
protein in complex with APH and report the details of the inhi-
bition mechanism of this particular inhibitor.
MATERIALS AND METHODS
Molecular Biology—Unless stated otherwise, all experiments were
performed according to the protocols of Ref. 32. Enzymes and buffers
were from New England Biolabs (Beverly, MA) or Fermentas (Vilnius,
Lithuania). Oligonucleotides were from Microsynth (Balgach,
Switzerland).
Antigen Cloning and Production—The APH gene was amplified from
the plasmid pETSACG1 (a kind gift from Prof. G. Wright (33, 34) with
the oligonucleotides APHf (5-GCCGGCCATGGGTACCGCTAAAATG-
AGAATA-3) and APHr (5-GCATAAGCTTTCATTAAAACAATTCATC-
CA-3). The PCR product was purified (QIAquick; QIAgen, Hilden,
Germany), cut with NcoI/HindIII, and ligated into pAT223 (GenBankTM
accession number AY327138), which is a pQE30 (QIAgen, Hilden,
Germany) derivative, yielding pAT223_APH. The expression from this
vector yields a fusion protein with an N-terminal avi tag for in vivo
biotinylation, phage  protein D (pD) as fusion protein, a His6 tag for
immobilized metal ion affinity chromatography (IMAC) purification,
and APH as target molecule (avi-pD-His6-APH).
Protein Production and Purification—The biotinylated proteins avi-
pD-His6-APH and avi-pD-His6 were produced according to protocols
from Avidity (Denver, CO) and QIAgen by in vivo biotinylation in E. coli
XL1-Blue (Stratagene, La Jolla, CA), which was co-transformed with
pBirAcm (Avidity) and pAT223 or pAT223_APH, respectively. Success-
ful biotinylation of the IMAC purified proteins was confirmed by detec-
tion of the biotin tag on immobilized proteins using ELISA and blotting
procedures with a streptavidin-alkaline phosphatase conjugate (Roche
Applied Science) as detection reagent.
Nonbiotinylated wild-type APH used for the in vitro kinetic assays
was expressed from pETSACG1 (33, 34) in BL21 cells (Stratagene) and
purified over a Q-Sepharose column (Amersham Biosciences), followed
by gel filtration (Superdex 75; Amersham Biosciences) as described (35)
with some modifications (for details, see Supplemental Data). The cor-
rect size of APH was confirmed by SDS-PAGE, mass spectrometry, and
multi-angle static light scattering.
For protein production of the AR proteins, the corresponding genes
were isolated from pQIA (see below) and inserted into pQE30 to avoid
co-purification of APH at a later stage. The proteins were expressed and
purified by IMAC as described (29).
In Vitro Selection with Ribosome Display—The PCR-amplified N2C
and N3C AR protein libraries (20) were transcribed, and selections were
performed by ribosome display as described (36) on avi-pD-His6-APH
immobilized over its biotinylated avi tag (for details, see Supplemental
Data). The number of total reverse transcription (RT)-PCR cycles after
each selection round was reduced from round to round from 40 to 35 to
30, adjusting to the yield due to enrichment of binders.
In Vivo Selection by Replica Plating—For the in vivo selection, the
vector pQIA was constructed with -lactamase and APH dicistronically
arranged under the control of the -lactamase promoter, as well as an
expression cassette for AR proteins under the control of an IPTG-
inducible T5-promoter (Fig. 3A). For details, see Supplemental Data.
The pools of binders selected by ribosome display were cloned into pQIA
using the restriction enzymes BamHI and HindIII, transformed into E.
coli (XL1-Blue) and plated on LB agar plates, containing 1% glucose, 50
g/ml ampicillin, and 100 M IPTG, and incubated overnight at 37 °C.
The colonies were replica-plated on selective plates containing 1% glu-
cose, 50 g/ml ampicillin, 500 g/ml kanamycin A, and 100 M IPTG
using Accutran replica plater devices (Schleicher & Schuell), incubated
for 2 h at 4 °C and finally incubated overnight at 37 °C. Colonies whose
replica failed to grow on the selective plates were taken up in LB and
replica-spotted again on selective plates to make sure no false positives
were selected due to incomplete replica plating. By this procedure, 198
kanamycin A-sensitive colonies were identified. All of these clones were
ranked for their kanamycin A sensitivity by spotting them on selection
plates with kanamycin A at concentrations of 50, 100, 250, and 500
g/ml. The plasmids of the most potent inhibitors were isolated and
sequenced using standard DNA sequencing.
Determining the Minimal Inhibitory Concentrations (MICs)—Cul-
tures of E. coli (XL1-Blue) harboring pQIA, encoding an AR protein,
were grown in LB with 1% glucose and 50 g/ml ampicillin (LB-Glc-
ampicillin) at 37 °C overnight. The cultures were diluted 1:30 into 5 ml
of the same medium and shaken at 37 °C until an A600 of 0.3 was
reached. The cultures were then diluted 1:1000 (2.5  105 colony-
forming units/ml) into deep well plates (Abgene, Epsom, Surrey, UK)
containing 1 ml of the different selection media: LB-Glc-ampicillin-
IPTG (100 M) plus kanamycin A (0, 1, 5, 10, 25, 50, 100, 150, 250, 500
or 1000 g/ml) and as a control LB-Glc-ampicillin with 1000 g/ml
kanamycin A (without IPTG) and shaken at 37 °C for 24 h. Growth was
monitored by following the A600. MIC end points were determined to be
the concentrations of aminoglycoside antibiotic where no visible growth
was obtained.
Analytical Size Exclusion Chromatography—Gel filtration experi-
ments were done on a SMART system (Amersham Biosciences) using a
Superdex 75 PC 3.2/30 column or a Superdex 200 PC 3.2/30 column
(Amersham Biosciences) at 20 or 37 °C. The void volume was experi-
mentally determined by using blue dextran. Samples of AR_1, AR_3a,
and AR_B (20 l) were loaded at a concentration of 25 M on the
Superdex 200 column and were run at 60 l/min in TBS150, pH 7.5
(50 mM Tris HCl pH 7.5, 150 mM NaCl), at 20 °C. Samples of APH and
APH in complex with the AR protein AR_3a (20 l) were loaded at a
concentration of 10 M on the Superdex 75 column and were run at 60
l/min in HEPES200 (50 mM HEPES, pH 7.5, 100 mM NaCl, 40 mM KCl,
60 mM MgCl2) at 37 °C. Cytochrome c (12.4 kDa), carbonic anhydrase
(29 kDa), bovine serum albumin (66 kDa), and -amylase (200 kDa)
were used as molecular mass standards.
ELISA—To determine the specificity of the interaction between the
selected AR proteins and APH, ELISA experiments were performed as
described (13). Biotinylated proteins (avi-pD-His6-APH, avi-pD-His6,
avi-pD-JNK2-His6, and avi-pD-p38-His6, final concentration 100 nM)
were immobilized in neutravidin-coated ELISA plates blocked with
bovine serum albumin (BSA). AR proteins (200 nM) were added for 30
min, and subsequently, the plates were washed five times. A first
antibody against the RGS-His6 tag of the AR protein (QIAgen; detects
only the RGS-His6 tag of the AR protein but not the His6 tag of the
antigen), followed by a secondary antibody/alkaline phosphatase conju-
gate (Pierce), was used for detection. After the addition of substrate
(p-nitrophenylphosphate; Fluka) and incubation at 37 °C for 45 min,
the A405 was measured in a plate reader. All incubation steps, including
the antibody or AR protein incubations, were carried out in TBS150 with
0.5% BSA and 0.05% Tween 20, whereas washing was done with TBS150
containing only Tween 20.
Surface Plasmon Resonance—SPR was measured using a BIA-
core3000 instrument (BIAcore, Uppsala, Sweden) at 20 °C. The running
buffer was 20 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM
dithiothreitol, 0.005% Tween 20. An SA chip (BIAcore) was used with
600 RU biotinylated avi-pD-His6-APH immobilized. The interactions
were measured at a flow of 60 l/min with 5-min buffer flow, 2-min
injection of APH-binding AR protein in varying concentrations (1–200
nM), and an off-rate measurement of 40 min with buffer flow. The signal
of an uncoated reference cell was subtracted from the measurements.
The kinetic data of the interaction were evaluated using BIAevaluation
3.0 (BIAcore), and global fits were used to determine KD. The affinities
of clones AR_3a and AR_3b were confirmed by competition BIAcore
(Supplemental Data).
Designed Ankyrin Repeat Proteins as Intracellular Inhibitors24716
Kinase Inhibition 81
In Vitro Inhibition Studies—APH activity assays were performed
essentially as described (35) with small modifications to facilitate inhi-
bition studies. Briefly, the kinase buffer we used (50 mM HEPES, pH
7.5, 160 mM NaCl, 40 mM KCl, 10 mM MgCl2, 0.025% BSA, 5 units of
pyruvate kinase/lactate dehydrogenase, 2.5 mM phosphoenolpyruvate,
0.12 mg/ml NADH, 1 mM ATP) contains HEPES instead of Tris and
additionally 160 mM NaCl, 0.025% BSA, and a lower concentration of
NADH (0.12 instead of 0.5 mg/ml). APH was present at a concentration
of 200 nM, whereas the AR proteins were present at 10 M for the
kanamycin A studies. This mixture (990 l) was preincubated for 15
min, and the assay was initiated by the addition of 10 l of kanamycin
A solution (K4000; 10 M final concentration; Sigma). Both the prein-
cubation and the assay were carried out at 37 °C. For the studies with
amikacin, both the preincubation and the assay were carried out at
20 °C in the presence of 2 M AR proteins, and the reaction was started
with 10 l of amikacin solution (A1774; 740 M final concentration;
Sigma). The initial rates were normalized for background activity by
subtracting the activity monitored in the absence of substrate.
RESULTS
To identify APH inhibitors, we applied a two-step approach
of in vitro selection and in vivo screening. First, we used ribo-
some display to select APH binders from highly diverse combi-
natorial AR protein libraries. The resulting pools of binders
were subsequently screened for inhibitors by replica plating. As
APH mediates bacterial resistance to aminoglycoside antibiot-
ics, inhibitors of the enzyme give rise to a kanamycin-sensitive
phenotype.
Selection for APH Binders with Ribosome Display—The AR
protein libraries used here (20) were termed N2C and N3C. The
digit describes the number of designed and randomized AR
modules between the N- and C-terminal capping repeats in the
library members (Fig. 1). Three rounds of ribosome display
selection were carried out for both the N2C and the N3C AR
protein libraries in parallel. Selections were performed using
purified target protein. For this purpose, APH was expressed
as a fusion to bacteriophage  pD (37) with an N-terminal avi
tag for in vivo biotinylation (38) and a His6 tag in the linker for
IMAC purification (avi-pD-His6-APH). This target protein and
the same construct without the kinase (avi-pD-His6) were ex-
pressed in soluble and biotinylated form in E. coli by using the
expression plasmids pAT223_APH and pAT223, respectively.
For ribosome-display selections, purified biotinylated APH was
immobilized on neutravidin-coated wells blocked with BSA. To
eliminate BSA-, neutravidin-, and avi-pD-His6-binding library
members, a prepanning step on correspondingly immobilized
avi-pD-His6 was applied, where neutravidin and BSA were also
present. In the actual panning step, binders to APH were thus
selected. The relative amounts of ribosomal complexes binding
to the target protein can be estimated by monitoring the yield
from RT-PCR on agarose gels. We observed a significant in-
crease of RT-PCR yield when comparing the results from the
first and the second selection round (Fig. 2). To our knowledge,
such pronounced enrichment after only one round of ribosome
display selection has not been reported for any kind of naive
library (scFv, cDNA, or random sequence). This might indicate
that AR protein libraries and ribosome display are a very
favorable combination. In the third selection round, the se-
lected pools of binders were analyzed for their specificity, com-
paring the RT-PCR yields after selection against APH or the
unrelated MBP (Fig. 2). High specificity to APH could be mon-
itored by comparing the agarose gel band intensities of these
RT-PCR products (Fig. 2). In summary, we observed a rapid
enrichment of binders and generated pools of specific binders in
only three rounds of ribosome-display selection.
Screening for APH Inhibitors by Replica Plating—The pools
of specific binders were subjected to an in vivo screen, based on
replica plating, to identify those APH-binding AR proteins that
are also inhibitors. For this purpose, the selected pools of bind-
ers were cloned into the selection vector pQIA (Fig. 3A). This
vector carries an expression cassette for the selected APH
binders under the control of an IPTG-inducible T5 promoter.
FIG. 1. Designed AR protein libraries. A, AR protein libraries are
made from building blocks of designed self-compatible library modules
with randomized positions (red), for potential target interaction and
capping modules, which shield the hydrophobic core (blue). A varying
number of library modules are genetically fused between an N- and a
C-terminal capping repeat (N-cap and C-cap), yielding AR protein li-
braries of a specific size. B, an N3C library consists of proteins made
from three random library modules, flanked by an N- and a C-terminal
capping repeat. C, space-filling representation of an unselected N3C
library member. The constant regions are colored in gray, and the
library positions are depicted in red. The large potential interaction
surface spans one side of the molecule (Protein Data Bank code 1MJ0)
(29). For further details, see Refs. 21 and 28.
FIG. 2. Enrichment and specificity of ribosome display selec-
tion rounds. The outcome of ribosome-display selection rounds was
monitored at the level of RT-PCR product yield by agarose gel electro-
phoresis. The RT-PCR yield of the first and the second selection round
were compared for both the N2C and N3C library. In the third round,
the specificities of the selected pools of the N2C and the N3C library
were checked by panning against APH and an unrelated protein, MBP.
All experiments were done in duplicates, which were combined for the
agarose gel. For the specificity check of panning on the control protein
MBP, both N2C and N3C duplicates were combined.
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pQIA also carries -lactamase and APH as dicistronic genes
under the control of the constitutively active -lactamase pro-
moter. Hence, this vector confers antibiotic resistance to ampi-
cillin and kanamycin, of which the kanamycin resistance can
be reverted, if an APH-inhibiting AR protein is expressed upon
IPTG induction (Fig. 3A). As a control, we tested E. coli trans-
formed with a pQIA variant harboring the unselected AR pro-
tein E3_5 (29) in the expression cassette. These cells were able
to grow on plates with kanamycin A at concentrations of1000
g/ml, regardless of the presence of IPTG.
The pools of binders were cloned into pQIA and plated under
nonselective conditions (ampicillin, IPTG, no kanamycin A).
About 1000 colonies from the N3C pool and 2000 colonies from
the N2C pool were subsequently replica-plated under selective
conditions (ampicillin, IPTG, kanamycin A (500 g/ml)). By
this procedure, 129 N3C and 69 N2C clones were identified
that showed a kanamycin-sensitive phenotype.
The identified clones were ranked for their in vivo inhibition
efficiency by spotting them on selective plates with different
kanamycin A concentrations, ranging from 10 to 500 g/ml,
and the most potent clones were sequenced. The sequencing
revealed that variants of one potent inhibitor (AR_3 family)
dominated the N3C inhibitor population, but also other se-
quences had been selected. Four different APH inhibitors
(named AR_1, AR_2, AR_3a, and AR_3b), with different in vivo
performances, were chosen for further characterization (for
sequences see Supplemental Data). Whereas AR_1 was se-
lected from the N2C library, AR_2, AR_3a, and AR_3b came
from the N3C library. AR_3a and AR_3b differ by three point
mutations at the DNA level, causing two amino acid mutations.
We also studied the properties of clone AR_B, an N2C molecule
that binds APH but fails to inhibit the target enzyme. As a
further control, the unselected AR protein E3_5 (28, 29) was
tested in parallel. The characterization of these AR proteins
included expression tests, determination of minimal inhibitory
concentrations (MICs), ELISA, BIAcore, and gel filtration stud-
ies as well as in vitro enzyme inhibition experiments.
In Vivo Performance (MIC)—The MICs of kanamycin A nec-
essary to inhibit cell growth in liquid culture experiments were
determined for the selected AR proteins. The plasmid pQIA
with the nonbinding control AR protein E3_5 as insert medi-
ated resistance to kanamycin A (MIC  1000 g/ml) regardless
of the presence of IPTG, showing that the expression of an AR
protein per se has neither an influence on kanamycin A resist-
ance nor on bacterial growth. Clone AR_B showed the same
phenotype as E3_5 (Fig. 3B). All AR proteins conferring kana-
mycin A sensitivity did not influence E. coli growth by them-
selves, even when induced, as long as no kanamycin A was
present (Fig. 3B). In contrast, induction of the inhibitors
stopped growth at different kanamycin A concentrations rang-
ing from 10 to 150 g/ml (Table I and Fig. 3B). Whereas clones
AR_1 and AR_2 had MICs of 100 g/ml and 150 g/ml, respec-
tively, clones AR_3a (25 g/ml) and AR_3b (10 g/ml) were
more potent inhibitors (Table I). To put these results into
perspective, we also evaluated the natural resistance of E. coli
to kanamycin A in the absence of APH. The MIC of E. coli
carrying a pQIA variant, where the APH gene had been re-
moved, expressing AR_B or AR_3a was found to be 5 g/ml
each. Taken together, these results lead to the conclusion that
the most potent clones AR_3a and AR_3b showed a phenotype
comparable with the APH gene knockout.
Expression of the Selected AR Proteins—Since the selected
AR proteins bind and inhibit APH inside the cell, we analyzed
the expression of the selected clones in the selection vector
pQIA under the expression conditions used for screening. Since
the exact intracellular concentration of the AR proteins is dif-
ficult to determine, we performed a qualitative comparison of
the selected clones by comparing the AR protein band intensi-
ties on Coomassie-stained SDS-PAGE. All AR proteins were
expressed as soluble proteins regardless of the vector and the
expression conditions (Fig. 4, A and B). The expression levels of
clones AR_1, AR_3a, and AR_3b seem to be similar and around
2-fold higher than the one of clone AR_2. For in vitro studies,
we recloned the AR proteins into an expression vector (pQE30)
to avoid co-purification of APH. All AR proteins could be puri-
fied to homogeneity in a single IMAC step by means of their
His6 tag (Fig. 4C). Around 100 mg of purified AR protein was
obtained from a standard 1-liter shake flask culture when
expressed from the pQE30-derived vectors, without optimiza-
tion of the expression and purification procedure. Even under
selection conditions, where expression is not fully induced, the
AR proteins show the most prominent bands on the gel (Fig.
4B). Since APH did not give rise to a pronounced band on the
gel, the inhibitors must be present in large excess over APH in
E. coli during screening.
Size Exclusion Chromatography of AR Proteins and Com-
plexes—The selected AR proteins free or in complex with APH
were analyzed by gel filtration experiments. Whereas most
previously investigated AR proteins are monomers (20, 21),
different oligomerization tendencies, depending on the individ-
ual protein, were detected for the AR proteins described here
(Fig. 5A). AR_1 was monomeric, AR_B was present as monomer
FIG. 3. Phenotype of the selected clones. A, the selection vector pQIA, carrying the -lactamase (BLA) and APH gene for ampicillin and
kanamycin resistance under a constitutive promoter in a dicistronic arrangement and the IPTG-inducible AR protein gene. Induction of the AR
protein can result in inhibition of APH, if the AR protein has inhibitory properties, yielding a kanamycin-sensitive phenotype. B, the plating results
of four APH inhibitors (AR_1, AR_2, AR_3a, AR_3b), one APH binder (AR_B), and an unrelated AR protein (E3_5) are shown. E. coli XL1-Blue cells
were transformed with pQIA, carrying the respective genes in the AR protein cassette and plated under different conditions: nonselective in the
case of only IPTG (100 M), where the AR protein is expressed but no kanamycin A is present or if only kanamycin A is present (200 g/ml) but
the AR protein is not expressed; selective where the combination of IPTG and kanamycin A creates an environment where inhibitors repress
growth.
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and trimer, and AR_2, AR_3a, and AR_3b appeared to be a
mixture of monomer, dimer, and soluble multimer (see Fig. 5A
for data of AR_B, AR_1, and AR_3a). Reapplying single peaks
from AR_3a resulted in a similar elution pattern, indicating
equilibrium between the oligomeric states. The exact molecular
weight of the different species was verified for AR_1 and AR_B
by static multi-angle light scattering (data not shown). Clone
AR_1 (14.8 kDa) was determined to have an apparent molecu-
lar mass of 15.2 kDa, and clone AR_B (14.8 kDa) of 15.9 and
49.1 kDa. The molecular weight of the presumably monomeric
and dimeric species of AR_3a and AR_3b could not be deter-
mined by static light scattering, since the peaks strongly over-
lapped. Since AR_1 and most other selected and unselected
library members are monomers (20, 21), it seems likely that the
oligomerization behavior is a consequence of the particular
selected interaction residues of the individual AR proteins.
The complexes of the AR proteins with APH were also ana-
lyzed by gel filtration experiments. All complexes gave one
distinct symmetric peak, which was shifted to higher molecular
weight, compared with the one of APH alone, and which corre-
sponded to the correct molecular weight of the complex. For
example, the complex of APH and AR_3a eluted in a single
peak at an apparent molecular mass of about 47 kDa (calcu-
lated molecular mass 49.6 kDa; Fig. 5B), although AR_3a alone
eluted in various oligomeric states (Fig. 5A). The complexes
showed no signs of oligomeric states, supporting the hypothesis
that the selected binding interfaces of the AR proteins are
responsible for and may be directly involved in the observed
partial oligomerization of some AR proteins (Fig. 5A). Binding
of the target thus abolishes oligomerization and leads to a
defined 1:1 APH-AR protein complex. Indeed, co-purification of
an APH mutant bound to AR_3a was used successfully for
crystallization and structure determination of the complex as
described elsewhere (31).
Binding Constants and Specificities of the Inhibitors—To
investigate the binding properties of the selected AR proteins,
the affinity and the specificity of the interaction were analyzed
by ELISA and BIAcore studies. In an ELISA experiment with
purified AR proteins of all analyzed clones, the binding to APH
was compared with the binding to other proteins, such as pD,
JNK2, p38, BSA, and neutravidin (Fig. 6). p38 and JNK2 are
two EPKs (39) sharing structural homology to APH. The se-
lected AR proteins bind specifically to APH but not to any of the
other proteins (Fig. 6). As expected, the unselected AR protein
E3_5 fails to bind any of the immobilized proteins. We conclude
that specific APH-binding AR proteins were selected.
To determine the dissociation constants of the selected AR
proteins to APH, kinetic surface plasmon resonance experi-
ments were performed. The dissociation constants of all APH
binders were found to be in the low nanomolar to subnanomo-
lar range (Table I). KD values of the two high-affinity inhibitors
AR_3a and AR_3b were verified by competition BIAcore (40);
for details, see Supplemental Data. The surface plasmon reso-
nance data were fitted with the assumption that all species
(monomer and dimer; see above) share the same binding prop-
erties or convert to monomers upon binding. If this is not the
case, the KD values given here reflect the average of all states.
In Vitro Inhibition of APH—To confirm that the in vivo
effects of the selected AR proteins were indeed due to direct
inhibition of the APH, in vitro enzyme assays were performed.
Enzyme activity was monitored by coupling the release of ADP
to a pyruvate kinase/lactate dehydrogenase reaction as de-
scribed previously (35) with some modifications to adapt the
assay for the inhibition studies (see “Materials and Methods”).
The inhibition assay was set up to mimic the in vivo situation,
where the AR protein concentration is higher than the one of
APH and the kanamycin A concentration is low, since it has
been suggested that kanamycin A import is the rate-limiting
process (41). For all clones showing a kanamycin A-sensitive
phenotype in vivo, enzyme inhibition was detected, whereas
the control proteins E3_5 and AR_B showed almost no influ-
ence on APH activity (Fig. 7). Under these conditions (200 nM
APH, 10 M AR protein, kanamycin as substrate), the inhibi-
tion was not complete; a remaining activity, ranging from 6
to 52%, depending on the individual inhibitor, was found
(Fig. 7A). The kinetic experiments with kanamycin A were,
however, complicated by an apparent substrate inhibition at
low micromolar concentrations (Fig. 7C). Substrate inhibition
had previously been described at higher kanamycin A concen-
TABLE I
Summary of ankyrin properties
Construct MICa Expression levelb KD
c kon
c koff
c
g/ml nM M1 s1 s1
No APHd 5
E35e 1000 
ARBf 1000  28.6  16.2 (1.4  0.5)  105 (4.1  0.8)  103
AR1 100  19.0  10.0 (1.2  0.4)  105 (2.2  0.4)  103
AR2 150  8.1  6.5 (2.8  1.0)  105 (2.3  1.0)  103
AR3a 25  1.7  1.3 (1.6  0.6)  106 (2.7  0.9)  103
AR3b 10  0.5  0.4 (2.5  1.5)  106 (1.1  0.4)  103
a With kanamycin A.
b Estimated from corresponding band intensities from Coomassie-stained SDS-PAGE of whole cell extracts (Fig. 4A).
c Apparent values as described under “Materials and Methods,” independently rounded.
d Control of E. coli, where no APH is present.
e Control of an unselected AR protein (28).
f Control of a selected binder, which did not show in vivo or in vitro inhibition.
FIG. 4. Expression and purification analysis of selected AR
proteins. The proteins were visualized on a 15% SDS-PAGE stained
with Coomassie Brilliant Blue. A, expression of AR proteins under
selection conditions: pQIA in E. coli XL1-Blue, carrying the respective
genes in the AR protein cassette, induced with 100 M IPTG. Cells were
collected 4 h after induction and lysed in loading buffer. B, preparative
expression of AR proteins with pQE30 (does not contain the APH gene)
in E. coli XL1-Blue, induced with 500 M IPTG. Cells were collected 4 h
after induction and lysed in loading buffer. Crude extracts are shown.
C, single step IMAC-purified AR proteins from the soluble E. coli
fraction of the preparative expression. The size marker is indicated in
kDa.
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trations (35). The measurements were thus repeated with ami-
kacin, another aminoglycoside substrate of APH containing an
additional hydroxybutyrate group, which does not show sub-
strate inhibition and has a similar turnover rate (35) (Fig. 7, C
and D). For this substrate, APH activity was reduced to 2–73%,
depending on the respective AR inhibitor, whereas control pro-
teins E3_5 and AR_B show almost no influence on activity
(Fig. 7B). Thus, the overall in vitro inhibition of APH by the AR
proteins using amikacin as substrate was similar to that ob-
served when using kanamycin A (Fig. 7A), with almost com-
plete inhibition for AR_3a and AR_3b (Fig. 7B). A more detailed
characterization of AR_3a is given elsewhere, including precise
titration analysis and structural insights in the inhibition
mechanism (31).
The different inhibition efficiencies of the selected inhibitors
seem to correlate well with the differences in KD values and
their inhibition performance in vivo (Table I). Nevertheless, it
is worth commenting on the fact that residual activities were
found at a concentration of AR proteins that is 103- to 104-fold
above the KD values determined by BIAcore analysis. Some of
the APHAR protein complexes may indeed possess a residual
activity. However, there are other possible factors leading to
this observation: (i) the presence of the substrates, ATP and
aminoglycoside, acting as competitors for a distinct conforma-
tion of APH, which will raise KI correspondingly above the KD
values; (ii) increased KD values of the complexes as a result of
different assay conditions of the kinetic measurements (e.g.
increased temperature and different buffer composition); (iii)
overestimation of the concentration of active AR proteins due to
some degree of oligomerization (Fig. 5A).
One more difference should be noted: the inhibition of APH
by AR_1 was less efficient with amikacin as a substrate (73%
residual APH activity) than with kanamycin A (43% residual
APH activity) under the assay conditions (Fig. 7, A and B). In
vivo tests revealed that AR_1, in contrast to the other inhibi-
tors, did not increase the amikacin sensitivity of E. coli har-
boring the appropriate plasmid but displayed the same pheno-
type as the noninhibitors E3_5 and AR_B (data not shown).
These results suggest that amikacin can compete more effi-
ciently than kanamycin A with the binding of AR_1 to APH.
In summary, all AR proteins tested showed direct inhibition
of APH, although the inhibition was not complete except for
AR_3b and AR_3a and might be substrate-specific in the case of
AR_1.
DISCUSSION
Methods that are able to directly and specifically interfere
with the function of a protein of interest intracellularly are
necessary to validate results obtained from gene knockouts and
especially from RNAi and antisense approaches. In addition,
they give further insights into the target protein itself. The
difficulty to create specific and intracellularly active binders
and inhibitors to most proteins has, however, so far constituted
FIG. 5. Size exclusion chromatography of selected AR proteins
alone and in complex with APH. The arrows indicate the elution
volumes of the marker proteins (MW in kDa given above the arrow) and
of blue dextran (BD). A, elution profiles of the AR protein clones AR_1,
AR_3a, and AR_B from a Superdex 200 column. Clone AR_1 (14.8 kDa)
eluted at an apparent molecular mass of 17 kDa; clone AR_3a (18.6
kDa) eluted at 400, 49, and 27 kDa; and clone AR_B (14.8 kDa) eluted
at 52 and 20 kDa. B, elution profiles of APH and APH in complex with
the AR protein AR_3a from a Superdex 75 column. The apparent
molecular masses of the APHAR_3a complex (49.5 kDa) and APH (30.9
kDa) are 47 and 34 kDa, respectively.
FIG. 6. Binding specificities of the selected AR proteins. The
interaction of the selected AR proteins (ARB, AR1, AR2, AR3a, and
AR3b; all 200 nM) with immobilized APH was compared with the
interaction with immobilized pD, p38, JNK2, neutravidin, and BSA. As
a control, an unselected library member (E35; 200 nM) was included.
The error bars show the standard deviation between three cells. The
background binding of the detection antibodies was not subtracted.
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a bottleneck in elucidating the function of many proteins. By
the rapid generation of selective high affinity intracellular
enzyme inhibitors, we demonstrate here that designed AR pro-
teins have the potential to solve this problem. The most potent
inhibitors lead to a phenotype that is comparable with a gene
knockout. This potency is achieved by a combination of factors;
the selected AR proteins are free of disulfide bonds, they are
able to fold well and are stable in the reducing intracellular
environment, they are expressed in soluble form at high levels
in the cytoplasm, and the interaction with the target enzyme is
of high affinity and specificity. The combination of these factors
leads to a clear advantage of AR proteins as intracellular in-
hibitors over antibodies, peptides, or other binding proteins
reported so far.
Intracellular Protein Inhibitors—The approach to obtain in-
tracellular protein inhibitors presented here, based on designed
AR proteins, is very promising. Whereas high affinities are
rather difficult to achieve with peptidic binders (except in the
case of target proteins with pronounced binding pockets), the
affinity and specificity of antibodies and designed AR proteins
are good and comparable. The main drawback of antibodies for
intracellular applications is that their stabilities rely on disulfide
bonds, which cannot form in the reducing intracellular environ-
ment. Consequently, low levels of soluble functional protein and
limited half-life of the antibody domains, due to aggregation, are
the rule when applied in the cytoplasm (12). In this respect, the
high intracellular expression level and stability of designed AR
proteins is a clear advantage. It seems highly probable that these
properties were responsible for the fact that we could identify not
only a few individual but many different functional inhibitors,
although the selection system described here selects for intracel-
lular stability and enzyme inhibition at the same time. Several
approaches have been described to generate antibodies that are
active intracellularly (for details, see reviews (10, 15)). Although
the inhibition of enzymes in vitro by antibodies has often been
described (42–44), only a few of these inhibitors have been ap-
plied intracellularly (45).
Besides antibodies and AR proteins, other protein scaffolds
have been used for the generation of enzyme inhibitors. Differ-
ent high-affinity protease inhibitors have been generated based
on protease-inhibitor scaffolds (54), and the function of -lac-
tamase inhibitory protein BLIP has been improved (46). These
scaffolds mostly exploited naturally occurring enzyme inhibi-
tors that were improved for affinity or specificity. All of these
inhibitors contain disulfide bonds and were used for extracel-
lular or periplasmatic applications.
In Vivo Inhibition of APH—The choice of APH as a model
system was guided by several aspects of the enzyme. APH
phosphorylates aminoglycoside antibiotics (e.g. streptomycin,
kanamycin, or amikacin), mediating bacterial resistance to
these antibiotics. This allowed the set-up of an efficient screen-
ing assay for the identification of inhibiting AR proteins (Fig.
3). Most importantly, APH displays high structural homology
to EPKs (30), a class of enzymes involved in a wide range of
diseases (see below). Finally, no satisfactory APH inhibitors
are known to date that are active in vivo. Whereas different in
vitro inhibitors of APH have been described in the literature
(47, 48), they fail to inhibit bacterial growth efficiently. We
describe here the first inhibitors that are fully functional in
vivo and show a phenotype comparable with the APH gene
knockout. Although the selected AR proteins are per se not
suitable as antibiotic agents on their own, they could in the
future accelerate the process of drug discovery by providing a
detailed structure of the drug target in an inactive state. This
FIG. 7. Inhibition properties of selected AR proteins and substrate-specific in vitro kinetics of APH. A and B, the enzymatic activity
of APH (200 nM) was determined with and without a large excess of AR protein present. A, with kanamycin A as substrate (10 M) and AR proteins
at a concentration of 10 M, E35 and ARB have no significant influence on APH activity, whereas the other AR proteins reduce the activity to
6–52%, depending on the inhibitor. B, with amikacin as substrate (740 M) and in the presence of 2 M AR proteins, the corresponding APH activity
is reduced to 2–73%. Again, the control proteins E35 and ARB show no significant influence on APH activity. For AR3b, the inhibition is
essentially complete. C and D, APH kinetics were measured at 37 °C using 50 nM purified monomeric APH, as described under “Materials and
Methods,” and two different substrates, kanamycin A (C) and amikacin (D). Initial velocities are plotted against substrate concentrations. C, when
using kanamycin A as a substrate, a pronounced apparent partial substrate inhibition in the low micromolar range was observed. At high
kanamycin A concentrations, kobs reaches 1.64 s
1. Although substrate inhibition of kanamycin A was previously reported (34), it seemed to be
observed at lower substrate concentrations under our experimental conditions. D, the activity of APH followed Michaelis-Menten kinetics when
using the substrate amikacin. The initial rates were fitted by nonlinear least squares fitting using the standard Michaelis-Menten equation. The
determined Km and kcat values were 418  29 M and 6.56  0.17 s
1, respectively.
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aspect is discussed elsewhere (31), where the crystal structure
of the selected AR protein AR_3a in complex with an APH
mutant is described.
Targeting Eukaryotic Protein Kinases—EPKs receive wide-
spread interest, since they are key players in cellular signaling,
making them targets for the treatment of a number of diseases,
such as various cancers, asthma, and autoimmunity to name a
few (49). In the case of EPKs, highly selective inhibitors are
desired (for a recent review on the EPK inhibitor field see Ref.
50). However, the generation of specific EPK inhibitors is dif-
ficult, due to the large number of EPKs (about 518 in humans
(49)), all sharing highly homologous active sites and using ATP
as a co-factor. Most inhibition strategies involve targeting of
the ATP binding pocket by small molecular weight drugs. This
is not ideal, since this region of EPKs is highly conserved, and
thus specificity is difficult to achieve and is further complicated
by the high ATP level inside the cell (1 mM) that must be
competed. Indeed, APH is inhibited by some EPK inhibitors,
which on the one hand underlines the structural homology of
APH and EPKs and on the other hand also demonstrates the
poor specificity of these EPK inhibitors (51). Proteinaceous
inhibitors could represent an attractive alternative, since they
can interact via a large surface and, therefore, their binding is
not restricted to grooves. This enables them to bind to the less
conserved surface regions on the target protein while blocking
its function.
It is noteworthy that many natural AR proteins are kinase
inhibitors, such as for example the cell division kinase inhibi-
tors p16INK4a and p19INK4d (52, 53). We have already success-
fully demonstrated the selection of mitogen-activated protein
kinase binders from designed AR protein libraries (20). Again,
the selected pools of binders might serve as starting points for
inhibitor screens, in this case using an in vitro activity assay.
Since mitogen-activated protein kinases are part of signaling
networks, functional inhibition might not only be achieved by
inhibition of the catalytic site, but also by simple binding,
provided that the inhibitor blocks either the protein substrate
or the activation of the kinase itself by an upstream kinase.
Although our approach can be applied now as a discovery tool,
therapeutic intracellular applications of designed AR proteins
will have to await further maturation of gene therapy or pro-
tein uptake techniques.
Acknowledgments—We thank Christian Zahnd for valuable discus-
sions and the groups of Prof. A. Plu¨ckthun and Prof. M. Gru¨tter for an
inspiring working atmosphere. We also thank David D. Boehr and Prof.
Gerard D. Wright for help and discussion of APH kinetics.
REFERENCES
1. Dove, A. (2002) Nat. Biotechnol. 20, 121–124
2. Dykxhoorn, D. M., Novina, C. D., and Sharp, P. A. (2003) Nat. Rev. Mol. Cell
Biol. 4, 457–467
3. Visintin, M., Meli, G. A., Cannistraci, I., and Cattaneo, A. (2004) J. Immunol.
Methods 290, 135–153
4. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., and Williams, B. R.
(2003) Nat. Cell. Biol. 5, 834–839
5. Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao,
M., Li, B., Cavet, G., and Linsley, P. S. (2003) Nat. Biotechnol. 21, 635–637
6. Colas, P., Cohen, B., Jessen, T., Grishina, I., McCoy, J., and Brent, R. (1996)
Nature 380, 548–550
7. Cohen, B., Ko Ferrigno, P., Silver, P. A., Brent, R., and Cohen, B. A. (2000)
Proc. Natl. Acad. Sci. U. S. A. 97, 13720–13725
8. Norman, T. C., Smith, D. L., Sorger, P. K., Drees, B. L., O’Rourke, S. M.,
Hughes, T. R., Roberts, C. J., Friend, S. H., Fields, S., and Murray, A. W.
(1999) Science 285, 591–595
9. Kamb, A., and Caponigro, G. (2001) Curr. Opin. Chem. Biol. 5, 74–77
10. Cattaneo, A., and Biocca, S. (1999) Trends Biotechnol. 17, 115–121
11. Hoogenboom, H. R., and Chames, P. (2000) Immunol. Today 21, 371–378
12. Biocca, S., Ruberti, F., Tafani, M., Pierandrei-Amaldi, P., and Cattaneo, A.
(1995) Bio/Technology 13, 1110–1115
13. Wo¨rn, A., and Plu¨ckthun, A. (1998) FEBS Lett. 427, 357–361
14. Auf der Maur, A., Zahnd, C., Fischer, F., Spinelli, S., Honegger, A., Cambillau,
C., Escher, D., Plu¨ckthun, A., and Barberis, A. (2002) J. Biol. Chem. 277,
45075–45085
15. Lobato, M. N., and Rabbitts, T. H. (2003) Trends Mol. Med. 9, 390–396
16. Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhle´n, M., and Nygren,
P.-Å. (1997) Nat. Biotechnol. 15, 772–777
17. Koide, A., Bailey, C. W., Huang, X., and Koide, S. (1998) J. Mol. Biol. 284,
1141–1151
18. Xu, L., Aha, P., Gu, K., Kuimelis, R. G., Kurz, M., Lam, T., Lim, A. C., Liu, H.,
Lohse, P. A., Sun, L., Weng, S., Wagner, R. W., and Lipovsek, D. (2002)
Chem. Biol. 9, 933–942
19. Koide, A., Abbatiello, S., Rothgery, L., and Koide, S. (2002) Proc. Natl. Acad.
Sci. U. S. A. 99, 1253–1258
20. Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P.,
Gru¨tter, M. G., and Plu¨ckthun, A. (2004) Nat. Biotechnol. 22, 575–582
21. Forrer, P., Stumpp, M. T., Binz, H. K., and Plu¨ckthun, A. (2003) FEBS Lett.
539, 2–6
22. Andrade, M. A., Perez-Iratxeta, C., and Ponting, C. P. (2001) J. Struct. Biol.
134, 117–131
23. Kobe, B., and Kajava, A. V. (2001) Curr. Opin. Struct. Biol. 11, 725–732
24. Bork, P. (1993) Proteins 17, 363–374
25. Chan, F. K., Zhang, J., Cheng, L., Shapiro, D. N., and Winoto, A. (1995) Mol.
Cell Biol. 15, 2682–2688
26. Sedgwick, S. G., and Smerdon, S. J. (1999) Trends Biochem. Sci. 24, 311–316
27. Mosavi, L. K., Cammett, T. J., Desrosiers, D. C., and Peng, Z. (2004) Protein
Sci. 13, 1435–1448
28. Binz, H. K., Stumpp, M. T., Forrer, P., Amstutz, P., and Plu¨ckthun, A. (2003)
J. Mol. Biol. 332, 489–503
29. Kohl, A., Binz, H. K., Forrer, P., Stumpp, M. T., Plu¨ckthun, A., and Gru¨tter,
M. G. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 1700–1705
30. Hon, W. C., McKay, G. A., Thompson, P. R., Sweet, R. M., Yang, D. S., Wright,
G. D., and Berghuis, A. M. (1997) Cell 89, 887–895
31. Kohl, A., Amstutz, P., Parizek, P., Binz, H. K., Briand, C., Capitani, C., Forrer,
P., Plu¨ckthun, A., and Gru¨tter, M. G. (2005) Structure, in press
32. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A
Laboratory Handbook, 2nd Ed., Cold Spring Harbor Laboratory Press, New
York
33. Boehr, D. D., Thompson, P. R., and Wright, G. D. (2001) J. Biol. Chem. 276,
23929–23936
34. Thompson, P. R., Hughes, D. W., and Wright, G. D. (1996) Chem. Biol. 3,
747–755
35. McKay, G. A., Thompson, P. R., and Wright, G. D. (1994) Biochemistry 33,
6936–6944
36. Hanes, J., and Plu¨ckthun, A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94,
4937–4942
37. Forrer, P., and Jaussi, R. (1998) Gene (Amst.) 224, 45–52
38. Beckett, D., Kovaleva, E., and Schatz, P. J. (1999) Protein Sci. 8, 921–929
39. Davis, R. J. (2000) Cell 103, 239–252
40. Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H. R., and Plu¨ck-
thun, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14130–14135
41. McKay, G. A., and Wright, G. D. (1995) J. Biol. Chem. 270, 24686–24692
42. Sun, J., Pons, J., and Craik, C. S. (2003) Biochemistry 42, 892–900
43. Desmyter, A., Spinelli, S., Payan, F., Lauwereys, M., Wyns, L., Muyldermans,
S., and Cambillau, C. (2002) J. Biol. Chem. 277, 23645–23650
44. Lauwereys, M., Arbabi Ghahroudi, M., Desmyter, A., Kinne, J., Holzer, W., De
Genst, E., Wyns, L., and Muyldermans, S. (1998) EMBO J. 17, 3512–3520
45. Jobling, S. A., Jarman, C., Teh, M. M., Holmberg, N., Blake, C., and Verho-
eyen, M. E. (2003) Nat. Biotechnol. 21, 77–80
46. Huang, W., Zhang, Z., and Palzkill, T. (2000) J. Biol. Chem. 275, 14964–14968
47. Burk, D. L., and Berghuis, A. M. (2002) Pharmacol. Ther. 93, 283–292
48. Kotra, L. P., Haddad, J., and Mobashery, S. (2000) Antimicrob. Agents Che-
mother. 44, 3249–3256
49. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S.
(2002) Science 298, 1912–1934
50. Noble, M. E., Endicott, J. A., and Johnson, L. N. (2004) Science 303, 1800–1805
51. Daigle, D. M., McKay, G. A., and Wright, G. D. (1997) J. Biol. Chem. 272,
24755–24758
52. Russo, A. A., Tong, L., Lee, J. O., Jeffrey, P. D., and Pavletich, N. P. (1998)
Nature 395, 237–243
53. Brotherton, D. H., Dhanaraj, V., Wick, S., Brizuela, L., Domaille, P. J., Volya-
nik, E., Xu, X., Parisini, E., Smith, B. O., Archer, S. J., Serrano, M.,
Brenner, S. L., Blundell, T. L., and Laue, E. D. (1998) Nature 395, 244–250
54. Stoop, A. A., and Craik, C. S. (2003) Nat. Biotechnol 9, 1063–1068
Designed Ankyrin Repeat Proteins as Intracellular Inhibitors24722
Kinase Inhibition 87
21
Supplemental Data
In vitro selection with ribosome display - The PCR amplified N2C and N3C AR protein libraries (13)
were transcribed and selections were performed by ribosome display as described (29) on avi-pD-His6-
APH immobilized over its biotinylated avi-tag. For the selection, the biotinylated antigen was
immobilized as follows: neutravidin (100 µl/well, 66 nM; PIERCE, Rockford, IL, USA) in TBS150 (50
mM Tris-HCl pH 7.4, 150 mM NaCl) was immobilized in a Maxisorp plate (Nunc; Roskilde,
Denmark) overnight at 4°C. The wells were then blocked with 300 µl 0.5% BSA (Fluka; Buchs,
Switzerland) in TBS150 for 1 h at 23°C. One hundred µl biotinylated antigen (concentration
approximately 500 nM) in TBS150 with 0.5% BSA were then bound to the immobilized neutravidin for
1 h at 4°C. Prior to the ribosome display round, the wells were extensively washed with washing
buffer containing Tween-20 (WBT; 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM MgCl2, 0.05%
Tween-20) (29). A standard round consisted of a 30-minute pre-panning step on neutravidin, another
pre-panning step of 30 minutes on avi-pD-His6, to avoid selecting binders against BSA, neutravidin or
pD, followed by a 60-minute panning step on avi-pD-His6-APH (bound to neutravidin, blocked with
BSA). Following selection, RNA purification and RT (with oligonucleotide tolAk), a first PCR was
made using oligonucleotides T7B (5’-
ATACGAAATTAATACGACTCACTATAGGGAGACCACAACGG-3’) and tolAk (5’-
CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGCCGCTTTCTTTCT-3’). This RT-PCR product
was agarose-gel purified and reamplified in a second PCR using the same oligonucleotides. This
second PCR product served as template for the next round of ribosome display. The number of total
RT-PCR cycles was reduced from round to round from 40 to 35 to 30, adjusting to the yield due to
enrichment of binders.
Construction of selection vector for replica screening - For the in vivo selection, the vector pQIA was
constructed with  -lactamase and APH dicistronically arranged under the control of the  -lactamase
promoter, as well as an expression cassette for AR proteins under the control of an IPTG-inducible
T5-promoter (Fig. 3A). For this purpose, the APH gene was PCR amplified from pETSACG1 with the
oligonucleotides APHsspf (5’-
TTTCAATATTTTAAAACAATTCATCCAGTAAAATATAGTATTTTATTTTC-3’) and APHsspr
(5’-TTCAATAATATTGAAAAAGGAAGAGTATGGCTAAAATGAGAATAT-3’). The PCR
product was purified, cut with SspI and ligated into pQI_pD (pAT194, GenBank accession number
AY327142), a pQE30 derivative with additional lacIq gene and pD under the control of the T5
promoter, cut with the same enzyme, to yield pQIA_pD, where the APH open reading frame lies
directly downstream of the one of  -lactamase in dicistronic manner. The proper function of the APH
gene was confirmed by successful growth of XL1-Blue cells harboring pQIA_pD in the presence of 50
µg/ml kanamycin A. For later cloning of the APH-binding AR protein pool, the multiple cloning site
and pD of pQIA_pD was replaced with the one of pPANK (GenBank accession number AY327140)
containing the unselected AR protein E3_5 (GenBank accession number AY195853), yielding the in
vivo selection plasmid pQIA containing the naïve AR protein E3_5 gene as a dummy insert under the
control of the IPTG-inducible T5 promoter (Fig. 3A). The pools of binders selected by ribosome
display were cloned into pQIA using the restriction enzymes BamHI and HindIII, replacing the E3_5
gene, transformed into E. coli (XL1-Blue) and plated on LB agar plates, containing 1% glucose, 50
µg/ml ampicillin and 100 µM IPTG, and incubated overnight at 37°C.
Protein production and purification - Non-biotinylated wild-type APH used for the in vitro kinetic
assays was expressed from pETSACG1 in BL21 cells (Stratagene) and purified over a Q-Sepharose
column (Amersham Pharmacia, Dübendorf, Switzerland), followed by gel-filtration (Superdex 75;
Pharmacia) as described (28) with some modifications.
After expression, the cell pellet of one liter bacterial culture was resuspended in 25 ml TBS500 (50 mM
Tris-HCl pH 8.0, 500 mM NaCl). The cells were lysed using an Emulsiflex C5 (Avestin, Ottawa, ON,
Canada). The cell debris was pelleted by centrifugation at 30'000 g for 30 minutes at 4°C. The
resulting supernatant was applied to a 25 ml Q-Sepharose column (Amersham Pharmacia, Dübendorf,
Switzerland) equilibrated with buffer 1 (50 mM Tris-HCl pH 8.0). APH was eluted by a linear
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gradient with increasing buffer 2 (50 mM Tris-HCl pH 8.0, 1 M NaCl). Fractions containing APH
were identified by SDS-PAGE analysis, pooled, and 10 mM MgCl2 and 2 mM dithiothreitol (DTT)
were added. APH was further purified by a preparative Superdex-75 (Amersham Pharmacia,
Dübendorf, Switzerland) size exclusion chromatography step in 50 mM HEPES pH 7.5, 200 mM
NaCl, 10 mM MgCl2 and 2 mM DTT, according to the published protocol (Hon et al., 1997). The peak
fraction with an approximate molecular weight of the monomeric APH was collected and used for
further experiments. The correct size of APH was confirmed by SDS-PAGE, mass spectrometry and
static light scattering.
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Supplemental Figures
Supplemental Figure S1 - Sequences of the selected AR proteins. The N-terminal capping repeat is
coloured in blue, the two or three randomized repeats are in black and the C-terminal capping repeat is
in red. E3_5 is an unselected AR protein; AR_1, AR_2, AR_3a and AR_3b are APH inhibitors, while
AR_B binds APH without inhibiting it. Note that AR_1 and AR_B are N2C molecules, while E3_5,
AR_2, AR_3a and AR_3b are N3C molecules. For comparison, the N3C library input sequence is
given on the top of the sequence alignment. In the alignment, only differences compared to the input
sequence are highlighted. x represents any amino acid except cysteine, glycine or proline; z represents
any of the amino acids asparagine, histidine or tyrosine.
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Supplemental Figure S2 - Competition BIAcore of the high-affinity APH inhibitors. A SA-Chip was
coated with 5000 RU of biotinylated APH. (A) AR_3a at a concentration of 4 nM or (B) AR_3b at a
concentration of 2.5 nM, preincubated with unbiotinylated APH at different concentrations (0, 1, 2, 3,
4, 5, 6, 7, 8, 12, 16, 20 nM) were run over the chip and on-rates were recorded. After subtraction of a
blank reference cell, the on-rates (slope) were determined, plotted against the inhibitor concentration
and fitted using Sigma Plot (SPSS Inc; Chicago, IL, USA) as described previously (33). The KD
determined for (A) AR_3a was 0.81 ± 0.09 nM and for (B) AR_3b 0.54 ± 0.07 nM, respectively.
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Allosteric Inhibition of Aminoglycoside
Phosphotransferase by a Designed
Ankyrin Repeat Protein
Andreas Kohl,1,2 Patrick Amstutz,1,2 2002; Boehr et al., 2001; Burk et al., 2001). The fold of
Petra Parizek,1,2 H. Kaspar Binz,1 APH is structurally homologous to the catalytic domain
Christophe Briand,1 Guido Capitani,1 Patrik Forrer,1 of the eukaryotic Ser/Thr/Tyr protein kinases (EPKs; for
Andreas Plückthun,1,* and Markus G. Grütter1,* example, the mitogen-activated protein kinase p38
1Department of Biochemistry [Wang et al., 1997], the insulin receptor kinase [Hub-
University of Zürich bard et al., 1994], or the Abelson tyrosin kinase [ABL]
Winterthurerstrasse 190 [Schindler et al., 2000]). It was concluded that APH and
CH-8057 Zürich EPKs share a common ancestor, which suggests that
Switzerland APH is an ideal model system for all kinases sharing
this fold (Hon et al., 1997).
EPKs are of great biological and medical importance
Summary because of their fundamental role in signal transduction
and regulatory pathways in eukaryotic cells. Diseases,
Aminoglycoside phosphotransferase (3)-IIIa (APH) is including cancer, inflammation and diabetes, are often
a bacterial kinase that confers antibiotic resistance to directly linked to the malfunctioning of EPKs (Noble et
many pathogenic bacteria and shares structural ho- al., 2004). The human genome encodes a total of 518
mology with eukaryotic protein kinases. We report kinases (Manning et al., 2002). The highly conserved
here the crystal structure of APH, trapped in an in- catalytic domain of kinases consists of an N-terminal,
active conformation by a tailor-made inhibitory an- mostly β sheet-containing lobe and a C-terminal,
kyrin repeat (AR) protein, at 2.15 Å resolution. The α-helical lobe. The ATP binding pocket is located in the
inhibitor was selected from a combinatorial library of groove between the two lobes. Most of the known EPK
designed AR proteins. The AR protein binds the inhibitors bind in the conserved ATP binding site, and
C-terminal lobe of APH and thereby stabilizes three  a degree of specificity is only achieved by making use
helices, which are necessary for substrate binding, in of small individual differences in the ATP binding pock-
a significantly displaced conformation. BIAcore anal- ets. This often leads to cross-reactivity and unwantedysis and kinetic enzyme inhibition experiments are side effects of EPK inhibitors (Noble et al., 2004). Alter-
consistent with the proposed allosteric inhibition native inhibition mechanisms, not directly or exclusively
mechanism. In contrast to most small-molecule ki- targeting the active site, have proven to be highly effi-
nase inhibitors, the AR proteins are not restricted to
cient, albeit very hard to achieve. A prime example is
active site binding, allowing for higher specificity. In-
the drug Gleevec, which only partially binds in the ATP
active conformations of pharmaceutically relevant en-
pocket and inhibits ABL by stabilizing an inactive con-
zymes, as can be elucidated with the approach pre-
formation of the kinase (Schindler et al., 2000).
sented here, represent powerful starting points for
We have developed proteinaceous APH inhibitorsrational drug design.
based on designed ankyrin repeat (AR) proteins (Am-
stutz et al., 2005). Designed AR proteins (Binz et al.,Introduction
2003; Forrer et al., 2003, 2004) are built from single 33
amino acid repeat modules, which stack together toBacteria have developed a variety of pathways and
form elongated protein domains (Sedgwick and Smer-mechanisms by which to inactivate antibiotics. Amino-
don, 1999). Molecules selected from designed AR pro-glycosides, including kanamycin, amikacin, and strep-
tein libraries have been shown to bind different targettomycin, are widely used in hospital care today, and,
proteins with high affinity and specificity (Binz et al.,therefore, bacterial resistance to these antibiotics is a
2004). Furthermore, AR proteins are highly stable, well-major concern in the health care field (Boehr et al.,
expressed, and do not contain disulfide bonds, allow-2003). In general, aminoglycosides interact with the
ing for intracellular applications. The selected APH in-bacterial ribosome, thereby disrupting protein synthe-
hibitors (Amstutz et al., 2005) inhibit the enzyme bothsis of the target cell. One way by which resistance to
in vitro and in vivo and confer kanamycin and amikacinaminoglycosides can be achieved is by phosphoryla-
sensitivity to a level comparable to the gene knockout.tion of hydroxy groups of the antibiotic. The aminogly-
Here, we describe the crystal structure of APH incoside phosphotransferase (3#)-IIIa (APH) is a proto-
complex with one of the most potent AR protein inhibi-type enzyme for this mechanism (Boehr et al., 2001).
tors, AR_3a, to 2.15 Å resolution. It shows that the ARIt was found to mediate aminoglycoside resistance in
protein binds to the C-terminal lobe of APH outside theEnterococci and Staphylococci. The crystal structure of
substrate binding pocket and stabilizes a significantlyAPH has been determined (Hon et al., 1997), followed
altered APH conformation with a distorted active site.by a very detailed functional and structural analysis of
Based on the structural data combined with the kineticthe enzymatic mechanism (Thompson et al., 1999,
measurements, we suggest an allosteric inhibition mech-
anism. A comparison to other known allosteric protein*Correspondence: gruetter@bioc.unizh.ch (M.G.G.); plueckthun@
kinase inhibitors reveals similarities and differences inbioc.unizh.ch (A.P.)
2These authors contributed equally to this work. the inhibition mechanism.
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AB and CD. A and C represent mAPH molecules,Table 1. Statistics of the Data Collection and Refinement of the
whereas B and D represent AR_3a proteins. In the crys-mAPH/AR_3a Complex
tal, mAPH forms a pseudodimer, in which the molecules
Data Collection are related by a non-perfect 2-fold axis (150° rotation;
Space group P21 10° tilt) (Figure 2B) instead of the perfect 2-fold axis
Cell dimensions, Å a = 59.67, b = 98.08, c = 81.30 in the wtAPH structure (Figure 2C). The pseudodimer
α = γ = 90.0, β = 110.01 contacts cover about 1350 Å2 buried accessible sur-
Resolution limits, Å 20.0–2.15
face area (ASA) per mAPH (Table 2). However, wtAPHObserved reflections total: 163,030; unique: 46,440
and mAPH employ the same set of residues to form theCompleteness, % 97.2 (81.0)a
Redundancy 3.5 dimer interface (Figures 2B and 2C). The two hetero-
Rsym (% on I) 5.3 (34.7)a dimeric complexes, AB and CD, exhibit different con-
Wilson B factor, Å2 45.0 formations (Figure 2D). A comparison of the structures
Refinement of the A and C mAPH molecules with wtAPH reveals
that molecule A has a higher similarity to wtAPH thanResolution range, Å 20.0–2.15
does molecule C. In addition, molecule C has a distortedR factor/Rfree, % 19.9/26.0
Ordered water molecules 353 ATP binding site with the side chains Glu24, Gly25, and
Rms deviation from ideal Met26 oriented differently. It also shows only weak
geometry electron density for the bound ADP at the position of
Bond lengths, Å 0.016
the β phosphate and for the coordinating second Mg2+Bond angles, ° 1.55
ion. In contrast, the ATP binding site in molecule A isAverage B factor, Å2 52.8
identical to that of wtAPH. The APH/AR_3a interface ofaNumbers in parentheses refer to the highest-resolution shell.
complex AB displays 12 defined H bonds, compared to
only 7 in the CD complex (Table 2 and Tables S1 and
S2 in the Supplemental Data available with this articleResults and Discussion
online). Therefore, the AB complex is better suited for
the following analysis of the structure. The differentStructure Determination and Overall Structure
conformations of APH in the crystal indicate that APHof mAPH/AR_3a Inhibitor Complex
To obtain crystals of APH in complex with the selected can adopt several different conformations, a phenome-
AR protein inhibitor, AR_3a, a mutant APH (mAPH) was non well known for EPKs (Huse and Kuriyan, 2002;
created in which the two surface cysteine residues Ozen and Serpersu, 2004).
(C19, C156) of APH were replaced by serine. In wild-
type APH (wtAPH), both cysteines can form intermolec-
ular C19-C156 disulfide bonds, which mediate the for- mAPH/AR_3a Complex Structure
mation of a homodimer in vitro (Hon et al., 1997). The In the following section, we analyze the structure of
protein complex mAPH/AR_3a was purified and crystal- mAPH, AR_3a, and the mAPH/AR_3a complex in detail.
lized in the presence of ATP, and X-ray diffraction data While the global fold of mAPH is conserved, the main
to 2.15 Å resolution were collected as described in Ex- differences in the mAPH structure, compared to wtAPH,
perimental Procedures. The structure was determined are located in the AR_3a binding region, including
by molecular replacement by using wtAPH (Hon et al., mainly α helices A and B (Figures 1 and 3; see below)
1997) and the designed AR protein E3_5 (Kohl et al., and the adjacent aminoglycoside positioning loop. In
2003) as search models (see Experimental Procedures). the wtAPH homodimer, this loop forms part of the dimer
The final model of the mAPH/AR_3a enzyme inhibitor interface, which is stabilized in the crystal by two inter-
complex has an R factor of 19.9% and an Rfree of 26.0% molecular disulfide bridges located on β strand one
(Table 1 and Experimental Procedures). (C19) and on the aminoglycoside positioning loop be-
Even though the protein is inactive in the complex tween α helices A and B (C156). These disulfide bonds
with the AR protein (see below), the overall fold of probably form only upon isolation of the protein, as this
mAPH is very similar to the one seen in all wtAPH struc- is a cytoplasmatic enzyme. In mAPH, with these cys-
tures (Hon et al., 1997), and it has structural homology teines mutated to serine, dimer formation in this region
to EPKs (see Figure 1). Between the N-terminal lobe, is not observed, and the aminoglycoside positioning
consisting mainly of β sheets, and the C-terminal,
loop is much more flexible and probably more similarmostly α-helical lobe, there is a deep cleft harboring
to the situation seen in solution. In the mAPH-A mole-the ATP binding site (Figure 2A). The substrate binding
cule, this loop could not be modeled due to missingpocket is adjacent to the ATP binding site and is formed
electron density for residues 149–166 (Figure 2A). In themainly by the C-terminal, α-helical lobe. The AR protein
mAPH-C molecule, electron density is visible for thisinhibitor AR_3a with the typical AR domain fold (Kohl
section, but it is not continuous throughout the loop.et al., 2003) binds to the α-helical lobe of mAPH. The
Interestingly, in the dimeric wtAPH structure, the amino-conformation of this C-terminal lobe differs significantly
glycoside positioning loop adopts a short α-helical con-from the one seen in structures of wtAPH alone. Strik-
formation, whereas in the mAPH-C molecule, a shortingly, AR_3a binds the C-terminal lobe of mAPH on the
antiparallel β sheet is formed instead. These resultsopposite side as compared to the substrate (Figure 2A).
demonstrate the high flexibility for the aminoglycoside
positioning loop of monomeric APH in solution.mAPH/AR_3a Conformations in the Asymmetric Unit
Superposition of molecules B and D (AR_3a mole-The asymmetric unit of the mAPH/AR_3a complex crys-
tals contains two full heterodimeric complexes, named cules) with the designed AR protein E3_5 (Kohl et al.,
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Figure 1. Topology and Structural Alignment of APH and Eukaryotic-Type Protein Kinase
(A) Topological diagram of APH and comparison with Eukaryotic-Type Protein Kinases (EPK). The contact regions between the APH molecule
and the ankyrin repeat protein are indicated with red arrows. Blue circles indicate differences in folding between APH and EPK.
(B) Structural alignment between APH and two EPK representatives: the catalytic domain of casein kinase-1 (2CSN) and the catalytic domain
of the phosphorylase kinase (1PHK). The C-terminal region of APH after helix α5 bears no resemblance to those seen in EPK’s and therefore
is not shown in the alignment. (Figure derived from [Hon et al., 1997]).
2003) and the maltose binding protein binder off7 AB heterodimer. The differences in the protein-protein
interaction result from the different crystal packing for(Binz et al., 2004) reveals virtually identical structures
(rmsdCα% 1.5 Å, Figure 3F). The main differences occur the two heterodimers in the asymmetric unit, as dis-
cussed above.in the C-terminal capping repeat of AR_3a, where weak
electron density and high B factors were observed.
The protein-protein interaction surface of the APH/ Structural Differences of Free and Inhibited APH
On the mAPH (A and C) surface, mainly residues in αAR_3a complexes was analyzed by the same methods
as those previously described (Binz et al., 2004). The helices A and B are involved in the interaction with the
AR protein (Tables S1 and S2). On the AR_3a surface,analysis revealed a protein-protein interaction interface
with global parameters highly comparable to other the interaction residues are located on the N-terminal
capping repeat and on repeat modules 1, 2, and 3.known AR protein-target protein complexes and other
heterodimeric protein-protein interfaces (Lo Conte et While the fold of the AR protein is not affected by the
binding (Figure 3F), the structure of mAPH is signifi-al., 1999). The buried accessible surface area (ASA)
on the AR_3a in the AB complex covers 850 Å2, with cantly distorted locally (Figures 3A–3C). α helices A and
B in the mAPH model are shifted by 5–7 Å in compari-12 H bonds located in the interface (Table 2). Even
though there are some differences found in the AB ver- son to the wtAPH structure (Figures 3B and 3C). In ad-
dition, α helix B is rotated by 45°–90°, depending onsus CD complex (Table 2), the interacting residues are
highly conserved (Tables S1 and S2). The main hy- which reference point is chosen (Figure 3C). For exam-
ple, Tyr172 is partially buried and is only slightly ex-drophobic contacts and six H bonds are formed by the
same set of amino acids in both interfaces (Table 2). posed to the solvent in the wtAPH structure, whereas in
the mAPH/AR_3a complex, it is involved in the protein-With 950 Å2 ASA, the interaction surface of the AR_3a
in the CD complex is even slightly larger than in the protein interaction with the AR protein and is rotated by
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Figure 2. Crystal Structure of the mAPH in Complex with the AR Protein AR_3a
(A) Stereo view of the AB heterodimer of the mAPH/AR_3a complex. The mAPH is shown in orange, and the AR_3a is shown in light blue.
AR_3a binds to the C-terminal lobe of the mAPH and stabilizes an inactive conformation.
(B) Asymmetric mAPH pseudo-homodimer found in the crystal of the mAPH/AR_3a complex.
(C) Symmetric wtAPH dimer found in the wtAPH crystal.
(D) Stereo view of the superposition of the mAPH hetereodimer AB (orange) and BC (light blue).
(E) wtAPH in the kanamycin A bound form (PDB: 1L8T). ADP and kanamycin A are labeled.
(F) mAPH/AR_3a AB heterodimer in the same orientation as the wtAPH in (E).
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Table 2. Comparison between AR Protein Target Complexes and Other Protein-Protein Interactions
Number of Number of H Bonds/ Number of Number of
PDB IDa Resolution (Å) ASAb (Å2) H Bonds 100 (Å2) ASAb,c Salt Bridgesc Planarityc Bridging H2Oc
1awc 2.2 853.62 5 0.58 0 2.30 3
1bi7 3.4 1205.5 7 0.29 4 2.50 0
1blx 1.9 845.4 11 1.30 1 2.50 12
1g3n 2.9 843.3 12 1.42 1 2.20 0
1svx 2.3 611.2 6 1.00 0 2.10 0
APH/AR_3a, AB 2.15 847.9 12 2.10 0 2.2 0
heterodimer
APH/AR_3a, CD 2.15 950.6 7 0.73 0 2.0 0
heterodimer
APH, AC 2.15 1371.7 3 0.22 2 3.0 0
homodimer
APH, CA 2.15 1367.6 3 0.22 2 3.0 0
homodimer
Heterodimeric — 983 ± 582 — 1.1 ± 0.5 — 2.8 ± 0.9 —
protein-protein
complexesc
aProtein Data Bank (PDB) accession code (Berman et al., 2000).
bSurface area per molecule occluded upon complex formation; if not stated otherwise, the AR protein is analyzed.
cAccording to Lo Conte et al. (1999).
almost 90°. In the wtAPH structure, α helix D is oriented In another recently determined crystal structure of
the selected AR protein off7 in complex with maltosethrough a number of contacts mainly formed with resi-
dues located on α helix B. As a consequence of the binding protein, no structural change of the target pro-
tein upon binding of the AR protein was observed (Binzalteration of α helix B by AR_3a, α helix D is severely
distorted, compared to the wtAPH conformation (see et al., 2004). We therefore believe that APH has a mal-
leable fold. We suggest that AR_3a traps APH in a con-below).
Figure 3. Superpositions and Comparison of wtAPH to mAPH/AR_3a
wtAPH is shown in green, and mAPH/AR_3a (AB heterodimer) is shown in yellow.
(A) Global superposition of the wtAPH structure and the mAPH.
(B) Closeup view of the α helices A, B, and D in the C-terminal lobes of the two APH molecules. The α helices A and B are involved in the
interaction with the AR_3a. In mAPH/AR_3a, the α helix D is not held in position anymore by the contacts with α helices A and B. Instead, it
is shifted by 5–7 Å with respect to the wtAPH structure.
(C) Closeup view of the α helices A, B, and D rotated by 90° around the horizontal axis with respect to the view in (B). To illustrate the changes
in more detail, the side chains of Asp144, Tyr172, and Phe264 are displayed.
(D) Kanamycin A binding pocket in the wtAPH structure and H bonding to Phe264 on α helix D. Phe264 forms three H bonds to kanamycin A.
(E) Disrupted binding site of kanamycin A in the mAPH/AR_3a complex. The kanamycin A is modeled into the mAPH/AR_3a structure. Phe264
on α helix D is not capable of forming H bonds to kanamycin A anymore.
(F) Superposition of the AR proteins E3_5 (green), off7 (purple), and AR_3a (blue). In all three AR proteins, the global fold is unchanged, but
local changes occur, especially in the N- and C-terminal capping repeats.
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Figure 4. BIAcore Analysis of the Interaction
of Inhibitor AR_3a to wtAPH and Inactive
ctermAPH in the Presence and Absence of
Kanamycin A
Equal amounts of wtAPH in flow-cell one
(FC1) (blue) and of ctermAPH in flow-cell two
(FC2) (red) were immobilized on a sensor
chip. By the additional two C-terminal resi-
dues, the active site of ctermAPH is oc-
cluded (indicated by a green rectangle in
the cartoon).
(A) Binding of the inhibitor was monitored in
the absence of kanamycin A, showing com-
parable binding on both forms of APH.
(B) Addition of a pulse of kanamycin A (200
M) during the washing procedure did not
affect the off-rate of the inhibitor.
(C) Addition of kanamycin A (200 M) during
the binding phase reduced the binding of the
inhibitor to the wtAPH, but did not affect the
binding to the mutant ctermAPH, which does
not bind kanamycin A.
formation that is less populated and perhaps present expressed and purified as described in Experimental
Procedures. wtAPH purification resulted in a mixture ofin solution.
monomer and dimer as described previously (McKay et
al., 1994). For the in vitro inhibition studies, only theBIAcore Analysis
isolated monomeric APH was used. Purified AR_3a pro-To investigate whether the binding to kanamycin or to
tein tended to form a mixture of monomers, dimers, andthe AR inhibitor is mutually exclusive, the binding beha-
multimers, which showed a fast equilibrium (Amstutz etvior of AR_3a to APH was characterized for its depen-
al., 2005). This is a property of this particular inhibitordence on the presence of substrate by BIAcore experi-
(Binz et al., 2003, 2004). The isolated wtAPH/AR_3aments. The C-terminal amino acid Phe264 of wtAPH,
complex was investigated by size-exclusion chroma-in particular its terminal carboxy group, is essential for
tography and gave rise to a single peak with a 1:1 ratiosubstrate binding, as mutations at this site drastically
(Amstutz et al., 2005).impair binding of substrate (Thompson et al., 1999). We
The steady-state velocities of enzyme activity wereconstructed an APH mutant (ctermAPH) with two addi-
monitored by coupling the release of ADP to a pyruvatetional C-terminal amino acids (Gln, Ala). This mutant
kinase/lactate dehydrogenase reaction as describedshowed no kinase activity.
previously (McKay et al., 1994), with some modifica-Similar amounts of both wtAPH and ctermAPH were
tions (see Experimental Procedures). We decided toimmobilized on parallel flow cells on a BIAcore chip.
use amikacin for these studies, as, with this substrate,Binding of AR_3a to wtAPH and ctermAPH was moni-
APH follows simple Michaelis-Menten kinetics. This istored in parallel. A pulse of 200 M kanamycin A was
in contrast to what is seen in kanamycin A, a case inapplied either during the injection phase, showing the
which the analysis is complicated by substrate inhibi-effect of kanamycin A on the association rate, or during
tion (Amstutz et al., 2005). Due to the nature of the cou-washing, showing the kanamycin A effect on the disso-
pled assay and the lack of knowledge of the exact mo-ciation rate (Figure 4). As expected, the association and
larity of the active species of both wtAPH and AR_3a,dissociation of AR_3a to ctermAPH—which does not
a quantitative analysis of the inhibition mechanism wasinteract with kanamycin A—is identical in the presence
not possible. Therefore, we focused on a qualitative in-or absence of kanamycin A. The association of AR_3a
vestigation of the inhibition mechanism and give rangesto wtAPH, however, is strongly reduced in the presence
of constants when possible.of kanamycin A (Figure 4). The apparent on-rate was
For determining the binding mode, progress curvesreduced more than 150-fold in the presence of 100 M
in the presence of wtAPH alone and wtAPH at variouskanamycin A (data not shown). The off-rate, on the
concentrations of the inhibitor AR_3a were analyzed. Ifother hand, was not influenced by kanamycin A (Figure
the reaction was started with the enzyme, each curve4). In conclusion, kanamycin A and AR_3a seem to
with inhibitor present showed an initial exponentialcompete for binding to wtAPH, albeit not for the active
“burst” phase, followed by a slower steady-state ratesite, but rather for a malleable APH molecule that can
after some minutes (data not shown). These curvesassume different conformations. The dissociation of
suggest slow, tight binding inhibition. The associationthe APH/AR_3a complex occurs with a given rate,
which seems not to be influenced by kanamycin A. and dissociation rate constants (kon = 1.6•106 M−1 s−1,
koff = 2.7•10−3 s−1) determined in BIAcore experiments
(Amstutz et al., 2005) further support a tight bindingInhibition
mechanism with observable pre-steady-state kineticsTo further elucidate the mechanism of inhibition of the
in this range.inhibitor AR_3a, in vitro inhibition studies were per-
formed. wtAPH, AR_3a, and wtAPH/AR_3a complex were For the classification of the inhibition mechanism,
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binds the free enzyme in BIAcore experiments (Figure
4). A purely competitive inhibition would not alter Vmax.
In Figure 5B, velocities of both wtAPH alone and in the
presence of various concentrations of AR_3a were plot-
ted as a function of inhibitor concentration. Inhibitor ti-
tration revealed that AR_3a completely inhibits the en-
zymatic activity of wtAPH in vitro. This is in agreement
with the structural data, by which the substrate binding
site is shown to be highly disordered upon inhibitor
binding (see below). Virtually identical results were ob-
tained with mAPH (data not shown), suggesting that the
introduction of the two cysteine to serine mutations
had no influence on the enzyme or on its inhibition by
AR_3a.
For the determination of the inhibition constant αKi,
the data were fitted to the equation for tight binding
conditions (Scheme 1; Szedlacsek et al., 1988) or di-
rectly with the model of Scheme 1 by DYNAFIT (Kuz-
mic, 1996). In either case, the αKi value obtained was
140 ± 18 nM, with the α coefficient in the range of 1–3.
Since the active species of enzyme and inhibitor could
not be determined, a separate specification of Ki and α
was not possible. Yet estimating α = 1–3 from the fit,
the Ki obtained in the in vitro inhibition studies is 30–
100 times higher than the KD determined in BIAcore
experiments (KD = 1.7 nM; Amstutz et al., 2005). There
are several contributing factors to this observation.
First, in the BIAcore measurements, only the interaction
between APH and AR_3a is investigated, whereas in
the kinetic studies, the substrates amikacin and
Mg•ATP are also present. The second reason might re-
sult from different assay conditions (different buffer
composition) of the kinetic measurements. Third, over-
estimation of the concentration of active AR_3a mole-
cules due to oligomerization (Amstutz et al., 2005) in
Figure 5. In Vitro Inhibition of wtAPH by AR_3a the kinase buffer might have an effect on the observed
(A) Enzyme activities of both wtAPH (open circles) and purified inhibition constant.
wtAPH/AR_3a complex (closed circles) were analyzed at various
Even though we cannot quantitatively determine theamikacin concentrations. The wtAPH/AR_3a complex shows a re-
kinetic parameters, it is important to emphasize thatduction of Vmax with little effect on the Km value.
these in vitro inhibition studies demonstrate that AR_(B) Amikacin phosphorylation by wtAPH was determined in the
presence of various concentrations of the inhibitor AR_3a. Steady- 3a completely inhibits APH (wtAPH and mAPH) by a
state velocities were measured at 740 M amikacin and were plot- mixed-type inhibition mechanism.
ted as a function of inhibitor concentration. wtAPH seems to be
completely inhibited by AR_3a. All assays were carried out at 20°C
Inhibition Mechanismwith 200 nM wtAPH or 200 nM equilibrated wtAPH/AR_3a complex.
Based on the structure of the complex and the in vitro
data on inhibition and binding, we propose the follow-
ing inhibition mechanism: the AR_3a inhibitor and thesteady-state velocities of wtAPH and wtAPH/AR_3a
complex were determined at various substrate concen- substrate compete for binding to APH. The conforma-
tion stabilized by the inhibitor is unproductive, while thetrations, and the steady-state velocities were plotted as
a function of substrate concentration (Figure 5A). The one binding substrate is the active form of APH. The
mixed-type inhibition seen kinetically (Figure 5A) sug-rates were fitted by using the standard Michaelis-Men-
ten equation. The Km and Vmax values determined for gests that the substrate can bind, albeit poorly, to the
enzyme-inhibitor complex, EI; however, the complete200 nM wtAPH are 46.43 ± 7.16 M and 10.22 ± 0.45
M/min (corresponding to kcat = 0.85 s−1), respectively, inhibition at high inhibitor concentrations (Figure 5B)
shows that the enzyme-substrate-inhibitor complexand are 42.41 ± 4.63 M and 2.78 ± 0.08 M/min (corre-
sponding to kcat = 0.23 s−1), respectively, for 200 nM (ESI) is not catalytically active.
The reaction mechanism for the phosphorylation ofequilibrated wtAPH/AR_3a complex. The wtAPH/AR_3a
complex thus shows a reduction of Vmax with little ef- kanamycin by wtAPH was analyzed in detail (Hon et al.,
1997; Thompson et al., 1999, 2002; Boehr et al., 2001;fect on the Km value. This is in agreement with a mixed-
type inhibition (Scheme 1), containing a competitive Burk et al., 2001). It was shown that, among other resi-
dues, the very C-terminal amino acid Phe264 in α helixand an uncompetitive component. A purely uncompeti-
tive inhibition, which would predict a lower apparent D is crucial for substrate binding (Figure 3D) (Thompson
et al., 1999). The terminal carboxylate of Phe264 formsKm, can furthermore be ruled out, because AR_3a also
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Figure 6. Structural Comparison of mAPH/AR_3a Structure to Other Inhibitor-Kinase Complexes
(A) The wtAPH monomer is shown in orange.
(B) mAPH/AR_3a structure (AB heterodimer) with mAPH, shown in orange, bound by AR_3a, shown in light blue. The AR protein binds to the
C-terminal lobe of the kinase and distorts the kanamycin A binding site.
(C) Cyclin-dependent kinase 6 shown in green, bound by AR protein p18, shown in red. p18 binds to the N-terminal lobe and distorts residues
in the ATP binding pocket, altering the binding surface for the cyclin substrate.
(D) Crystal structure of the Abelson tyrosine kinase, shown in green, and the inhibitor STI-571 (Gleevec), shown in red. STI-571 stabilizes an
inactive conformation of ABL, in which the central activation loop remains unphosphorylated; therefore, the kinase is inactive.
three H bonds to the substrate and thus orients the by AR_3a. All results indicate that inhibition of APH is
achieved through stabilization of an inactive conforma-aminoglycoside in the active site. Point mutations or
deletions of Phe264 turned out to have a drastic effect tion of APH by AR_3a.
on the enzymatic activity, impairing the binding of kana-
mycin to APH and thus inhibiting the enzyme (Thomp- Comparison to Other AR Protein Kinase Inhibitors
and Gleevec: Implications for Drug Designson et al., 1999). In the mAPH/AR_3a complex, we ob-
serve that, by binding of the AR protein to mAPH, α and Cell Biology
Natural AR proteins are well known as regulators andhelices A and B are oriented differently than in the
wtAPH structure. In the wtAPH structure, the α helices inhibitors of kinases. Several crystal structures of the
cyclin-dependent kinase 6 (Cdk6) with different AR pro-A and B and the aminoglycoside positioning loop are
needed to form a shell that positions the C-terminal α tein inhibitors of the INK4 family (p16, p18, and p19)
illustrate an allosteric inhibition mechanism (Russo ethelix D. In the inhibited mAPH/AR_3a complex, this
shell is removed and α helix D is much more flexible. al., 1998; Brotherton et al., 1998; Pavletich, 1999; Jef-
frey et al., 2000). Upon binding of the AR protein, a con-This leads to a shift of up to 7 Å and a movement of
the C-terminal α helix D (Figures 3B and 3E). As a con- formational change occurs in Cdk6. The N-terminal
lobe of Cdk6 rotates by 10°–15°, leading to a misalign-sequence, the terminal carboxylate of Phe264 cannot
form the essential H bonds with kanamycin anymore, ment of residues needed to bind ATP and to a confor-
mational change in the interface needed for the bindingfinally resulting in enzyme inhibition (Figure 3E). The in-
hibition data are in agreement with the effects seen for of cyclin (Figure 6C), which in turn is needed to activate
the kinase. The AR proteins p16, p18, and p19 bindPhe264 point mutations and deletions (Thompson et
al., 1999) and also confirm the inactivity of the mutant mainly to the N-terminal lobe of Cdk6, at the back of
the ATP binding cleft. The inhibition mechanism seen inextended by two amino acids (data not shown). BIA-
core experiments demonstrate that kanamycin A, which the mAPH/AR_3a complex is remarkably similar, even
though the AR protein binds to a different part of theinteracts with the terminal carboxylate of Phe264, stabi-
lizes a conformation, which is only poorly recognized protein. The binding of AR_3a to the C-terminal lobe of
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APH induces a structural change in the substrate bind- possibility of preventing specific interactions with a se-
ing site, leaving the ATP binding pocket unchanged, but lected AR protein would offer individual researchers
resulting in an inhibited APH (Figures 6A and 6B). many novel possibilities to design their experiments
As shown here and in Amstutz et al. (2005), selected and has several advantages over conventional meth-
AR protein inhibitors for kinases are highly specific and ods used so far (for a more detailed discussion, see
do not need to target the ATP binding site for inhibition, [Amstutz et al., 2005]).
but exploit “natural” conformational fluctuations of ki-
nases. Most conventional small-molecule kinase inhibi- Experimental Procedures
tors target the ATP binding pocket and act as competi-
Cloning and Production of Proteinstive inhibitors to ATP. As this site is highly conserved,
Biotinylated wtAPH was produced as described in Amstutz et al.,specificity is difficult to achieve (Noble et al., 2004). For
(2005). A biotinylated mutant of APH (ctermAPH), carrying two ad-example, inhibition of APH by some EPK inhibitors has
ditional amino acids at the C terminus (Gln, Ala), was constructedbeen described (Daigle et al., 1997). This emphasizes
and produced as described for the biotinylated wtAPH (Amstutz et
the structural homology of APH and EPKs, especially al., 2005), with the sole difference that the reverse primer for the
for the ATP binding site. It also demonstrates the poor PCR of the APH gene was APHmutCTr (5#-TACTCAAGCTTGAAA
specificity of these EPK inhibitors. For human EPKs in- CAATTCATCCA-3#). For the construction of the untagged double
cysteine to serine mutant (mAPH), in which cysteines 19 and 156volved in diseases, specificity is absolutely required.
of APH were mutated to serines, the mutations were introduced byUnspecific binding of inhibitors to several EPKs can
PCR. The mAPH gene was inserted into pQE60 (Qiagen, Hilden,cause severe side effects and can prevent their phar-
Germany) without a tag and expressed in E. coli XL-1Blue, as de-
maceutical use (Noble et al., 2004). scribed for the AR proteins (Binz et al., 2003, Kohl et al., 2003).
The Abelson tyrosine kinase (ABL) inhibitor ST1-571 APH variants (wtAPH, mAPH, ctermAPH) were purified by using
(Gleevec) binds to the N-terminal lobe of ABL and in a 25 ml Q-Sepharose column (Amersham Pharmacia, Dübendorf,
Switzerland), followed by preparative Superdex-75 (Amershamthe ATP binding pocket, and thereby traps the kinase in
Pharmacia) size-exclusion chromatography in 10 mM HEPES (pHan inactive conformation, with its activation loop bound
7.5), 100 mM NaCl, 50 mM MgCl2, and 2 mM dithiothreitol (DTT),back into the peptide binding cleft (Figure 6D; Schindler
according to the published protocol (Hon et al., 1997). Only frac-et al., 2000). This prevents the phosphorylation of the
tions corresponding to the monomeric APH were used for subse-
binding loop and thus the activation of ABL kinase. So quent experiments. For BIAcore and inhibition experiments, the
far, targeting such an inactive form of a kinase was a APH inhibitor AR_3a was expressed and purified as described
pure trial-and-error process and relied on high-through- (Binz et al., 2003, Kohl et al., 2003).
put screening (Noble et al., 2004). The structure pre-
sented here, and especially the approach via the selec- mAPH/AR_3a Complex
tion of specific protein-based inhibitors, could open wtAPH, mAPH, and the selected APH inhibitor AR_3a were ex-
pressed as described above. The cell pellets of 1 l bacterial culturenew opportunities in the structure-based drug design
of APH and AR_3a were resuspended and combined in 30 ml buffer(Anderson, 2003). The mAPH/AR_3a crystal structure
(50 mM HEPES [pH 7.5], 200 mM NaCl, 10 mM MgCl2). The cellsshowing a nonproductive kinase conformation, and
were lysed by using an Emulsiflex C5 (Avestin, Ottawa, ON, Can-similar studies for other EPKs, could serve as a starting
ada) with the addition of Complete Protease Inhibitor (Roche, Ba-
point for structure-based drug design of APH and other sel, Switzerland) and DNaseI (Roche). The cell debris was pelleted by
kinase inhibitors. In principle, the same approach of centrifugation at 50,000 × g for 30 min at 4°C. The resulting superna-
using selected AR protein inhibitors for cocrystalliza- tant was applied to an immobilized metal-ion affinity chromatogra-
phy column (Qiagen), equilibrated with 50 mM HEPES (pH 7.5), 200tion could also be applied to EPKs. In fact, pools of
mM NaCl, 20 mM imidazole, 10 mM MgCl2. After extensive washingbinders to JNK2 and p38 have already been selected,
with equilibration buffer, the complex was eluted with 50 mMand the binding of some individual binders has been
HEPES (pH 7.5), 200 mM NaCl, 250 mM imidazole, 10 mM MgCl2characterized (Binz et al., 2004). The pools of binders
and was further purified by preparative Superdex-75 (Amersham
could act as a starting point for inhibitor screens, fol- Pharmacia) size-exclusion chromatography in 10 mM HEPES (pH
lowed by cocrystallization of identified inhibitor/enzyme 7.5), 100 mM NaCl, 50 mM MgCl2, and 3 mM DTT. The peak fraction
complexes. Subsequent structure-based drug design with the expected molecular weight of the complex, containing one
of the APH variants and AR_3a in equimolar amounts (determinedmight allow for the development of highly specific drugs.
by SDS-PAGE), was collected and used for further experiments.This approach is not at all limited to kinases, and it
Dynamic light scattering of these fractions was measured as de-might be applied to any other enzyme.
scribed (Kohl et al., 2003) and showed a monodisperse distributionIn a cell, kinases are not only regulated by direct acti-
for both complexes.
vation or inactivation, but they are regulated by their
localization as well (their interplay with other kinases,
Crystallizationtheir corresponding phosphatases, and other regulat-
The mAPH/AR_3a complex was concentrated to 10–12 mg/ml, and
ing proteins [Sharrocks et al., 2000]; [Enslen and Davis, 5 mM ATP (pH 7.0) was added. Initial crystallization screening was
2001]; [Pawson and Nash, 2003]; [Tanoue and Nishida, done by using a four channel Lissy (Zinsser, Germany) liquid han-
2003]). Amstutz et al. (2005) showed that AR proteins dler for pipetting the reservoir and a Cartesian eight channel Micro-
can be used intracellularly as well as extracellularly, Sys (Zinsser) system for the sitting drop setup. As a default, 100
l reservoir solution was used in combination with 100 nl proteinproviding a similar phenotype as a knockout mutant.
solution, added to 100 nl reservoir solution in 96-well sitting dropTherefore, AR proteins may also interfere in signaling
CrystalQuick round well crystallization plates (Greiner Bio-One,cascades of kinases or in other pathways. It can be
Frickenhausen, Germany). The initially obtained crystals were re-
easily envisioned that the binding of a selected AR pro- fined by using standard techniques in a 1 l + 1 l setup. The
tein can prevent the docking of the kinase to the scaf- crystals used for data collection were grown in 1–3 days in 15%–
folding protein, the interaction with a phosphatase, or 20% PEG 5500, 0.1 M Mes/HCl (pH 5.9–6.2). For cryoprotection,
10% ethylene glycol was employed.the interaction with an upstream activating kinase. The
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Data Collection, Reduction, Structure Solution, and Refinement ml NADH, 1 mM ATP) containing either 200 nM purified wtAPH or
wtAPH/AR_3a complex (1:1) was added in a 10 mm QS cellData of single crystals were collected at the Swiss Light Source
biocrystallography beamline (Villigen, Switzerland). The data were (HELLMA, Basel, Switzerland). The mixtures were preincubated for
15 min, and the assay was initiated by addition of 10 l of differentprocessed with DENZO, SCALEPACK, and TRUNCATE (Otwinowski
and Minor, 1997). The crystal belonged to space group P21, with a amikacin concentrations (Sigma, A1774). Both the preincubation
and the assay were carried out at 20°C. The oxidation of NADHMatthews coefficient VM of 2.1 Å3/Da, corresponding to an esti-
mated water content of 41%. was followed by continuously monitoring the absorbance at 340
nm. The steady-state rates were normalized for background activ-The crystal structure was determined by molecular replacement
by using the program AMoRe (Navaza, 1994, 2001), with the struc- ity by subtracting the activity monitored in the absence of ami-
kacin. Velocities were plotted as a function of the substrate con-ture of the unselected N3C library member E3_5 (PDB-ID 1MJ0
[Kohl et al., 2003]) and a monomeric APH model (PDB-ID 1J7L) centration. The data were fitted to the standard Michaelis-Menten
equation to determine Vmax and Km values.used as search models. First, we applied a conventional AMoRe
protocol with a wtAPH monomer as a search model. This yielded For the analysis of the inhibition constant, the kinetic measure-
ments were carried out with 200 nM wtAPH or wtAPH in complextwo solutions for mAPH with only very little additional density for a
potential AR protein and no success in further refinement. An with various amounts of inhibitor AR_3a. For the formation of com-
plexes, 35 M wtAPH was mixed with AR_3a in a molar ratio ofAMoRe search with the AR protein E3_5 as a search model did not
yield a meaningful solution. The program AMoRe offers the possi- 1:0.5 to 1:13 and was incubated for 2 hr at 4°C prior to the dilution
(1:175) in the enzyme assay. The reaction was started with 740 Mbility to apply an n-body translational search, which is routinely
used in AMoRe, but usually only with one search model. Here, we amikacin. Enzyme activities were plotted as a function of the inhibi-
tor concentration, and the data were fitted by the general equationapplied a modified protocol for an n-body search with two search
models. Two separate structure factor tables, followed by separate for tight binding inhibition based on the mechanism in Scheme 1
(Szedlacsek et al., 1988).rotational searches for each of the two search models, were calcu-
lated from APH (1J7L) and from the AR protein (1MJ0). A conven-
tional translational search was applied for a first APH molecule,
which led to a clear solution. This solution was fixed, and the trans-
lational search was repeated for a second APH molecule, leading
to a second solution, which was again fixed. In the next step, the
structure factor table and the rotational search list of the AR protein
E3_5 were used in a translational search in combination with the
already fixed solutions for the APH, now yielding a solution for the
AR protein. A second search with two fixed APH molecules and
one fixed AR protein failed to give a solution distinguishable from
the background for a second AR protein. However, in the electron
Scheme 1.density derived, using the phases of two APH and one AR protein,
clear additional density was seen for a second AR protein. The
In this scheme, E is the enzyme, S represents the substrate, Psecond AR protein was modeled into the density with the program
represents the product, and I represents the inhibitor. KS = [E][S]/O (Jones et al., 1991). Subsequent refinement with CNS (Brünger
[ES], Ki = [E][I]/[EI], αKS = [EI][S]/[ESI], αKi = [ES][I]/[ESI], kcat =et al., 1998), REFMAC (Murshudov et al., 1999), the CCP4 program
catalytic constant, and α is a coefficient. The αKi value was deter-suite (CCP4, 1994), and, for the model building, O (Jones et al.,
mined to 140 ± 18 nM with the α coefficient in the range of 1–3.1991) resulted in a final model with an R factor of 19.9% and an
Rfree of 26.0%, Table 1.
Supplemental Data
Analysis of the Complexes Supplemental Data including the accessible surface area per resi-
The structural analysis of the complexes was done as suggested due buried and the hydrogen bonds formed in the APH/AR_3a
by Jones and Thornton (1996) and as described previously (Binz et complex are available at http://www.structure.org/cgi/content/full/
al., 2004). 13/8/1131/DC1/.
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Table S1. mAPH Residues on Molecules A and C Involved in the Interaction with AR_3a 
Molecules B and D, Respectively
Residue# Residue Chain Interface
∆ASA a
% Interface
∆ASA a
HBb Chain Interface
∆ASA a
% Interface 
∆ASA a
HBb
136 LEU A 23.25 2.51 C 17.44 1.82
137 ASP A 75.26 8.13 2 C 54.15 5.64
140 LEU A 46.03 4.97 C 50.61 5.27
141 ALA A 23.22 2.51 C 39.38 4.10
143 LEU A 15.06 1.63 C 7.00 0.73
144 ASP A 80.87 8.73 2 C 61.20 6.37 1
146 LEU - - - C 17.46 1.82
147 LEU A 13.88 1.50 C 28.16 2.93
148 ASN A 1.12 0.12 - - -
164 PRO - - - C 9.34 0.97
165 PHE - - - C 75.94 7.90 1
166 LYS A 36.98 3.99 1 C 4.66 0.48
168 PRO A 51.21 5.53 C 72.11 7.51
169 ARG A 108.25 11.69 C 122.56 12.76
171 LEU A 44.93 4.85 C 25.03 2.61
172 TYR A 144.88 15.65 2 C 148.57 15.46 1
173 ASP A 34.11 3.68 3 C 29.62 3.08 2
175 LEU A 75.73 8.18 1 C 71.17 7.41 1
176 LYS A 96.27 10.40 C 83.61 8.70
177 THR A 8.64 0.93 1 C 6.62 0.69 1
178 GLU A 3.51 0.38 C 4.02 0.42
179 LYS A 40.84 4.41 C 29.01 3.02
256 TYR A 1.86 0.20 - - -
264 PHE - - - C 3.13 0.33
a:?∆ASA buried accessible surface area
b: HB hydrogen bond
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Table S2. AR_3a Residues on Molecules B and D Involved in the Interaction with mAPH
Molecules A and C, Respectively
Residue# Residue Chain Interface
∆ASA a
% Interface 
∆ASA a
HBb Chain Interface
∆ASA a
% Interface
∆ASA a
HBb
16 LYS B 38.44 4.54 1 D 27.55 2.90
20 GLU B 30.80 3.64 D 39.95 4.20
23 ARG B 107.87 12.75 2 D 115.72 12.17 2
43 ASN - - - D 1.56 0.16
44 ASP B 4.39 0.52 D 31.59 3.32
45 TRP B 107.79 12.74 1 D 73.90 7.77
46 PHE B 91.92 10.87 D 151.67 15.96 1
47 GLY - - - D 1.31 0.14
48 ILE B 36.95 4.37 D 34.35 3.61
52 HIS B 2.80 0.33 D 2.62 0.28
53 LEU B 11.12 1.31 D 17.03 1.79
56 ASN B 50.62 5.98 1 D 51.71 5.44
57 ASN B 29.80 3.52 D 27.23 2.86
77 ASP B 14.94 1.77 1 D 11.52 1.21 1
78 LYS B 31.96 3.78 2 D 80.35 8.45
79 SER B 46.11 5.45 1 D 53.68 5.65 1
81 TRP B 53.73 6.35 D 43.55 4.58
86 LEU B 19.71 2.33 D 19.44 2.05
89 TYR B 57.78 6.83 1 D 63.13 6.64 1
90 ARG B 53.17 6.28 2 D 49.25 5.18 1
92 HIS B 7.95 0.94 D 1.95 0.21
110 ASP B 2.07 0.25 - - -
111 TYR B 9.69 1.15 - - -
112 GLN B 10.46 1.24 D 18.67 1.96
114 TYR B 7.92 0.94 - - -
119 LEU B 13.21 1.56 D 8.91 0.94
122 GLU B 4.78 0.57 D 12.57 1.32
123 ASP - - - D 11.32 1.19
 
a: ∆ASA buried accessible surface area
b: HB hydrogen bon
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Previews
ing popularity as a model for research on protein kinaseAllostery Trumps
screening and inhibition (e.g., Zhang et al., 2005).Antibiotic Resistance The inhibitor of APH(3#)-IIIa identified by Kohl and
colleagues is an ankyrin repeat protein selected for
specific binding to the kinase. Ankyrin repeats are com-In this issue of Structure, Kohl and colleagues report
mon elements incorporated into modular proteins that
on the structure of an antibiotic resistance kinase in
participate in protein-protein interactions (Mosavi et al.,
complex with an inhibitor selected from an ankyrin
2004). The ankyrin repeat element (AR) consists of a
repeat library that binds the enzyme with high affinity
helix-loop-helix motif connected to another repeat
and reverses antibiotic resistance in vivo (Kohl et
through a variable loop or β-hairpin. This helix-loop-
al., 2005).
helix-loop/β-hairpin motif forms the core element in the
AR structure, and a single protein can include anywhereKinases are ubiquitous modulators of protein function,
from 2 to over 30 tandem AR motifs. These AR domainsmodifiers of small molecules and nucleic acids, key
form extended surfaces suitable for protein-protein in-catalysts in biotransformations, and essential compo-
teractions. As a result, the motif appears in a numbernents in cellular networks that sense and respond to
of biochemical contexts, including cell surface proteinsexternal and internal stimuli. The superfamily of Ser/
and regulatory proteins.Thr/Tyr kinases has in particular garnered tremendous
Plückthun and colleagues have developed the AR re-attention from the research community as a result of
peat for engineering of protein binding proteins (Binz ettheir vital roles in cellular signal transduction. Here pro-
al., 2004). Using a modular approach consisting of N- andtein and the related lipid kinases play key switching
C-terminal caps sandwiching AR cassettes, they haveroles in cell death and mitogenesis, controlling the cell
designed and constructed protein libraries that displaycycle and associated phenomena. As a result, this su-
random amino acids on one surface of the protein (Figureperfamily of enzymes figures prominently in associated
1A). These libraries are then used in ribosome-display se-diseases of cell growth and regulation such as cancer.
lection to identify AR binders of bait proteins. UsingModulation of kinase activity therefore has been tar-
APH(3#)-IIIa in this mode, the group identified severalgeted by members of the scientific community and the
members of a randomized library that bound to the ki-pharmaceutical sector interested in identifying new
nase with low dissociation constants (nM) and inhibitedsmall-molecule anticancer agents.
the in vitro aminoglycoside antibiotic phosphorylation ac-Members of the protein kinase superfamily share
tivity (Amstutz et al., 2005). Furthermore, coexpression ofoverall structural homology, with an N-terminal β sheet
some of these AR inhibitors in E. coli expressing APH(3#)-domain and a C-terminal α-helical domain. All kinases
IIIa reversed the antibiotic resistance phenotype, therebybind ATP with micromolar dissociation constants in a
demonstrating that these selected AR proteins have bothstructurally conserved deep binding pocket. The gen-
potent in vitro and in vivo activity. The mode of interactionerally more shallow phosphate-accepting substrate
of these AR proteins with APH(3)-IIIa was, however, un-binding site, which is located primarily in the structur-
known until now.ally divergent C-terminal domain, is difficult to block
The report in this issue by Kohl et al. (2005) ad-with nonpeptide inhibitors. As a consequence, the fo-
dresses the question of how AR inhibition of aminogly-cus of most kinase-targeted drug discovery campaigns
coside kinase occurs through determination of thehas been on the ATP binding pocket, which is readily
X-ray structure of APH(3#)-IIIa in complex with one ofamenable to small-molecule binding and for which am-
the more potent AR proteins selected in the screen,ple precedent is available. The challenge inherent in
AR_3a. The costructure reveals that AR_3a binds to thethis strategy is the ubiquity of cellular protein kinases
C-terminal helical aminoglycoside binding domain ofand the resultant off-target interactions of kinase inhibi-
APH(3#)-IIIa. Remarkably, the AR protein does not bindtors. Approaches that identify new binding strategies
in a competitive fashion with antibiotic in the aminogly-to inhibit kinases, both as in vivo tools to probe kinase
coside binding pocket, but rather to an orthogonalfunction and as drug leads, are therefore highly sought.
region of the protein. This nonactive site interaction re-In this issue, Kohl et al. (2005) report the structure of
sults in trapping of an inactive conformation of the en-an inhibited kinase issuing from a new kinase inhibitor
zyme. Binding of aminoglycoside substrates to APH(3#)-binding strategy (Amstutz et al., 2005). The authors
IIIa is associated with movement of helices in thehave taken advantage of an antibiotic resistance ki-
C-terminal domain and formation of an obligate ionicnase, APH(3#)-IIIa, that phosphorylates aminoglycoside
interaction between the antibiotic substrate and theantibiotics. This kinase shares structural homology with
carboxylate of the C-terminal residue Phe264 (Thomp-protein kinases (Hon et al., 1997), has detectable pro-
son et al., 1999). The interaction of APH(3#)-IIIa and AR_tein kinase activity (Daigle et al., 1999), and can be in-
3a results in a conformational change that distorts thehibited by inhibitors of protein kinases that target the
aminoglycoside binding pocket through movements ofATP binding site (Daigle et al., 1997). The antibiotic re-
key α helices, leading to conformation(s) of the C-ter-sistance phenotype conferred by APH(3#)-IIIa facilitates
inhibitor screening, and therefore this enzyme is gain- minal domain that are unproductive for antibiotic bind-
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ing mode has been uncovered for an important antibiotic
resistance enzyme. This type of interaction can now serve
as a model for the design of small-molecule inhibitors
that inhibit APH(3#)-IIIa in a similar fashion, which could
find clinical utility in blocking antibiotic resistance. Fur-
thermore, the affinity of the AR_3a inhibitor for the en-
zyme also provides an opportunity to develop displace-
ment assays that could be used to discover these
molecules in a random screen. This general approach
should be amenable to several enzyme classes, espe-
cially where a powerful biological readout (e.g., drug re-
sistance in this case) can serve as primary screen.
Gerard D. Wright
Antimicrobial Research Centre
Department of Biochemistry and Biomedical Sciences
McMaster University
1200 Main Street West
Hamilton, Ontario, L8N 3Z5
Figure 1. AK Repeat Libraries and Inhibition of APH(3#)-IIIa
(A) The AK repeat library consists of N- and C-terminal caps (in
Canadayellow and green, respectively) and a series of AK modules (blue)
with a variable region (red) that presents on one side of the folded
protein.
Selected Reading(B) Interaction of AR_3a with APH(3#)-IIIa (green) results in a confor-
mational change that alters the aminoglycoside binding site and
Amstutz, P., Binz, H.K., Parizek, P., Stumpp, M.T., Kohl, A., Grütter,prevents productive binding of antibiotic for detoxification.
M.G., Forrer, P., and Plückthun, A. (2005). J. Biol. Chem. 280,
24715–24722.
Binz, H.K., Amstutz, P., Kohl, A., Stumpp, M.T., Briand, C., Forrer,
ing (Figure 1B). This structural rearrangement also im- P., Grutter, M.G., and Pluckthun, A. (2004). Nat. Biotechnol. 22,
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Rapid Selection of Highly Specific MAP Kinase-
Binders from Designed Ankyrin Repeat Protein 
Libraries
Patrick Amstutz 1, Holger Koch 1, Hans Kaspar Binz, Patrik Forrer, and 
Andreas Plückthun * 
Abstract
We here describe the rapid selection of highly specific c-jun N-terminal kinase 
2 (JNK2) binders from a combinatorial library of designed ankyrin repeat (AR) 
proteins. A combined in vitro/in vivo selection approach, based on ribosome 
display and the protein fragment complementation assay (PCA) yielded a 
large number of different binders, fully functional in the bacterial cytoplasm. 
Only one round of ribosome display with subsequent small scale PCA 
selection was necessary to isolate a first specific binder. After two rounds of 
ribosome display selection, virtually all AR proteins identified by PCA showed 
specific binding, with affinities in the low nM range. The selected AR proteins 
specifically bound to JNK2, while they did not interact with the 81% identical 
JNK1. Taken together, the combination of ribosome display and PCA 
selections allowed the identification of large pools of binders at unparalleled 
speed. Moreover, quite in contrast to other intrabody selection protocols, our 
remarkably high selection efficiency demonstrates the potency of this 
alternative selection approach.
Keywords: ribosome display, protein fragment complementation assay, MAP kinase, JNK2, 
ankyrin repeat proteins, intrabody 
Abbreviations used: AR, ankyrin repeat; pD, major surface protein of bacteriophage lambda; 
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complementation assay; SPR, surface plasmon resonance; TMP, trimethoprim.  
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Introduction
Mitogen activated protein kinases (MAPKs) are 
key factors in cellular signal transduction and are 
involved in a whole range of diseases, including 
cancer and inflammation 1. The investigation of 
specific MAPKs is challenging, as these enzymes 
are highly homologous, with highly conserved 
active sites. This problem becomes even more 
pronounced for distinguishing members within the 
different subfamilies. For example, the c-Jun 
NH2-terminal kinase (JNK) subfamily (Kallunki et 
al., 1994) consists of three members, JNK1, 
JNK2 and JNK3, each with different splice 
variants. While JNK1 and JNK2 are expressed 
ubiquitously, JNK3 expression is mostly restricted 
to the brain, heart and testis 2. These kinases are 
responsible for the activation of cellular 
responses to extracellular signals (Davis, 2000). 
JNK-dependent signal transduction is important 
in a wide range of different processes, including 
cellular proliferation, oncogenic transformation or 
programmed cell death and many others. While 
JNK specific functions are known, assigning them 
to the different JNK isoforms is still difficult. For 
this purpose binding molecules which can reliably 
differentiate between these isoforms, are desired. 
Antibodies, the most commonly used binding 
molecules, are not ideal to target MAPKs, as 
these enzyme are located within the cell and 
antibodies tend not to sustain such a reducing 
environment, as their stability relies on disulfide 
bonds 3. While different successful attempts have 
been reported to select antibodies, which are 
functional inside the cell, the number of selected 
and characterized binders is usually limited 4; 5.
These results might be explained by the selection 
pressure, which is not only specific binding but 
also stability under reducing conditions.  Although 
considerable scientific effort has focused on the 
construction of stable antibody libraries, which 
are adapted to reducing selection conditions 6,
the intracellular selection of specific antibodies 
still remains challenging. To overcome the 
limitations of antibodies and their derivatives, a 
variety of novel scaffolds for the generation of 
antibody-like binding molecules, possessing 
favorable biophysical properties, has been 
developed 7. Designed ankyrin repeat (AR) 
proteins represent such a novel scaffold 8; 9.
These proteins are built from single repeat 
modules of 33 amino acids with fixed framework 
residues (27 amino acids) and randomized 
potential interaction residues (6 amino acids), 
which stack together to form the AR protein. This 
modular architecture is ideal for the assembly of 
very large combinatorial AR protein libraries. The 
library used for the selection experiments 
described here was built from three randomized 
AR modules, flanked by an N- and a C-terminal 
capping repeat shielding the hydrophobic core 
(N3C). While the theoretical diversity of such a 
library is 3.79 x 1023, the experimentally sampled 
one had a diversity of greater than 1010. As the 
number of modules in one designed AR protein 
can be adjusted 9, the target binging surface may 
be adapted as desired and is not fixed in 
dimensions as it is for other scaffolds, including 
antibodies.  
It has been shown that the designed AR proteins 
match all requirements for functional intracellular 
applications: these molecules are very well 
expressed in the bacterial cytoplasm, they are 
stable and cysteine-free 10. Moreover, specific 
binders with high affinity and specificity can be 
selected from designed AR protein libraries 11.
While the selection of specific binders from other 
novel scaffold libraries has also been reported 12,
their intracellular applications are scarce 13. In 
contrast, specific binders and inhibitors of a 
prokaryotic kinase, which are fully functional 
inside the cell, have been selected from the AR 
protein libraries 14.
We here report and analyze the selection of 
JNK2-specific AR proteins. The combination of 
ribosome display, a complete in vitro selection 
technology, and protein fragment 
complementation assay (PCA), an in vivo
selection technology, allowed the rapid selection 
of large pools of intracellularly active JNK2 
specific binders.  
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Results
The goal of this project was the selection of AR 
proteins, which are able to discriminate between 
JNK2 and JNK1, to monitor the selection process 
and to test the functionality of the selected AR 
proteins in vitro as well as in vivo. For initial 
selections of binding molecules from large AR 
protein libraries, ribosome display was applied. 
As this complete in vitro selection technology 
circumvents any transformation step which would 
otherwise limit the applicable library size, it is 
ideally suited to handle large libraries (diversity t
1010). PCA, a bacterial intracellular selection 
technology, based on the reconstitution of DHFR 
activity by two binding partners 15, was 
subsequently applied to analyze the ribosome-
display generated pools of binders (Fig. 1), to 
further enrich these binders and to demonstrate 
their activity under reducing conditions. Selected 
AR proteins were further examined for their target 
binding properties with respect to affinity and 
specificity in ELISA and SPR experiments.  
In vitro and in vivo selection of JNK2-binding 
AR proteins  
For the selection of JNK2-specific binders from 
an N3C AR protein library, four standard 
ribosome-display selection rounds against 
immobilized JNK2 were performed 16. A pool of 
DNA fragments encoding AR proteins 
(approximately 2500 individual clones) from the 
naïve starting library and after each ribosome-
display selection round was inserted into the PCA 
selection plasmid as mDHFRI fusion. In parallel 
experiments, co-transformation of these pools 
with the JNK2-mDHFRII-bait-plasmid allowed 
determining the bacterial survival under selective 
conditions in dependence of the respective 
ribosome-display selection round (Fig. 2). As 
expected, nearly no bacterial growth resulted 
from co-transformation of the bait-plasmid with 
the naïve AR protein library. The pool after the 
first round of ribosome display also gave almost 
no growth under selective PCA conditions. In 
contrast, co-transformations of the AR protein 
pools corresponding to ribosome-display 
selection rounds 2, 3, and 4 gave rise to a large 
number of bacterial survivors, which increased 
with the selection round number (Fig. 2). As a 
control, the individual pools were also plated 
under non-selective conditions, where no 
difference in bacterial cell growth was observed, 
indicating that all pools had been treated equally 
(data not shown). These results suggest that two 
rounds of ribosome display are sufficient for 
selection of binders. 
ELISA screen to identify JNK2-specific AR 
proteins  
To elucidate whether the increased bacterial 
growth, observed in the in vivo PCA selection, did 
indeed result from an enrichment of JNK2-
specific AR proteins, the binding of the selected 
AR proteins to JNK2 was tested in ELISA 
screens. Seventeen clones from each of the 
selection rounds 1, 2, and 4, obtained either with 
or without additional PCA selection were 
randomly picked. Crude E. coli extracts from 
small-scale expression cultures were used to 
compare the binding of the selected clones either 
to JNK2 or, as a control, to the bacteriophage 
lambda protein D (pD) in ELISA experiments (Fig. 
3).
Figure 1. Schematic representation of the 
selection and analysis strategy.  
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Figure 2. Number of colonies obtained by in
vivo PCA selection with different AR protein 
library pools. 
The naïve AR protein library and the AR protein 
pools obtained after each round of ribosome-
display selection was cloned as N-terminal 
mDHFRI fusion (see Material and Methods) 
and co-transformed in E. coli with the JNK2-
mDHFRII antigen construct under selective 
conditions. A comparable level of bacterial 
growth under selective conditions resulted from 
co-transformation of the naïve AR protein 
library or the AR protein pool of the 1st
ribosome-display selection round with the 
JNK2-DHFRII encoding plasmid. In contrast, 
increasing numbers of colonies are observed 
from co-transformation of the AR protein pools 
of ribosome-display selection round 2, 3, and 4. 
Under non-selective growth conditions, a 
similar number of colonies were obtained in all 
cases. 
Of the AR proteins, which were exclusively 
selected by ribosome display, no JNK2-specific 
AR protein was found in the pool from selection 
round 1, whereas approximately 30% of the AR 
proteins of both the selection rounds 2 and 4 
showed JNK2 binding. In comparison, when a 
PCA selection was carried out after the first 
ribosome-display selection round, one JNK2 
binder was obtained. Furthermore, approximately 
80% of the AR proteins of round 2 and nearly 
100% of the AR proteins of round 4 showed 
binding to JNK2, when the ribosome display 
rounds were followed by PCA selection. It seems 
that ribosome display is afflicted with an intrinsic 
background, which cannot be reduced by further 
selection rounds. Thus, the expression plasmids 
which were obtained by ligation of the ribosome-
display product, encode a constant percentage of 
non-binders. While this was almost 70% in the 
present experiments, values are as low as 20% 
have also been observed 11. In contrast, when the 
same pools are sieved by PCA selection, already 
after the second round of ribosome display, the 
majority of clones are specific binders.  PCA 
alone, on the other hand, suffers from 
background problems, if selection is carried out 
with naïve libraries 5. Thus, the combination of 
both methods allows an efficient analysis of 
binders after very few rounds, when there is still 
significant diversity. 
Sequencing of the JNK2-specific AR proteins 
From the group of JNK2-specific AR proteins, 
which were identified in the initial ELISA screen, 
10 AR proteins resulting from exclusive ribosome-
display selection and 24 AR proteins obtained by 
the additional PCA selection were chosen for 
DNA sequencing. From the binders which were 
selected only by ribosome display none was 
found multiple times. In contrast, the JNK2 binder 
pB4, which was isolated from the PCA selection 
following ribosome-display round 1, was found 
three times (pB4, pC4, and pD4). Another binder 
was found twice, once in round 2 (pF7) and once 
in round 4 (pA12) from the PCA selection 
following ribosome display. Furthermore, this 
particular binder (pF7, pA12) was also found in 
the pool of only ribosome-display selected AR 
proteins (rD12). Another binder was found in both 
groups of ribosome-display selected (rC6) and 
PCA enriched (pE8) AR proteins (for sequences 
of the selected AR proteins see suppl. info.). 
Of the non-binder population, 13 clones without 
and 13 clones with additional PCA selection were 
sequenced. Thereby, no deletions, premature 
stop codons or frame shifts were detected. 
However, a substantial variation of sizes, ranging 
from one to five internal repeats was found. This 
finding might be explained by recombination 
events during RT-PCR.  
Rapid Selection of Kinase Binders 113
Figure 3. ELISA screening for the identification of JNK2-specific AR proteins.  
The JNK2-binding of randomly picked AR proteins of different ribosome-display selection 
rounds (with or without additional PCA selection step) are compared. Crude cell extracts of E.
coli expressing the AR proteins as mDHFRI fusions were applied to wells coated with JNK2 or 
pD (control). No JNK2-specific AR protein was identified from the group of potential binders 
resulting from selection round 1 of the ribosome display selection, whereas three JNK2-
specific AR proteins (identical clones) were found in round 1 of the additional PCA selection. 
From the groups of AR proteins, originating from ribosome-display selection round 2 and 4, 
approximately 30% possess JNK2-specificity. Again, many more JNK2-specific AR proteins 
were identified from the corresponding selection rounds after additional PCA selection: 
approximately 80% of the AR proteins of round 2, and nearly all AR proteins of round 4 show 
specific binding to JNK2. All the binders, which were chosen for further characterization, are 
marked bold (pB4=pC4=pD4; rD12=pF7=pA12). In summary, the performance of the 
additional PCA screen leads to a much stronger enrichment of JNK2-specific AR proteins in 
all evaluated selection rounds. 
Also, when monitoring the outcome of the RT-
PCR after a ribosome-display selection round by 
agarose gel electrophoresis, a certain proportion 
of the AR proteins were found to be shortened by 
one AR module (N2C instead of N3C). This 
shortening was found for 10% of the ribosome-
display selected AR proteins, but, surprisingly, for 
50% of the AR proteins resulting from the 
subsequent PCA screen. This observation might 
indicate a growth advantage of the N2C AR 
proteins over the N3C molecules in this context of 
the PCA selection system. 
In conclusion, from 34 sequenced JNK2-binding 
AR proteins, 29 different AR proteins were 
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identified, indicating that the generated binder 
pool still holds substantial diversity.  
Figure 4. Cross-specificity comparison of 
selected AR proteins and commercially 
available JNK-specific antibodies by 
ELISA.
Binding of different selected AR proteins to 
JNK2, JNK1 and p38 is compared. In 
addition, the inhibition of JNK2-binding by 
free JNK2 is tested for each molecule. Two 
commercially available antibodies (sc C17 
and sc N18, see Material and Methods) and 
one unselected AR protein (E3_5) served as 
controls. Purified AR proteins were applied at 
a concentration of 250 nM, whereas the 
purchased antibodies were diluted (1:500) 
according to the recommendation of the 
supplier. As the dissociation constant of the 
AR protein pB4 is higher, pB4 was applied at 
a concentration of 5 PM. The binding to 
immobilized JNK2 of all binders including the 
purchased antibodies was inhibited 
completely by a threefold excess of free 
JNK2. All selected AR proteins and the JNK1 
antibody (sc C17) were highly specific to their 
respective antigen, while the JNK2 antibody 
(sc N18) does not discriminate between the 
JNK isoforms. The unselected AR protein 
(E3_5) does not bind to any of the evaluated 
antigens. Furthermore, none of the tested 
binding proteins show interaction with p38. 
Specificity and affinity of selected AR proteins   
Target binding of 6 JNK2-binding AR proteins 
was characterized by surface plasmon resonance 
(SPR) and by ELISA experiments. Binders from 
the different selection rounds, with and without 
additional PCA-selection step, were included 
(Fig. 3). 
Kinetic SPR measurements using multiple 
concentrations of the selected AR proteins were 
used to determine their dissociation constants 
(Table1). While the KD of pB4, the clone that 
resulted from the first selection round, was 
around 1 PM, all other binders had low nM 
affinities. Interestingly, the affinity of binders from 
selection round 2, can equal the ones from 
selection round 4. Binders generated with or 
without additional PCA selection seemed to bind 
with similar affinities (Table1). As PCA yielded 
binders possessing affinities ranging from the nM 
to the PM range, it seems that the selection 
system can tolerate a broad spectrum of 
affinities, all resulting in bacterial growth.
ELISA experiments were used to investigate the 
specificity of the JNK2 binders. The binding to 
JNK2 was compared to that to JNK1 and p38. 
While JNK2 and JNK1 share 81% identity and 
86% similarity, JNK2 and p38 still share 51% 
identity and 59% similarity on the amino acid 
level in our format. For comparison, two 
commercially available antibodies (see Material 
and Methods), one binding to JNK1, the other to 
JNK2, were tested in parallel. All AR proteins and 
the JNK1 antibody were highly specific to their 
cognate antigen, while the JNK2 antibody 
seemed to not discriminate between JNK1 and 
JNK2 (Fig. 4). None of the binding proteins 
interacted with p38. We also tested whether the 
binding to immobilized JNK2 could be inhibited by 
free JNK2. The binding to immobilized JNK2 of all 
binders including the antibodies was inhibited 
completely by a threefold excess of free JNK2 
over the binder (Fig. 4).  
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Clone Round Selection Size kon (1/Ms) koff (M) KD (nM)
pB4 1 RD&PCA N3C (4.14 r 2.15)·104 0.0342 r 0.0041 914 r 568 
pB8 2 RD&PCA N2C (1.42 r 0.63)·105 (9.24 r 2.93)·10-4 6.5 r 4.3 
pG7 2 RD&PCA N3C (3.5 r 1.31)·105 (4.0 r 0.57) ·10-3 11.3 r 5.9 
pB11 4 RD&PCA N3C (1.96 r 0.48)·105 (3.98 r 0.58) ·10-3 22.0 r 9.8 
pE11 4 RD&PCA N2C (4.15 r 1.47)·105 (9.57 r 0.73)·10-4 2.31 r 1.0 
rD12 4 RD N2C (4.67 r 0.24)·105 (6.75 r 0.92)·10-4 1.44 r 0.3 
Table 1. Affinity of selected AR proteins 
Discussion 
We demonstrate here the selection of a large 
pool of intracellularly active AR proteins binding 
to JNK2 with very high specificities and affinities. 
For the generation of kinase-specific AR proteins 
a combined in vitro and in vivo selection was 
performed. Ribosome display was applied for the 
selection of JNK2 binders from a large 
combinatorial AR protein library. PCA was used 
to monitor the ribosome-display selection 
process, to further enrich specific AR proteins 
from the pools of binders generated by ribosome 
display and to test the functionality of the 
selected AR proteins under reducing conditions. 
The analysis of the binders from different 
selection rounds showed that the selection 
process of obtaining kinase-specific AR proteins 
was extremely rapid. Only two rounds of 
ribosome display were sufficient for enrichment of 
a whole variety of different JNK2-specific AR 
proteins. Almost all selected AR proteins possess 
high specificity and affinity. These results suggest 
that the combination of the AR protein library with 
both ribosome display and PCA selections is an 
ideal set-up to rapidly generate diverse pools of 
specific binders, fully functional under reducing 
conditions. These pools can then be used as 
starting points to screen for functionality for a 
whole range of different applications, including 
intracellular ones. 
Targeting kinases – an issue of specificity  
Up to date, around 518 human protein kinases 
(EPKs) are known 17. Most of these are part of 
complex signalling cascades, and the different 
kinases often share very high homology. This 
homology complicates the selection of specific 
EPK binders. To address EPK function, often 
binders and inhibitors are used, which lack 
sufficient specificity, and thus the observed 
effects cannot be allocated correctly. All selected 
AR protein binders reported here were highly 
target kinase specific, binding to JNK2, while not 
recognizing JNK1, despite over 80% identity of 
the target proteins. This high specificity of 
designed AR proteins may be a useful in the 
quest to understand the function of individual 
kinases in more detail. 
We believe that the high specificity of the 
selected AR proteins has two reasons: the 
potential binding epitope and the binding mode. 
Most peptides and small molecules used to date 
bind EPKs in grooves 18. These grooves, 
including the active site, are often highly 
conserved, preventing specific targeting. As the 
randomized positions on the AR protein span a 
large surface the selected binders will interact 
with the target protein on exposed surface areas. 
These surface areas are more likely to be kinase-
specific, and thus specificity is achieved more 
easily. From the crystal structures of AR protein 
library members, unselected or in complex with 
the target 10; 11, we know that the AR protein 
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behaves essentially like a rigid body. This might 
restrain the binding epitopes, but results in very 
high specificity, as the AR protein will not adapt to 
conformations of other proteins.  
Selection process – rapid enrichment of many 
functional binders 
The efficient selection of specific and stable 
binding molecules, which remain functional under 
reducing conditions, demands new selection 
technologies. Here we present an alternative 
approach, in which PCA was used as read-out for 
antigen-specific AR proteins previously selected 
by ribosome display. By combination of ribosome 
display and PCA, not only a very rapid 
enrichment of antigen-specific AR proteins was 
revealed, but also all selected AR proteins could 
simultaneously be tested for functionality under 
reducing conditions. The monitored window of 
2500 clones of every ribosome-display selection 
round that was applied to PCA was sufficient to 
yield a high variety of different binders. Already 
after one round of ribosome-display selection the 
first binder was found by PCA and after round 
two, the selection process was virtually complete. 
If the starting library diversity indeed was in the 
range of 1010, this equals an enrichment factor of 
approximately 106, a very high number for 
ribosome-display selections 19. The diversity of 
the selected binders was remarkably high, as 
from 34 sequenced clones, only three clones 
were found multiple times, while 29 where 
different. Similar antibody-based selections with 
ribosome display, including five to six selection 
rounds (in the absence of PCA), tended to 
converge to a small number of high-affinity 
binders 19. The high diversity of selected AR 
protein binders is especially attractive, if not only 
simple binding, but a specific function is desired. 
Here the pools of binders might serve a starting 
point for functional screens, as recently shown for 
a prokaryotic kinase 14.
This rapid enrichment of diverse pools of different 
binders might be explained by the high quality of 
the designed AR protein library. We believe that 
this scaffold, with its highly beneficial biophysical 
properties, is ideal for library generation. Due to 
its inherent stability the designed AR domain fold 
will tolerate a very large diversity in the potential 
interaction surface, leading to a very large 
percentage of functional library members. If more 
proteins are functional, fewer will be aggregated 
and display exposed hydrophobic patches. This 
high percentage of folded proteins will reduce the 
problem of unspecific binding during ribosome-
display selections. Furthermore, a large and 
diverse population of active library members 
increases the probability of successfully selecting 
many different binders 20.
Selection method – ribosome display and 
PCA
Successful selections from large protein libraries 
demand potent selection technologies. Ribosome 
display, which works completely in vitro, allows 
the handling of very large libraries, as no 
transformation step limits the applicable library 
size 16. Indeed the combination of the AR protein 
libraries with ribosome display rapidly yielded 
several high-affinity binders. Nevertheless an 
intrinsic background of non-target binders was 
observed, remaining constant from ribosome-
display selection round two on. The origin of this 
background was not determined. To eliminate 
this background as well as to analyze the 
selection process, PCA selections were 
performed. In the PCA experiments the 
background was completely eliminated. 
Nevertheless, a direct PCA selection from naïve 
libraries seems still difficult, as this selection 
yielded survivors not linked to a specific binding 
event. Generally, PCA selections from naïve 
protein libraries, while able to select specific 
binders, seem to suffer from background 
problems, also for antibody-based selections 5.
We believe that ribosome display for selecting 
large pools of binders in combination with PCA 
for sieving these pools is an ideal combination for 
rapid identification of many different binders. This 
combination of in vitro selection and in vivo
screen has also been described for the selection 
of intracellulary active antibody fragments 4; 6.
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Usually phage display had been applied for the 
initial selection of binders and then yeast two-
hybrid systems had been applied to select the 
intracellularly active ones. Thereby, only very 
stable antibodies sustained the reducing 
intracellular environment, and many binders 
might be lost due to insufficient stability. One 
strategy to overcome this problem is the use of 
antibody libraries based on highly stable 
frameworks 21. AR proteins are per se stable 
under reducing conditions and therefore, 
probably no binders will be lost in the second in
vivo selection step.  
Material and Methods 
Molecular biology: Unless stated otherwise, all 
experiments were performed according to the 
protocols of Sambrook et al. 22. Enzymes and 
buffers were purchased from New England 
Biolabs (Beverly, MA, USA) or Fermentas 
(Vilnius, Lithuania). Oligonucleotides were 
obtained from Microsynth (Balgach, Switzerland). 
Antigen expression and purification: For 
expression of the antigen constructs the vectors 
pAT222 (GenBank accession AY327137), 
pAT222_p38 and pAT222_JNK2 11, as well as 
pAT222_JNK1 were used. pAT222_JNK1 was 
constructed by inserting the PCR amplified JNK1 
open reading frame (oligonucleotides jnk1f 5’- 
TTC CGC GGA TCC GGT ACC TCC CGT AGC 
AAG CGT GAC AAC -3’ and jnk1r 5’- AAA CCC 
AAG CTT GCT GCA CCT GTG C -3’; template 
pAT58, 23 into pAT222, using the restriction 
enzymes BamHI and HindIII. Expression from the 
vectors pAT222, pAT222_p38, pAT222_JNK1 
and pAT222_JNK2 yields a fusion protein 
comprising an N-terminal avi-tag for in vivo
biotinylation, bacteriophage lambda protein D 
(pD), followed by the target molecule (or nothing 
in the case of pAT222), and a C-terminal His-tag 
for purification (avi-pD-target-His6). Alternatively, 
for expression of His6-tagged JNK2 without any 
further fusion partner, the vector pQE30_JNK2 
was used. pQE30_JNK2 was constructed by 
inserting the BamHI/HindIII JNK2 fragment of 
pAT222_JNK2 into pQE30 (QIAgen, Hilden, 
Germany). Expression, biotinylation and 
purification of His6-tagged proteins pD, pD_JNK1, 
pD_p38, pD_JNK2, and non biotinylated JNK2 
were performed as described 11. Biotinylation was 
quantified by using ELISA and SDS-PAGE 
followed by blotting with a streptavidin-alkaline 
phosphatase conjugate (Roche, Basel, 
Switzerland).  
In vitro ribosome display selection: The PCR 
amplified AR protein libraries were transcribed 
and 4 selection rounds were performed as 
described 11. After each ribosome-display 
selection round the RT-PCR product of the 
encoding AR protein pool was analyzed by 
agarose gel-electrophoresis. To prevent an 
enrichment of N2C molecules, the N3C pool of 
each selection round was gel purified prior to re-
amplification of the corresponding DNA. The DNA 
of each selection round was finally inserted in the 
PCA selection plasmid and cloned by 
transformation of E. coli XL10 (Stratagene, La 
Jolla, CA, USA).  
In vivo selection using PCA: The RT-PCR 
products of each ribosome-display selection 
round, as well as the naïve AR protein library, 
were separately amplified by PCR using the 
oligonucleotides Ank-Sph-FOR (5’- GCT CAG 
GCA TGC TTG ACC TGG GTA AGA AAC TGC -
3’) and Ank-Eco-BACK (5’- GCT GCA GAA TTC 
TTG CAG GAT TTC AGC CAG G -3’) and 
inserted via SphI and EcoRI into the PCA 
selection plasmid pHK46 5. Transformation of E.
coli XL10 with the ligation products yielded 
approximately 2500 colonies for each of the five 
AR protein pools (four ribosome-display selection 
rounds and the naïve AR protein library) and 
virtually no background of re-ligated vector was 
observed. The colonies of each transformation 
were pooled separately and the plasmids were 
isolated.
For performance of the in vivo PCA selection 
electrocompetent E. coli BL21/pRep4 (Qiagen, 
Hilden, Germany) cells (transformation efficiency 
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t 3 x 108/Pg DNA) were co-transformed in parallel 
with 100 ng of each AR protein pool-mDHFRI and 
JNK2-mDHFRII fusion constructs. After 1 h 
incubation at 37qC the cells were washed with M9 
minimal medium and plated on selective M9 
minimal media supplemented with 50 Pg/ml
kanamycin, 100 Pg/ml ampicillin, 10 Pg/ml
chloramphenicol, 2 Pg/ml TMP, 100 PM IPTG, 
and 5 % (w/v) of casamino acids (Difco, Detroit, 
MI, USA) and incubated at 25qC for 72 h. In 
parallel to the selective co-transformation, E. coli
BL21/pRep4 was transformed with 100 ng of 
each AR protein pool-mDHFRI fusion constructs 
and incubated overnight at 37qC on standard LB 
plates (no selection pressure).  
ELISA screening to identify specific JNK2-
binding AR proteins: seventeen clones each, 
from ribosome-display selection rounds 1, 2, and 
4, with or without additional PCA selection step 
(Fig. 1, Fig. 2), were randomly picked and 
cultured overnight in 1.2 ml LB (LB, 1% glucose, 
100 Pg/ml ampicillin, and 50 Pg/ml kanamycin) in 
96-deep-well plates (Abgene, Surray, UK). On 
the next day, 300 Pl each of these pre-cultures 
were added to 1200 Pl LB medium, and 
incubated at 37°C. After 1 h incubation, 
expression of the AR protein-mDHFRI fusions 
was induced by 0.5 mM IPTG, followed by 
incubation for 3 hours at 37°C. The cultures were 
harvested by centrifugation and subsequently 
lysed by shaking for 10 min in 50 Pl B-Per 
(Pierce, Rockford, IL, USA). After addition of 250 
Pl TBS500 (50 mM Tris-HCl, pH 7.8, 500 mM 
NaCl) the lysed cells were centrifuged again 
(4°C). One hundred fifty Pl supernatant each 
were transferred to a MaxiSorp plate (Nunc, 
Roskilde, Denmark), coated with either pD_JNK2 
or pD (for immobilization of pD or pD_JNK2, see 
Binz et al. (2004)). After incubation for 45 min at 
4°C, AR protein-mDHFRI fusions were detected 
using an anti-RGS(His)6-antibody as described 11.
Expression and purification of selected AR 
proteins: DNA encoding the selected AR 
proteins were PCR amplified using 
oligonucleotides Ank-Sph-FOR and Ank-Hind-
BACK (5’- GAG GAT CCA AGC TTC TAT TAT 
TGC AGG ATT TCA GCC AGG TC -3’) and 
inserted via SphI and HindIII into the expression 
vector pQE32 (Qiagen), which is the PCA 
selection plasmid without the mDHFR fusion 
protein. Successful cloning was verified by DNA 
sequencing. Expression and purification of the 
AR proteins was carried out as described 10.
Purity of the samples was assessed by SDS-
PAGE and concentrations were determined by 
UV absorbance at 280nm.   
Cross-specificity of selected AR proteins: The 
biotinylated proteins JNK2, JNK1, and p38 were 
immobilized on neutravidin-coated MaxiSorp 
plates (Nunc, Roskilde, Denmark) as described 
11
. One hundred Pl of selected and purified AR 
proteins (250 nM) were incubated in TBST (50 
mM Tris-HCl, pH 7.8, 150 mM NaCl, 0.05% 
Tween, and 0.5% BSA) in each well for 30 min at 
4°C. In addition, one unselected AR protein (100 
Pl 250 nM E3_5, 9) and two JNK antibodies 
(Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) in a dilution of 1:500 (dilution 
recommended by the supplier) in TBST served as 
controls (JNK1 antibody C17/sc-474 and JNK2 
antibody N18/sc-827). Furthermore, one aliquot 
of each binder (AR protein and antibodies) was 
additionally pre-incubated with free JNK2 (750 
nM) prior to incubation with the immobilized 
antigen. Clone pB4 was applied at higher 
concentrations (5 PM purified AR protein; 
inhibited with 15 PM free JNK2). Binding of the 
selected AR proteins was analyzed by detection 
of their N-terminal RGS(His)6 motif as described 
11
. Binding of the purchased JNK antibodies was 
detected by a goat anti-rabbit IgG-AP antibody 
conjugate (100 µl/well, 1:3000, 45 min; Sigma 
(St. Louis, MO, USA)). After extensive washing, 
the bound AR proteins as well as the purchased 
JNK antibodies were visualized using a 4-
nitrophenyl phosphate solution (3 mM 4-NPP, 50 
mM NaHCO3, and 50 mM MgCl2 in H2O; 100 
µl/well). Absorbance was measured at a 
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wavelength of 405 nm. All measurements were 
performed in triplicates.   
Surface plasmon resonance (SPR): SPR was 
measured using a BIAcore3000 instrument 
(BIAcore, Uppsala, Sweden). All measurements 
were done in HBS buffer (20 mM HEPES pH 7.4, 
150 mM NaCl, 10 mM MgCl2, 1mM DTT, 0.005% 
Tween 20) at a flow rate of 50 Pl/min. Biotinylated 
pD_JNK2 fusion protein was immobilized (600 
RU) on a SA chip (BIAcore). For the 
determination of kinetic data, the interactions 
were measured as follows: five minutes initial 
buffer flow, followed by a two-minute injection of 
AR protein in varying concentrations (1 nM to 200 
nM) and a final off-rate measurement of 45 
minutes with buffer flow. Clone pB4 was 
measured at higher concentrations (50 nM to 1 
PM) using a shorter dissociation time (15 min). 
The signal of an uncoated reference cell was 
always subtracted from the measurements. The 
kinetic data of the interaction were evaluated with 
a global fit using BIAevaluation 3.1 (BIAcore). 
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Selecting Designed Ankyrin Repeat Proteins for Co-
Crystallisation of Membrane Proteins 
Patrick Amstutz, Simon Jenni, H. Kaspar Binz, Jasmine Lozza, Nenad Ban & 
Andreas Plückthun 
 
SecYEG is a protein complex in the membrane, which forms a protein 
conducting channel, allowing polypeptides to be transported across or 
integrated into membranes (Matlack et al., 1998). To understand this 
fundamental mechanism in molecular detail, a three-dimensional structure is 
needed (Breyton et al., 2002; van den Berg et al., 2004). The crystallization of this 
complex is not trivial as it spans the membrane with 15 transmembrane helices 
(SecY, 10; SecE, 3; SecG, 2). 
 
The aim of this project was to select specific binders of secYEG from AR 
protein libraries. These binders could be used to stabilize distinct conformations 
of the membrane protein and enlarge its hydrophilic surface, thus aiding the 
crystallization process, as it has been showed for antibodies (Dutzler et al., 2002; 
Ostermeier et al., 1995). 
 
First, selection experiments were performed to show that ribosome display 
as well as the AR proteins function in the presence of detergents. For this 
purpose, one round of ribosome display with a maltose binding protein binder 
(off7) was carried out, in the presence and absence of detergents (dodecyl 
maltoside (DDM): 0.03%). The presence of DDM seemed not to have any 
influence on the outcome of the selection round (Fig. 1). 
Four rounds of ribosome display with the designed AR protein library were 
carried out on immobilized secYEG (as described in Binz et al., 2004) with 0.03% 
DDM in all buffers. SecYEG carried an N-terminal biotinylated avi-tag on secY for 
immobilisation and a N-terminal His-tag on secE for purification. Crude extract 
ELISAs were performed to screen for specific binders. Of around 200 screened 
clones from selection round four, 15 showed specific and 10 showed unspecific 
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binding (data not shown). The binders were analysed in more detail in ELISA 
experiments (Fig. 2). Even though specific binders were obtained, the project 
was stopped at this stage as the crystal structure of secYEG was published (van 
den Berg et al., 2004).  
 
 
 
 
Figure 1. Ribosome display selection round with AR proteins in the presence 
of detergents. A standard ribosome display selection round was performed, 
displaying off7, a MBP binder (Binz et al., 2004). The round was done in duplicate 
and analysed at the level of PCR after RT, testing binding to MBP and 
background binding to neutravidin (Neu) in the presence and absence of 0.03% 
DDM. The outcome, specific binding signal if MBP was present and no signal if 
not, was not found to be detergent dependant. 
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Figure 2. The binding of selected clones in ELISA experiments. The binding to 
secYEG was compared to binding to MBP and competition experiments with 
free secYEG (0 nM, 100 nM, 500 nM, 1000 nM) inhibiting the binding to 
immobilized secYEG were performed. The binders that had been selected 
against secYEG (#1, #2, #3) show no binding to MBP, while binding to 
immobilized secYEG. This interaction can be inhibited by addition of free 
secYEG. The unspecific binder (#4) gives rise to signal under all conditions, 
indicating that it sticks or binds to neutravidin or BSA, which were used for 
coating and blocking of the wells during ribosome-display selection and the 
ELISA. 
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Selection of Semliki Forrest Virus Inhibitors from Designed 
Ankyrin Repeat Protein Libraries 
Stefan Deuber, Patrick Amstutz, H. Kaspar Binz, Andreas Plückthun & Jovan 
Pavlovic 
 
Semliki Forrest Virus (SFV) is a positive stranded RNA virus. SFV is a member of 
the Alpha virus genus of the Togaviridae family, which replicates in the 
cytoplasm of the host cell. The viral replication machinery is encoded by its non-
structural proteins 1-4 (2342 amino acids), which are synthesized as one 
polyprotein and subsequently cleaved (Kujala et al., 2001). The functions of the 
different NSPs are still under investigation. It is known that NSP1 is involved in RNA 
capping and mutations leading to inhibition of the guanylyltransferase activity 
are lethal to the virus (Ahola & Kääriäinen, 1995; Wang et al., 1996). NSP4 was 
shown to have RNA polymerase activity, whereas the functions of NSP3 are less 
clear. NSP2 has several different functions including NTPase, helicase and 
protease activity (Kujala et al., 1997).  
 
The aim of this project was to select ankyrin repeat (AR) proteins as 
intracellular viral inhibitors. Inhibition of NSP function by an AR protein inside the 
cell should inhibit viral replication. In analogy to the selection of APH inhibitors, 
our plan of action was to use ribosome display to select binders of the NSPs from 
AR protein libraries and to use these pools of binders for in vivo screens 
detecting individuals protecting cells from SFV.  
 
The initial experiments included panning against NSP2. Four rounds of 
standard ribosome display were performed (as described in Binz et al., 2004)). 
The pool of selected binders was cloned by ligation to pQE30. Single clones 
were analysed in crude extract ELISAs for binding specificity (Fig 1). In the 
meantime the production of all NSPs was improved and selections against NSP1, 
NSP2 and NSP4 are ongoing.  
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Figure 1. Crude Extract ELISA for the identification of NSP binders after four 
rounds of ribosome display selection. Of 48 analysed clones, four binders 
showed strong and specific binding (ratio: specific/unspecific binding >5), 19 
showed specific binding (ratio: >2.5), 22 showed no binding and four were 
unspecific (ratio: ~1). We concluded that a pool of specific binders was 
selected, containing also unspecific ones. 
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Selection of Binders and Activity Modulators of AMPK from 
Designed Ankyrin Repeat Protein Libraries 
Nadine Straumann, Patrick Amstutz, H. Kaspar Binz, Patrik Forrrer, Andreas 
Plückthun & Theo Wallimann 
 
AMP-activated protein kinase (AMPK) is the metabolic master switch of the 
cell. AMPK senses the AMP level in the cell, not to be confused with cAMP, 
detecting stress to meet cellular energy demands (Kemp et al., 1999). Low AMP 
levels, as found in exercising muscle, activate AMPK. After activation, energy-
producing processes, such as for example glucose uptake and metabolism, are 
started, and energy consuming ones, such as fatty acid synthesis, transcription 
or apoptosis, are stopped. This central role in energy sensing might suggest 
AMPK as drug target (Ruderman & Prentki, 2004). AMPK activation might help 
patients with type 2 diabetes (Winder & Hardie, 1999). This disease shows 
symptoms, which would be predicted for decreased AMPK activity. In fact, 
indirect activation of AMPK by AICAR reduced glucose and insulin levels in the 
blood of test animals. This implies that AMPK activators could find therapeutic 
use. Inhibitors of AMPK are also of high interest. Tumor cells are known to have 
high metabolic activity and AMPK seems to contribute to tolerance of tumor 
cells to metabolic stress (Kato et al., 2002). AMPK inhibition studies with RNAi 
indeed stopped tumor growth in mice.  
 
The aim of this project was to select AR proteins binding to AMPK by 
ribosome display. The selected pool of binders would be the starting point for 
inhibitor and activator screenings. AMPK is a heterotrimer, consisting of one α-, β- 
and γ-subunit each. An avi tag was genetically fused to the N-terminus α-subunit 
for in vivo biotinylation expression, purification (Neumann et al., 2003) and 
subsequent immobilisation during selection rounds and ELISA. 
 
Four rounds of standard ribosome display against AMPK were performed 
and the pool of selected binders was analysed by crude extract ELISA (selection 
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and screening procedure as described in Binz et al., 2004)). Several binders were 
obtained (Fig. 1).  
DNA of the 10 most promising binders and of the complete pools were 
handed over to Nadine Straumann in the group of Theo Wallimann for further 
characterisation and screening.      
 
 
 
 
Figure 1. Crude Extract ELISA for identification of NSP binders after four 
rounds of ribosome display selection. Binding to AMPK (black bar) was 
compared to binding to an unrelated target protein (grey bar). Of 48 analysed 
clones 15 gave a strong and specific ELISA signal, while most others (17) still 
showed significant binding. We concluded that a pool of specific binders was 
selected, constituting an ideal starting point for the screening of activators and 
inhibitors. 
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BACE Inhibitors Selected from Libraries of Designed Ankyrin 
Repeat Proteins 
Hans Kaspar Binz, Oliver Middendorp, Patrick Amstutz, Urs Lüthi, Andreas 
Plückthun & Alcide Barberis 
 
β-site amyloid precursor protein cleaving enzyme (BACE1) is a membrane 
bound protease. One distinct cleavage product, a peptide, is responsible for 
the formation of amyloid plaques and thus is involved in the pathogenesis of 
Alzheimer’s disease I (De Strooper & Konig, 1999; Lin et al., 2000; Vassar et al., 
1999). In collaboration with ESBAtech AG (Schlieren, Switzerland) this project 
aims to generate AR protein based inhibitors. In analogy to the selection of APH 
inhibitors, a two-step procedure was applied, first selecting a pool of binders by 
ribosome display, which is subsequently screened for inhibitors in an in vivo set-
up. We performed four ribosome-display selection rounds against BACE1 (as 
described in Binz et al. (Binz et al., 2004)) and obtained pools of BACE1-binding 
AR proteins (see Fig. 1). These pools were further subjected to an in vivo 
screening assay in yeast for the identification of BACE1 inhibitors. Several AR 
proteins could be isolated that inhibited BACE1 activity in vivo in yeast. These 
inhibitors were then recloned for recombinant expression in E. coli. The proteins 
were produced and purified. Currently, in vitro BACE1 inhibition tests are being 
conducted to demonstrate that indeed enzyme inhibitors have been selected. 
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Figure 1. Crude extract ELISA for the identification of BACE1 binding AR 
proteins of the pools of selected N2C and N3C AR proteins. Of 16 clones from 
the N2C pool, 11 specifically bound BACE1, one bound unspecifically and 4 
gave no signal. Fifteen of 16 clones from one N3C pool specifically bound 
BACE1 while one clone did not show any signal. 
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1. Discussion and Conclusions 
The results described in this thesis demonstrate that designed AR proteins 
are a valid alternative to antibodies. The selected AR proteins equal antibodies 
with respect to their binding characteristics, affinity and specificity, but surpass 
them in terms of production yield, selection speed and stability, especially under 
reducing conditions.  
The success of designed AR proteins might be explained by their 
extraordinary biophysical properties (Kohl et al., 2003). A consensus design 
approach was the foundation for the generation of sequences with these 
properties (Binz et al., 2003; Forrer et al., 2004). AR proteins based on this 
sequence are stable, well expressed and show the typical AR fold. These 
beneficial properties have a positive influence and accelerate experiments at 
all levels of binder generation, including library quality and selection, and 
subsequent analysis, i.e. determining specificity, affinity and structure.  
Concerning the library quality, the intrinsic stability of the framework 
sequence is of high importance. A stable framework will tolerate more diversity 
in the library positions without misfolding. If a library has more functional 
members, a higher diversity is the consequence. This higher diversity is the key to 
success for selection experiments. We were indeed able to select not only one 
binder, but also a whole range of different binders for every target protein. This is 
especially important if functional properties other than binding are desired. 
Here, pools of binders may serve as a starting point for functional screens, for 
example to identify of enzyme inhibitors. 
The high stability of the AR proteins also facilitates the actual selection 
process. Selections for binders from naïve libraries are very challenging. The task 
is to select the very rare specific binders out of a very large number of non-
binders, which might also have “sticky” properties. The better behaved the 
starting library is or, in other words, the smaller the population of “sticky” proteins 
in the library, the easier the selection process will be. Misfolded proteins are 
expected to have exposed hydrophobic patches, sticking to surfaces in an 
unspecific fashion. In our hands the selection of binders from naïve libraries with 
ribosome display takes around five to six rounds for antibody libraries (Hanes et 
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al., 2000), compared to two to three rounds with AR protein libraries. We believe 
this observation is directly linked to the biophysical characteristics of these 
proteins. 
The stable and rigid backbone of the designed AR proteins might also be 
beneficial for their binding characteristics. The binding of a selected AR protein 
to its target protein is a rigid body interaction. Therefore, little entropy is lost upon 
binding, which might explain the high affinities detected. Furthermore, the 
specificity of the designed AR proteins might be explained by their rigidity. The 
selected AR proteins will only bind to the selected surfaces and will not be 
flexible enough to adapt to the surfaces of other proteins.  
The high expression level of AR proteins allows the preparation of large 
amounts of material in a very simple fashion. Expression in a 100 ml shake flask 
culture will yield around 10 mg of pure protein, which is enough for detailed 
analysis of the binding affinity and specificity. This rather small volume allows the 
handling of around 20 clones in parallel, of which the best can be chosen for 
further applications. For simple binder screening, the expression volume can be 
downscaled to less than one ml, allowing the convenient use of 96 well plates.  
As AR proteins are devoid of free cysteines, they are intrinsically stable 
under reducing conditions, as found in the cellular cytoplasm. This does not hold 
true for antibodies. Proteins not evolved for intracellular stability are often 
unstable under these conditions and must therefore be especially adapted for 
such applications (Biocca & Cattaneo, 1995). Our results obtained with AR 
proteins inside the cell demonstrate their efficacy. This opens new perspectives 
ranging from target validation to future gene therapy strategies. 
Taken together, the rapid and successful generation of all the results 
described in this thesis reflects in the favorable nature of designed AR proteins 
 
2. Outlook 
The results described here may be viewed as a general proof of principle. 
They provide a foundation for a whole range of future applications in basic 
research, diagnostics and therapy.  
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The modular architecture of the repeat proteins, which allows module 
shuffling, deletion and elongation, is ideal for affinity maturation of binders. This 
potential will be exploited for Her2 and TNFα binders (Palladino et al., 2003; 
Yarden & Sliwkowski, 2001). By a conventional error prone PCR approach, 
picomolar Her2 binders have already been selected (Zahnd et al., unpublished 
results). The experiments with module alteration are on the way. This might be 
especially fruitful for TNFα binders, as the epitope can be expanded. Here, not 
only binders are desired, but inhibitors of receptor binding are the goal (Zahnd 
et al., unpublished results). An extended epitope will raise the chance of finding 
a competitor.  
 
The very high specificity of the selected binders along with their intracellular 
efficacy will allow the study of specific proteins in their natural environment, 
even if they share high homology to related proteins. The target proteins on 
hand include kinases, caspases and all proteins with different splice variants. This 
new level of specificity might allow the specific assignment of activity to 
individual proteins, not possible to date. Thus drug targets might be validated 
more accurately. The selected AR proteins might then prove useful as first lead 
drug compounds or at least accelerate the drug discovery process. 
 
To date, the structures of both AR protein-target complexes which have 
been under investigation have been solved. This extraordinarily high success 
rate indicates that AR proteins might be used as crystallization tools. Target 
proteins, which are highly flexible, might be stabilized in a distinct conformation 
by an AR binding molecule, allowing crystal growth. Membrane proteins display 
large hydrophobic areas, compared to rather small hydrophilic ones and are 
therefore very difficult to crystallize. Antibodies, binding to membrane proteins, 
enlarge the hydrophilic portion and can propagate crystal growth (Dutzler et 
al., 2002; Ostermeier et al., 1995). AR proteins should, in principle, be able to do 
the same. 
 
The applications of AR proteins for diagnostics are at hand. All ELISA based 
tests could be done with AR proteins. Furthermore, immunohistochemistry and 
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FACS should also be feasible. Again, the high affinity, specificity and stability of 
AR proteins should be beneficial. The superior binding characteristics of AR 
proteins compared to antibodies might even enable more specific and more 
sensitive diagnostic tests. The high stability of AR proteins, on the other hand, 
might propagate new test formats, such as protein chips. Such applications 
might find use in personalized medicine strategies. Experiments in these 
directions are planned (Binz et al., unpublished results). 
 
Antibody therapeutics is one of the fastest growing product classes of the 
pharmaceutical industry. If the drug effect is not based on the effector function 
of the antibody, but on target binding, AR proteins should in principle perform 
likewise. For tumor targeting the small size of the AR protein might even allow 
better tumor penetration (Batra et al., 2002). Final answers will only be found in 
animal experiments. Also the immunogenicity and pharmacokinetics have to be 
investigated. Experiments in these directions are under way (Stumpp et al., 
unpublished results). 
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Designed Ankyrin Repeat Proteins: New Tools in Biotechnology
H. Kaspar Binz, Patrick Amstutz, Patrik Forrer, Michael T. Stumpp, Petra Parizek, Christian Zahnd and Andreas
Plückthun1.
Biochemisches Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland
Abstract. We show here that designed ankyrin
repeat proteins are powerful binding molecules
suitable for a wide range of biotechnological
applications. Binders against a great variety of 
target proteins could be isolated showing
specific, high-affinity binding. We demonstrate
that selected AR proteins can successfully be
used in Western blots, antigen co-purification
and in sandwich ELISA experiments. Designed
ankyrin repeat proteins are hence a true
alternative to antibodies in many aspects.
From Antibodies to Ankyrin Repeat Proteins
Antibodies are renowned for the potential to bind 
their targets specifically and with high affinity. 
These characteristics have made antibodies to one
of the most useful proteins for biotechnological
applications requiring binding molecules. Yet, the
difficult recombinant expression of antibodies (often 
with moderate yields), their complicated
composition (several chains, glycosylation) and the 
dependence of the antibody stability on disulfide
bonds has triggered the quest for alternative protein
scaffolds that can be used for the generation of
binding molecules1-4. We have previously
introduced designed ankyrin repeat (AR) proteins
as alternative binding molecules5-9. Using a 
consensus design strategy10, we generated
combinatorial libraries of designed AR proteins of 
varying repeat numbers5. The analysis of 
unselected library members revealed that designed
AR proteins are unparalleled in terms of 
recombinant expression yield and thermodynamic
stability5,6. From the combinatorial AR protein
libraries we were able to select binders with high
affinity and specificity to maltose binding protein
(MBP) or to the mitogen activated protein kinases
(MAPKs) JNK2 and p38 (Table 1)8. The crystal
structure of a selected binder in complex with MBP 
revealed the correct binding mode, i.e. involving the
randomized potential interaction residues of the 
ARs8. We further selected inhibitors against an 
intracellular kinase (aminoglycoside
phosphotransferase, APH(3’)-IIIa), proving that AR 
proteins are a valuable alternative to antibody 
based intrabodies7.
Here we report on binding molecules selected from 
combinatorial AR protein libraries and we 
summarize the binders described earlier (Table 1).
These results suggest that AR protein libraries can
be used for the generation of binding molecules
against a great variety of proteins. We demonstrate
that designed AR proteins are a real alternative to 
antibodies for various biotechnological applications.
We show for example that selected AR proteins can
be used for the co-purification of a target protein 
from a complex protein mixture. AR proteins can
also be used as highly specific primary detection
reagents in Western blotting experiments.
Analyzing different binders of the same target 
(APH(3’)-IIIa), we found that the binding of the AR
proteins is not restricted to one epitope, but 
different epitopes are targeted by different selected
molecules. We took advantage of this fact and 
designed a sandwich ELISA experiment that
allowed the detection of minimal amounts of target 
protein in a highly concentrated E. coli cell extract.
Target diversity
The popularity of antibodies is due to their ability to
bind many different target proteins with high affinity 
and specificity. To be competitive, alternatives to 
antibodies should perform accordingly. We have
shown that libraries of designed AR proteins can be
used for the generation of MBP-, JNK2-, p38- and
APH(3’)-IIIa-binding molecules. Here we show more
binders against p38 and JNK2 (Table 1). The
target-affinities of these binders are – as for the 
previous binders – in the low nanomolar range
(Table 1).
Target Co-purification
Immunoprecipitation or target protein co-purification
are important for the detection of antigens in cell
extracts and for co-crystallization. Considering the 
high affinity and specificity of AR proteins, it should
be possible to efficiently isolate target proteins from
cell extracts. We prove this by co-purification of
APH(3’)-IIIa with a His-tagged APH(3’)-IIIa-binding
AR protein from an E. coli cell extract (Fig. 1). In a 
single IMAC purification step virtually pure protein
1
 Correspondence should be addressed to A.P. (plueckthun@bioc.unizh.ch), Tel: +41 1 635 55 70; Fax: +41 1 635 57 12 
Abbreviations: APH(3’)-IIIa, Aminoglycoside 3’-phosphotransferase type IIIa; AR, Ankyrin repeat; ELISA, Enzyme-linked
immunosorbent assay; IMAC, Immobilized metal affinity chromatography; IPTG Isopropyl-β-D-thiogalactopyranoside; MAPK, Mitogen-
activated protein kinase; MBP, Maltose binding protein; Ni-NTA, Nickel-nitrilotriacetic acid; SDS-PAGE, Sodium dodecyl sulphate
polyacrylamide gel electrophoresis 
Keywords: Ankyrin repeat, Protein design, Protein purification, Sandwich ELISA, Scaffold, Western blot
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Table 1. Affinities of AR proteins selected against different targets.
Target Selected AR protein Sizea KD [M] kon [M-1s-1] koff [s-1] Reference
MBP m3_16 N2C 1.7·10-8 6.0·105 1.0·10-2 8
off7 N3C 4.4·10-9 4.2·105 1.9·10-3 8
m3_5 N3C 2.2·10-8 2.0·105 4.4·10-3 8
JNK2 JNK2_2_3 N2C 2.1·10-9 9.7·105 2.0·10-3 8
JNK2_2_4 N2C 5.2·10-9 8.8·105 4.6·10-3 b
p38 p38_2_3 N2C 3.7·10-9 9.5·105 3.5·10-3 8
p38_3_8 N3C 3.7·10-9 9.8·105 3.6·10-3 b
APH(3’)-IIIa 3a N3C 1.8·10-9 1.6·106 2.7·10-3 7
3b N3C 5.3·10-10 2.5·106 1.1·10-3 7
#1 N2C 1.9·10-8 1.2·105 2.2·10-3 7
#2 N3C 8.1·10-9 2.8·105 2.3·10-3. 7
B N3C 2.8·10-8 1.4·105 4.1·10-3 7
a
 N2C and N3C represent AR proteins composed of an N-terminal capping repeat, two or three designed AR modules and a C-terminal
capping repeat 
b
 this study
Materials: The N2C and N3C AR protein libraries as well as the cloning, expression and purification of the target proteins have been 
described (see ref. 8 and ref. 7). The ribosome display selection procedure, the screening for binders in the selected AR protein pools by
ELISA, quantitative ELISA and kinetic BIAcore measurements of binding AR proteins were done as described8.
complex could be isolated that contained APH(3’)-
IIIa and the AR protein in a 1:1 stoichiometry (Fig.
1). This stoichiometry was further confirmed by 
subsequent gel-filtration experiments (data not
shown).
Western Blotting 
One of the most important biotechnological
applications of binding molecules is Western
blotting. Antibodies are most frequently used as
detection molecules in Western blots. Other
detection molecules are not routinely used, unless
they recognize a specific tag sequence that was
added to a protein of interest on purpose (for
example streptavidin/strep-tag)11. We show here
that designed AR proteins are a true alternative to 
antibodies for Western blotting (Fig. 2). Two
APH(3’)-IIIa-binding AR proteins were tested for 
their ability to specifically bind APH(3’)-IIIa in a 
crude E. coli cell extract. Both AR proteins detected
APH(3’)-IIIa specifically (Fig. 2). One high-affinity
AR protein detected APH(3’)-IIIa even at levels
where no band for APH(3’)-IIIa was observed on
the SDS-PAGE (uninduced E. coli extract; Fig. 2).
The lower-affinity AR protein detected APH(3’)-IIIa
only at high concentrations, where the APH(3’)-IIIa-
band was also visible on the SDS-PAGE (Fig. 2). A
Western blot with a control AR protein showed no
observable APH(3’)-IIIa detection signal (Fig. 2).
The finding that AR proteins can be used in 
Western blotting is not self-evident. Similar to many
antibodies, which recognize structural epitopes, an
alternative scaffold might also not be suited for 
Western blotting, since the recognized epitope may 
no longer be accessible under PAGE or blotting
conditions (e.g. discontinuous epitope). Especially
for AR proteins, which do not have a groove
comparable to antibodies for the interaction with a 
continuous epitope, it is surprising that Western
blotting is feasible. For one APH(3’)-IIIa-binding AR
protein (#3a, see Fig. 2), we were able to determine
the crystal structure in complex with APH(3’)-IIIa12.
In the complex, the AR protein is bound to a
structural, but rather continuous epitope of APH(3’)-
IIIa, i.e. mostly a helix close to the kanamycin
binding site. This helix is probably also accessible 
under blotting conditions or it may refold during the 
blocking procedure. Note that the sensitivity level of 
the Western blot has not been investigated.
Fig. 1. AR proteins as co-
purification agents. The co-
purification of APH(3’)-IIIa using
the selected APH(3’)-IIIa-binding
AR protein #3a is illustrated by a
15% SDS-PAGE. Mr: molecular
marker. C: soluble fraction of a
crude Escherichia coli (E. coli)
extract containing a 1:1 mixture
of an E. coli culture expressing
the His-tagged AR protein #3a
and a culture expressing
untagged APH(3’)-IIIa. P: Single
step IMAC-purified complex of
APH(3’)-IIIa and the AR protein
#3a from mixture C. 
Materials: The AR protein #3a7 and
APH(3’)-IIIa were expressed each on a
1.5 l scale as described5-7. Before cell
lysis, the cell pellets of both cultures were
mixed (1:1 ratio). The cell lysis and
protein purification has been carried out
as described12.
Sandwich ELISA
Sandwich ELISA is a powerful technology to
specifically detect a target molecule in a complex
protein solution (e.g. E. coli cell extract). A
sandwich ELISA requires two binding molecules
that recognize different epitopes of a target. One
binding molecule is immobilized on a support, which
is then incubated with the protein mixture including
2
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Fig. 2. Application of designed AR proteins in Western blots. (a) 15% SDS-PAGE of crude cell extracts of
Escherichia coli (E. coli) expressing APH(3’)-IIIa. Samples were taken at different time-points after induction of
APH(3’)-IIIa expression with IPTG, as indicated above the gel picture (0, 15, 30, 45, 60 and 120 minutes).
APH(3’)-IIIa appears visibly at approximately 32 kDa after approximately 15 minutes of induction. Mr: molecular
weight marker (b, c, d) Western blots of the APH(3’)-IIIa samples of (a) with different designed AR proteins. (b)
Western blot with #3a7, a N3C AR protein selected to bind and inhibit APH(3’)-IIIa. (c) Western blot with #27,
another N3C AR protein selected to bind and inhibit APH(3’)-IIIa. (d) Western blot with E3_5, an unselected N3C
AR protein library member5.
Materials: The AR proteins, unselected or selected to bind APH(3’)-IIIa, as well as their expression and purification have been described5-7.
APH(3’)-IIIa was expressed as described7 and aliquots were taken at the indicated time-points (see (a)). After 15% SDS-PAGE, the samples
were transferred onto an Immobilon-P transfer membrane (Millipore, Billerica, MA, USA) in transfer buffer (12.5 mM Tris base, 96 mM
glycine, 10% methanol, pH 8.3) using electroblotting. The membranes were blocked with 0.5% BSA in TBS (50 mM Tris-HCl pH 7.4, 150 mM
NaCl) for 180 minutes at room temperature. Between all following incubation steps (all 30 minutes, room temperature), the membranes were
extensively washed with TBST (TBS supplemented with 0.05% Tween 20). The membranes were incubated with 100 nM purified AR protein
#3a (or #2 or E3_5) in TBS buffer containing 0.5% BSA. For detection of the bound AR proteins, the membranes were then incubated with
an αRGS-His IgG (QIAgen) in TBS containing 0.5% BSA. Next, the membranes were incubated with an αmouse-IgG goat IgG-AP fusion
(Sigma, St. Louis, MO, USA) in TBS containing 0.5% BSA. Finally, the blots were developed using Nitroblue tetrazoliumchloride (NBT) and
5-bromo-4-chloro-3-indolylphosphate (BCIP) as substrates (100 µl of each NBT and BCIP stocks in 10 ml 100 mM Tris-HCl pH 9.5, 0.5 mM
MgCl2; NBT stock: 30 mg/ml in 70% dimethylformamide; BCIP stock: 15 mg/ml in dimethylformamide).
the target protein. After extensive washing, the 
second binding molecule is used for the detection of 
the target protein bound by the first binding
molecule (Fig. 3). The high sequence diversity in 
the pool of APH(3’)-IIIa-binding AR proteins (see
ref. 7) indicated that the individual binders recognize
different epitopes7. Indeed, we could identify AR
proteins that bound different epitopes of APH(3’)-
IIIa (data not shown). One pair was chosen for a 
quantitative sandwich ELISA analysis of APH(3’)-
IIIa binding (Fig. 3). In the sandwich ELISA, the two 
AR proteins specifically recognized APH(3’)-IIIa in a 
highly concentrated E. coli cell extract at APH(3’)-
IIIa concentrations far below the detection limit on 
SDS-PAGE (significant signal at 500 pM; Fig. 3).
The detection signal was linear with the APH(3’)-IIIa
concentration in a range from at least 1 nM to 
200 nM (Fig. 3). The control reactions showed that 
a signal was only observed, if the two AR proteins
and APH(3’)-IIIa were present, but not if any of
these components was missing. The sensitivity of 
this sandwich ELISA depends on the affinity of the 
binders for the target. Hence, the sensitivity of this
assay might be increased by using affinity-matured
binders or by increasing the avidity of the binders.
In this manner designed AR proteins could
represent powerful tools for protein-chip
applications.
In conclusion, we have further validated designed
AR proteins as binding molecules. More binders
have been isolated and characterized, and the
technical applicability of designed AR proteins was 
proven to be equivalent to antibodies. Antigen co-
purification, Western blotting and sandwich ELISA 
could all successfully be made using designed AR
proteins.
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Fig. 3. Sandwich ELISA with two selected AR proteins detecting monomeric APH(3’)-IIIa in a crude E. coli
extract. (a) Schematic drawing of the sandwich ELISA and the detection reagents used. Biotinylated AR
protein #3b was immobilized on neutravidin-coated plates. A highly concentrated E. coli extract spiked with a
low concentration of monomeric APH(3’)-IIIa was then added. A second AR protein (#B), which binds a
different epitope of APH(3’)-IIIa than the one of protein #3b, was used to detect the presence of bound
monomeric APH(3’)-IIIa. The RGS-His-tag of this second AR protein was then detected using an antibody
detection system. (b) Sandwich ELISA signals obtained with different monomeric APH(3’)-IIIa concentrations
in the E. coli extract (5 µM to 100 pM). The concentrations of monomeric APH(3’)-IIIa used are indicated below
the signals. Note that in this representation the background signals of the detection antibodies have not been
subtracted. Below, the combination of detection molecules used in the sandwich ELISA is depicted describing
the setup of the measurement samples (leftmost eleven signals) and the control samples (rightmost eight
signals). The 15% SDS-PAGE at the bottom depicts the crude E. coli extracts containing the different
concentrations of monomeric APH(3’)-IIIa used in the sandwich ELISA. (c) Linearity of the monomeric
APH(3’)-IIIa detection signal for the range of 1 nM to 200 nM monomeric APH(3’)-IIIa in the sandwich ELISA.
For this representation, the background value (no monomeric APH(3’)-IIIa in the E. coli extract; 12th signal of
(a) from the left) was subtracted from the measured values.
Materials: Monomeric APH(3’)-IIIa and the RGS-His tagged AR protein #B were produced and purified as described5-7. The biotinylated
AR protein #3b was prepared as follows: Plasmid pQE30 (QIAgen, Hilden, Germany) harboring #3b7 was cut with BamHI/HindIII and the
AR protein encoding DNA was ligated into pAT2228 cut previously with the same enzymes. The resulting vector pAT222_#3b encodes the
fusion protein Avi-tag:pD:AR protein:His6-tag under the control of a T5 promoter. pAT222_#3b and the BirA encoding plasmid pBirAcm
(Avidity, Denver, CO, USA) were cotransformed into E. coli XL1-Blue (Stratagene, La Jolla, CA, USA), and in vivo biotinylated #3b AR
protein was produced and purified as described for biotinylated MBP8. The E. coli cell extract was prepared as follows: E. coli BL21-Gold
(Stratagene) was transformed with pAT11813 encoding a truncated form of phage lambda capsid protein D. Seventy five ml culture (LB,
1% glucose, 100 mg/l ampicilin) grown at 37°C overnight were used to inoculate a 1.5 l culture of the same medium. After 7 hours growth
at 37°C (without induction of the protein expression), the culture was harvested by centrifugation and the cells were resuspended in 50 ml
TBS500 (50 mM Tris-HCl pH 8.0, 500 mM NaCl). After cell lysis with an Emulsiflex C5 (Avestin) followed by additional sonication, the cell
extract was centrifuged for 20 min at 50’000 g. The supernatant, spiked with different concentrations of APH(3’)-IIIa, was then used for the
ELISA. The ELISA was performed as follows: A Maxisorp plate (Nunc, Roskilde, Denmark) was coated with neutravidin and blocked with
BSA as described8. Saturating amounts of biotinylated #3b AR protein in TBST (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.05% Tween 20)
was added to the required wells (100 µl) for 1 hour at 4°C. Between the following incubation steps (all 1 hour at 4°C), the plate was always
washed extensively with ice-cold TBST. The wells were incubated with 100 µl cell extracts containing different concentrations of APH(3’)-
IIIa. Next, 100 µl (2 µM) RGS-His-tagged #B AR protein were added to the required wells (in TBST containing 0.5% BSA). Following this,
100 µl αRGS-His antibody (QIAgen) in the same buffer were added to the wells according to the manufacturer. Finally, the wells were
incubated with 100 µl of the secondary antibody (αmouse-IgG goat IgG-AP fusion; Sigma), again in the same buffer. The ELISA was
developed using para-nitrophenylphosphate (4-NPP; Fluka, Buchs, Switzerland) as described8.
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In Vitro Selection for Catalytic Activity with Ribosome Display
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Abstract: We report what is, to our knowledge, the first in vitro selection for catalytic activity based on
catalytic turnover by using ribosome display, a method which does not involve living cells at any step.
RTEM--lactamase was functionally displayed on ribosomes as a complex with its encoding mRNA. We
designed and synthesized a mechanism-based inhibitor of -lactamase, biotinylated ampicillin sulfone,
appropriate for selection of catalytic activity of the ribosome-displayed -lactamase. This derivative of
ampicillin inactivated -lactamase in a specific and irreversible manner. Under appropriate selection
conditions, active RTEM--lactamase was enriched relative to an inactive point mutant over 100-fold per
ribosome display selection cycle. Selection for binding, carried out with -lactamase inhibitory protein (BLIP),
gave results similar to selection with the suicide inhibitor, indicating that ribosome display is similarly efficient
in catalytic activity and affinity selections. In the future, the capacity to select directly for enzymatic activity
using an entirely in vitro process may allow for a significant increase in the explorable sequence space
relative to existing strategies.
Naturally occurring enzymes catalyze a wide variety of
chemical reactions and are increasingly used in pharmaceutical,
industrial, and environmental applications as a result of their
high reactivities and specificities. However, the direct improve-
ment of biocatalysts remains challenging, and the yet more
ambitious goal of developing enzymes with new catalytic
functions still seems almost elusive. Although our knowledge
of structure-function relationships of enzymes has significantly
increased, rational protein design is still a difficult task,
especially for improved catalysis. The recently developed
strategy of directed evolution can be used as a complement to
rational design. In directed evolution, a protein function of
interest is evolved in the laboratory by mimicking Darwinian
evolution in multiple successive rounds of diversification (library
generation) with subsequent selection or screening (reviewed
in refs 1-3).
Screening, which involves the analysis of single protein
variants, can be automated for high-throughput protocols but
remains laborious and time-consuming, therefore limiting the
size of libraries which can be handled.4 As opposed to screening,
selection methods sample the entire library in a single experi-
mental step. Such experiments require a direct coupling of the
phenotype, which is to be selected for, and its encoding genetic
information, the genotype.
For the selection of enzymatic activities, three general
approaches can be distinguished: methods performed entirely
in vivo, those working “partially” in vitro, and those performed
completely in vitro.1 In the in vivo approach, a genetic library
encoding enzyme variants is transformed into cells where the
variants are expressed and selection takes place. Because
selection protocols are generally based on a growth advantage,
e.g. complementation of an auxotrophy or resistance to a
cytotoxic compound,5-8 in vivo selection of catalysis is limited
to those activities giving rise to a growth advantage. Moreover,
microbial genomes have evolved to deal with environmental
selection pressure. The expression host can therefore be surpris-
ingly “creative” in escaping selection pressure, such as by higher
expression of a poor catalyst or the use of alternative metabolic
pathways, completely by-passing the enzymatic activity that is
the actual target of selection.
Partially in vitro methods can offer an alternative to in vivo
methods. In these methods, the library is also introduced into
cells, resulting in display of the protein of interest, usually on
the surface of phage,9 bacteria, or yeast.10 Selection then occurs
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in vitro, that is, outside the cell, allowing fine-tuning of the
selection pressure and selection conditions.
Both entirely in vivo or partially in vitro techniques require
a transformation step, limiting the applicable library size to
cellular transformation efficiencies. Typically, transformation
efficiencies of 107-108 cells/µg DNA for yeast and 109-1010
cells/µg DNA for Escherichia coli (E. coli)11,12 are achievable.
A considerable amount of work arises from the need of ligating
and transforming such a library after each round of randomiza-
tion. Furthermore, cytotoxic proteins cannot be displayed at all.
Technologies working completely in vitro can overcome these
limitations, because no living cells are involved at any step.
Two approaches that are carried out completely in vitro can
be distinguished. In one, a compartmentalization of individual
variants is achieved in water-in-oil emulsions.13 Since the in
situ detection of fluorescent products and direct optical sorting
of such droplets, harboring the catalytic proteins, have not yet
been reported, the physical link between genotype and pheno-
type is still required, and the emulsions have to be broken up
before an affinity selection or sorting can be performed. The
other approach makes use of the concomitant presence of mRNA
and nascent protein at the ribosome during an in vitro translation
for coupling of genotype and phenotype.14 Here, the most
prominent techniques are ribosome display;15,16 mRNA display,
also termed “in vitro virus”17 or “mRNA-protein fusion”;18 and
“ribosome-inactivation display system”.19 Below, we will
describe the first application of ribosome display to the selection
of catalytic activity in an effort to increase the library sizes
accessible beyond those in previously published accounts with
in vivo or partially in vitro methods.
To select catalysts in vitro, catalysis must be correlated or
coupled to binding. Although reversible binding of enzymes to
transition state analogues has been used frequently in the
selection of novel catalysts,20,21 a more direct selection for
enzymatic turnover can be achieved by the use of mechanism-
based (or “suicide”) inhibitors.22 These compounds are substrate
analogues that, upon turnover, are converted into a reactive
species that binds with the enzyme in a covalent manner, thus
causing irreversible inhibition. Mechanism-based inhibitors can
thus be used for labeling active enzyme molecules. The selection
of -lactamase displayed on phage with a biotinylated mech-
anism-based inhibitor has been reported.23-26 In these reports,
active enzyme was enriched relative to less active mutants and
relative to penicillin binding protein. The elution of covalently
trapped clones from the matrix to which they had been linked
is generally achieved by cleaving within a linker region, either
chemically between the suicide inhibitor and the affinity tag or
enzymatically between the displayed protein and the phage.
Even though entirely in vitro display techniques have great
potential for selection of catalytic activity, this has not previously
been reported. We believe that ribosome display is particularly
well suited to applications based on mechanism-based inhibition,
because ribosome display offers an elegant solution for elution
of the selected genetic information. Because genotype and
phenotype are coupled in a noncovalent complex at the ribosome
(Figure 1), dissociation of these complexes and therefore elution
of the genetic information is easily achieved.
In the present study, we use ribosome display for selection
of catalytic activity with a suicide inhibitor. We have chosen
-lactamase as a model enzyme, and we displayed it on the
ribosome in complex with its encoding mRNA. We have devised
a synthetic scheme for the preparation of a biotinylated
mechanism-based inhibitor of -lactamase. We then applied the
inhibitor to the selective enrichment of active, displayed enzyme.
We show that selection of enzymes is possible entirely in vitro,
combining the advantages of both the in vitro technology of
ribosome display and direct selection for catalytic turnover with
a suicide substrate to select for protein catalysts.
Results and Discussion
In this study we assessed the potential of ribosome display
for enzyme selection based on catalytic activity and on binding
specificity. In such an in vitro selection technology, the
theoretical library size would be limited only by the number of
active ribosomes in the reaction. As a model system, we
displayed RTEM -lactamase in a ribosomal complex with its
encoding mRNA. We describe a rapid synthesis of a biotinylated
mechanism-based -lactamase inhibitor for activity selection.
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Figure 1. Principle of ribosome display selection for catalytic activity.
DNA encoding the protein of interest is transcribed and translated in vitro.
Because the mRNA carries no stop codon and translation is stopped with
high Mg2+ concentrations, stable ternary complexes of mRNA (black),
ribosome (blue) and tethered nascent protein (red) are formed. These can
be used directly for selection with a biotinylated suicide inhibitor. Excess
inhibitor is removed by gel filtration, and the labeled complexes are captured
with avidin coated magnetic beads. After washing to remove any untrapped
ribosomal complexes, the selected complexes are destroyed to elute the
mRNA. Finally, reverse transcription (RT) and PCR are used to amplify
the genetic information of the selected clones.
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We demonstrate that the enzyme folds on the ribosome to its
correct three-dimensional structure and is active there. Further-
more, we demonstrate selection based on activity as well as
selection for affinity with this system.
Rapid Synthesis of a Bifunctional Mechanism-Based
Inhibitor: Biotinylated Ampicillin Sulfone. Penicillin ana-
logues with an electron withdrawing group in position 1 (Figure
2) are known to lead to opening of the thiazolidine ring after
nucleophilic attack of the -lactam ring by the active-site serine
of type-A -lactamase, forming an acyl-enzyme intermedi-
ate.27,28 The attack of a second active-site nucleophilic side chain
on this reactive intermediate results in a covalently inhibited
enzyme (Figure 2). Clavulanic acid and penicillanic acid sulfone
are well-characterized mechanism-based inhibitors of type-A
-lactamase that follow this mechanism.29,30 By tethering biotin
to such an inhibitor, an affinity handle is generated that links
biotin exclusively to active enzyme molecules as a consequence
of enzymatic turnover. The resulting irreversible trapping allows
for the possibility to select directly for catalytic activity.23
We developed a four-step synthesis for biotinylated ampicillin
sulfone, a -lactamase suicide inhibitor, with 64% overall yield.
The synthesis of ampicillin sulfone involved only protection of
the amino group of ampicillin, oxidation of the sulfur in the
thiazolidine ring to the sulfone, followed by deprotection
(Scheme 1). Since the compound is highly sensitive to hydrolysis
at the lactam ring, the choice of the protecting group proved to
be of utmost importance. Only protection with 4-methoxyben-
zyloxycarbonyloxyimino-2-phenyl-acetonitrile (MOZ-ON), but
not with benzylchloroformate or paranitrobenzylchloroformate,
yielded intact ampicillin sulfone upon deprotecting. In a fourth
step, the biotin moiety was added to yield the biotinylated
suicide inhibitor (Scheme 1). Our synthesis is simpler than that
of a similar penicillanic acid sulfone, because we do not need
a disulfide bond in the linker region between the penicillin and
the biotin moiety.31 This disulfide bridge was required in the
context of phage display selection of -lactamase to release the
covalently trapped phages by cleaving with DTT. In contrast,
ribosome display does not require elution of the covalently
trapped and displayed protein, because the genetic information
coding for the displayed protein can easily be released by
chelating the Mg2+ ions so as to disrupt the ribosomal complex.
Mechanism-Based Enzyme Inhibition. The ability of ampi-
cillin sulfone to irreversibly inhibit -lactamase was tested by
steady-state kinetic assays. The inhibition pattern of the RTEM
-lactamase from E. coli, obtained directly from in vitro
translation, was compared to that of the -lactamase from
Enterobacter cloacae. Both enzymes behaved identically. The
enzyme inhibition profile as a function of time showed a
dramatic fall of activity within the first 20 min, followed by a
slower activity decay (Figure 3). These biphasic inhibition
kinetics are typical for mechanism-based inhibitors of -lacta-
mases, such as clavulanic acid, 6-(methoxymethylene)penicil-
lanic acid and 6--((carboxy)methylsulfonamido)penicillanic
acid sulfone.27,32 The kinetics have been interpreted as being
due to a first inhibition phase where the enzyme is transiently
inhibited, while in a slower second phase, the compound inhibits
the enzyme irreversibly (Figure 2). Since not every turnover
results in enzyme deactivation (Figure 2), the inhibitor-to-
enzyme ratio needed for complete inhibition is a measure for
inhibitor potency. From various inhibition experiments, we
determined that this ratio is 8 × 104 for ampicillin sulfone, which
is about an order of magnitude higher than that for the previously
characterized -lactamase suicide inhibitor sulbactam.28,33 This
reduced inhibition efficiency is most likely due to the fact that
(27) Fisher, J.; Charnas, R. L.; Knowles, J. R. Biochemistry 1978, 17, 2180-
2184.
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Figure 2. Proposed interaction of ampicillin sulfone with the active site
serine -lactamase.27,28 The active site serine attacks the carbonyl group of
the lactam ring, and before a water molecule can attack, the sulfone in
position 1 acts as a leaving group from carbon 5 and evokes the formation
of an acyl-enzyme intermediate (a). This acyl-enzyme intermediate is in
an equilibrium with a more stable tautomer (b), resulting in transient
inhibition. A normal deacylation, triggered by water, can also occur, and
no inhibition is seen (c). Finally, transamination with a lysine in the active
site can occur (d), which results in an irreversibly inactivated enzyme, bound
covalently to the inhibitor and the biotin moiety.
Scheme 1. Synthesis of Biotinylated Ampicillin Sulfone, a
Mechanism-Based Inhibitor for Selection of Active Site Serine
-Lactamases.a
a (I) H2O, CH2Cl2 (4:1); NaHCO3; MOZ-ON. (II) H2O, KMnO4. (III)
CH2Cl2, TFA (10:1). (IV) H2O, EZ-Link Sulfo-NHS-LC-LC-Biotin (Pierce)
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ampicillin sulfone is derived from ampicillin, a very good
substrate of -lactamase that is rapidly hydrolyzed.28 The
covalent nature of the inhibition was confirmed by dialysis of
the inhibited enzyme. Even upon extensive dialysis, no recovery
of activity could be detected, whereas the noninhibited enzyme
remained fully active (data not shown). The biotinylated form
of the inhibitor gave results comparable to ampicillin sulfone
itself in all assays (data not shown). These results confirm that
the biotinylated form of ampicillin sulfone acts as a bona fide
mechanism-based inhibitor of -lactamase and could be used
for selection of -lactamase activity.
Prevention of Nonspecific Protein Labeling by Ampicillin
Sulfone. Besides its reactivity, we also investigated the specific-
ity of the suicide inhibitor. Although hydrolysis of the lactam
ring, leading to formation of the reactive species, will be greatly
accelerated at the active site of the enzyme, the labile nature of
the lactam ring may allow for labeling outside of the active
site. In addition, ampicillin is known to react nonspecifically
with -amino groups of proteins in a covalent manner, a cause
for ampicillin allergies.35 Nonspecific labeling could lead to
significant background in selection rounds by the suicide
inhibitor reacting with inactive enzyme displayed on the
ribosome or with ribosomal proteins. We thus investigated
possible nonspecific binding in order to minimize it. Aliquots
of E. coli S30 extract were incubated with biotinylated ampicillin
sulfone under various conditions and for different incubation
times. The proteins were then separated from excess suicide
inhibitor by gel filtration. The resulting samples were analyzed
by Western blotting. The results showed significant labeling of
proteins other than -lactamase (Figure 4). Nonspecific labeling
also occurred when incubating the biotinylated suicide inhibitor
with purified control proteins, such as citrate synthase, GFP
(green fluorescent protein), anti-GCN4-single-chain Fv, and
M13 helper phage (data not shown). The signal intensity of
nonspecific labeling increased with time (lanes 1-4), temper-
ature (lane 5), and higher pH (lane 7) and could be competitively
inhibited by preincubation with ampicillin sulfone (lane 6)
(Figure 4). These observations are in agreement with the
published results on -lactamase selections with phage display
using similar mechanism-based inhibitors.23-26 In all the phage
display experiments, the labeling time was short (<30 min),
the pH was kept below 6, and there was at least 1% BSA
present, presumably to reduce nonspecific labeling. Under those
conditions, the authors reported the selection of highly active
-lactamase over less active mutants or penicillin binding
protein, which binds but does not hydrolyze the -lactam ring.
The broadly based nonspecific labeling of proteins that are
not linked to their genotype, as illustrated above, is not likely
to be detrimental to the selection of displayed enzyme. However,
it suggests that nonspecific labeling of inactive displayed enzyme
and of ribosomal proteins may also occur under certain
conditions. To favor specific labeling in our in vitro system,
the selection for enzymatic activity of -lactamase was carried
out at pH 6.0 and at 4 C for short times (10 min to 1 h) (10
min in Figure 4, lane 1). These conditions are also compatible
with those required for ribosome display.
Ribosome-Displayed -Lactamase is Active. In ribosome
display, selection is performed with a ternary complex of
mRNA, ribosome and displayed protein (Figure 1). For this
strategy to be successful, the protein must fold to its native three-
dimensional structure before the polypeptide is released from
the ribosome. Furthermore, the ribosome-bound protein must
be active. To allow the displayed protein of interest to exit the
ribosomal peptide channel and fold into its active conformation,
the encoding gene was fused to a 171-amino acid-long C-
terminal fusion partner TolA of E. coli serving as a tether. To
demonstrate functionality of -lactamase in the ribosomal
complex, the complexes were separated by gel filtration from
enzyme released during translation, under conditions securing
complex stability (see Experimental Procedures). Usually such
protein-ribosome complexes are purified by sucrose gradient
(34) Brenner, D. G.; Knowles, J. R. Biochemistry 1984, 23, 5839-5846.
(35) Schneider, C. H.; De Weck, A. L. Nature 1965, 208, 57-59.
Figure 3. Time course of RTEM--lactamase inhibition by ampicillin
sulfone. -lactamase (10-9-10-10 M, from in vitro translation) was
incubated with ampicillin sulfone (1 mM) for different time periods at room
temperature, and the remaining activity was measured in nitrocefin assays.
The data, given as activity relative to that at time ) 0, were fitted as double
exponential decay. Similar inhibition curves have been reported for other
-lactamase suicide inhibitors.27,31,34 The data for this plot were obtained
from three independent experiments.
Figure 4. Analysis of nonspecific labeling of proteins by ampicillin sulfone.
A protein mix, here E. coli S30 extract, was incubated with biotinylated
ampicillin sulfone (0.1 mM). The proteins were separated from excess
inhibitor by gel filtration, followed by SDS-PAGE and Western blotting
for detection of biotin with avidin-alkaline phosphatase conjugate. The
arrow indicates the signal obtained from pyruvate carboxylase, a biotinylated
E. coli protein in the extract, used as internal standard. Lanes 1-5 and 7
show different labeling conditions and incubation times. In lane 6, the protein
mix was preincubated with 1 mM ampicillin sulfone at room temperature
for 1 h. The nonspecific labeling is most likely caused by the attack of
nucleophilic surface residues on the lactam ring and has been reported also
for ampicillin.35
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centrifugation.36-38 The use of small gel filtration columns is a
rapid and gentle alternative and allows the parallel processing
of a large number of samples. Thus, we were able to quantify
the amount of active -lactamase in ribosomal complexes (Table
1). An aliquot of this fraction was treated with RNase A,
destroying the ribosomal complex, thus releasing the enzyme.
No significant increase in activity was measured, indicating that
ribosome-bound -lactamase is fully active, and no additional
active enzyme molecules are obtained by releasing them from
the ribosome (Table 1). When the RNase A treatment was
carried out prior to the gel filtration procedure, however, some
background activity was detected in the complex fraction (Table
1), either from insufficient complex destruction or incomplete
separation by gel filtration. These results confirm that the
tethered -lactamase can fold to its correct three-dimensional
structure and can catalyze substrate turnover while still bound
to the ribosome. Comparing the total activity after in vitro
translation of the ribosome display construct prior to gel filtration
to the amount of ribosome-displayed activity, we estimated the
percentage of -lactamase in ribosomal complexes to be ∼50%
of total -lactamase produced. We presume that the other half
is released from the ribosome by hydrolysis of RNA or
proteolysis of the tether. The possibility that a fraction of the
produced protein is bound to the ribosome in an inactive state
and does not refold upon complex destruction remains, but that
seems unlikely, because -lactamase is known to fold ef-
ficiently.39 Although co-translational folding and activity on the
ribosome have been demonstrated for firefly luciferase in
different experiments,36-38 we show here that -lactamase also
folds and acquires activity on the ribosome, thereby fulfilling
the major requirements for ribosome display selections.
Affinity Selection and Selection for Activity Are Equally
Efficient. We extended our analysis of -lactamase functionality
in the ribosome display format by performing selection rounds
based on affinity and catalytic activity. The -lactamase
inhibitory protein (BLIP) binds near the active site of -lacta-
mase with high affinity (Kd ) 0.6 nM)40 and had been used in
affinity selection with phage display.41,42 In contrast to His-
tagged BLIP, gpHDBLIP, a C-terminal fusion of BLIP to the
His-tagged protein D (gpHD),43 could be expressed at high
levels in inclusion bodies and could be refolded efficiently. The
fusion partner, gpHD, not only improved the expression of BLIP
very significantly but also provides a His tag, which we used
for purification of the fusion protein and its immobilization for
affinity selection. We performed selection rounds with active
ribosome-displayed -lactamase on either immobilized gpHD-
BLIP or the immobilized biotinylated suicide inhibitor. The
experiments were carried out as described44 with some modi-
fications to adapt the system for activity selection, notably lower
pH (pH 6.0) and the presence of 1% BSA, for reasons discussed
above. After in vitro translation and incubation on ice, aliquots
of ribosomal complexes displaying -lactamase were incubated
for 1 h with gpHDBLIP or biotinylated ampicillin sulfone.
Excess ampicillin sulfone or unbound gpHDBLIP was removed
by gel filtration, and the complexes selected with the biotinylated
suicide inhibitor were captured with avidin-agarose, whereas
the ones binding to gpHDBLIP were immobilized via a tetra-
His antibody which was captured with protein G-PLUS agarose.
Extensive washing removed unbound complexes. The mRNA
was eluted, and after RT and PCR, the yields were quantified
according to band intensities on an agarose gel (Figure 5). We
observed identical results with affinity- and activity-based
selections, indicating that the ribosome-displayed -lactamase
is active in terms of both binding and enzymatic activity and
that selection for activity and affinity in this system are equally
efficient.
Selection of Active -Lactamase over an Inactive Mutant
Completely In Vitro. To assess the efficiency and specificity
of selection for activity with ribosome display, the enrichment
of active -lactamase over an inactive point mutant was tested.
The serine residue at position 70 of the active enzyme, whose
hydroxyl group carries out the nucleophilic attack of the lactam
ring (Figure 2), was replaced by alanine, yielding an inactive
mutant enzyme with otherwise unimpaired structure.45-48 Ri-
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Table 1. Activity of Ribosome-Displayed -Lactamase
sum of free and
ribosome-displayed
-lactamasea
ribosome-bound
-lactamaseb
ribosome-displayed
-lactamase
after releasec
background activity
in complex fractiond
rel enzyme activitye 100 ( 4.8 50 ( 5.1 54 ( 7.0 17 ( 5.8
a Total activity measured after in vitro translation. b After gel filtration (activity of ribosomal complex fraction). c Complexes destroyed by RNAse A
treatment after gel filtration (activity of ribosomal complex fraction). d Complexes destroyed by RNAse A treatment prior to gel filtration (activity of ribosomal
complex fraction). e Data from three independent experiment measured in triplicates.
Figure 5. -Lactamase selection for activity and affinity. The DNA yield
after one round of ribosome display by affinity with gpHDBLIP (BLIP),
by biotinylated ampicillin sulfone (suicide inhibitor) or with beads alone
(background) were compared. Only active -lactamase was used, resulting
in PCR amplification of a band at 834 bp. Lane M indicates DNA molecular
weight marker. Background binding to the beads is very weak, and the
efficiency of selection for affinity and activity are comparable.
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bosome display was performed with RNA encoding active and
mutant -lactamase mixed in a ratio of 1:10. After translation,
biotinylated ampicillin sulfone was added, and after 30 min,
excess suicide inhibitor was removed by gel filtration. The
biotin-labeled complexes were captured with streptavidin mag-
netic beads, and the mRNA was eluted and amplified by RT
and PCR. Five completely independent selection experiments
were performed. Enrichment of the active enzyme was quanti-
fied by two independent methods: first, an MscI restriction site
had been introduced along with the S70A mutation, allowing
restriction fragment analysis to distinguish the PCR products
encoding active and inactive enzyme. Figure 6 illustrates a
representative enrichment (lane E1, factor of 110) as well as
the best enrichment obtained (lane E2, factor of 1400). To
independently determine the magnitude of the enrichment factor,
gene pools after one round of ribosome display were sequenced
for the 2 experiments illustrated in Figure 6, and the signal
intensities of the respective bases were analyzed, giving
enrichment factors of 110 and 250 (data not shown). The fact
that the enrichment factor varied within 1 order of magnitude
in different selection experiments is most likely due to the small
amount of inhibitor used, giving a low yield difficult to quantify,
and the inhibitor concentration was not increased to prevent
unspecific labeling.
In summary, all experiments clearly showed enrichment of
active enzyme over inactive mutant. We concluded that after
only one round of mechanism-based selection with ribosome
display, an enrichment >100-fold was achieved. To demonstrate
that the enrichment was, indeed, due to specific labeling of
active -lactamases, several control experiments were per-
formed. To ascertain that enrichment was not an artifact of RT
and PCR, input mRNA was directly applied to this procedure,
showing no enrichment of the active species (Figure 6, lane
C1). To rule out mRNA stability during translation as enrich-
ment source, a second control was performed. A normal
ribosome display round was performed using the same ratio of
input mRNA but in the absence of biotinylated ampicillin
sulfone. Here, no enrichment of active enzyme was detected
(Figure 6, lane C2). The possibility of different translation
efficiencies of mutant and active construct was ruled out by
performing radioactive translations and comparing protein yields
after SDS-PAGE and autoradiography. The band intensities
were identical for both constructs (data not shown). It follows
that active -lactamase is efficiently enriched with ribosome
display in vitro due to its catalytic activity.
Conclusions
In conclusion, we have shown for the first time that ribosome
display may be used for selection of enzymes based on their
catalytic activity. It follows that this strategy is ideally suited
to performing directed evolution of enzymes. This novel
potential of ribosome display was demonstrated by selecting
-lactamase based on its enzymatic activity. We show that the
enzyme -lactamase folds correctly on the ribosome and is
active in the ternary complex, thus fulfilling the major require-
ments for ribosome display. To select for enzymatic activity of
-lactamase with ribosome display, we synthesized ampicillin
sulfone, a mechanism-based inhibitor of -lactamase, which can
be derivatized with biotin, yielding a bifunctional activity label.
This label was applied to ribosome display experiments, in
which active -lactamase could be enriched over an inactive
mutant >100-fold/selection round. The efficiency of selection
for activity was comparable to that of affinity selection, which
was carried out with immobilized BLIP.
Taken together, we demonstrate that ribosome display, a
technique that combines the advantages of very rapid selection
rounds with the use of large libraries, known to be capable of
evolving high affinity binders, may also be applied to the
selection of catalytic proteins. Therefore, we believe this method
will have great potential for directed evolution of enzymes and
the selection of new catalytic proteins.
Experimental Section
Synthesis of Biotinylated Ampicillin Sulfone. Ampicillin was
obtained from Roche Diagnostics, and 4-methoxybenzyloxycarbony-
loxyimino-2-phenyl-acetonitrile (MOZ-ON) and other chemicals were
from Fluka. IR spectra were measured on a Perkin-Elmer 297
spectrometer; NMR spectra, on a Bruker ARX-300 (1H) and a Bruker
ARX-75 (13C) spectrometer; and mass spectra, on a Perkin-Elmer Sciex
API III+ ESI-MS.
Ampicillin (1.5 g, 4.02 mmol) was dissolved in 4 mL of H2O. One
equiv of MOZ-ON (1.25 g, 4.02 mmol) in 4 mL dioxane was added.49
The pH of the reaction mixture was adjusted to 7.8. After stirring for
6 h, the mixture was treated with 8 mL of H2O (pH 7.8) and extracted
with EtOAc (3×, 100 mL). The pH was adjusted to 3.0 with 10% H3-
PO4, and the aqueous phase was extracted with EtOAc (5×, 100 mL).
The combined EtOAc extractions were dried with NaSO4 and evapo-
rated in vacuo. MOZ-ampicillin (1.58 g, 3.08 mmol, 76.5% yield) was
collected as an egg white powder: IR (CHCl3 [cm-1]) 3405, 2960,
1785, 1725, 1695, 1612, 1515, 1495; 1H NMR (300 MHz, DMSO): δ
1.42, 1.55, 3.74 (3× 3H, 3s), 4.23 (1H, s), 4.98-4.99 (2H, m), 5.38-
5.41 (1H, m), 5.50-5.54 (2H, m), 6.91 (2H, d like m, J ) 6.9), 7.24-
7.35 (5H, m), 7.44-7.53 (2H, m), 7.88 (1H, br d, J ) 7.9), 8.99 (1H,
br d, J ) 7.7); 13C NMR (DMSO): δ 26.4, 30.2, 54.9 (3q), 57.4, 58.1
(2d), 63.5 (s), 65.4 (t), 67.1, 70.2 (2d), 113.6 (2C, d), 125.4 (d), 127.1,
128.0 (2× 2C, 2d), 128.6 (1C, s), 129.5 (d), 137.7, 155.6, 158.9, 168.9,
170.4, 173.2 (s); MS: 514.2 m/z.
(47) Jacob, F.; Joris, B.; Frere, J. M. Biochem. J. 1991, 277, 647-652.
(48) Mazzella, L. J.; Pazhanisamy, S.; Pratt, R. F. Biochem. J. 1991, 274, 855-
859. (49) Chen, S. T.; Wang, K. T. Synthesis 1989, 36-37.
Figure 6. Restriction analysis for detection of enrichment of active
-lactamase with ribosome display. The results of two independent
experiments are shown, where E1 represents a usual result and E2, the most
successful result obtained. In each experiment, an MscI digest of the DNA
pool was carried out after one round of enrichment for enzymatic activity
of -lactamase with ribosome display. The round was performed with a
ratio of inactive mutant to active -lactamase of 10:1. After RT, the
-lactamase gene was amplified (834 bp) by PCR and digested with MscI,
resulting in cleavage of only the DNA encoding the inactive mutant (662
bp + 172 bp). Lane M indicates DNA molecular weight marker. Lane C1
shows the input mRNA directly reverse-transcribed and amplified by PCR
without undergoing a display cycle. C2 shows the background of a standard
enrichment round without biotinylated ampicillin sulfone present. E1 and
E2 represent two independent enrichment rounds performed with biotiny-
lated ampicillin sulfone. The enrichment factors were estimated to be 110
for E1 and 1400 for E2.
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MOZ-ampicillin (513 mg, 1.00 mmol) was dissolved in 3.6 mL of
cold H2O, and the pH was adjusted to 7.0. KMnO4 (190 mg, 1.2 mmol)
was dissolved in 5 mL H2O and treated with 65 µL 10% H3PO4. The
KMnO4 solution was added dropwise to the first solution on ice, while
maintaining the pH between 6.8 and 7.3 with 10% H3PO4 and 10%
NaOH. After 40 min, the reaction mixture was brought to pH 8.0 and
filtered over Celite, and the filtrate was acidified to pH 3.0 with 10%
H3PO4.50 The product was extracted with EtOAc (5×, 100 mL, dried
with NaSO4, and concentrated in vacuo to afford 495 mg (91% yield)
of MOZ-ampicillin sulfone as an egg white powder: IR (CHCl3 [cm-1])
3410, 2960, 1810, 1730, 1700, 1612, 1515, 1495, 1328, 1118; 1H NMR
(DMSO): δ 1.33, 1.46, 3.74 (3 × 3H, 3s), 4.36 (1H, s), 4.97 (2H, s),
5.31 (1H, d, J ) 4.5), 5.51 (1H, d, J ) 8.3), 5.90 (1H, dd, J ) 4.4,
8.8), 6.90 (2H, d, J ) 8.6), 7.28-7.31 (5H, m), 7.35-7.50 (2H, m),
7.97 (1H, br d, J ) 8.5), 8.65 (1H, br d, J ) 8.8); 13C NMR (DMSO):
δ 17.4, 19.8, 55.1 (3q), 56.8, 59.1, 63.7 (3d), 64.6 (s), 65.4 (d), 67.3
(t), 113.8, 127.0 (2× 2C, 2d), 128.4 (s), 128.7 (d), 129.1, 129.9 (2×
2C, 2d), 136.0, 156.0, 159.5, 168.9, 170.6, 173.6 (6s); MS: 546.2 m/z.
A solution of MOZ-ampicillin sulfone (220 mg, 0.40 mmol) in 2
mL of CH2Cl2 and 0.2 mL of TFA was stirred at room temperature for
30 min.49 The solvent was removed in vacuo. The product was triturated
with ether that was removed as the supernatant after centrifugation.
This procedure was repeated twice, and the product was dried in vacuo.
Ampicillin sulfone (150 mg, 0.39 mmol, 97% yield) was isolated as a
pale yellow powder: IR (KBr [cm-1]): 3390, 2980, 1802, 1674, 1525,
1458, 1433, 1376, 1323, 1116; 1H NMR (DMSO): δ 1.32, 1.42 (2×
3H, 2s); 4.33 (1 H, s); 5.31-5.29 (2H, m); 5.95 (1 H, dd, J ) 8.4,
4.5,); 7.30-7.54 (5H, m); 9.12 (1H, d like m, J ) 8.5); 13C NMR
(DMSO): δ 17.0, 19.1 (2q); 54.7, 55.6, 63.1 (3d); 63.7 (s), 64.6 (d),
127.4, 128.7 (2× 2C, 2d), 129.1 (d), 132.9 167.7, 168.0, 173.1 (4s),
MS: 382.2 m/z.
EZ-LinkSulfo-NHS-LC-LC-Biotin (7.6 mg, 1.14 × 10-2 mmol,
Pierce) was dissolved in 7 mL borate buffer pH 7.8. Ampicillin sulfone
(7.1 mg, 2.3 × 10-2 mmol) was added. This solution was sonicated
and stirred for 1 h at room temperature. Tris(hydroxymethyl)ami-
nomethane base (2 mg, 1.7 × 10-2 mmol) was added, stirred for an
additional 10 min, and lyophilized to afford 71.5 mg of a white powder
(as a complex with borate) from which 30 mg was dissolved in MeOH
and applied to a silica gel column (1 g, in a Pasteur pipet). The product
was eluted with 10 mL of MeOH, which was removed in vacuo. The
product was obtained quantitatively as a white powder from ampicillin
sulfone. MS: 834.4 m/z.
Inhibition Studies. -Lactamase (from E. cloacae (Fluka) or E. coli
R-TEM -lactamase from in vitro translation) in concentrations from
10-9 to 10-10 M (as determined by activity measurements,51 and
assuming that the specific activity of the in vitro translated -lactamase
is similar to that of the bacterially expressed enzyme) was incubated
at room temperature in 50 mM potassium phosphate buffer (pH 6.0,
5% DMSO), with or without 1 mM ampicillin sulfone. DMSO is
required to dissolve ampicillin sulfone. Aliquots of 500 µL were taken
after 10, 20, 30, 45, and 90 min and were mixed with 500 µL of 0.4
mM nitrocefin (Becton Dickinson) in 50 mM potassium phosphate
buffer (pH 6.0, 1% DMSO). Reaction kinetics were followed at OD486
during 2 min at room temperature with a Perkin-Elmer Lambda 20
spectrophotometer.51 To show the covalent nature of the inhibition, a
sample (500 µL) of inhibited and, as a control, not inhibited enzyme
were dialyzed against 500 mL potassium phosphate buffer (50 mM,
pH 7) in “Slide-A-Lycer 10K” devices (molecular weight cut-off, 10
kD, 0.5-3 mL sample volume) (Pierce) for 2 h before activity was
measured.
Western Blot Analysis. E. coli S30-extract (as used for ribosome
display 44) was diluted 2-fold in 50 mM potassium phosphate buffer
(pH 6.0, 1% DMSO) and incubated with 0.1 mM biotinylated ampicillin
sulfone on ice. Aliquots were taken after various time points and excess
inhibitor was removed by gel filtration (NAP-500 column, Pharmacia,
according to the manufacturer’s instructions). Alternatively, one aliquot
was incubated at 25 C for 2 h while another was kept on ice at a pH
8 for 2 h. For inhibition studies, one aliquot was preincubated with 1
mM ampicillin sulfone for 1 h at room temperature prior to incubation
with biotinylated ampicillin sulfone (as described above). The proteins
were separated by SDS-PAGE (12%) and blotted onto a membrane
(Immunoblot, Millipore). The membrane was blocked with milk, and
the presence of the biotinylated suicide inhibitor was detected with an
avidin-alkaline phosphatase conjugate (Pierce).
DNA Constructs for the Model System. The -lactamase gene
encoding the double cysteine to alanine mutant was PCR amplified
from the plasmid pAP5•2C•2A 51 with the primers SDA-BLA
5 -(AGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAA-
CTTTAAGAAGGAGATA TATCCATGGACTACAAAACCAGCCA-
GAAACGCTGGTGAAAGT), which codes for the Shine Dalgarno box
and the beginning of the -lactamase gene, and BLArev 5 -(ACA-
CAGGCCCCCGAGGCCCAATGCTTAATCAGTGA), annealing at
the end of the -lactamase gene and introducing a unique SfiI restriction
site, while removing the stop codon. To create an inactive -lactamase
to use as a negative control for activity, the active site serine was
mutated to alanine (S70A) by PCR mutagenesis. A unique MscI
restriction site was added at the site of the mutation to allow for
discrimination of the genes encoding active and inactive enzyme. In
parallel, a 171 amino acid portion of the tolA gene (residues 131 to
302) was amplified by PCR from chromosomal E. coli DNA in order
to serve as a C-terminal tether for the displayed -lactamase. The
primers used were tolAforSFI 5 -(TATATGGCCTCGGGGGCCGAAT-
TCCAGAAGCAAGCTGAAG), introducing an SfiI-site, and tolAmrev
5 -(CCGCACACCAGTAAGGTGTGCGGTTAGCTCACCGAAAA-
TATCATC), which introduced a RNA-stabilizing 3 -loop. The inactive
S70A mutant and the active -lactamase were fused to the tolA spacer
by SfiI digestion-ligation. The resulting constructs were further
amplified by PCR with the primers tolAmrev and T7B 5 -(ATAC-
GAAATTAATACGACTCACTATAGGGAGACCACAACGG), which
introduced an RNA stabilizing 5 -loop and the T7 promoter for in vitro
transcription. Both constructs were verified by DNA sequencing.
Separation of Ternary Complexes from Free -Lactamase by
Gel Filtration. For ribosome display, the in vitro transcription and in
vitro translation of the constructs were carried out essentially as
previously described.44 Following a 10-min translation in 110 µL, the
reaction was stopped by 4-fold dilution in ice-cold wash buffer (WB;
50 mM potassium phosphate buffer, pH 6.0; 150 mM NaCl; 50 mM
MgCl2). A 250-µL aliquot was treated with 2.5 µL RNase A (Qiagen,
10 mg/mL in WB) for 180 min at 4 C to release ribosome-bound
-lactamase, while another aliquot was treated with WB only. An
aliquot (200 µL) of each solution was applied to a 1-mL gel filtration
column (CL-4B, Pharmacia) that had been equilibrated with 10-20
mL of ice-cold WB. Fractions of 100 µL were collected, and the enzyme
activity was assayed in a nitrocefin assay (200 µM nitrocefin in WB
buffer, pH 6.0, 1% DMSO). In addition, an aliquot of diluted translation
mix was treated with RNaseA for 1 h at room temperature without
subsequent gel filtration. The -lactamase activity of this sample was
determined in order to quantify the total activity, as free enzyme,
resulting from translation.
Enrichment for Catalytic Activity with Ribosome Display. RNA
coding for active as well as inactive S70A mutant -lactamase was
mixed in a ratio of 1 to 10 (10 µg total of RNA in 10 µL water) and
translated in 110 µL for 10 min.44 Translation was stopped by 4-fold
dilution into ice-cold WB with 1% BSA (bovine serum albumin,
Sigma). Biotinylated ampicillin sulfone (stock solution, 0.01 M in
DMSO) was added to a final concentration of 0.01 mM. A control
sample contained the same final concentration of DMSO but no
biotinylated ampicillin sulfone. After 30 min at 4 C, the reaction was
stopped by removal of the excess biotinylated ampicillin sulfone by
(50) Johnson, D. A.; Panetta, C. A.; Cooper, D. E. J. Antibiot. 1963, 28, 1927-
1928.
(51) Laminet, A. A.; Plu¨ckthun, A. EMBO J. 1989, 8, 1469-1477.
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gel filtration (250 µL ribosomal complexes, 1 mL CL-4B column, as
described above). Avidin-coated agarose beads (100 µL) (Roche
Diagnostics), equilibrated in ice-cold WB containing 6% biotin-depleted
sterilized milk,44 were added to the flow-through (500 µL) and gently
shaken at 4 C for 30 min to capture the labeled complexes. The beads
were then washed five times with 500 µL of ice-cold WB. During this
procedure, the beads were transferred to a new prechilled tube. To elute
the mRNA, 250 µL EB20 buffer (50 mM Tris-HCl, pH 7.5, 20 mM
EDTA) was added, and the solution was gently shaken for 10 min at
4 C before centrifugation (2 min, 2000g). The supernatant (200 µL)
was used for mRNA purification (High Pure RNA Isolation Kit, Roche
Diagnostics). Reverse transcription (RT) and PCR was carried out as
described,44 except that the primers used were SD-BLA and BLArev.
Monitoring the Enrichment of Active -Lactamase Relative to
the Inactive S70A Mutant. The product from RT-PCR was purified
with a spin column (QIAquick, Qiagen) according to the manufacturer’s
protocol. The DNA was subsequently analyzed by restriction analysis
with MscI or by sequencing. After digestion with MscI, the ratio of
active (uncleaved) to mutant (cleaved) -lactamase was estimated from
the relative intensity of bands on a 2.5% Metaphor agarose gel (FMC)
using the program NIH image. DNA sequencing was carried out with
10 ng PCR product according to the manufacturer’s protocol (SequiTh-
erm EXCEL II, Epicenter Technologies). The enrichment factor was
estimated by determining the relative signal intensities of the 2
nucleotides that were mutated in the inactive S70A enzyme, with NIH
image.
-Lactamase Inhibitory Protein (BLIP) Expression as pD Fusion.
We constructed a fusion protein of BLIP with protein D, carrying an
N-terminal His6 tag (gpHD). The BLIP (Swiss-Prot P35804) gene was
amplified by PCR and cloned into the vector pAT39 43 between the
BamHI and HindIII sites to yield gpHDBLIP, consisting of gpHD, a
Gly-Ser linker (GSGGGSGGGG), and BLIP. The fusion protein was
amplified from pAT39 by PCR and ligated into the vector pET40-b
(Novagen), carrying a kanamycin resistance gene. Plasmids were
verified by sequencing and subsequently used for expression in the E.
coli strain BL21 (DE3) [pLysS] (Stratagene) in 1 L of LB medium
containing 100 µg/mL kanamycin. Expression was induced with IPTG
(1 mM) at OD600 ) 0.8. The cells were grown for 3 h at 37 C and
harvested by centrifugation. The cell pellet was resuspended in PBS
(10 mM sodium phosphate buffer, pH 7.4, 140 mM NaCl, 15 mM KCl),
and the cells were lysed by sonication. The resulting crude extract was
centrifuged (5 min, 6000 g, 4 C), and the pelleted inclusion bodies
were washed once with PBS and resuspended with a solution containing
6 M GdnHCl, 0.1 M Tris, pH 8.0, and 10 mM imidazole. The
solubilized inclusion bodies were applied to a Ni-NTA column (15
mL) (Qiagen) and washed with GdnHCl buffer. The protein was
refolded on the column by replacing the GdnHCl-buffer with refolding
buffer (20 mM Tris pH 8, 500 mM NaCl, 20% glycerol, GSH (0.2
mM)/GSSG (1 mM)) in a linear gradient and eluted with 250 mM
imidazole in refolding buffer.52 The protein was dialyzed against PBS
and concentrated to 2.5 mg/mL. One liter of E. coli culture yielded 60
mg of gpHDBLIP, which was frozen in liquid nitrogen and stored at
-80 C. The protein gave a single band in SDS-PAGE upon staining
with Coomassie-Blue. The -lactamase inhibitory activity of gpHDBLIP
was quantified in -lactamase inhibition experiments as described for
ampicillin sulfone (data not shown).
Comparison of Affinity Selection and Selection for Catalytic
Activity. Ribosome display was carried out as described above, but
only with active -lactamase. After stopping the translation, the stopped
mix was incubated for 4 h on ice. A 200-µL aliquot was treated for 1
h on ice with biotinylated ampicillin sulfone (final concentration, 0.01
mM), while another aliquot was treated with gpHDBLIP (final
concentration, 0.3 µM). The selection procedure for the aliquot treated
with biotinylated ampicillin sulfone was as described above. A gel
filtration step was performed, as described for the fraction with the
suicide inhibitor. The ribosomal complexes binding to gpHDBLIP were
captured via the His6 tag by incubating the flow-through with 10 µL
of Tetra-His antibody (Qiagen, 0.1 µg/µL, in WB) and 100 µL of protein
G PLUS-Agarose (Santa Cruz) equilibrated in WB in the presence of
4% sterilized milk powder. The agarose was washed as described for
the magnetic beads. Rescuing of the mRNA, RT, and PCR was carried
as out described above.
Abbreviations: RT, reverse transcription; PCR, polymerase chain
reaction; GSH and GSSG, the reduced and oxidized forms of glu-
tathione, respectively; GdnHCl, guanidine hydrochloride; bp, base pairs;
BLIP, -lactamase inhibitory protein; E. coli, Escherichia coli; GFP,
green fluorescent protein; gpHD, His-tagged gene product D from phage
lambda; IPTG, isopropyl--D-thiogalactoside; PAGE polyacrylamide
gel electrophoresis; PBS, phosphate-buffered saline; MOZ-ON, 4-meth-
oxybenzyloxycarbonyloxyimino-2-phenyl-acetonitrile.
Note Added in Proof: After this paper was submitted, it
was reported (Takahashi, F.; Ebihara, T.; Mie, M.; Yanagida,
Y.; Endo, Y.; Kobatake, E.; Aizawa, M. FEBS Lett. 2002, 514,
106-110) that 4 random point mutants of dihydrofolate
reductase, which had been obtained in a ribosome display
selection for binding to the inhibitor methotrexate, were active.
This suggests that enrichment of active enzyme variants may
also be possible simply by binding to an inhibitor under some
circumstances, not requiring the turnover-based selection re-
ported here, even though inactive mutants that still bind to an
inhibitor are certainly conceivable.
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We generated a single chain Fv fragment of an anti-
body (scFv) with a binding affinity of about 5 pM to a
short peptide by applying rigorous directed evolution.
Starting from a high affinity peptide binder, originally
obtained by ribosome display from a murine library, we
generated libraries of mutants with error-prone PCR
and DNA shuffling and applied off-rate selection by us-
ing ribosome display. Crystallographic analysis of the
scFv in its antigen-bound and free state showed that
only few mutations, which do not make direct contact to
the antigen, lead to a 500-fold affinity improvement over
its potential germ line precursor. These results suggest
that the affinity optimization of very high affinity bind-
ers is achieved by modulating existing interactions via
subtle changes in the framework rather than by intro-
ducing new contacts. Off-rate selection in combination
with ribosome display can evolve binders to the low
picomolar affinity range even for peptide targets.
Directed evolution of proteins in vitro has become a widely
applied strategy to generate proteins with a desired property
(1). Especially in the generation of high affinity binders, the
iterative succession of randomization and selection was shown
to efficiently mimic natural affinity maturation. The success of
this approach is dependent on the size and the quality of the
library and the power of the selection method used. Technolo-
gies that work entirely in vitro such as ribosome display (2) and
mRNA display (3) are more favorable than methods that work
partially in vivo such as phage display (4) or fully in vivo such
as the yeast two-hybrid system (5) or the protein complemen-
tation assay (6) as the in vitro technologies do not need trans-
formation of cells after each new round of randomization.
Therefore, they allow the handling of much larger libraries and
more cycles of randomization, and the experimental work is
accelerated greatly.
A prerequisite of any evolution is randomization between
different selection rounds. In ribosome display this is facili-
tated by the use of linear DNA. The randomization occurs at a
low rate by the intrinsic error rate of the polymerase used but
can be enhanced by error-prone PCR (7), by DNA shuffling (8),
or both, thereby generating highly diverse pools.
While the generation of binders having binding constants in
the subnanomolar range can be achieved, e.g. with synthetic
antibody libraries and established techniques (9), the genera-
tion of very high affinity binders with binding constants in the
lowest picomolar affinity range is difficult for several reasons.
First, a very stringent selection pressure must be applied to
separate improved binders from the already very high affinity
precursors. Second, selected binders must be eluted efficiently,
which may become very difficult for binders with very slow
off-rates. Here ribosome display offers a significant advantage
since bound binders must not be eluted, but the ribosomally
bound mRNA can be recovered by the addition of chelating
agents, which destabilize the ribosomal complex (1). In partic-
ular the generation of very high affinity peptide binders is
made difficult by the relatively high flexibility of the peptide in
the unbound state and the corresponding loss of entropy upon
binding. This is less of a problem for comparatively rigid anti-
gens such as hydrophobic small molecular weight compounds
for which subpicomolar binders are known (10).
We applied a competitive selection for increased off-rates to
affinity mature a high affinity peptide binder previously se-
lected with ribosome display from a murine library (11). The
peptide was derived from the yeast transcription factor GCN4.
We constructed different mutants of a high affinity binder and
generated from them second generation libraries using DNA
shuffling and error-prone PCR. From these libraries we suc-
cessfully isolated binders in the low picomolar affinity range.
By determining the crystal structure both in the free and
antigen-bound state we could show that the gain in affinity of
500-fold, compared with its likely germ line precursor, was
almost exclusively a result of second sphere mutations not
being in direct contact with the antigen. These findings may
have great impact on future library design and affinity matu-
ration strategies.
EXPERIMENTAL PROCEDURES
Expression and Purification of Single Chain Fv Fragments—The
scFv1 genes were cloned into the periplasmic expression vector pAK400
(12) introducing a His6 tag, expressed in Escherichia coli SB536 (13),
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31-65344.01. The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The atomic coordinates and structure factors (code 1P4I and 1P4B)
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for Structural Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
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 To whom correspondence should be addressed. Tel.: 41-1-6355570;
Fax: 41-1-6355712; E-mail: plueckthun@bioc.unizh.ch.
1 The abbreviations used are: scFv, single chain Fv fragment; VL,
variable domain of the light chain; VH, variable domain of the heavy
chain; 8-oxo-dGTP, 8-oxo-2-deoxyguanosine 5-triphosphate; dPTP, 6-
(deoxy--D-erythro-pentofuranosyl)-3,4-dihydro-8H-pyrimido-[4,-
5c][1,2]oxazine-7-one-5-triphosphate; RIA, radioimmunoassay; CDR,
complementarity-determining region.
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and purified by immobilized metal ion affinity chromatography and
subsequent antigen affinity chromatography as described previously
(11). For structure determination, a seleno-Met-containing variant of
clone H6 was grown in 1 liter of M9 minimal medium to an OD600 of 0.6.
An amino acid mixture containing 100 mg/liter each of Lys, Thr, and
Phe and 50 mg/liter each of Leu, Ile, Val, and seleno-Met was added.
After 1 h, isopropyl-1-thio--D-galactopyranoside was added to a final
concentration of 1 mM for expression overnight. The protein was puri-
fied as described above.
The Library Construction—The scFv fragments C11L34, L24, L107,
L135, L107–135, H6, and H67 in the vector pAK400 were PCR-ampli-
fied using primers SDAla (5-AGACCACAACGGTTTCCCTCTAGAA-
ATAATTTTGTTTAACTTTAAGAAGGAGATATATCCATGGCGGACT-
ACAAAGAT) and Sfi_rescue (5-GCCCTCGGCCCCCGAGGC). A total
of 1 g of PCR product of an equimolar mixture of all clones was used
for DNase I shuffling (14) as described previously (15). Some of the
reassembled PCR products were further randomized by error-prone
PCR using primers SDAla and Sfi_rescue. Error-prone PCR was
performed using the dNTP analogues 8-oxo-dGTP and dPTP according
to Ref. 7 with small modifications. Twenty-six cycles of error-prone PCR
were performed in the presence of 85 M dPTP, 85 M 8-oxo-dGTP, and
50 M dGTP, dATP, dTTP, and dCTP each. The final mutation rate
after DNase I shuffling and error-prone PCR and the distribution of the
mutations were determined by sequencing about 2000 bp. A gene III
linker was fused to the library as described earlier (11).
Selection for Improved Affinities—The library was transcribed and
translated in vitro as described in Ref. 11. The ternary complexes of
ribosome, mRNA, and displayed proteins were equilibrated with 1 nM
biotinylated peptide GCN4(7P14P) (16) at 4 °C overnight. Every sample
was split into two aliquots, and only to one, 1 M non-biotinylated
GCN4(7P14P) was added. The aliquots were incubated for a defined
time span, which was increased from round to round, starting with 2 h
in the first round and going up to 10 days after the fourth round in a
rollover shaker at 4 °C. The complexes were recovered by binding to
streptavidin-coated magnetic beads (Roche Applied Science) for 30 min.
The beads were washed five times, and the RNA was eluted and puri-
fied as described in Ref. 11.
Affinity Comparison of Pools and Single Clones by Radioimmunoas-
say (RIA) and Inhibition BIACORE—For the analysis of single clones,
the selected pools were cloned into pTFT74 (17). RNA of single clones
was transcribed directly from plasmid pTFT74, whereas the pools were
transcribed from a PCR product. RIAs were performed as described
previously (18). Of some clones, absolute affinities were measured using
the inhibition method on a BIACORE 3000 (19). The purified protein
was diluted to 1 nM and incubated with different concentrations of
antigen overnight at 4 °C. The samples were injected over a chip, which
was coated to maximal density with the antigen used for selection. The
slope of the association curves in the linear phase was plotted against
the concentration of soluble antigen. KD was determined from at least
three independent curves as described previously (11).
Crystallization—Crystals of clone H6 in complex with the antigen
and clone C11L34 in the absence of the peptide were obtained using the
hanging drop method. Drops of 1 l (protein concentration, 8 mg/ml) of
the unliganded Fv GCN4 were mixed with 1 l of the well solution
(1.1 M ammonium sulfate, 150 mM sodium citrate, pH 4.8). Crystals
appeared after 2 days at 20 °C belonging to space group P212121 (a 
35.08 Å, b  60.53 Å, and c  123.05 Å) and contained one molecule per
asymmetric unit (Vm  2.29 Å
3/Da, 46% solvent (20)). Crystals of the
complex of H6 and the peptide YHLENEVARLKK were obtained by
mixing the scFv and the peptide in a 1:2 molar ratio. Drops of 1 l of the
complex (protein concentration, 7.4 mg/ml) were mixed with 1 l of a
solution containing 32–28% (w/v) polyethylene glycol 4000, 0.1 M Tris/
HCl, pH 7.5. The space group was P21 (a  37.24 Å, b  36.29 Å, c 
84.46 Å,  90.5°) with one complex per asymmetric unit and a specific
protein volume of 2.03 Å3/Da.
Data Collection and Processing—Data of the free scFv fragment were
collected at 100 K on a MAR-Research Imaging Plate (MAR, Hamburg,
Germany) placed on a Rigaku RU200 rotating anode using the CuK
radiation. Crystals were frozen using 25% glycerol, and they diffracted
to 2.6 Å. Data integration and reduction were performed using DENZO
(21) and SCALA (22). A crystal of the complex was frozen with 16%
glycerol. Data were collected at 100 K in the beam-line ID14-EH4 at
the European Synchrotron Radiation Facility (Grenoble, France),  
0.988 Å. The data reduction was performed with SCALA (22). The data
of the complex were merged with TRUNCATE (22) in CCP4i using the
anisotropic correction option. The RSym for the free scFv and the com-
plex were 5.9 and 6.2%, respectively. The statistics of the data sets are
shown in Table I.
Structure Determination and Refinement—Both structures were
solved by molecular replacement (23) using the program AMoRe (24).
Rotation and translation searches were performed using the murine Fv
SE155-4 (Protein Data Bank entry 1MFA) for the unliganded Fv. The
structure of the unliganded Fv was used to solve the structure of the
complex. The molecular replacement solution for the unliganded Fv
gave an initial correlation coefficient of 45% and R-factor of 47%, while
the values for the complex were 46 and 48%, respectively, between 8.0
and 3.0 Å. Refinement was performed first with CNS (25) using stand-
ard protocols followed by REFMAC (26) using maximum likelihood,
incorporating bulk solvent corrections and translation-libration-screw
(TLS) anisotropic refinement. After each refinement cycle, a new map
was calculated, and the model was fitted with Turbo-Frodo (27). Final
refinement data are summarized in Table I. The coordinates and struc-
ture factors of the free and peptide-bound Fv have been deposited in the
Protein Data Bank at Research Collaboratory for Structural Bioinfor-
matics as entries 1P4I and 1P4B, respectively.
RESULTS
Library Construction—In a previous study, we selected a
group of scFv fragments from a murine library by using ribo-
some display, a selection method that works entirely in vitro
and therefore allows the selection from very large libraries
(Fig. 1). The selected scFv fragments bound with very high
affinity to the peptide GCN4(7P14P) derived from the yeast
transcription factor GCN4 (11, 16). The highest affinity clone,
named “C11L34,” had an affinity of 40 pM and acquired a
crucial amino acid substitution during ribosome display rounds
TABLE I
Crystal parameters and refinement statistics
Free scFv Complex
Data collection
Space group MP212121 P21
Total/unique number of reflections 51,966/6,870 129,374/10,027
Percentage of data 1 (overall/last shell)a 96.0/96.0 97.2/97.6
Overall I/ (I) (last shell) 11.9/2.6 8.5/4.1
Resolution limits 24.6/2.8 20.0/2.3
Rmerge (%) (overall/last shell)
a 5.9/28.1 6.2/18.4
Refinement
Number of protein/solvent atoms 1,658 17,648/66
Number of reflections 6,796 9,940
Resolution limits (Å) 12.0–2.8 15.0–2.35
R/Rfree value (%) 20.05/26.4 18.0/21.5
r.m.s.d.b on bonds (Å)/angles (°) 0.012/2.0 0.025/2.1
r.m.s.d. on impropers/dihedrals (°) 1.14/27.8 0.86/25.2
Mean B-factor (Å2) (main/side chain) 35.4 23.8/27.0
Peptide (main/side chain) 25.0/28.0
Water 33.0
a Last shell, 2.9–2.8 Å (free scFv); 2.43–2.35 Å (complex).
b r.m.s.d., root mean square deviation.
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that led to a 65-fold affinity improvement compared with its
likely progenitor from the murine B-cells (11).
We constructed a second generation library in two steps.
First, we generated five different point mutants of the high
affinity clone and a double mutant, based on mutations that
had been enriched in the first selection experiment, and meas-
ured their affinities (Table II and see Fig. 4). These mutants
were taken as a template for the construction of three second
generation libraries. The first pool, named “S,” was generated
by using DNA shuffling of all seven clones including C11L34,
thereby recombining all mutations (8). Two other pools were
generated by the use of error-prone PCR. Pool “R” was gener-
ated by error-prone amplification of C11L34, and pool “SR” was
generated by the combination of the two approaches: the mu-
tants were amplified by error-prone PCR and then subjected to
DNA shuffling.
To enhance the mutation rate of the polymerases, we used
high concentrations of the nucleotide analogues 8-oxo-dGTP
and dPTP leading to mismatch incorporation (7). The final
mutation rates of the pools were determined as 8.9 kbp1 for
pool S, 61 kbp1 for pool R, and 78 kbp1 for pool SR. Taking
into account that many mutations are silent or have no effect
on binding, e.g. because they are located in the linker or the
lower framework, we estimated that the randomized pools will
have two to three relevant amino acid substitutions per gene.
As a consequence of the PCR-based randomization we found
that mutations that were introduced during an early PCR cycle
were more prominent in the final library. This clustering of
mutations could be circumvented in future experiments by the
use of a high template concentration and very high error rates,
thereby reaching the final mutation rate within fewer amplifi-
cation cycles.
Ribosome Display and Off-rate Selection—For ribosome dis-
play, all three libraries had to be fused to a protein spacer
derived from gene III to allow the displayed protein to fold
properly (15). Since panning followed by extensive washing
would hardly be able to discriminate between binders with
different affinities all lying in the picomolar range, we used a
competitive selection for decreased off-rates. The ribosomal
complexes formed after in vitro translation were equilibrated
overnight with a 1 nM solution of biotinylated antigen. A 1000-
fold excess of competitor antigen carrying no biotin label was
then added, and the pools were incubated at 4 °C. All com-
plexes dissociating from the biotinylated antigen, to which they
were initially bound, will be captured by the competitor carry-
ing no biotin label and thus cannot be bound to streptavidin-
coated magnetic beads. Hence the duration of incubation with
competitor is defining the stringency of the selection. The in-
cubation was prolonged from round to round (2, 10, and 240 h),
thereby increasing the selection pressure. After every round,
selected mRNA was isolated and reverse transcribed, and the
enriched pools were subjected to DNA shuffling. The pool SR
was further randomized after the second round using the same
conditions as in round 1.
Interestingly the mRNA of pool R, which had been generated
by error-prone amplification of C11L34 only but which had not
been subjected to DNA shuffling, could not be restored after the
first round of selection. This indicates the importance of recom-
bination in conjunction with high mutation rates to preserve a
fraction of the pool in an active form. Furthermore the long
off-rate selection times underscore the stability of the non-
covalent ribosomal complex, which can survive more than 20
days at 4 °C.
Analysis of the Pools after Off-rate Selection—After every
round of ribosome display, the pools were checked for improved
binding by RIA (18). The pools were expressed in vitro in the
presence of [35S]Met, equilibrated with different amounts of
free antigen, and allowed to bind to surface-immobilized anti-
gen. The amount of competitor antigen needed to inhibit the
binding of the scFv fragments to surface-immobilized antigen
correlates with the mean affinity of binders found in the pool
under investigation and decreased from round to round (Fig. 2).
In the initial error-prone randomized pool even high concen-
trations of competitor did not affect binding of the pool to the
plate. After 240 h of off-rate selection, however, 0.1 nM antigen
was sufficient to prevent 50% of the pool from binding to the
surface compared with the uninhibited signal, giving evidence
that the mean affinity of the binders in the pool had improved
affinities compared with clone C11L34. The total signal inten-
sity of the pools decreased from round to round, indicating that
the percentage of rescued binders decreased from round to
round due to the very stringent selection pressure.
Screening for Binders—After the third round, pools SR and S
were cloned, plasmids of single colonies were isolated, and in
vitro expressed protein was analyzed by RIA. Only 7 of 54
clones (13%) showed a significant binding signal to the surface-
immobilized antigen in the absence of competitor. All of these
clones could be completely inhibited with 10 nM antigen. Four
of them were inhibited at even lower concentrations than
C11L34 and were therefore ranked as affinity improved. In
pool S, which was generated by DNA shuffling, 4 of 15 (25%)
clones analyzed showed binding to the antigen after the third
round of directed evolution, but only one had an improved
inhibition signal (Table II).
Only a few molecules had reached improved affinities that let
them survive the applied selection pressure, whereas the back-
ground signal, consisting of unspecific complexes and RNA stick-
ing to the streptavidin-coated magnetic beads, remained con-
stant. To improve the ratio of binders over background, a non-
stringent enrichment round was performed. After this
FIG. 1. Ribosome display. Ribosome display is a method to select
binders from large libraries. A library of mRNA molecules, encoding for
potential binders, is translated with an approximately stoichiometric
amount of ribosomes in vitro. Since the mRNA contains no stop codon
and the reaction is stopped with a buffer containing high concentrations
of magnesium, the ribosome will not dissociate and form a stable com-
plex with the translated protein and the mRNA. A spacer fused to the
C terminus of the library takes up the place in the ribosomal tunnel and
thereby ensures that the freshly translated protein can fold into its
native structure even if it is displayed on the ribosome. The complexes
are used for the selection of binders to immobilized antigen. After
washing, the mRNA is eluted using chelating agents such as EDTA to
dissociate the ribosome. Eluted mRNA is reverse transcribed, amplified
by PCR, and potentially randomized to introduce more diversity. mRNA
for the next selection round is transcribed directly from a PCR product.
Note that at no step does the library have to be transformed into cells,
which would otherwise drastically reduce the size of the library that is
available for screening. The PCR can also be carried out under error-
prone conditions thereby allowing the library to evolve (for details, see
text). RT, reverse transcription.
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enrichment, 14 of 16 (87%) randomly picked clones showed bind-
ing to the antigen, of which eight showed improved inhibition
patterns compared with C11L34. Furthermore the signal inten-
sity of the pool in the RIA increased by a factor of 120, indicating
a strong enrichment of the binders in the pool over the nonspe-
cific RNA. Thus, a non-selective enrichment round after exten-
sive off-rate selection may be useful in general to amplify the
selected clones.
Sequences of the Clones with Improved RIA Signal—The
clones showing the most promising RIA signal were sequenced.
They carried an average mutational load of one to four amino
acid substitutions, whereas zero to two mutations derived from
shuffled input DNA (Table II). The mutations were distributed
over both domains, and some mutations showed up several
times. It is likely that they were found independently since
they had different codon usage. Interestingly the only mutation
lying in CDRs, L135(Asn 3 Asp), originated from the clones
used for DNA shuffling. All other mutations were located in
framework positions.
BIACORE Measurements—The affinity of all clones gener-
ated by site-directed mutagenesis and used for the library
construction was measured. In addition, the binding constant
of the evolved clone showing the best RIA signal after off-rate
selection was determined. All clones were expressed in the
periplasm of E. coli and purified by immobilized metal ion
affinity chromatography and antigen affinity chromatography
(18). The dissociation constant KD of the purified proteins was
determined in solution by competition BIACORE analysis (19,
28, 29).
The dissociation constants of the clones used for the library
generation were between 20 and 50 pM (Table II). Clones
L135(Asn 3 Asp) and H6(Glu 3 Gln) showed a significantly
improved affinity of 23.3 and 20 pM, respectively. Therefore, we
also constructed the double mutant L135H6. It had an affinity
of 16 pM. However, this clone had not been available when the
library was constructed. The affinities of the evolved clones
were mainly monitored by RIA. The affinity of the clone with
the best RIA signal, named 52SR4, was determined. It was
found in pool SR after the third round, and its affinity in
solution was determined to be 5.2 pM by the competitive BIA-
CORE method (11). All measurements were repeated three
times independently, resulting in uncertainties of 5–45%.
Measuring affinities in this range is very difficult. The minimal
concentration of the scFv that could be detected using BIA-
CORE was about 1 nM. Due to the very high affinities, this is
much above the KD value at which concentration the measure-
ment should have been performed ideally. However, even if the
KD of this highest affinity binder cannot be given with satisfy-
TABLE II
Summary of the mutations and affinities of different GCN4 binders
Clonea Mutationsb KD
c
pM
C11L34d L42(Asn3 Ser) 40  4
L24 L24(Arg3 His) 32  13
L107 L107(Ala3 Val) 48  6
L135 L135(Asn3 Asp) 23  4
H6 H6(Glu3 Gln) 20  2
H67 H67(Ile3 Val) 47  7
L107L135 L107(Ala3 Val) L135(Asn3 Asp) 47  5
L135H6 L135(Asn3 Asp) H6(Glu3 Gln) 16  13
52SR4 L13(Thr3 Ser) L107(Ala3 Val) 5.2  2.3
L135(Asn3 Asp) H30(Ser3 Leu)
63S3 L145(Leu3 Pro) NDe
70SR4 L13(Thr3 Ala) L135(Asn3 Asp) ND
H96(Leu3 Pro)
82SR4 H70(Tyr3 His) H94(Asn3 Ser) ND
84SR4 H32(Thr3 Ala) H70(Tyr3 His) ND
H94(Asn3 Ser)
a The first eight clones listed were found in a previous selection (11), and their mutations compared with C11L34 were introduced by site-directed
mutagenesis. Clones H6 and L135H6 were constructed because it was shown recently that the residue on position H6 is often critical for stability
and affinity (32, 34). All these clones were used for the generation of different libraries by DNA shuffling and error-prone PCR with the exception
of clone L112H6, which was constructed at a later point in the project. The last five clones listed were found during the directed evolution and
showed promising signals in a competition RIA.
b The mutations are given in the AHo nomenclature (35).
c The affinities were determined by inhibition BIACORE. The affinity improvement during the directed evolution was monitored mainly by
competition RIA (see text).
d Clone C11L34 was found to have a single point mutation compared with its likely progenitor (11). All other clones are derived from C11L34
and contain its mutation, L42(Asn 3 Ser). For historical reasons, its name is indicated in the Kabat nomenclature (36) and was retained.
e ND, not determined.
FIG. 2. Inhibition RIA of pools after subsequent rounds of
off-rate selection. Three rounds of ribosome display were performed
using selection for improved off-rates by competing biotinylated peptide
with unlabeled peptide (see text). After each round, 35S-labeled protein
of the pools was expressed in vitro and equilibrated with different
amounts of antigen. The equilibrated pools were then bound to surface-
immobilized antigen. The binding signal of the pool is a measure of the
amount of free scFv fragment present at equilibrium. High affinity
binders are completely complexed by small concentrations of free anti-
gen and thus do not bind to the immobilized antigen. The less free
antigen is needed to prevent a pool from binding to the surface-immo-
bilized antigen, the higher the mean affinity of the pool is. It can be seen
that the concentration of free antigen needed to prevent the pool from
binding to surface-immobilized antigen decreases from round to round.
d, days.
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ing accuracy (5.2  2.3 pM, determined from several independ-
ent protein preparations), a clear improvement of the scFv over
the initial constructs can be observed (Fig. 3). The KD values of
C11L34 and 53SR4 were also determined by kinetic BIACORE
analysis with very low coating density, and the equilibrium KD
data were confirmed (data not shown).
The Overall Structure of the scFv—The crystal structure of
C11L34 was determined in the absence of the antigen to 2.35 Å,
and the crystal structure of variant H6 in the presence of the
antigen was solved to 2.8-Å resolution (Fig. 4A). The C-termi-
nal His tag and the linker connecting the two variable domains
were not defined in the electron density as is typical for other
scFv fragments. The N-terminal part of VH of the scFv in
complex with the peptide was poorly defined. Initial attempts
to crystallize the complex with the 33-amino acid peptide used
for selection were not successful. Previous studies with CD had
suggested that the peptide would adopt a random coil confor-
mation (16) in the antibody-bound form, which implied that not
more than 10–12 amino acids of the extended peptide would be
recognized by the scFv. Therefore, we used a truncated peptide
of 12 amino acids for a second crystallization trial. With this
approach crystals were obtained. When the structure was
solved, the peptide was found to bind in a three-turn helical
conformation, thereby making its total contact area smaller
than expected. Therefore, not all of the potentially interacting
residues can be seen in the present structure. To better illus-
trate the complete potential binding interface, the peptide was
elongated at its N terminus, and the corresponding residues,
which we denote, M1 to M5, in contrast to the structurally
resolved residues of the peptide, P1 to P12, were modeled in an
-helical conformation into the complex. We repeated the CD
measurements, which led to the original assumption that the
bound peptide would adopt a random coil conformation (16).
From the spectra of the scFv alone compared with the scFv
bound to the peptide we attempted to deduce the spectrum of
the peptide when bound to the scFv. Whereas the peptide in
solution was clearly random coil, the spectrum of the peptide in
complex with the scFv, originally interpreted as random coil,
was very noisy and did not allow a clear conclusion (data not
shown). The antibody had originally been raised against a
variant of the coiled-coil leucine zipper of the yeast transcrip-
tion factor GCN4 in which two residues were changed to pro-
line (16). The origin of the peptide explains that there is some
residual tendency for -helix formation. Indeed the almost
perfect helical conformation of the peptide in complex with the
scFv suggests that the helical conformation is further induced
by binding to the antibody.
Conformational Changes Due to Antigen Binding—Superpo-
sition of the Fv structure in the antigen-bound and free state
results in a root mean square deviation of only 0.75 Å. Devia-
tions are located between residues H9–18 and H48–52, and
they are mostly due to the poor definition of the N-terminal
part of VH in the structure of the complex. These changes
located opposite to the binding site are probably not related to
the complex formation. A major rearrangement, however, was
seen in CDR H3. Specifically residues Gly-H109 and Leu-H110
deviate strongly by 3.4 and 1.4 Å, respectively. Since this
segment is well defined in both electron density maps, it is
clear that the conformational change is directly induced by the
binding of the peptide to the scFv, namely by Arg-P9 (Fig. 4B).
Beside these changes, only small structural changes in the
CDRs are observed upon peptide binding, which are all less
than 1 Å. Upon peptide binding, the two domains of the scFv
undergo a small rotation relative to each other by 1.25°. This
may allow a more optimized binding geometry (see below).
The Interaction of the scFv with the Antigen—The scFv forms
a deep (6–8 Å) and broad (8 Å) cleft of 20 Å in length to which
all six CDR sequences contribute. The bottom of the cleft is
formed mainly by the relatively short CDR3 loops of the heavy
and light chain. The borders are formed by the loops of CDR1
and CDR2 of both chains. The antigen lies as an almost ideal
three-turn -helix in the binding cleft. This engulfed binding of
the antigen results in a buried surface of 700 Å2, which corre-
sponds to 45% of the total water-accessible surface of the pep-
tide. Modeling the peptide in its full length into the binding
groove by extending the helix yields in an interaction interface
of about 1580 Å2, which is bigger than the interface between
the light chain and the heavy chain (1479 Å2). This buried
surface value is also larger than those observed between most
Fab fragments/Fv fragments in complex with proteins (30).
The interaction is made up by a great number of specific
contacts between the scFv and exclusively the side chains of the
peptide. The helical peptide faces the scFv with the same side
that is responsible for the leucine zipper formation in the
natural protein (31). Almost 30% of the surface of the peptide is
contributed by His-P2. Its aromatic plane forms a hydrophobic
stacking interaction with the indole moiety of Trp-H59. His-P2
also establishes a hydrogen bond to Asp-H65 and is further
stabilized by a hydrophobic contact to Ile-H67. The neighboring
residue Leu-P3 is held between three aromatic residues (Tyr-
L40, Trp-L109, and Trp-L137), and Arg-P9 on the adjacent
helical turn makes a strong (double) ionic interaction with
Asp-H137. The interaction with Arg-P9 enforces the conforma-
tion of CDR H3 (H109–137), especially that of Gly-H109. The
conformation of Arg-P9 is most likely locked by a hydrogen
bond to Glu-P6 (Fig. 4B). In addition, Glu-P6 establishes a
contact to the backbone carboxyl oxygen of Gly-H40 via a water
molecule. An ionic hydrogen bond is also made between Lys-P4
and Asp-H69. A great number of hydrophobic interactions,
namely stacking of aromatic rings and packing of aliphatic side
chains, are found. The pattern of charged and hydrophobic
residues observed on the surface of the peptide is comple-
FIG. 3. Affinity determination using inhibition BIACORE. The
dissociation constant KD in solution of different single chain Fv frag-
ments using inhibition BIACORE was determined at 20 °C. The trian-
gles correspond to the starting clone C11L34, having a KD of 40 pM, the
diamonds correspond to clone H6 from which the crystal structure in
complex with the antigen was determined to have a KD of 20 pM, and the
circles correspond to 52SR4, which was the evolved clone with the best
RIA signal having a KD of 5.2 pM. For better comparison, the theoretical
curves for a 10 pM affinity (dash-dotted line) and a 1 pM affinity (dashed
line) are indicated in the inset. Due to the very high affinities the
measurements become close to the detection limit. The given value of
5.2  2.3 pM was obtained in three independent measurements.
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FIG. 4. Overall structure of clone H6 in complex with the peptide and the location of the mutations. In A, the backbone of the complex
is shown. All mutations, which were found more than once in the directed evolution in any clone, are drawn with side chains including mutation
L42(Asn 3 Ser), which led to clone C11L34 with 65-fold improved affinity compared with its likely murine progenitor. The C atoms of other
mutations mentioned in the text are indicated by a sphere and a number. The light chain is drawn in olive green, the heavy chain is drawn in light
blue, and the peptide is drawn in orange. The side chains of mutations lying in the interface of the two domains are shown in red. B, 2Fo  Fc
electron density map contoured around the dodecapeptide. C shows the CDR H3 region overlaid in the antigen-bound and free state where the
structural changes in the scFv due to antigen binding are significant. The antigen-bound form of the scFv fragment is drawn in light orange, and
the free form is in blue, whereas the peptide is drawn in orange. Not all side chains are drawn. Arg-P9 establishes a strong interaction including
two charged hydrogen bonds with Asp-H137 and thereby induces the conformational shift. The conformation of Arg-P9 may be locked by another
weak hydrogen bond to Glu-P6. The greatest conformational change is undergone by Gly-H109, but there is a slight reorientation also by Leu-H110,
which interacts hydrophobically with Leu-P10. The shift in the loop is stabilized by water molecule WAT18, which is hydrogen bonding to Glu-P6,
Gly-H109, and Gly-H40. D, three mutations were lying close together in adjacent -strands of the light chain facing the heavy chain. They may
have an effect on the domain orientation and domain spacing. Residue Ser-L42 found in the previous selection is drawn in red. Ala-L107 (orange)
and Phe-L139 (gray) were mutated to valine and leucine, respectively. The figures were prepared using the program MolMol (33).
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mented electrostatically by the surface of the scFv (Fig. 5).
Water molecules contribute strongly to the stabilization of the
conformation of the peptide and are directly involved in inter-
actions between the peptide and the antibody fragment. The
conformational change in CDR H3 is probably favored by water
molecule WAT18 (Fig. 4B).
A Structural Interpretation of the Evolution—Almost all the
mutations that produced the high affinity binder are so-called
“second sphere” mutations, which do not directly interact with
the antigen and fulfill their beneficial effects via indirect inter-
actions. The mutation L42(Asn3 Ser), which leads to a 65-fold
improved affinity of C11L34 relative to all its precursors and
had been found in the original selection with ribosome display,
is at least 6.6 Å away from the antigen. The light chain of
C11L34 is of subtype . Interestingly murine germ line se-
quences of this subtype never carry a Ser at this position,
whereas in murine light chains of -type, Asn and Ser side
chains are common. In murine -type light chains, however,
Asn side chains often make a hydrogen bond to residue H110 of
VH, stabilizing the interface, while Ser is rather seen in hapten
binders, having a deep binding pocket, where the hydrogen
bond is made directly to the hapten (e.g. Protein Data Bank
entry 1C5C). In the case of C11L34, Ser-L42 plays an unusual
role and forms a hydrogen bond to the backbone oxygen of
Tyr-L40, stabilizing the conformation, which is typical for a
backbone of -subtype. This stabilizing effect most likely re-
duces the flexibility of CDR L1, which is directly interacting
with the peptide, through a hydrophobic contact between Tyr-
L40 and Leu-P3. In addition, the space gained in the interface
due to the smaller side chain may allow a more favorable
domain orientation. A comparison of the scFv in the antigen-
bound and unbound state reveals a domain rotation upon an-
tigen binding and a reorientation of the CDR H3 loop, which
brings CDR H3 1.5 Å closer to Ser-L42 than in the unbound
state. In addition to Ser-L42, two other mutations, L107(Ala3
Val) and L139(Phe 3 Leu), that showed up during the exten-
sive off-rate selection lie in close proximity to Ser-L42 on adja-
cent -strands of the light chain (Table II and Fig. 4C). These
mutations are close to the pseudo-twofold axis of the scFv. It is
likely that the interface mutations influence the relative do-
main orientation or domain spacing and thereby optimize the
binding geometry.
The mutation H6(Glu 3 Gln) improved the affinity, by a
factor of 2, to 20 pM when compared with clone C11L34. This
residue is much too far away to interact with the antigen
directly and must exert its beneficial effect by some long range
interactions or “molecular shimming,” influencing the orienta-
tion or flexibility of a loop or a domain. While the free scFv
carries a glutamate at position H6, the structure of the scFv in
complex with the peptide solved here is a variant carrying
glutamine at this position. Position H6 was shown to define the
conformation of the N-terminal part of the heavy chain (32).
The conformation of the backbone in the free state is as it was
expected for a glutamate. In the complex, however, this part of
the structure is poorly resolved. Therefore, the occupancy of
this area was set to 0. The poor density might indicate a
conformational inhomogeneity or a higher than normal mobil-
ity, the reasons of which are unknown. The only mutation
found during the selection that may interact directly with the
antigen was introduced by site-directed mutagenesis during
the library construction: L135(Asn 3 Asp). It most likely es-
tablishes a hydrogen bond to Lys-M4. However, this part of the
peptide was not used for crystallization (see above). Most other
mutations found during directed evolution are lying on the
surface of the scFv fragment, and many may be neutral. How-
ever, some could also have indirect beneficial effects such as
H30(Ser 3 Leu), which was found in the best affinity clone.
DISCUSSION
We have evolved a pool of single chain Fv antibody fragments
against a peptide, which adopts a random coil in solution but a
helical conformation in the complex, to achieve affinities of
about 5 pM. We started from an already very tight peptide
binder and generated a library by combining site-directed mu-
tagenesis, DNA shuffling, and error-prone PCR. We applied
directed evolution using ribosome display to improve the affin-
ity a further 8-fold. Our result demonstrates that ribosome
display is ideally suited for the identification of affinity-improv-
ing mutations and for the selection of binders under very strin-
gent conditions even when already starting from picomolar
affinities. In contradiction to previous concerns the stability of
the ribosomal complex and the attached mRNA is not a limi-
tation of the method.
One of the key results of the present study, analyzing the
results from directed evolution crystallographically, is that
only one mutation was making direct contact to the peptide.
Three mutations were lying close together in the VL/VH inter-
face. They may modulate the domain orientation, domain spac-
ing, and the CDR loop flexibility. Many of the mutations found
in the affinity-improved clones were found to lie on the surface
FIG. 5. Electrostatic potential of the antibody with the antigen moved from the binding site. A surface plot of the scFv and the antigen
covering all amino acids potentially covering the binding pocket is shown. The six N-terminal amino acids DLPKQY of the peptide were modeled
into the binding groove in a helical conformation. For better visualization, the antigen was removed from the scFv and rotated such that the binding
face is visible. Folding the figure in the middle would restore the original orientation of the peptide.
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of the scFv not making direct contact to the antigen. Most likely
these accumulated during the library generation and do not
contribute to the improved affinities.
After the selection for a “first sphere” containing all impor-
tant short range interactions, the overall geometry of the bind-
ing pocket was rearranged in a subtle manner. This was exclu-
sively achieved by the mutation of key residues in the so-called
second sphere, influencing the flexibility of binding loops and
the orientation of domains rather than by changing interacting
residues.
To our knowledge we have evolved the highest affinity rea-
gent against a short unmodified peptide. Due to its very high
affinity and the relatively small size of the antigen we expect
the evolved scFv-peptide pair to be a powerful tool for biotech-
nological applications where tight binding to a tag is needed.
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